Generation of Natural Killer Cells from Umbilical Cord Blood Stem Cells, Characterisation and Application for Immunotherapy by Luevano Salinas, ME
  1 
 
GENERATION OF NATURAL KILLER CELLS 
FROM UMBILICAL CORD BLOOD STEM CELLS, 
CHARACTERISATION AND APPLICATION FOR 
IMMUNOTHERAPY 
 
 
 
 
 
Martha Elia Luevano Salinas 
 
 
 
A thesis submitted to the University College London for the degree of  
Doctor of Philosophy 
 
 
2013 
 
 
Anthony Nolan Research Institute 
Cancer Institute 
University College London (UCL) 
  2 
Declaration 
 
 
 
I, Martha Elia Luevano Salinas, confirm that the work presented in this thesis is my 
own. Where information has been derived from other sources, I confirm that this has 
been indicated in the thesis. 
 
Signed:!!!!!!!!. 
 
Date:!!!!!!!!!.. 
 
  
  3 
 
 
 
 
 
 
This thesis is dedicated to my family and especially to 
my beloved life companion and husband Brian Davis.  
  4 
Abstract 
 
Adoptive (Natural killer) NK cell therapy relies on the use of a large amount of NK cells 
that are cytotoxic, and yet not exhausted. For this purpose, NK cells can be isolated 
from cord blood, peripheral blood or generated in vitro from haematopoietic stem cells 
(HSC). In vitro generation of high numbers of activated NK cells using HSC would 
facilitate multiple infusions and treatment of patients with large tumour burden, allowing 
to by-pass the limitations of NK cell numbers and activation state of blood-derived NK 
cells. However, comprehensive studies about the use of fresh or cryopreserved HSC 
and of different HSC sources for protocols of NK cell production in vitro have yet to be 
performed. The aim of this thesis was to investigate these variables and establish an 
optimal protocol for the generation of NK cells in vitro. 
 
This work investigated the use of a published protocol and a modified version using 
only IL-15 for the last weeks of culture for NK cell generation; moreover, the 
comparison of NK cells derived from fresh cord blood stem cells (CBSC) and frozen 
CBSC and a different HSC source, mobilised peripheral blood stem cells (PBSC), was 
performed. Using this protocol, we showed that frozen CBSC generated higher NK cell 
numbers expressing activating receptors, lacking killer-cell immunoglobulin like 
receptor expression but with better immunoregulatory and cytotoxic properties 
compared to NK cells from fresh CBSC and PBSC cultures. More than half of the NK 
cells generated in vitro from all HSC types expressed the myeloid-marker CD33; 
blocking of this marker did not impact on NK cell functions. Finally, CBSC and PBSC 
showed a different threshold for NK cell activation with interleukin 12. In conclusion, 
our study provides evidence that frozen CBSC are a suitable source of HSC for NK cell 
generation in vitro compared to fresh CBSC and frozen PBSC. 
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 Introduction Chapter 1:
 
1.1 The immune system 
The immune system is a network of cells, cell products, tissues and organs that protect 
the body against pathogens, non-self and transformed cells. The immune system is 
complex and comprises numerous physical defences and cells with a specific function. 
Traditionally, the immune system is divided into two categories, the innate immune 
system (non-specific) and the adaptive immune system characterised by specificity and 
memory. The following is a brief description of these two arms of immunity.   
 
1.1.1 Innate immunity  
 
The innate immune system refers to physical barriers such as the skin and mucosa as 
well as non-specific cellular defences triggered immediately or within hours after 
exposure to any foreign microbe/antigen/substance. The main components of the 
innate immunity include physical barriers, effector proteins, effector cells and cytokines 
(figure 1.1). The first line of defence is provided by the skin and mucosae, which act as 
physical barriers and anatomical traps preventing the entrance or growth of most 
microbes. They can contain antibacterial enzymes such as defensins and cathelicidins 
that destroy bacterial membrane walls and physically trap microbes (figure 1.1). The 
second line of defence involves antimicrobial proteins and phagocytic cells able to 
recognise broad classes of pathogenic organisms through germ-line encoded antigen-
specific pattern recognition receptors (PPRs) such as Toll-like receptors (TLRs). 
Another class of innate immune lymphocytes are natural killer (NK) cells, which are the 
focus of this thesis; a detailed description of this cell subset is provided in the following 
sections. A variety of proteins are also involved in the defence against pathogens such 
as cytokines. 
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Figure 1.1. Components of the innate immune system. 
 
While often effective, these non-specific responses are not impregnable, if they fail to 
eliminate the foreign invader, a highly specific immune response needs to be mounted 
by the adaptive immunity. 
 
1.1.2 Adaptive immunity 
 
The fundamental features of the adaptive immune system are: specificity, diversity, 
memory, clonal expansion, specialisation, homeostasis and non-reactivity to self (Abul 
K. Abbas, 2011). There are two types of adaptive immune responses: humoral and 
cell-mediated immunity. The humoral immunity is mediated by antibodies produced by 
B lymphocytes. The cellular-mediated immunity (cellular immunity) is mediated by T 
lymphocytes. Intracellular invaders, such as viruses or bacteria, are able to survive and 
proliferate inside the host cells, where antibodies have no access. In this case, cellular 
immunity supports the destruction of these infected cells. Figure 1.2 shows the main 
components of the cellular and humoral immunity and how they interact, additionally a 
summary of both immune responses is shown in the following sections. 
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Figure 1.2. Immune system interactions. The immune system consists of several cellular 
interactions that lead to different functional responses by different immune cells. Numerous cell 
surface receptor–ligand interactions, cytokines, and inflammatory molecules coordinate and 
affect the immune response. Antigen presenting cells such as dendritic cells can interact with 
CD8 T cells to stimulate cellular (cytolytic) immune responses, or with CD4 T cells to prime 
humoral (antibody) based responses. A CD4 T cell can differentiate into a variety of effector 
subsets, which include those that stimulate B cells to produce antibodies or those that help 
activate other immune clearance and regulatory processes. Modified with permission from 
Elsevier. (Look et al., 2010)  
 
Antigens 
 
The term antigen was previously used for any molecule that induced the generation of 
a specific antibody by B cells. However, now antigen is defined as any substance that 
can induce an immune response. Antigens can be a natural substance or man-made 
(John Hall, 2010).  
 
Cell-mediated immunity: T cells 
 
T cells are lymphocytes that mediate cellular immunity. The two major T lymphocyte 
subsets are helper T lymphocytes (TH) and cytotoxic T lymphocytes (CTLs), which 
express the antigen receptor "(. Most TH cells express CD4 and most CTLs express 
CD8 (Abul K. Abbas, 2011). T cells express TCR (T cell receptor); a molecule 
restricted to the recognition of peptides bound to major histocompatibility complex 
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(MHC) molecules on antigen presenting cells (APCs). Although other cells can act as 
APCs (B cells and macrophages), dendritic cells (DCs) are the most effective at 
presenting antigens. CD8 T cells recognise peptides presented by class I MHC 
molecules while CD4 T cells recognise peptides via class II MHC molecules. The TCR 
engagement triggers positive or negative signals that result in cellular proliferation, 
cytokine production or even cell death (Lin and Weiss, 2001). DCs can activate naïve T 
cells, which are able to differentiate into different cell classes that produce specific 
cytokines and have special effector functions. The activation of naïve CD4 T cells can 
lead to the differentiation into TH1, TH2, TH17 and Tregs (Mosmann et al., 1986; Korn et 
al., 2009) (figure 1.2). TH1 cells protect against intracellular pathogens and TH2, against 
extracellular pathogens. TH17 are characterised by the production of IL-17, a 
proinflammatory cytokine, and Tregs are immunosuppressive and maintain self-
tolerance (Sakaguchi, 2004). After the expansion phase most T cells will die, however, 
a memory cell pool is maintained for a faster and stronger secondary immune 
response. Protective memory is mediated by effector memory T cells (TEM) and central 
memory T cells (TCM). TEM cells have immediate effector functions and TCM have higher 
sensitivity to antigenic stimulation compared to naïve T cells (Lanzavecchia and 
Sallusto, 2000). Similarly, activation of naïve CD8 T cells allows its differentiation into 
activated CD8 T cells that acquire cytotoxic properties or differentiate into memory CD8 
T cells (resident memory CD8+ T cells and effector-like memory CD8+ T cells) 
(Hamilton and Jameson, 2012). 
 
Humoral immunity: B cells 
 
B cells have a unique function in adaptive immunity, as they are the only cells able to 
synthesise and secrete antibodies. Antibodies are glycoproteins that mediate humoral 
immunity through binding to a wide range of antigen structures with high affinity and 
strength. Antibodies can mediate effector functions, including neutralisation of 
microbes, activation of the complement system, opsonisation and antibody-dependent 
cell-mediated cytotoxicity (ADCC). In mammals, five antibody classes (IgA, IgD, IgE, 
IgG, IgM) have been described. Each one has a different function and distribution 
within the body. A naïve B cell can circulate throughout the body and carries out 
immune surveillance via its surface-bound IgM or IgG. The B cell response to antigens 
usually requires interaction with TH cells. B cells can act as APCs to T cells, TCRs on 
TH cells bind to the MHC-II-antigen complex on B cells resulting in T cell activation and 
enabling the release of a second activating signal to the B cell. B cell activation occurs 
when a naïve B cells encounters its antigen and leads to proliferation/expansion of the 
antigen-specific cells and further differentiation generating effector plasma B cells that 
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secrete specific antibodies (figure 1.2). Additional signals regulate the plasma cell 
antibody switching and regulate antibody production. After the initial activation, some B 
cells develop into memory B cells that express high affinity immunoglobulins (usually 
IgG) and survive for long periods of time enabling a quicker second immune response 
(Abul K. Abbas, 2011). 
 
1.2 Major histocompatibility complex 
 
MHC class I and class II are similar in function; they present peptides to CD8+ and 
CD4+ cells, respectively. These peptides have a different origin, intracellular for MHC 
class I and exogenous for MHC class II (Rock et al., 2004; Watts, 2004).  
 
MHC class I molecules are encoded by the heavy chain human leukocyte antigen 
(HLA)-A, HLA-B or HLA-C and the (2-microglobulin invariant subunit ((2m) and are 
present on all nucleated cells. Antigens are degraded in the cytosol by proteasomes 
and the transporter associated with antigen presentation (TAP) translocates the 
resulting peptides into the endoplasmic reticulum (ER). Within the ER, the MHC class I 
heterodimer is formed with the assistance of chaperones and tapasin, a glycoprotein 
that mediates interaction between TAP and MHC class I molecules. This complex is 
then translocated from the ER to the cell surface (Vyas et al., 2008).  
 
Similar to MHC class I, MHC class II molecules are encoded by three polymorphic 
genes (HLA-DR, HLA-DQ and HLA-DP) able to bind different peptides. MHC class II 
molecules are mainly expressed by APCs, such as dendritic cells (DCs), B cells and 
macrophages. MHC class II chains are assembled in the ER and associated with the 
invariant chain (Ii). The complex Ii-MHC class II is transported to a late endosomal 
compartment where it is digested leaving a residual class-II associated Ii peptide 
(CLIP) (Busch et al., 2005). This complex is then transported to the cell membrane to 
present their cargo to CD4+ T cells.  
 
1.3 Natural Killer cells 
 
Almost forty years ago, Kiessling (Kiessling et al., 1975a; Kiessling et al., 1975b) and 
Herberman (Herberman et al., 1975a; Herberman et al., 1975b) observed a 
lymphocyte subset able to lyse target cells in the absence of a priori stimulation. 
Consequently, these cells were named “natural killer” (NK) cells and are large non-
phagocytic granular lymphocytes of the innate immune system present in both, 
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lymphoid organs and non-lymphoid organs (Trinchieri, 1989; Cooper et al., 2004). 
Initially, NK cells were regarded as “experimental artefacts” in T cell cytotoxicity 
assays, however, later it was appreciated that NK cells displayed different morphology 
depending on their activation status (Dvorak et al., 1983), rendering them difficult to 
detect according to size and morphology. NK cells are now characterised by their 
surface expression of CD56 and CD16 and absence of CD3 (Ritz et al., 1988; Lanier et 
al., 1989) and comprise around 15% of all lymphocytes.  
 
NK cells are part of the innate immune system and mediate the response against 
viruses, parasites, bacteria and tumour cells (Moretta et al., 2002; Raulet, 2004). 
Additionally, NK cells contribute to the adaptive immune response by linking innate and 
the adaptive immunity through their receptor Fc!RIIIA (CD16). These responses are 
mediated through two main effector functions, direct lysis of target cells and the 
secretion of cytokines. The mechanism by which NK cells discriminate between healthy 
and target cells was discovered in 1986 by Karre et al. During this work, the 
observation that NK cell cytotoxicity inversely correlates with the level of MHC class I 
expression on target cells led to the "missing self hypothesis" (Karre et al., 1986; Karre, 
2002).  
 
Natural Killer cell subsets 
 
Two distinct subsets of human NK cells have been identified based on CD56 
expression: CD56dim and CD56bright NK cells (Lanier et al., 1986). The majority of 
human peripheral blood (PB) NK cells are CD56dim (90%) and expresses high levels of 
CD16; a minority (10%) are CD56bright and CD16dim/neg. These NK cell subsets are 
phenotypically and functionally distinct. In addition, other NK cell subsets have been 
identified according to their tissue distribution. These cells have a different repertoire 
and effector functions compared to PB NK cells. These NK cell subsets are described 
in section 1.4.8.1. 
 
1.3.1 CD56bright Natural Killer cells 
 
NK cell development has been considered a linear model in which haematopoietic 
stem cells (HSCs) commit to the NK cell lineage and acquire NK cell receptors before 
becoming a fully functional CD56dim mature NK cell. It has been proposed that 
CD56bright cells are immature NK cells that will develop into CD56dim cells. Some 
evidence supports this observation, for instance during NK cell development in vitro or 
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even after HSCT, the first subset to arise is the CD56bright (Grzywacz et al., 2006; 
Dulphy et al., 2008). In addition, PB CD56dim cells display shorter telomeres compared 
to CD56bright cells from PB and lymph nodes (LNs) (Romagnani et al., 2007). Although 
the notion of two different terminally differentiated cell populations is also a conceivable 
scenario. It has been suggested that CD56bright NK cells are indistinguishable from 
mature NK cells (CD56dim) activated with IL-12, suggesting that CD56bright NK cells are 
not progenitors of the CD56dim subset but different populations (Loza and Perussia, 
2004a). 
 
CD56bright cells are known for their capacity to produce and secrete cytokines, such as 
granulocyte–macrophage colony-stimulating factor (GM-CSF), IFN-%, interleukin (IL)-
10, IL-13 and TNF-(. In addition, resting CD56bright and CD56dim NK cell subsets show 
differences in their NK cell receptor repertoires (Voss et al., 1998). CD56bright NK cells 
are characterised by the expression of the high/intermediate affinity IL-2 receptor, that 
confers the capacity to expand in vitro and in vivo in response to low doses of IL-2 
(Caligiuri et al., 1990; Caligiuri et al., 1993). CD56bright NK cells do not express CD16 
and express low levels of CD69, Killer-cell immunoglobulin-like receptors (KIRs) and 
intracellular perforin (Ferlazzo et al., 2004b). In terms of distribution, CD56bright NK cells 
are dominant in LNs (around 75%). Additionally, the CCR7 LNs homing receptor is only 
expressed by CD56bright NK cells. CD56bright NK cells are capable of cytokine secretion 
but resting cells have low cytotoxicity. Nevertheless, after activation with IL-2 or IL-12, 
CD56bright cells exhibit similar or enhanced cytotoxicity against NK cell targets 
compared to CD56dim cells. Figure 1.3 shows the phenotype and effector functions of 
CD56bright cells in PB. 
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Figure 1.3. Phenotype of CD56bright NK cell subset. CD56bright NK cells express 
CD94/NKG2A, CCR7 and L-selectin, but lack KIRs and have low or no CD16 expression. 
CD56bright NK cells are characterised for its abundant cytokine secretion. 
 
1.3.2 CD56dim Natural Killer cells 
 
CD56dim NK cells are considered to a terminally differentiated and mature NK cell 
subset. CD56dim NK cells are cytolytic and function as efficient effectors of natural and 
antibody-dependent target cell lysis. In contrast to CD56bright NK cells, resting CD56dim 
NK cells express only the intermediate-affinity IL-2 receptor and proliferate weakly in 
response to high doses of IL-2 in vitro (Baume et al., 1992). An important feature of 
CD56dim NK cells is the expression of KIRs and CD16 but not CCR7 and L-selectin. 
CD56dim cells are enriched in the bone marrow (BM), blood and spleen (Fehniger et al., 
2003; Ferlazzo et al., 2004b; Freud et al., 2006). CD56dim cells express perforin and 
granzymes and are more cytotoxic against NK cell-sensitive targets (K562 and 
COLO205 cell lines) than CD56bright NK cells (Nagler et al., 1989). Figure 1.4 shows the 
phenotype and functions of CD56dim NK cells. 
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Figure 1.4. Phenotype of the CD56dim NK cell subset. CD56dim NK cells express KIRs and 
CD16, lack CCR7 and L-selectin expression. CD56dim NK cells are characterised for its 
cytotoxic effector functions, expressing high levels of perforin and granzymes.  
 
1.4 Natural Killer cell development  
 
1.4.1 Natural Killer cell development in the bone marrow 
 
HSCs have the potential to self-renew and proliferate without losing multipotency and 
ultimately to differentiate into all blood cell types. HSCs can be found in the liver during 
foetal life, but towards the end of the first semester HSCs populate the BM. In adults, 
HSCs reside mainly in the BM, where specialised stromal cells provide the specific 
microenvironment for self-renewal or differentiation (Orkin and Zon, 2008). During 
differentiation, the expression or repression of specific genes allows commitment 
towards a specific lineage.  
 
Traditionally, haematopoiesis has been described as a process in which multipotent 
HSCs commit to either the myeloid-erythroid lineage or the lymphoid lineage. In theory, 
common lymphoid precursors (CLPs) do not generate myeloid cells and common 
myeloid precursors (CMPs) do not hold the potential to generate lymphoid cells (Akashi 
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et al., 2000). The controversy of the myeloid or lymphoid origin of NK cells has been 
disputed for a long time (Ortaldo and Herberman, 1984). Two decades ago, Sanchez 
et al. demonstrated that NK cells are closely related to T cells by the discovery of a 
T/NK cell precursor in humans (Sanchez et al., 1994). Later experiments in mice 
allowed the identification of a CLP that was able to generate NK cells as well as B and 
T cells (Kondo et al., 1997). Additional reports in humans have described the 
phenotype of the earliest NK cell progenitor using either BM or umbilical cord blood 
(CB) HSCs (Miller et al., 1994; Miller et al., 1998; Haddad et al., 2004). Thus, it has 
been widely accepted that NK cells originate from lymphoid precursors. This model has 
been questioned recently by the observation of progenitors that preserve lymphoid and 
myeloid potential and lack erythroid potential (Katsura, 2002). In addition, recent 
reports have demonstrated that NK cells can also be derived from myeloid precursors 
cells (CMPs, granulo-monocytic precursors as well as CD33+CD13+ and macrophage 
colony-stimulating factor progeny) in vitro (Perez et al., 2003; Grzywacz et al., 2011). 
 
Based on studies in mice, it was discovered that a natural killer cell precursor (NKP) 
was formed in the BM and developed into a mature NK cell. Nowadays, it is recognised 
that human NK cell development is a complex process that is still not fully understood. 
NK cells are derived from CD34+ HSCs. HSCs give rise to CLP that further differentiate 
into T/NKP cells able to give rise to NKP and later immature NK (iNK) and then mature 
NK (mNK) cells as illustrated in figure 1.5 (Huntington et al., 2007). 
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Figure 1.5. NK cell development. NK cells are derived from HSCs and capable of 
differentiation into CLP and CMP lineages. CLP give rise to T, B and NK cells and further 
differentiate into T/NKP, NKP, iNK, CD56bright and finally CD56dim NK cells. The surface 
expression of specific cell surface antigens for each stage is shown on the right bottom corner. 
 
Studies in mice identified 5 stages in NK cell development (Kim et al., 2002). However, 
due to differences in phenotypic markers between human and mouse NK cells, human 
NK cell development studies cannot be directly correlated to murine studies. Therefore, 
the majority of the data involving human NK cell development has been achieved 
through HSCs culture in vitro using supporting feeder layers.  
 
1.4.1.1 Common lymphoid progenitors 
 
During haematopoiesis, HSCs differentiate into CMPs or into CLPs. CLPs are able to 
differentiate into B, T and NK cells. CLPs will further give rise to a T/NK progenitor that 
will subsequently differentiate into iNK cells and lastly mNK cells (figure 1.5). Although 
it was thought that haematopoiesis follows a strict pathway from pluripotent (HSCs) to 
oligopotent (CLPs or CMPs) and then to monopotent progenitors (Graf, 2002), recent 
studies have shed light into the plasticity of these cells (Grzywacz et al., 2011). The 
following NK cell development description follows the traditional view of NK cells 
derived from CLPs. 
 
HSC 
CD34(+) CD38(-) 
 
Stage   Surface expression 
CLP   CD34(+)Lin(-)CD10(+) 
T/NKP  CD34(+)CD45RA(+)CD10(+)CD117(+)CD161(-) 
NKP   CD34(+)CD45RA(+)CD10(-)CD117(+)CD161(+/-) 
iNK   CD34(-)CD117(+)CD161(+)NKp46(-)CD94/NKG2A(-) 
CD56bright  CD117(+/-) NKp46(+)CD94/NKG2A(+)KIR(+/-) 
CD56dim  CD117(-) NKp46(+)CD94/NKG2A(+/-)CD16(+)KIR(+) 
CLP T/NKP NKP iNK CD56brigth 
B cell 
lineage 
CD56dim 
CMP 
T cell 
lineage 
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A subpopulation of Lin-CD34+CD38+CD10+ cells has previously been described as 
CLPs able to give rise to B, NK and T cells but not to cells of the myeloid lineage (Galy 
et al., 1995). CLPs undergo differentiation towards a NK/T progenitor. Some studies 
using CB or BM HSCs have suggested that the expression of CD7 or CD10 defines 
NK/T and B cell precursors, respectively (Miller et al., 1994; Haddad et al., 2004). 
Although more reports suggest that Lin-CD34+CD10+ cells are restricted to the B cell 
lineage (Ryan et al., 1997; Rossi et al., 2003), CD7 or CD10 does not strictly identifiy a 
homogenous precursor population. 
 
1.4.1.2 Natural Killer cell precursors, immature Natural Killer cells and mature 
Natural Killer cells 
 
T/NKP cells commit to NKPs through a transition characterised by the expression of 
CD122 (IL-2/15R( subunit) (Ikawa et al., 1999). The expression of CD122 confers IL-
15 responsiveness, a cytokine that has been described to be key for NK cell 
development and maturation (Huntington et al., 2009). NKPs cannot give rise to any 
other cell lineage, but NK cells. Next, NKPs differentiate into iNK cells. A population of 
“immature” NK cells (CD3-CD161+CD56-) can be obtained in vitro by the culture of Lin-
CD34+ CB cells (Bennett et al., 1996), suggesting that CD161 identifies iNK cells 
(Lanier et al., 1994). iNK cells are characterised by the expression CD2 and 2B4 
(CD244) (Bennett et al., 1996; Yu et al., 1998; Sivori et al., 2002). Furthermore, iNK 
cells do not express perforin and granzyme B (Grzywacz et al., 2006) and display low 
cytolotytic activity, however further culture with IL-2 and IL-12 enhanced their 
cytotoxicity and CD56 acquisition (Bennett et al., 1996; Zamai et al., 1998b). iNK cells 
mature as acquisition of activation and inhibitory receptors occurs. The expression of 
activating markers occurs prior to the appearance of HLA class I, raising the question 
of what mechanisms are controlling auto-reactivity? A recent suggestion to explain 
these mechanisms is the expression of 2B4. It was reported that 2B4 expression 
occurs early during NK cell development and acts as an inhibitory receptor, avoiding 
the killing of autologous cells (Sivori et al., 2002). The acquisition of receptor and of 
effector functions during NK cell development is a complex process still not well 
understood. The study of Grzywacz et al. used CD117 and CD94 to distinguish 
between iNK and mNK cells using a differentiation model in vitro (Grzywacz et al., 
2006). iNK cells (CD56+CD117highCD94-) gave rise to mNK cells 
(CD56+CD117lowCD94+), the transition was associated with the acquisition of activating 
receptors NKp30, NKp46 and NKG2D, the inhibitory receptor NKG2A and functionality 
(cytotoxicity and IFN-! production).  
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1.4.2 Natural Killer cell licensing/education  
 
NK cells undergo a final maturation step through the recognition of self-molecules. A 
prototypical example of this process is the MHC class I-induced NK cell “education” or 
‘licensing”. It has been suggested that NK cells undergo an “education” process to 
become functionally competent and also to recognise “self” and “non-self”. This 
process requires the recognition of self-MHC class I molecules. The functional NK cell 
maturation process includes the licensing, also referred as education, arming or tuning, 
in which NK cells acquire functional competence after recognition of self-MHC class I 
molecules. A summary of these models is presented below. 
 
1.4.2.1 Licensing model 
 
In 2005, Yokohama and Kim introduced the “licensing” concept, commonly used 
synonymously as “arming”. It was demonstrated in mice that NK cells that expressed 
self-inhibitory receptors (“licensed”) produced more IFN-% compared to those that did 
not express self-inhibitory receptors (“unlicensed”). The licensed cells can be inhibited 
by the same self-MHC class I that initially licensed them while the unlicensed do not 
need to be inhibited by MHC class I as they are not functionally competent (figure 1.6) 
(Kim et al., 2005b; Yokoyama and Kim, 2006). These publications suggest that 
inhibitory receptors might have a dual role, transmitting activating signals during NK 
cell development and inhibitory signals in mature NK cells. 
 
Although experiments in mice have been able to prove the “licensing/arming” theory, 
translating this knowledge to human systems is extremely difficult. Some efforts have 
been made in this regard, as recent studies confirmed the “licensing” mechanism in 
human NK cells (Kim et al., 2008). For instance, human NK cells lacking the 
expression of self-inhibitory receptors (KIRs or NKG2A) were hyporesponsive in terms 
of cytokine secretion and cytotoxicity. On the contrary, NK cells with self-specific 
inhibitory receptors were fully functional (Anfossi et al., 2006). Additionally, it was 
recently reported that infection with human cytomegalovirus (HCMV) promotes the 
differentiation and expansion of NK cells with self-specific inhibitory KIRs (Beziat et al., 
2013). Subjects that were not infected with HCMV had a random KIR repertoire, 
highlighting the effect of HCMV infection on the KIR repertoire (Beziat et al., 2013).  
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Figure 1.6. The licensing model. In the licensing or arming model, NK cells need the presence 
of an inhibitory receptor to become functional. In the absence of “arming”, NK cells remain 
hyporesponsive. Adapted from Höglund and Brodin, 2010 with permission from Nature 
Publishing Group. 
 
1.4.2.2 The education or disarming model 
 
In 2005, Fernandez et al. showed that a population without self-inhibitory receptors in 
mice existed (Fernandez et al., 2005). In contrary to the common belief that NK cell 
self-tolerance was achieved due to the expression of inhibitory receptor specific for 
MHC class I, these cells were self-tolerant and hyporesponsive (Fernandez et al., 
2005). Based on these results, the “disarming” model was proposed (Raulet and 
Vance, 2006; Joncker and Raulet, 2008). In summary, the balance of the stimulatory 
and inhibitory signals along with the presence of self-cells as NK cell develop will 
dictate the subsequent responsiveness of the mature NK cell (figure 1.7). In this 
context, if NK cells encounter cells with activating ligands and no MHC class I, NK cells 
are rapidly activated. However, in the case of prolonged stimulation, NK cell 
desensitisation occurs rendering them unable to interact with other cells. Thus, in the 
absence of host MHC class I, the interaction between NK cells and cells expressing 
activating ligands and no MHC class I also results in desensitisation. 
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Figure 1.7. Disarming model of NK cell education. On the left side of the figure, the 
disarming model is presented. NK cells are fully functional by default, however, in the absence 
of self-inhibitory MHC class I, NK cells become hyporesponsive. But in the presence of self-
inhibitory MHC class I, NK cells become responsive. In the Arming model (right side), NK cells 
need the presence of an inhibitory receptor to become functional. In the absence of “arming”, 
NK cells remain hyporesponsive. Adapted from Höglund and Brodin, 2010 with permission from 
Nature Publishing Group.  
 
1.4.2.3 Cis-interaction model  
 
A property of inhibitory receptors is their ability to interact in cis with their ligand, that is, 
at the same membrane (Doucey et al., 2004). The basis for this model is that Ly49 
receptors in mouse can transmit inhibitory signals even when not engaged but only if 
present in the immunological synapse. In the cis-interaction model, the interaction 
between Ly49 receptor and MHC class I in cis sequesters Ly49, inhibiting its relocation 
to the immunological synapse. Therefore, the inhibitory signals of the unengaged Ly49 
are absent and NK cells become more responsive (Chalifour et al., 2009).  
 
1.4.2.4 Rheostat model  
 
It is known that NK cells express inhibitory receptors with various affinities. Thus, it is 
hard to conceptualise that NK cell responsiveness will depend on the expression of 
self-MHC class I based on the licensing and education models. The question arises as 
to whether NK cells exist either in hyper-responsive or hypo-responsive homogenous 
sets or if they would vary in their responsiveness. A previous report showed a direct 
correlation between the expression of MHC class I molecules and the capacity for 
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missing-self recognition (Johansson et al., 2005) suggesting that NK cell 
responsiveness is influenced by the number of inhibitory receptors (Ly49 or NKG2A) 
able to engage self MHC class I molecules. The signals needed to achieve a response 
vary continuously in the Rheostat model (figure 1.8). NK cells can be tuned to a point in 
which a balance of inhibitory and activating signals is set in healthy cells. If NK cells 
lack self-MHC class I, the responsiveness will be adjusted downward below the 
threshold needed to attack healthy cells. If the NK cell expresses one inhibitory 
receptor for self-MHC class I, the threshold will be adjusted to a higher point, and even 
higher if the cell expresses two or more sets of inhibitory receptor for self-MHC class I 
(Joncker and Raulet, 2008). Hence, NK cell responses can be tuned “up” or “down” in 
a quantitative manner instead of a binary system (Brodin et al., 2009).  
 
 
Figure 1.8. The Rheostat model. The tuning of NK cells is achieved during development, when 
cells are exposed to inhibitory and stimulatory interactions with self-cells. The balance of signals 
upon encounter with normal cells sets the responsiveness state of NK cells. A) A state of high 
responsiveness is acquired through the interaction of NK cells expressing several inhibitory 
receptors with normal cells expressing stimulatory signals. B) The partial hyporesponsiveness 
results from the encounter of NK cells expressing only one inhibitory receptor with self-cells 
expressing stimulatory signals. C) If no inhibitory receptors are expressed, the strong 
continuous stimulation induces hyporesponsiveness. Therefore, the NK cell responsiveness is 
tuned in a quantitative manner by the level of expression of inhibitory and stimulatory receptors 
on the cells in contact with NK cells during their development. (Joncker and Raulet, 2008). 
Copyright 2009, The American Association of Immunologist, Inc. 
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1.4.3 Cytokines required for Natural Killer cell development 
 
Decades ago, very little was known about NK cell development and its requirements. 
CD34+ HSC were cultured over BM stroma with the addition of IL-2 CD56+CD3- that 
were phenotypically and functionally nearly identical to peripheral NK cells could be 
obtained in five weeks (Miller et al., 1994). But, was IL-2 the key cytokine for NK cell 
development in vivo? This question arose because IL-2 is mostly available when T 
cells are activated and it was difficult to imagine that millions of NK cells were produced 
daily in vivo knowing that T cells would not be constantly producing IL-2. Effectively, it 
was shown later that NK cells were present in IL-2 and IL-2R" knockout mice (Sadlack 
et al., 1995; Willerford et al., 1995); however, IL-2R( and IL-2%c knockout mice lacked 
NK cells (DiSanto et al., 1995; Suzuki et al., 1997). These results suggested that not 
IL-2 but a cytokine that binds to IL-2R( and IL-2%c was needed for NK cell 
development in vivo. Later, it was discovered that this cytokine was IL-15, as IL-15-/- 
and IL-15R"-/- mice lacked NK cells (Lodolce et al., 1998; Kennedy et al., 2000).  
 
Further experiments demonstrated that the culture of HSC with IL-15 gave rise to NK 
cells, however regardless of the high purity, only CD56bright cells and very low numbers 
were produced. These observations prompted the idea that additional cytokines were 
needed to produce high numbers of NK cells in vivo and raised the argument that 
CD56bright cells were precursors of CD56dim cells. The work by Matos et al. investigated 
the expression of c-kit receptor (CD117) on peripheral CD56bright cells and CD56dim 
cells, and found that about 50% of CD56bright cells expressed c-kit, a receptor also 
expressed in CD34+ cells (Matos et al., 1993). The use of c-kit ligand (SCF, stem cell 
factor) and FLT3-L (produced by BM stroma cells) demonstrated that increased NK cell 
numbers could be obtained when these factors were used together with IL-15 in vitro 
(Yu et al., 1998). The mechanism through which SCF and FLT3-L increase NK cell 
numbers and aid NK cell development is by the induction of the expression of IL-
2/15R( receptor on CD34+ cells, making CD34+ cells IL-15 responsive (Yu et al., 
1998). In summary, NK cell development is aided by the action of early acting 
cytokines (FLT3-L and SCF) and late acting cytokines (IL-15).  
 
1.4.4 Transcription factors involved in Natural Killer cell development 
 
NK cell development is finely orchestrated by molecular events that lead to the 
activation or repression of transcription factors (TFs). These TFs are able to bind to 
promoter regions in the DNA and regulate gene transcription. Depending on the stimuli, 
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some TFs are expressed or repressed, the balance of these events leads to the 
differentiation towards a certain cell lineage.  
 
Although the expression of TFs in human NK cell development in vitro has recently 
been analysed (Pinho et al., 2012), the majority of the data has been obtained using 
knockout mice. The following section includes the studies of TFs using knockout mice, 
however it is indicated when studies of TFs in humans have been performed.  
 
The expression of TFs controlling NK cell development cannot be seen as a linear 
sequence of events, instead, it is a complex process in which interaction between 
these TFs occurs and different stimuli affect their expression and thus cell fate. For the 
purpose of simplifying the data obtained from murine models, the TFs described in this 
section are divided into three groups: 1) TFs involved in NK cell commitment, 2) TFs 
involved in NK cell differentiation and maturation and 3) TFs involved in regulation of 
NK cell effector functions (figure 1.9). Although a sequential approach was intended 
during this description, some of these TFs play a role early in NK cell development and 
also have an impact on NK cell effector functions.   
 
 
Figure 1.9. Transcriptions factors involved in NK cell development. The figure shows the 
expression of TFs divided into three groups. The first group acts on NK cell commitment, the 
second on NK cell maturation and the last one on NK cell effector functions.  
 
1.4.4.1 Transcription factors involved in Natural Killer cell commitment 
 
In the first group, the TFs Ikaros, Pu.1 and Ets-1 are included (Barton et al., 1998; 
Boggs et al., 1998; Colucci et al., 2001). It has been shown that NKPs are reduced in 
mice lacking Ikaros, Pu.1 or Ets-1. Ikaros is a zinc finger protein able to bind the 
promoter of CD3 delta, initially described as an important TF for T lymphocyte 
development (Georgopoulos et al., 1992) and later on for NK cell and B cell 
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development (Georgopoulos et al., 1994). This TF might be important for the 
commitment of HSCs into CLPs. Ikaros knockout mice have reduced number of NK, T 
and B cells (Boggs et al., 1998). Similarly, Pu.1 is essential for T and B cell 
development and to a lesser extent for NK cell development. Pu.1 knockout mice have 
lower numbers of mature NK cells which have a decreased response to cytokines (IL-2 
and IL-12) (Colucci et al., 2001). In progenitor cells, Pu.1 is needed for CD45 
expression, suggesting that Pu.1 might also regulate CD45 expression in NK cells. NK 
cells deficient in CD45 are functionally defective, and resemble Pu.1 deficient NK cells 
(Huntington et al., 2005; Hesslein et al., 2006). Ets-1, a helix-turn-helix TF belongs to 
the Ets family, it also regulates NK cell development and functions. Ets-1 Knockout 
mice have a reduced number of NK cells in the spleen and BM (Barton et al., 1998). 
Ets-1 participates in the regulation of other TFs such as T-bet and Id2 (Ramirez et al., 
2012) and plays a role in the induction of the IL-15R( (CD122) chain, required for IL-15 
signalling (Ye et al., 2005).  
 
1.4.4.2 Transcription factors involved in Natural Killer cell differentiation and 
maturation 
 
Once NKPs are generated, another set of TFs is needed for the subsequent steps 
leading to NK cell maturation, including Id2, Irf-2, Gata3 and T-bet. Id proteins act as 
transcriptional repressors that bind and antagonise the activity of E proteins that 
associate to specific DNA sequences (Sun et al., 1991). Id proteins are essential for 
NK cell development and maturation; mice lacking Id2 have a reduced number of mNK 
cells in the spleen (Yokota et al., 1999). Further analysis demonstrated that even 
though a decrease in mNK cell numbers was observed, there was no effect on the 
numbers of iNK cells (Boos et al., 2007). Since NKP numbers were normal in Id2-/- 
mice, it was suggested that Id3 might compensate for Id2 giving rise to normal 
numbers of NKPs (Ramirez and Kee, 2010). The overexpression of Id3 in CD34+ 
precursors cells was able to inhibit T cell development and favoured NK cell 
development (Heemskerk et al., 1997).  
 
In the absence of Irf-2, Gata3 and T-bet, NK cells are generated, but they are reduced 
in numbers and exhibit an immature phenotype and reduced effector functions 
(Samson et al., 2003). Members of the interferon regulatory factor (Irf) have been 
previously described to bind DNA sequences common to the promoters of IFN-" and 
IFN-(. Irf-2 binds to a specific sequence in the IFN-( gene and acts as a transcriptional 
repressor (Harada et al., 1990). Irf-2-/- mice have decreased mNK cells, but the liver 
and spleen contain normal numbers of iNK cells (Taki et al., 2005). NK cells from Irf-2 
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knockout mice had reduced cytotoxicity and lower production of IFN-% (Lohoff et al., 
2000). Similarly, NK cells from Gata3-/- mice exhibited immature phenotype and were 
poor producers of IFN-% (Samson et al., 2003). An interesting observation was that BM 
NK cells from Gata3-/- mice were not able to migrate to the liver (Samson et al., 2003). 
T-bet and H2.0-like homeobox (Hlx) were described to be transcriptional targets of 
Gata3, providing a possible explanation for the similar phenotype observed in T-bet-/- 
mice (Samson et al., 2003). T-bet-/- mice have reduced numbers of NK cells in the PB, 
spleen and liver, but NK cell accumulation in LNs and BM showed an immature 
phenotype (Townsend et al., 2004; Jenne et al., 2009). In addition to the immature 
phenotype, NK cells had low cytotoxic and cytokine production potential and decreased 
longevity (Townsend et al., 2004; Werneck et al., 2008). 
 
Another transcription factor studied in mice, Gata2, has been reported to be important 
for the maintenance of the HSCs pool (Tsai and Orkin, 1997). However, there is 
actually no study linking this TF to NK cell development. In humans, the analysis of 
patients with GATA2-deficiency showed decreased NK cell numbers in the periphery, 
in particular of CD56bright NK cells. During this study, it was demonstrated that GATA2 
is necessary for the presence of CD56bright NK cells and is necessary for the functional 
maturation of CD56dim NK cells, suggesting that this TF plays a key role during NK cell 
maturation (Mace et al., 2013).     
 
There are some TFs that are crucial for the differentiation of certain lineages; these are 
called master regulators. For instance, Pax5 is a master regulator for B cell 
development in mice. Cells lacking Pax5 are not able to differentiate into B cells, but 
retain the ability to differentiate into T or NK cells (Schaniel et al., 2002). Notch1 and 
Gata3 play a similar role supporting T cell development (Pear and Radtke, 2003; 
Maillard et al., 2005). A similar TF was recently discovered for NK cell commitment, 
E4bp4. This TF was the only one described so far necessary for NK cell development. 
Using knockout mice for E4bp4, Gascoyne et al. showed that B, T and NKT cells were 
present in E4bp4-/- mice but observed a decrease in iNK cells numbers and a greater 
reduction of mNK cells (Gascoyne et al., 2009). Gene expression analysis revealed 
that Gata3 and Id2 expression was reduced in the absence of E4bp4, indicating that 
both act downstream of E4bp4. Others found similar observations in mice (Kamizono 
et al., 2009) and recent studies in humans confirm the exclusive expression of this TF 
by NK cells (Vacca et al.). E4bp4 plays a key role in the progression of NKPs to iNK 
cells and mNK cells. 
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1.4.4.3 Transcription factors involved in regulation of Natural Killer cell effector 
functions 
 
Lastly, another set of TFs appears to regulate terminal maturation, NK cells lacking 
these TFs show normal phenotype but fail to exhibit normal cytotoxicity or cytokine 
expression. These TFs include CCAAT-enhancer binding protein (Cebp-g), 
microphthalmia transcription factor (Mitf), myeloid ELF1-like (Mef) and Eomes. Mice 
deficient in Cebp-g have normal numbers of T lymphocytes, B lymphocytes and NK 
cells, but NK cell cytotoxicity and IFN-% production are impaired (Kaisho et al., 1999). 
Similar observations have been reported in mice with a deficiency in Mitf, a regulator of 
melanocyte, osteoclast and mast cell differentiation and function (Cheli et al., 2010). 
For studies of this TF, Mitfmi/Mitfmi mice were generated with the mi mutant allele 
encoding an abnormal Mitf (Kataoka et al., 2005). Mitfmi/Mitfmi mice had normal 
numbers of NK cells, suggesting that this TF is not involved in NK cell development. 
However, the NK cells had impaired cytotoxicity and IFN-% production in response to 
IL-12 and IL-18 stimulation (Ito et al., 2001; Kataoka et al., 2005), which was 
subsequently explained as due to a lack of perforin expression. It could be that Mitfmi 
interacts with Mef, preventing its entrance to the nucleus and obstructing further 
interaction with the perforin promoter (Lacorazza et al., 2002). Mef is a member of the 
Ets family and like for Ets-1 Mef knockout mice have a reduced number of NK cells in 
the spleen. The few splenic NK cells are not able to produce IFN-% and the remaining 
cells were able to bind cell targets but had low cytotoxicity (Lacorazza et al., 2002). 
The observed lack of cytotoxicity was explained by the lack of perforin in NK cells. 
Similarly, Eomes has been reported to control perforin and also granzyme B 
expression in CD8+ T cells (Intlekofer et al., 2005) and was demonstrated to be 
important in maintaining mature NK cell attributes (Gordon et al., 2012).  
 
1.4.5 Natural Killer cell development sites 
 
Knowledge to date indicates that NK cells derive from CD34+ HSCs (Miller et al., 1994), 
and that NK cell development occurs mainly within the BM microenvironment (Colucci 
et al., 2003). However, a large and growing body of literature indicates that the site(s) 
of NK cell maturation might not be restricted to BM. HSCs can give rise to lymphoid 
precursors able to migrate to different sites that support NK cell differentiation.  
 
NK cell development was originally thought to occur solely in the BM. Experiments in 
mice provided evidence supporting the important role of BM for NK cell development in 
vivo (Haller and Wigzell, 1977). However, LNs and secondary lymphoid tissues (SLT) 
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were relatively recently identified as sites of NK cell development due to their 
haematopoietic progenitor cell (HPCs) content (Freud and Caligiuri, 2006). The most 
accepted NK cell development model comes from this study, in which consecutive NK 
cell developmental stages were identified starting from LNs CD34+ cells. Freud et al. 
found a CD34+dimCD45RA+ population expressing integrin "4(7 in LNs able to 
differentiate into NK cells in the presence of IL-15 (Freud et al., 2005). The expression 
of integrin "4(7 has been previously linked to gut and LN homing (Yoshida et al., 
2001), thus this group suggested that CD34lowLin-integrin"4(7+CD117hiCD56-CD94-
CD16- cells could migrate to LN and differentiate into CD56bright NK cells. Interestingly, 
one of the intermediates identified during the development process was 
CD161+CD117hiCD94-, also found during the culture of CB CD34-lin- cells (Grzywacz et 
al., 2006). More importantly, these two CD117hiCD94- populations were able to give 
rise to CD56+CD94+ cells in vitro, demonstrating the presence of NKP. This 
developmental model is based on the identification of four NK cell stages within LN: 
pro-NK cells (stage 1), pre-NK cells (stage 2), iNK cells (stage 3) and NK cells (stage 
4) (figure 1.10). A final stage 5 (CD56dim cells) is proposed as the last step of NK cell 
maturation (Freud et al., 2006). Although in this model CD56 acquisition is not a critical 
criterion, its expression increases as NK cell stages develop.  
 
LNs are not known to be a HSC depository suggesting that NK cell lineage 
commitment is likely to take place somewhere else outside LNs. It has been proposed 
that the LN NKP population is derived from the BM, but recent data in mice suggests 
that the thymus might be also a NKP source (Veinotte et al., 2008). It is possible that 
the LN microenvironment provides some of the signals and factors for NK cell 
development, including IL-15. As it is known that IL-15 is key for NK cell development, 
LNs must deliver this interleukin probably through the trans-presentation provided by 
dendritic cells or macrophages.  
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Figure 1.10. NK cell development in lymph nodes. The model proposed by Freud et al. 
suggests that NK cells derive from BM HSCs, the stages within the grey box may occur in LN. 
HSCs develop from pro-NK cells to pre-NK cells losing their capacity for T and B cell 
differentiation. From stages 3-5, NK cells mature through the acquisition of receptors and 
effector functions. CD56bright NK cells produce IFN-% while CD56dim mediate cellular cytotoxicity. 
During the final steps, KIR acquisition is likely to occur. Freud and Caligiuri, 2006 (permission 
for reproduction granted by John Wiley and Sons).  
 
Some years ago, a cell population in the foetal LN able to differentiate into NK cells 
and DC was described (Mebius et al., 1997). Later, these cells were identified as 
lymphoid tissue inducer (LTi) cells, now known to play an important role in the 
organisation of LNs, intestinal cryopatches and Peyer’s patchers (Eberl and Littman, 
2003). Recently, it was demonstrated that foetal and adult LTi cells could differentiate 
into an atypical NK cell subset in vitro expressing CD127+ and expressing RORC 
(Cupedo et al., 2009). It has been reported that other tissues, such as the intestinal 
epithelial layer, also contain NKPs (Chinen et al., 2007). The culture of these 
precursors with IL-15 gave rise to CD56+ cells with less cytotoxic activity but higher 
IFN-% production in comparison to PB NK cells.  
 
Another possible site of NK cell development is the thymus. Vosshenrich et al. have 
described NK cell development in the thymus in mice (Vosshenrich et al., 2006). 
Thymic-NK cell development results in NK cells with a distinct phenotype characterised 
by high expression of IL-7R (CD127+) and the transcription factor GATA3. The thymic 
environment provides different signals or factors that shape NK cell phenotype and 
functions, highlighting the importance of the environment in NK cell development. In 
2012, Hidalgo et al. identified human NK cell precursors in the thymus characterised by 
the expression of the TF BMPRIA. The culture of these precursors in the presence of 
SCF and IL-15 resulted in functional NK cells (Hidalgo et al., 2012). Another interesting 
feature of thymic NK cells is the expression of intracellular CD3& (iCD3&), absent in 
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peripheral NK cells (De Smedt et al., 2007). The significance of this expression is still 
unclear. Some authors have suggested that iCD3& might arise due to the thymic 
microenvironment, including Notch ligands such as OP9-Delta-like 1 (DL1) (De Smedt 
et al., 2007).  
 
Finally, the membrane lining the uterus during pregnancy or maternal decidua has 
been shown to contain HPCs. These HPCs could differentiate in vitro into NK cells with 
a singular phenotype (Vacca et al.). Decidua NK cells (dNK) have a CD56brightCD16- 
phenotype but show different functions compared to their counterpart in PB. Given the 
high density of CD56 expression, it has been thought that dNK cells derive from the 
CD56bright NK cell subset. However, there are some differences, the main ones being 
the expression of KIRs and CD69, which does not occur in CD56bright PB cells. In 
addition, dNK cells secrete vascular endothelial growth factor (VEGF), IL-8 and 
stromal-cell derived factor (SDF)-1 involved in angiogenesis and tissue remodelling. 
 
Nonetheless, even with the evidence that NK cell development can occur at different 
sites, it is plausible that their presence in different tissues could be due to migration of 
NK cells from either the BM or PB. Shaping of the NK cell surface marker repertoire 
and functions by the environment may account for the differences observed between 
the different subsets.  
 
1.4.5.1 Natural Killer cell subsets with specialised functions 
 
1.4.5.1.1 Uterine Natural Killer cells 
 
Uterine NK (uNK) cells comprise around 70% of the endometrial leukocytes found in 
the first trimester decidua (Bulmer et al., 1991). The exact function of uNK cells 
remains largely unclear, but it seems they interact with the trophoblast; as a 
consequence, uNK cells release factors that modify the uterine spiral arteries (Hanna 
et al., 2006). VEGF is important factor secreted by uNK cells (Moffett-King, 2002; 
Vacca et al., 2011) that stimulates angiogenesis. uNK cells are characterised by their 
lack of expression of L-selectin, CD16 and CD57 while expressing KIRs and CD69 and 
CD56 (superbright). Additionally, the study of endometrial NK cells (eNK) and uNK 
cells revealed that pregnancy alters the KIR repertoire of uNK cells with bias towards 
HLA-C recognition (Male et al., 2011). uNK cells have low cytolytic activity against 
K562 cells (Ferry et al., 1990). Importantly, uNK cells have a different cytokine 
secretion profile (TNF-", TGF-(, GM-CSF and G-CSF [granulocyte colony-stimulating 
factor] among others) compared to CD56bright NK cells (Saito et al., 1993).  
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1.4.5.1.2 Liver Natural Killer cells 
 
The liver is another organ in which up to 30-50% of the hepatic leucocytes present are 
NK cells. NK cells in the liver are involved in the regulation of hepatic immunity against 
pathogens. It has been shown that liver resident NK cells or blood-recruited NK cells 
have a distinct phenotype and function. The liver contains a 50/50 ratio of CD56bright 
and CD56dim NK cells. Liver CD56dim NK cells express KIR and NKG2A, and interaction 
with Kupffer cells can lead to cytolytic activity and cytokine production (Tu et al., 2008; 
Burt et al., 2009). Liver NK cells have high expression of CD69 and NKp44 and lower 
L-selectin expression with a decreased cytotoxic potential compared to PB NK cells 
(Burt et al., 2009). The liver contains lower number of licensed NK cells compared to 
PB, thus the lower cytotoxicity of liver NK cells could be due to their unlicensed status 
(Burt et al., 2009).  
 
1.4.5.1.3 Thymic Natural Killer cells 
 
Vosshenrich et al. described the development of thymic NK cells in mice (Vosshenrich 
et al., 2006). This report included the characterisation of human thymic cells; 
CD56hiCD16- cells that expressed CD127 (IL-7Rα) and the transcription factor GATA-
3. CD56hiCD16- cells produced cytokines but were less cytotoxic compared to their PB 
counterpart CD56+CD16+CD127-. The thymic microenvironment likely has an important 
role in establishing this phenotype, however, the signals that regulate this process are 
still undefined.   
 
1.4.5.1.4 NK-22 cells 
 
NK cells can be found in healthy intestine mucosae, mainly within the lamina propria 
and in the tonsils or Peyer’s patches (Cella et al., 2009). These cells are characterised 
by the expression of NKp44, usually expressed in activated NK cells, and CCR6. NK-
22 cells do not express perforin and little granzyme B. Moreover, NK-22 cells have very 
low intracellular IFN-% but high IL-22 secretion, which is the hallmark of NK-22 cells. 
 
A summary of NK cell subsets within different tissues is illustrated in figure 1.11. 
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Figure 1.11. NK cell subset distribution. NK cells can be found in liver, thymus, peyer’s 
patches and uterine decidua. The main features defining each subset are presented. 
 
1.4.5.1.5 Memory Natural Killer cells? 
 
Studies in mice suggest that NK cells can also have memory-like properties, similar to 
cells of the adaptive immune system (O'Leary et al., 2006). In 2009, using a mouse 
model of murine cytomegalovirus (MCMV) infection, Sun et al. demonstrated that NK 
cells bearing the receptor Ly49H (MCMV-specific) were able to degranulate and 
produce cytokines after reactivation when these cells were transferred into naïve mice 
that were challenged with MCMV (Sun et al., 2009). In the same year, the study by 
Cooper et al. suggested that murine NK cells could retain an intrinsic memory of prior 
activations (Cooper et al., 2009). Later in 2010, a study from Paust et al. reported that 
adoptive transfer of virus-sensitised NK cells into naïve mice enhanced the survival of 
the mice after challenging with the sensitised virus but not with other virus. Only 
hepatic NK cells were able to develop specific memory and it was dependent on 
CXCR6 expression (Paust et al., 2010). The latest study from Keppel and Cooper et al. 
proposed that cytokine activation of murine NK cells could generate memory-like NK 
cells able to produce IFN-%. These cells once stimulated in vitro using cytokines or 
target cells had an intrinsic enhanced capacity to produce IFN-% (Keppel et al., 2013). 
Although strong evidence for adaptive features of murine NK cells has been provided, 
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studies of NK cell memory in humans are more complex but efforts to demonstrate 
similar behaviour have been made. Similar to the MCMV model, it has been observed 
after HSC transplantation (HSCT) the specific expansion of human NK cells expressing 
inhibitory receptors for ligands missing in the host (Ruggeri et al., 1999; Ruggeri et al., 
2002). Strong evidence supporting the memory-like features of NK cells is clearly 
required and must address how long this “memory” persists. A recent report studying 
the serial killing by NK cells (cell line NK92) found that there was a short-term memory 
effect in which the first killing was slow but following events were faster (Choi and 
Mitchison, 2013). Further research in this area is likely to reveal more NK cell 
properties that may be useful for therapeutic purposes.  
 
1.5 Natural Killer cell receptors  
 
The surface marker repertoire acquired by NK cells is regulated by a dynamic process 
that is modulated by the environment. Unlike T and B cells, NK cells lack antigen-
specificity whilst expressing a wide variety of activating and inhibitory receptors. The 
engagement of these receptors provides signals, which dictates whether an NK cell is 
activated or inhibited. NK cells are ready-to-go; therefore the regulation of this 
immediate response needs to be tightly regulated for the protection of healthy cells. In 
the following sections a description of the activating and inhibitory receptors expressed 
by NK cells is presented.  
 
1.5.1 Activating receptors  
 
For some time, it was thought that inhibition of NK cells was only controlled by KIRs 
recognising reduced expression of class I MHC (missing-self hypothesis). However, it 
has now been well established that the signalling downstream specific activating 
receptors is needed for NK cell activation and killing. The evidence for this came from 
the development of monoclonal antibodies able to block NK cell-mediated killing of 
malignant cells (Vitale et al., 1998; Pende et al., 1999). The activating NK cell 
receptors can be grouped into three categories: 1) receptors that signal through ITAM 
(immunoreceptor tyrosine-based activation motifs)-containing subunits, 2) the DAP10 
associated receptor NKG2D and 3) other receptors that signal using different 
pathways. 
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1.5.1.1 ITAM bearing Natural Killer cell receptors 
 
Many NK cells express receptors with ITAMs that induce a strong activation upon 
cross-linking. ITAMs are connected via non-covalent association of adaptor molecules 
such as DNAX-activating protein 12 kDa (DAP12), Fc&R-% or CD3). These adaptor 
molecules contain an aspartic acid residue with a negative charge required for 
oligomer formation. DAP12 and Fc&R-% contain a single ITAM, and CD3) has three per 
chain (Lanier, 2008). The activation of the ITAM receptor induces reorganisation of the 
cytoskeleton, necessary for polarisation and release of cytotoxic granules, and the 
transcription of cytokines and chemokines. ITAM-bearing receptors include the natural 
cytotoxicity receptors (NCRs), CD94/NKG2 heterodimers, CD16 and activating KIRs.  
 
NCRs 
 
NCRs are NK cell-specific receptors involved in natural cytotoxicity against many 
targets without prior sensitisation. It has been reported that NCRs interact with viral 
proteins (Arnon et al., 2005) and although their involvement in tumour cell killing is 
known (Pessino et al., 1998; Pende et al., 1999), most NCRs ligands still await 
identification. NKp30, NKp46 and NKp80 are expressed on resting and activated NK 
cells, whereas NKp44 is expressed only on activated NK cells (Moretta et al., 2000). 
Known ligands for NCRs are described in table 1.1. 
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Table 1.1. NCR ligands. (Koch et al., 2013). Reproduced with permission from Elsevier. 
Receptor Ligand Source Reference 
 
 
NKp30 
B7-H6 Tumour cells (Brandt et al., 
2009) 
BAG6 Stressed cells, tumour cells (Pogge von 
Strandmann 
et al., 2007) 
Pp65 HCMV (negative effect) (Arnon et al., 
2005) 
PfEMP1 Plasmodium falciparum (Mavoungou 
et al., 2007) 
Viral HA Poxvirus, vaccinia virus (negative 
effect) 
(Jarahian et 
al., 2011) 
Heparin and heparin 
sulphate  
All animal cells (Ito et al., 
2012) 
 
 
 
 
NKp44 
Sialylated and 
sulfated 
proteoglycans 
All animal cells (Ito et al., 
2012) 
Viral HA and HN Influenza virus, Sendai virus, 
Newcastle disease virus 
(Jarahian et 
al., 2009) 
Unknown Bacterial cell wall components of 
mycobacteria and others 
(Esin et al., 
2008) 
Heparin and heparin 
sulphate  
All animal cells (Hecht et al., 
2009) 
 
 
NKp46 
Unknown Fusobacterium nucleatum (Chaushu et 
al., 2012) 
Viral HA and HN Influenza virus, poxvirus, Sendai 
virus, Newcastle disease virus 
(Arnon et al., 
2004; 
Glasner et 
al., 2012) 
Unknown Variety of normal and tumour cells (Arnon et al., 
2006) 
Heparin and heparin 
sulphate  
All animal cells (Hecht et al., 
2009) 
 
The first NCR discovered was NKp46 (Sivori et al., 1997), expressed both in activating 
and resting NK cells but no other cell type. NKp46 activation is mediated through 
association with the adaptor molecules CD3) and Fc&R-% (Lanier, 2003). It is clear that 
NKp46 plays a key role during NK cell activation against various targets (Sivori et al., 
1999) although the identification of NKp46 ligands is still a challenge. It was suggested 
that heparan sulfate proteoglycans (HSP) were involved in the recognition of tumour 
cells by NK46 and NKp30 receptors (Bloushtain et al., 2004) and absence of heparan 
sulfate expression reduced NK cell-mediated killing. Other ligands such as 
hemagglutinin molecules derived from influenza virus were also reported as ligands for 
NKp46 and NKp44 (Arnon et al., 2001) (see table 1.1).  
 
NKp44 was the next NCR discovered on human NK cells, revealed by blocking of this 
receptor partially inhibiting the killing of MHC-deficient targets (Vitale et al., 1998). 
NKp44 signalling occurs via association with the adaptor molecule DAP12 and 
expression is restricted to activated cells in vitro (Vitale et al., 1998). However in vivo, 
several NK cell subsets express NKp44, such as those found in human tonsils 
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(Ferlazzo et al., 2004a) and dNK cells during pregnancy (Hanna et al., 2006). Similar to 
NKp46, very little is known about NKP44 ligands although the influenza hemmaglutinin 
has been described earlier in addition to other viruses as potential ligands (see table 
1.1) (Arnon et al., 2001; Arnon et al., 2004). 
 
The third NCR discovered was NKp30, expressed in all human NK cells (Pende et al., 
1999). NKp30 may cooperate with NKp46 and NKp44 by triggering cytolysis through 
the transmembrane signalling molecule CD3) (Byrd et al., 2007). It was reported that 
NKp30 recognises an unknown ligand on immature but not mature DCs (Cooper et al., 
2004). Hence, NKp30 is involved in the regulation of the immune response through 
interactions with DCs, resulting in their maturation (Pende et al., 1999). A HCMV 
protein, pp65, was reported to interact with NKp30, antagonising NKp30 activation due 
to the dissociation of the adaptor molecule CD3) from NKp30 (Arnon et al., 2005). As 
pp65 is an intracellular protein, it was proposed that soluble pp65 derived from the lysis 
of infected cells could bind NKp30 and block NK cell activity. Later, it was found that 
NKp30 could bind intracellular ligands such as HLA-B-associated transcript 3 (BAT-3), 
which is released from the tumour cells. BAT-3 binding to NKp30 mediated cytotoxicity, 
making BAT-3 the first cellular ligand identified for NKp30 (see table 1.1) (Pogge von 
Strandmann et al., 2007).  
 
CD94/NKG2 heterodimers 
 
Another family of receptors is the C-type lectin family CD94/NKG2A/C/E. CD94 is a 
type II integral membrane glycoprotein that forms heterodimers with different members 
of the NKG2 family. These receptors are thought to be important for the recognition of 
HLA-E, the non-classical MHC class I molecule (Braud et al., 1998). HLA-E presents 
peptides derived from other class I molecule leader peptides. The heterodimers 
CD94/NKG2C and CD94/NKGE associate with DAP12, and consequently play a role in 
NK cell activation (Borrego et al., 1998; Braud et al., 1998; Lee et al., 1998). NKG2C+ 
NK cells have been associated with HCMV infection and other diseases (Guma et al., 
2006a; Guma et al., 2006b). In mice, NKG2E has been shown to be required for the 
protection of B6 mice against mousepox (ectromelia virus) (Fang et al., 2011). It has 
been shown that dNK cells have poor cytotoxicity (Ferry et al., 1990), however, during 
HCMV infection both NKG2C and NKG2E have been reported to be involved in the 
acquisition of cytotoxic functions thus controlling infection (Siewiera et al., 2013).  
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CD16 
 
Another activating receptor, CD16 (Fc%RIIIa), couples with CD3) and with Fc&R-% 
(Moretta et al., 2002). CD16 has low affinity for IgG receptor mediating ADCC, a 
process in which NK cells recognise the Fc portion of IgG bound to 
infected/transformed cells triggering cell death (Mandelboim et al., 1999). CD16 is a 
potent activating receptor, being the only one able to elicit cytotoxicity alone without the 
need of other receptors (Bryceson et al., 2006b). 
 
Activating KIRs 
 
Besides KIRs acting as inhibitory receptors, another set of KIRs was found to enhance 
NK cell cytotoxicity (Moretta et al., 1995). They posses a short cytoplasmic tail without 
any signalling motif; however, they associate with the adaptor protein containing an 
ITAM-signalling motif DAP12 (Biassoni et al., 1996). The ligands that associate with 
activating KIRs are poorly characterised, although major efforts have been made to 
define them. For instance, the study of KIR2DS4 on NK cells revealed interactions with 
MHC class I molecules and non-MHC class I molecules on melanomas enhancing NK 
cell cytotoxicity (Katz et al., 2004).  
 
1.5.1.2 NKG2D 
 
NKG2D is expressed as a homodimer on almost all NK cells and does not 
heterodimerise with CD94. NKG2D associates with an adaptor molecule, DAP10, a 
subunit that carries a phosphatidylinositol-3 kinase (PI3K)-binding motif (Wu et al., 
1999). Some of NKG2D ligands are related to MHC class I molecules, usually 
expressed at low levels by normal cells but upregulated during cellular transformation 
or stress. This type of recognition, in which unhealthy cells upregulate self-ligands for 
activating receptors is called “induced self-recognition” (Diefenbach and Raulet, 2001), 
contrasting with “missing self-recognition”. Some reports show that NKG2D signals 
alone are sufficient to activate NK cells (Sutherland et al., 2002; Lodoen and Lanier, 
2005), while another study revealed co-stimulation with other receptors such as 2B4 
was necessary (Bryceson et al., 2006b).  
 
NKG2D recognises MHC class I polypeptide-related chain A and B (MICA and MICB) 
and up to six different proteins named ULBPs (UL-16 binding proteins). Some of the 
ULBPs are transmembrane proteins (ULBP4-5) and others are 
glycophosphatidylinositol (GPI)-anchored proteins (ULBP1-3 and ULBP6) (Raulet et 
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al., 2013). Cellular stress plays a key role in the regulation of NKG2D ligands. Although 
“stress” is a very ambiguous term, some efforts in this area have shed light into the 
molecular pathways leading to cellular stress. The heat shock stress pathway (Groh et 
al., 1996) has previously been reported to regulate MICA and MICB expression. It was 
also reported that the DNA damage response in human cell lines induced the 
expression of ULBP1, 2, and 3 and in some studies MICA and MICB (Gasser et al., 
2005; Soriani et al., 2009). In terms of infection, HCMV upregulates MICA (but only the 
truncated MICA*008 molecule), MICB and ULBPs expression on infected cells (Groh et 
al., 2001) 
 
NKG2D engagement induces NK cell degranulation and while some data suggests that 
the soluble ligands stimulate cytokine secretion (Andre et al., 2004; Lanier, 2008) 
others have reported they inhibit NK cell functions (Waldhauer and Steinle, 2006; 
Waldhauer et al., 2008). NK cell activation via NKG2D is triggered by the tyrosine 
phosphorylation of the adaptor proteins, which induces a cascade of events. As 
mentioned, NKG2D signals through the adaptor molecule DAP10, which has a small 
cytoplasmic domain containing only one known signalling motif (YINM). DAP10 
phosphorylation recruits either PI3K through the p85 subunit (Wu et al., 1999) or the 
adaptor Grb2 (Chang et al., 1999). 
 
1.5.1.3 Other receptors 
 
Some other activating receptors do not contain ITAMs or associate with adaptor 
molecules carrying ITAMs. Among these, CD2, 2B4, DNAM-1 and NKp80 are included 
and some of these receptors act as co-stimulators (Bryceson et al., 2006b). 
  
NKp80 
 
NKp80 was identified in 2001 during the investigation of novel NK cell receptors able to 
trigger NK cell cytotoxicity (Vitale et al., 2001). NKp80 is expressed on all NK cells and 
a subset of CD8 T cells and %* T cells. Welte et al. demonstrated that it recognises and 
binds to the activation-induced C-type lectin (AICL) receptor (expressed on myeloid 
cells), stimulating NK cell cytotoxicity and cytokine secretion (Welte et al., 2006). The 
transmembrane region of NKp80 does not contain classic ITAM-adaptors; hence the 
signalling transduction pathway remained unknown until very recently. Using the cell 
line NK-92MI (an IL-2 dependent cell line), it was reported that NKp80 signals through 
an atypic hemi-ITAM activating Syk-kinase pathway (Dennehy et al., 2011).  
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DNAM-1 
 
DNAM-1 (CD226) is a receptor member of the Ig superfamily, expressed not only by 
NK cells but also by platelets, monocytes, T cells and some B cells (Lanier, 2005). 
DNAM recognises CD155 and CD112 receptors, both of them are upregulated in 
tumour cells (Bottino et al., 2003). The interaction between CD155 and CD122 with 
DNAM enhances NK cell-mediated cytotoxicity and cytokine secretion (Tahara-
Hanaoka et al., 2004). More recently, the interaction between DNAM-1 and CD155 
demonstrated the ability of NK cells to mediate suppression of metastases in a mouse 
model (Chan et al., 2010). The signalling triggered by DNAM-1 activation is not well 
characterised.  
 
1.5.1.4 Signalling downstream activating receptors 
 
Contrary to T and B cells, NK cells do not express a single activating receptor, instead, 
a wide variety of receptors are expressed by NK cells, which can synergise to regulate 
NK cell functions (Bryceson et al., 2006a). NKp30 and NKp46 can associate with CD3) 
and Fc&R-% whereas NKp44 associates with DAP12. These signalling partners contain 
an ITAM. Briefly, when NCRs are engaged, Src mediates the phosphorylation of the 
ITAM sequence on the associated molecule that results in the recruitment and binding 
of tyrosine kinases Syk and ZAP70 to the ITAM. Syk and ZAP70 phosphorylate 
transmembrane molecules like LAT (linker for activation of T cells) or NTAL (non-T-cell 
activation linker) leading to phosphorylation of several signalling complexes, including 
PI3K, phospholipase C (PLC-%1 and PLC-%2), and VAV-1, 2 and 3 (figure 1.12).  
 
NKG2D associates with DAP10. The short cytoplasmic tail of DAP10 contains a 
tyrosine-based signalling motif that can be phosphorylated by Src kinases and bind 
PI3K or the molecule Grb2. PI3K is essential for the production of PIP3 (phosphatidyl-
inositol-3,4,5-trisphosphate), needed for the recruitment of PLC-%1, PLC-%2 and VAV-
1. VAV-1 is recruited by Grb2 and plays a key role in the induction of actin 
reorganisation and polarisation of the microtubule organising centre (MTOC) (Cella et 
al., 2004) and is also important for the activation of SLP76 and PLC-%2 (figure 1.11). 
NKG2D does not involve signalling through ZAP70 or Syk, and does not require 
transmembrane adapters such as LAT or NTAL (Chiesa et al., 2006).  
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Figure 1.12. Activating pathways. The signalling pathways of activation through ITAM-
coupled receptors and DAP10 are shown in the figure. Adapted from Watzl et al, 2010 with 
permission from John Wiley and Sons. 
 
1.5.2 Inhibitory receptors 
 
NK cells have receptors that trigger killing mechanisms, as well as receptors that inhibit 
these mechanisms in order to protect self-cells. As described previously, the process 
by which NK cells recognise self from non-self was termed several decades ago by 
Karre in a theory called “missing self-hypothesis” (Karre et al., 1986). In 1995 the 
molecular mechanisms of the inhibitory signals were revealed by the identification and 
cloning of MHC class I binding NK cell receptors (Colonna and Samaridis, 1995; 
Moretta et al., 1995). Although this theory was proven correct, it is known today that 
other mechanisms and molecules apart from MHC-ligands inhibit NK cell activity. 
Some receptors act upon MHC class I molecules, whereas others bind to non-MHC 
class I ligands. These receptors include the inhibitory KIRs that bind to classical MHC 
class Ia molecules (HLA-A, -B, and –C) and the inhibitory CD94- natural killer group 2A 
(NKG2A) heterodimeric C-type lectin-like receptors that bind to the non-classical MHC 
class Ib (HLA-E) (Lanier, 2001; Lanier, 2008). Even though these receptors differ in 
their extracellular domains, there is one particular motif that defines their inhibitory 
function: the ITIM motif. When these receptors engage their ligands, recruitment of 
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different phosphatases suppresses NK cell responses by dephosphorylating the 
protein substrates of the tyrosine kinases linked to activating NK cell receptors 
(Ravetch and Lanier, 2000) including the protein tyrosine phosphatases (PTP) SHP-1 
and SHP-2 (Vivier et al., 2004). 
 
Killer Ig-like receptors 
 
KIR receptors belong to the Ig-superfamily and comprise transmembrane glycoproteins 
with two or three Ig-like extracellular domains (Colonna and Samaridis, 1995). The KIR 
receptor family may represent the most versatile and polymorphic one among the 
receptors expressed by NK cells (Yawata et al., 2002). KIRs glycoproteins can be 
divided into two subgroups based on the number of Ig-like extracellular domains; 
KIR3D contains three Ig-like domains and KIR2D only two Ig-like domains (Moretta et 
al., 1996). KIRs may have short or long cytoplasmic tails (S or L) and can transduce 
activating or inhibitory signals. The long cytoplasmatic tails of KIRs contain an ITIM 
motif in their cytoplasmic domain responsible for inhibitory signals. Although all KIRs 
interact with MHC class I molecules, they possess allele specificity. KIR2D recognises 
primarily HLA-C alleles whilst KIR3D recognises HLA-A3, HLA-A11 and HLA-B (Lanier, 
2005). KIRs inhibit NK cell activation in several ways. For instance, the binding of an 
inhibitory KIR to a MHC class I molecule blocks the phosphorylation of the activating 
receptors NKG2D and 2B4 (Natarajan et al., 2002) or blocks the accumulation of actin 
filaments on the immune synapse (Endt et al., 2007). The S forms (KIR2DS and 
KIR3DS) do not contain ITIM motifs; instead of inhibitory signals they transmit 
activating signals (Moretta et al., 2001).  
 
Signalling of inhibitory KIRs 
 
During the signalling through ITIM, PTPs (SHP-1 and SHP-2) or the inositol 
phosphatase SHIP are recruited to the activating motifs of adaptor/receptor molecules 
(Bakker et al., 2000). The recruitment of SHP-1 and SHP-2 to the ITIM motif blocks the 
progression of activating signals through dephosphorylation of other molecules such as 
Syk, PLC γ , VAV-1, transmembrane-associated adaptor proteins (CD3)), and 
cytoskeletal structures (actin and myosin) (Ravetch and Lanier, 2000; Lin et al., 2004). 
ITIM-containing receptors also bind to additional molecules through their 
phosphorylated ITIMs, for instance, KLRG1 binds SHIP and KIRs bind to (-arrestin 2, 
facilitating SHP-1 and SHP-2 recruitment to the inhibitory KIR (Yu et al., 2008). SHIP 
dephosphorylates PIP2, a PLC% substrate, preventing PKC activation and calcium 
signalling (Ravetch and Lanier, 2000). Studies have shown that ITIMs from KIR 
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preferentially recruit SHP-1 (Ono et al., 1997) known to dephosphorylate VAV-1, which 
has a central role in Rac-1-dependent actin cytoskeletal and receptor arrangement 
during the synapse formation (figure 1.13A) (Watzl and Long, 2003; Endt et al., 2007). 
A second component of the inhibitory signalling by KIR, and also by CD94/NKG2A, 
involves the small adaptor molecule Crk, which becomes phosphorylated and binds to 
Abl (Peterson and Long, 2008). The Abl-Crk binding disrupts the complex Cbl-Crk-
C3G, known to contribute to NK cell activation through Rap1 activation (figure 1.13B). 
 
 
Figure 1.13. ITIM signalling in KIRs. SHP-1 and SHP-2 recruitment to phosphorylated ITIMs is 
enhanced by the binding of (-arrestin 2. A) Activating receptors usually phosphorylate Vav1, 
however, SHP-1 dephosphorylates Vav1 and inhibits Rac1 activation preventing actin 
polymerization. B) Upon engagement of inhibitory receptors, Abl induces the phosphorylation of 
Crk, resulting in the disruption of the complex Cbl-Crk-C3G. Modified from Watzl and Long, 
2010 with permission from John Wiley and Sons. 
 
CD94/NKG2 
 
As mentioned earlier, NKG2 family members couple with CD94 and form heterodimers. 
NKG2C and NKG2E transmit activating signals while NKG2A transduces inhibitory 
signals. Unlike KIRs, CD94/NKG2A recognises only one molecule, the non-classical 
and MHC class I molecule HLA-E. Since HLA-E expression relies on the presence of 
bound MHC class I leader peptides, CD94/NKG2A serves as an indirect pathway of 
monitoring HLA class I molecules (Braud et al., 1998; Kaiser et al., 2005). HLA-E 
assembles at the ER using the leader peptides from HLA-A, B, C and G (Braud et al., 
1997). If MHC class I downregulation occurs, HLA-E expression is reduced, rendering 
!-
ar
re
st
in
 2
  
!"
!"
#$!%&
"
!"
'('%&"
)*+"
),-"
(*+"
!"
)./"
012&"
013&"
Actin polymerization 
Activating receptor 
KIR 
A) Dephosphorylation  
B) Phosphorylation 
Complex disruption 
Chapter 1 
 59 
CD94/NKG2-HLA-E interaction as a key mechanism used by NK cells to monitor MHC 
class I molecules (Kaiser et al., 2005). 
  
Others 
 
Leukocyte Ig-like  
Another group of inhibitory receptors from the Ig superfamily is the LIRs or the Ig-like 
transcripts (ILTs). Only two out of the thirteen members of the LIR family genes encode 
for inhibitory receptors, LIR1 and LIR2, but only one is expressed on NK cells (LIR1). 
Although LIR1 contains 4 ITIM motifs in its intracellular region, unlike inhibitory KIRs 
LIR1 binds with low affinity to MHC class I molecules (HLA-A, HLA-B, HLA-C and non-
classical HLA-G) (Colonna et al., 1999). However, the most efficient LIR1 binding is 
observed with HLA-G (Gonen-Gross et al., 2003).  
 
MHC class I-independent inhibition 
As predicted by the “missing-self” hypothesis, NK cell inhibition is mainly regulated by 
MHC class I molecules, but in some instances, their absence does not augment 
susceptibility to NK cell-mediated killing. In addition to MHC class I, other molecules 
contribute to the negative regulation of NK cell activity. For example, the 
carcinoembryonic antigen (CEA)-related molecule I (Markel et al., 2002; Stern et al., 
2005), the killer cell lectin-like receptor G1 (KLRG1) (Ito et al., 2006), NK cell receptor 
protein 1A (NKR-P1A, CD161) (Lanier et al., 1994), inhibitory receptor protein 60 
(Cantoni et al., 1999) and sialic-acid-binding immunoglobulin-like lectins (SIGLECs) 
(Nicoll et al., 1999).  
 
1.5.3 2B4, a receptor with dual function  
 
2B4 is a member of the SLAM-related receptor family expressed on all NK cells and 
binds to CD48 on other cells; its cytoplasmic tail contains four Ig-like motifs called 
ITSM (Claus et al., 2008). Upon phosphorylation of the ITSM motif, 2B4 can bind to 
small SH2-domain containing adapters such as SAP intracellular protein, EAT-2 or the 
Scr homology 2 domain-containing protein tyrosine phosphatase SHP-1 and SHP-2. 
SAP can recruit Fyn, which facilitates downstream signalling to modulate effector 
function (Veillette, 2006). Another adaptor protein able to bind phosphorylated 2B4 is 
3BP2, able to interact with VAV-1, LAT and PLC-%. It has also been shown that 2B4 
stimulation leads to phosphorylation of Cbl, Grb2 and SHIP (figure 1.14) (Bottino et al., 
2000; Chen et al., 2004). 
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Figure 1.14. 2B4 signalling. 2B4 signalling is initiated upon CD48 binding, followed by 
phosphorylation of the ITSM sequences by Src kinases. 2B4 associates with LAT and SAP 
directly, LAT activates PCL-% and Grb2 whereas SAP binds to Fyn, both molecules promoting 
NK cell activation. Modified with permission from Elsevier. (McNerney et al., 2005)  
 
2B4 plays a role as activating receptor on mature NK cells, although it is thought to 
also serve as a co-stimulatory receptor (Bryceson et al., 2005). The main evidence 
comes from experiments in which NK cell-resistant targets were transfected with the 
2B4 ligand CD48, rendering them susceptible to NK cell-mediated killing and triggering 
IFN-% production (Tangye et al., 2000). Additionally, an inhibitory role was assigned to 
2B4 during the study of NK cell development. It was suggested that this receptor 
transmits inhibitory signals early on in NK cell development, when the acquisition of 
activating markers occurs, as a mechanism to prevent self-killing (Sivori et al., 2002). 
The understanding of this dual nature of 2B4 is not completely understood although a 
model in which 2B4 is dynamically modulated by the engagement of CD48 and SAP 
availability has been proposed (figure 1.15) (Chlewicki et al., 2008), further studies will 
reveal the mechanisms regulating 2B4 signalling. 
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Figure 1.15. Dual function of 2B4 receptor. NK cell activation occurs when the engagement 
of CD48 with 2B4 in the presence of enough SAP protein (middle panel). Inhibition occurs when 
not enough SAP protein is available (left panel) or when increased receptor expression makes 
SAP expression limiting (Waggoner and Kumar, 2012). Reproduced with permission from 
Frontiers in Immunology under the Creative Commons Attribution 3.0 Unported License.  
 
1.5.4 Adhesion and trafficking Natural Killer cell receptors  
 
Recently, more importance has been given to the receptors affecting adhesion and 
trafficking of NK cells. NK cell develop in the BM, but they traffic to and from different 
lymphoid and non-lymphoid tissues. Now it is known that adhesion and trafficking 
receptors play a key role in NK cell functions in health and disease.  
 
1.5.5 Integrins and selectins  
 
Selectin family 
NK cells express L-selectin (CD62L), expressed preferably by the CD56bright NK cell 
subset. In mice, L-selectin facilitates the adhesion to peripheral LNs and is not needed 
for recruitment of NK cells to the liver, spleen and lung (Fogler et al., 1996; Chen et al., 
2005). Similarly, it has been shown in humans that L-selectin is involved in leukocyte 
adhesion to peripheral LNs (Uksila et al., 1997). L-selectin expression can be 
modulated through different stimuli such as IL-2, IL-15 and TGF-(, which downregulate 
its expression whilst IL-12, IL-19 and IFN-" upregulate it.  
 
 
Target 
NK cell 
Net: inhibition Net: Activation Net: inhibition 
CD48 2B4 SAP 
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Integrins 
NK cells express a variety of (1, (2 and (7 integrins. Among (1 integrins "5(1, "4(1, 
"6(1 serve as receptors for fibronectin, VCAM-1 and laminin respectively (Gismondi et 
al., 1991). The expression of integrins varies according to the activation state of NK 
cells; "5(1 and "4(1 expression is acquired during activation whilst "6(1 expression is 
downregulated (Perez-Villar et al., 1996). The "4 subunit is able to associate with 
another ( chain, (7, giving the "4(7 receptor a different function. NK cells express 
"4(7, which allows binding to the mucosal vascular addressin MAdCAM-1.  
 
Members of the (2 family allow cell-cell interactions and NK cells express all members 
from this family (Timonen, 1997). Studies on signalling events after (2 binding on NK 
cells have shown the rapid phosphorylation and activation of proline-rich tyrosine 
kinase 2 (Pyk2) (Gismondi et al., 2000). Pyk2 interacts with several signalling or 
cytoskeletal molecules like Src family members, Grb2 and paxillin (Salgia et al., 1996; 
Gismondi et al., 1997). A member of the (2 family, LFA-1 (CD11a/CD18), plays a key 
role in the immunological synapse formation, endothelial binding (Allavena et al., 1991) 
and functions as a costimulatory receptor on NK cells (Davis et al., 1999). LFA-1 
expression is tightly regulated in NK cell subsets, and can be upregulated upon 
activation with cytokines such as IL-2 or IL-12 (Allavena et al., 1994). 
  
1.5.6 Chemokine Natural Killer cell receptors 
  
The recruitment of leucocytes into different tissues is governed by a superfamily of 
inflammatory mediators named chemokines. Chemokines play an important role in the 
regulation of NK cell migration.  
 
NKP and iNK cells can mature in different organs/tissues (Freud et al., 2005). 
Chemokine receptors and adhesion molecules are expressed differently on NK cell 
subsets, suggesting different trafficking patterns for these subsets depending on the 
chemokine receptor expression. G protein-coupled receptors (GPCRs) are membrane 
proteins that possess seven-transmembrane-domains. Through interaction with 
GPCRs, chemokines mediate physiological processes including immune system 
development and pathological processes such as tumorigenesis and cancer 
metastasis. Chemokines have been divided into four major groups according to the 
arrangement of cysteine residues in the N-terminal region: CXC, CC, CX3C and C 
subfamilies. CXC chemokines attract neutrophils and lymphocytes, CC attract 
mononuclear cells, basophils and eosinophils, CX3C attract T cells, NK cells and 
monocytes and C chemokines attract T cells. Chemokines are produced either 
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constitutively or in response to stimuli. Some chemokines bind to more that one 
receptor and some receptors recognise more than one chemokine.  
 
NK cells express several C, CC, CXC, and CX3C chemokines. The chemokine 
receptor expression is commonly heterogeneous and depends on the NK cell subset 
and activation state (Gregoire et al., 2007). Table 1.2 shows the main chemokine 
receptors expressed by NK cell subsets. NK cells commonly lack the expression of 
CCR1-7 and CCR9, but the CD56brightCD16- subset can express CCR5 and CCR7, with 
the latter being mainly involved in homing to LN (Campbell et al., 2001). In terms of 
CXCR and CX3CR, CD56dimCD16+ cells express high levels of CXCR1 and CX3CR1, 
low levels of CXCR2 and CXCR3 and barely any detectable level of CXCR5. 
Conversely, CD56brightCD16- express high levels of CXCR1 and CX3CR1 and low 
levels of CXCR1, CXCR2 and CXCR5. Both subsets express high levels of CXCR4, 
important for migration to the BM (Campbell et al., 2001). In consequence, these 
subsets strongly respond to ligand of CXCR4, CXCL12 (Taub et al., 1995). 
Interestingly, it was reported that CXCR4 was highly expressed in NKP cells and that 
CXCR4 expression decreases as NK cells mature. NKP cells also express CXCR3 and 
CCR1 that may participate in the recruitment from the BM to other organs (Bernardini 
et al., 2008).  
 
Table 1.2. Chemokine receptor expression on the main NK cell subsets. 
Chemokine Chemokine ligands Expression on 
CD56dimCD16high 
Expression on 
CD56brightCD16low 
CXCR1 CXCL2,3,5,6,7,8 ++ - 
CXCR2 CXCL1,2,3,5,6,7,8 + - 
CXCR3 CXCL9,10,11   + ++ 
CXCR4 CXCL12 (SDF-1) ++ ++ 
CCR1 CCL3,5,7,8,13,14,15,16,23 - - 
CCR2 CCL2,7,8,12,13 - - 
CCR3 CCL5,7,8,11,13,14,15,24,26 - - 
CCR4 CCL17,22 - - 
CCR5 CCL3,4,5,8,11,13,14,20 - ++ 
CCR6 CCL20 - - 
CCR7 CCL19,21   - ++ 
CCR9 CCL25   - - 
CX3CR1 CX3CL1 ++ + 
++ Indicates high levels of expression, + Intermediate levels of expression, - undetectable levels 
of expression 
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The expression of chemokine receptors on NK cells can be modulated by cytokines. 
For example, NK cells exposed to IL-12 for 8-10 days upregulate the expression of 
CCR1, CCR2, CCR4, CCR5 and CCR8, while IL-15 downregulates the expression of 
CXCR4 and CX3CR1 on NK cells (Inngjerdingen et al., 2001; Barlic et al., 2003). IL-18 
has a different effect on NK cells; it induces the expression of CCR7 selectively on 
CD56dim NK cells, enhancing their capability to migrate to the LN, but does not affect 
CCR7 expression on CD56bright NK cells (Mailliard et al., 2005). An interesting 
mechanism by which lymphocytes can acquire surface molecules from antigen 
presenting cells and express them on their own surface is termed trogocytosis. 
Noteworthy is that of the capture of CCR7 by NK cells from allogeneic DC or T cells 
(Marcenaro et al., 2013). This process was facilitated when NK cells expressed 
KIR2DS1, allowing NK cell traffic to LNs. An important implication of this process could 
be observed during cord blood transplantation (CBT), in which NK cells would migrate 
to LN and destroy patient’s T cells and DCs preventing graft versus host disease 
(GvHD) (Marcenaro et al., 2009). Finally, besides conferring migration properties, 
chemokines can activate NK cells. CC and CXCL10 chemokines enhance NK cell 
degranulation and NK cell cytotoxicity by promoting NK cell-target interactions 
(Maghazachi et al., 1996; Nieto et al., 1998). 
 
1.6 Natural Killer cell killing machinery  
1.6.1 Recognition of malignant or foreign cells and immunological synapse 
 
NK cells are able to kill without prior sensitisation and recognise cells as “self” through 
the engagement of KIR with MHC-class I molecules. As suggested by the “missing-
self” hypothesis, NK cells are able to lyse foreign or transformed cells when there is 
low expression or absence of MHC class I molecules. It has now been recognised that 
although MHC expression plays a key role in this recognition, the balance between the 
signalling from activating and inhibitory receptors in the NK cell-target cell engagement 
will dictate the outcome.  
 
More studies have now shed light into the mechanisms that regulate NK cell effector 
functions. This process involves several stages. First, the actin cytoskeleton has to be 
rearranged in order to form an immune synapse (IS) between the target cell and the 
NK cell. During this step, interactions between LFA-1 and its ligand ICAM-1 are crucial 
to maintain adhesion and initiate the IS. In addition, integrins not only serve as 
adhesion molecules but also participate in the signalling before moving to the IS (Davis 
et al., 1999).  
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The IS provides the platform in which cell-cell signalling occurs and defines a specific 
area for accurate cytotoxicity and cytokine targeting (McCann et al., 2003). During the 
cell-cell interaction, if the target is capable of activating NK cells through their receptor 
expression or lacks of MHC class I molecules, an irreversible cytolytic response is 
initiated. Recent data suggests that NK cells remain attached to target cells until a 
second adjacent target is encountered, forming a ternary complex (Choi and Mitchison, 
2013). In this scenario, the first target primes activating signals and the second target 
accelerates the detachment of the previous target. In the same study, it was revealed 
that a long delay is observed before the first killing occurs, but subsequent killings took 
place in a shorter time (Choi and Mitchison, 2013).  
 
Once NK cells are activated, the cytotoxic granules are mobilised towards the IS via 
the MTOC. It was recently demonstrated that granule convergence toward the IS 
needs Scr kinases; interestingly, cytokines such as IL-2 are able to induce the lytic 
granule convergence (James et al., 2013). Finally, fusion of the vesicles containing the 
granules and release of the lytic contents occurs, namely perforin and granzymes.  
 
1.6.2 Perforin and Granzymes  
 
Perforin was isolated from the cytoplasmic granules of CTL and NK cells and 
demonstrated to lyse rapidly and unspecifically tumour cells, thus playing a pivotal role 
in granule-mediated killing. Perforin function depends on Ca+2 and is sensitive to the 
temperature and pH. These are important features since they secure the inadvertent 
pore formation protecting the NK cell. The cytoplasmic granules maintain an acidic pH, 
once they are released and encounter high Ca+2 concentrations and basic pH in the IS, 
conformational changes and activation of perforin occurs (Voskoboinik et al., 2005). 
The pores formed have a diameter from 120-170 Å, enough to allow the diffusion of the 
granzyme molecules, usually of 50 Å in diameter (Law et al., 2010).  
 
Recent studies have enabled insight of the details of granule-dependent NK cell killing. 
For instance, a study by Lopez et al. was able to demonstrate that membrane 
permeabilisation of a target cell by perforin can be achieved very fast, in 30 seconds. 
The repair of the target cell membrane is completed within 80 seconds, but even with 
the short time of frame in which granzymes have to be delivered, rapid apoptosis was 
observed in the target cells during this study (Lopez et al., 2013). CD107a is a 
lysosome-associated membrane protein (LAMP1) transported to the NK cell surface 
when degranulation occurs. Interestingly, no functional roles were attributed to this 
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marker until recently; Krzewski et al. demonstrated that CD107a facilitates the mobility 
of the transport vesicles involved in perforin trafficking (Krzewski et al., 2013).  
 
Other granules are needed besides perforin for efficient cell killing by CTL and NK 
cells. In fact, 90% of the protein mass contained in the cytolytc granules consists of a 
family of serine proteases named granzymes. There are five granzymes described in 
humans: A, B, H, K and M (Chowdhury and Lieberman, 2008). Not all of them have 
been well characterised and studied. We know that granzyme H is a chymase, K is a 
tryptase, so is A, and that M is a metase (Kam et al., 2000). Granzyme A induces cell 
death through a caspase-independent pathway that results in nicking of DNA and an 
increase of reactive oxygen species (ROS) (Martinvalet et al., 2005). Less is known 
about granzyme K, but a recent report showed that granzyme K dependent-apoptosis 
is triggered in a caspase-independent manner similar to granzyme A (Guo et al., 2010). 
Actually, it was shown that CD56bright NK cells could attack autologous T cells using a 
perforin-dependent mechanism mediated by granzyme A and granzyme K (Jiang et al., 
2011). Granzyme B is by far the best-characterised granzyme. Several mechanisms of 
delivery of granzyme B to target cells have been recently identified. Two models have 
been proposed and are in constant debate. One of them suggests that granzyme B 
binds to mannose-6 phosphate (M6P) directly on the target surface; endocytosis of the 
complex (granzyme B-M6P) and release into the cytoplasm causes apoptosis (Motyka 
et al., 2000). In the second model, perforin mediates the entrance of granzymes 
forming de novo pores in the cell membrane of the target. Granzyme B greatly 
contributes to the NK cell–cell mediated killing through the activation of caspases 
directly or indirectly through the mitochondria (Lord et al., 2003). Granzyme B activates 
Bid, a death agonist that initiates a cascade of events leading to the release of 
mitochondrial mediators such as cytochrome c. Cytochrome c activates caspases that 
lead to apoptosis (Waterhouse et al., 2004).  
 
1.6.3 Death-receptor mediated cytotoxicity  
 
NK cell cytotoxicity via the granule-exocytosis is highly efficient. Perforin-deficient mice 
have impaired cytotoxic functions but alternatives pathways are used to destroy 
malignant cells. NK cell cytotoxicity can occur via death ligands and receptors (TNF 
and TNFR, respectively). Fas belongs to the TNF receptor family of molecules 
containing a conserved intra-cytoplasmic “death domain” that indirectly activates the 
caspase enzymatic cascade and ultimately apoptotic mechanisms in numerous cell 
types. FasL is expressed almost exclusively by NK cells and CTL and it can exist as a 
membrane-bound protein or a soluble ligand (Tanaka et al., 1996). The receptor for 
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FasL, Fas (CD95) is expressed in various tissues and upon ligation it trimerises and 
causes the endocytosis of the FasL-Fas complex. The death domains then bind to the 
protein FADD (Fas-Associated Death Domain), which functions as a molecular bridge 
to caspase 8, a protease that initiates cell death cascade (Gibson et al., 2000).  
 
TNF-related apoptosis-inducing ligand (TRAIL) is another death receptor expressed by 
NK cells and CTL. TRAIL can bind to 5 different receptors; three of them act as “decoy” 
(they do not induce apoptosis), while the binding of the other two (DR4 and DR5) leads 
to the recruitment of the protein FADD initiating the apoptotic-signalling cascade 
(Gibson et al., 2000). TRAIL can be upregulated upon activation with cytokines such as 
IL-2 and IL-15 (Smyth et al., 2005). 
 
1.6.4 Cytokine production 
 
Cytokines released by activated NK cells include GM-CSF, TNF-" and regulatory 
cytokines such as TGF-( and IFN-% (Newman and Riley, 2007). The co-engagement of 
some receptors such as NKG2D, 2B4 or CD16 can stimulate IFN-% and TNF-" 
secretion (Fauriat et al., 2010). Together with secreted chemokines, these cytokines 
stimulate inflammatory responses. Cytokines can modulate monocyte, dendritic cell, 
and granulocyte growth and differentiation, and can also influence acquired immune 
responses. IL-12 is produced very early during infection and is responsible for driving 
IFN-% production in NK cells (Byrne et al., 2004). IFN-% affects host responses to 
tumours by restricting angiogenesis and inhibiting viral replication (Yokoyama et al., 
2004). Although the secretion of cytokines including IFN-% has been associated with 
the CD56bright NK cell subset, new evidence reveals that CD56dim NK cells can also 
secrete vast amounts of IFN-% usually within 4 h of cell activation (Fauriat et al., 2010; 
De Maria et al., 2011).  
 
1.7 Cancer immunotherapy 
 
Immunotherapy treatment involves strategies to enhance the patient’s immune system 
to fight tumour cells. The methods for immunotherapy include the induction of an 
immune response against cancer using IFNs or other cytokines or cells able to kill 
malignant cells (cell-based immunotherapy or cellular immunotherapy). During cellular 
immunotherapy, the patient is administered cells that stimulate anti-tumour activity or 
that have intrinsic anti-tumour activity (either autologous or allogeneic), such as NK 
cells, T cells, or CTLs (Armstrong et al., 2001). In addition, allogeneic HSCT is a form 
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of immunotherapy, as the donor’s immune cells will often attack malignant cells in the 
phenomenon known as graft versus leukaemia (GvL). 
 
1.7.1 Haematopoietic stem cell transplantation 
 
Replacement of the haematopoietic system was a procedure used for the first time in 
man more than 50 years ago. HSCT is currently used to treat a variety of diseases, 
such as haematological and autoimmune disorders, neuroblastoma, ovarian cancer, 
several types of anaemia (aplastic, Franconi’s and others) among other diseases 
(Copelan, 2006).  
 
HSCs can be derived from autologous or allogeneic sources. Autologous HSCs can be 
extracted from the patient prior to cytoreductive therapy and infused back. Since no 
histocompatibility barriers exist in this scenario, better engraftment, faster reconstitution 
but higher rate of cancer relapse are usually observed. Allogeneic HSC are derived 
from a related or unrelated HLA-matched donor and transplanted into the patient. 
Treatment of leukaemia by transplantation of BM or PBSC is limited by the scarcity of 
HLA-matched related or unrelated donor; only 50–60% of patients are eligible. In this 
scenario, donor cells can attack tumour host cells (GvL) but also normal host cells 
(GvHD), a major cause of morbidity (Welniak et al., 2007). HLA-matched sibling donors 
are the best option for allogeneic HSCT avoiding GvHD by HLA matching but 
maintaining GvL due to minor histocompatibility antigen differences. In the absence of 
an HLA-matched donor, partial-HLA or unrelated-HLA matches might be necessary.  
 
Successful HSCT can be hindered by graft rejection (lack of initial donor engraftment), 
infections and malignant disease recurrence (relapse), but one of the major and most 
important immunological complications is GvHD. GvHD is a multifactorial disease in 
which cytokine release is enhanced, APC presentation of alloantigens to incoming 
donor T cells is augmented and an immunological storm is initiated (Przepiorka et al., 
1995). Infused donor T cells are able to recognise alloantigens in the recipient, 
resulting in T cell activation, expansion and proliferation. T cell activation triggers 
cytolytic and cytokine apoptotic injuries targeting the skin, gut and liver (Ferrara and 
Reddy, 2006; Ferrara et al., 2009). GvHD therapy includes the suppression of T cell 
activity using pharmacological immunosuppressive drugs and the suppression of 
cytokine release to establish donor-host immunotolerance. Additionally, the incidence 
of GvHD can be reduced by T cell depletion of the graft before transplantation. 
However, T cell depletion provides a higher risk of opportunistic infections such as 
Chapter 1 
 69 
Epstein-Barr virus (EBV), lymphoproliferative disease and relapse rate (Wagner et al., 
2005).  
 
Allogeneic HSCT relies on the suppression or elimination of the host immune system, 
which can prevent engraftment. This can be performed using a conditioning regime, 
generally radiation or chemotherapy that can be either myeloablative or reduced 
intensity. Reduced intensity regimes are associated with lower rates of early infections 
compared to myeloablative regimes, however the risk of late infections are similar. The 
timing of immune reconstitution determines the timing of infections. The immune 
reconstitution will depend on the ability of the graft to produce de novo lymphoid and 
myeloid cells in addition to the function of the mature cells contained in the graft. The 
sequence of immune reconstitution and infections can be divided in three phases after 
HSCT following myeloablative-conditioning regimes: 1) the first is the aplastic phase, 
the patient is at risk of fungal, viral and bacterial infections (Ninin et al., 2001), 2) the 
second phase comprehends the period from the initial HSCs engraftment to the third or 
fourth month and HCMV is the main infection during this phase due to reactivation 3) 
the third phase begins after the fourth month, recipients of allogeneic HSCT are 
susceptible to bacterial infections such as S. pneumoniae and H. influenza. 
 
Several sources of HSCs have been used during the past years including BM, 
mobilised peripheral blood and CB (Welniak et al., 2007). A brief description of these 
sources is presented in the following sections.  
 
1.7.1.1 Bone marrow and mobilised peripheral blood stem cell transplantation 
 
BM is a rich source of HSCs and was the only HSC source for a long time. In 1956, 
Donnall Thomas performed the first BM transplant (BMT) using infusion from marrow of 
an identical twin to treat leukaemia (Thomas et al., 1957). Encouraging data was later 
presented in 1965 showing retention of allogeneic grafts in the treatment of acute 
leukaemia (Mathe et al., 1965). But BMT was not confined to haematological diseases, 
in 1968 and 1969 infants with severe combined immunodeficiency disease were 
transplanted with their HLA-matched siblings (Bach et al., 1968). Now, BMT is used for 
the treatment of several malignancies including leukaemia, inherited disorders and 
more recently solid tumours. The method to obtain BM is relatively simple, however 
sometimes painful for the donor. BM aspirations are performed under general 
anaesthesia, and later transfused to the patient. 
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It has been more than 25 years since peripheral blood stem cells (PBSC) were 
considered for transplants. In the 1960’s the term “blood stem cell” was introduced, but 
it was not until 1981 when the technology allowed the recollection and cryopreservation 
of enough autologous stem cell numbers that the first blood-stem cell infusion was 
performed (Goldman et al., 1981). However, compared to the well-established BMT, 
PBSC numbers retrieved were very low. Several strategies were implemented, such as 
the temporary expansion of PBSC using haematopoietic growth factors or CXCR4 
antagonists. Two candidates to obtain higher PBSCs numbers were G-CSF and GM-
CSF. Today, G-CSF is considered the gold standard drug to mobilise PBSC offering 
advantages over GM-CSF as demonstrated in follow-up studies (Lane et al., 1995). In 
2001, a multicentre clinical trial was performed to assess PBSC compared to BM HSC 
in transplantation. Interestingly, the conclusions of this study revealed that PBSC 
transplantation had a faster platelet and neutrophil recovery, higher survival and 
disease-free survival probability (2 years) and no difference in the cumulative incidence 
of GvHD (Bensinger et al., 2001). 
 
1.7.1.2 Cord blood stem cell transplantation 
 
Since 1939, CB was already a prospect for therapeutic uses, a concept that outside the 
neonatology was slowly accepted (Halbrecht, 1939). After BMT in the 50’s was 
successfully achieved, awareness of the use of CB grew slowly and it was not until 
1989 that the first successful CBT was performed (Gluckman et al., 1989). The use of 
a source of HSCs that was usually discarded was exciting news that led to CB being 
considered for the treatment of malignant haematological disorders. There is 
considerable evidence that placental blood obtained from CB at delivery is a promising 
HSCs source. The establishment of international CB banks, advances in supportive 
care and donor graft selection as well as novel clinical approaches aiming at improving 
engraftment have led to a dramatic increase in the number of CBT performed 
worldwide (Tse et al., 2008). To date, more than 20,000 unrelated CB transplants have 
been performed and more than 570,000 units have been collected and stored in more 
than 50 public worldwide CB banks (http://www.bmdw.org/). 
 
Cord blood transplantation; advantages and disadvantages 
 
HSCT is a potential cure for haematological malignant diseases. However, its 
application relies on the presence of a suitable HSC donor. Unfortunately, many 
patients do not have family with a suitable HLA match. CBT is an emerging therapy for 
patients without matched donors that offer advantages over BM or PB HSCT such as 
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non-invasive procurement and rapid availability without the lengthy process of 
screening (Wall and Chan, 2008). Moreover, international studies strongly suggested 
that CBT has the advantage of greater tolerance for HLA disparity, lower risk of 
transmitting latent virus infections (HCMV, Epstein-Barr virus), lower incidence of 
GvHD and identical GvL effect compared to unrelated BM transplantation (Rocha et al., 
2004). The lower GvHD rates have been associated with the naivety of CB cells, 
characterised by the lower production of inflammatory cytokines such as IFN-% and 
TNF-" (Chalmers et al., 1998).  
 
Nevertheless, CBT has been limited by numerous disadvantages, for instance the 
limited number of HSC and a higher risk of infections due to the delayed immune 
reconstitution. One of the main causes of morbidity after HSCT is the HCMV infection. 
A recent report suggested that regardless of the early T cell priming after double CBT 
(day 42), T cells fail to achieve enough numbers to control infection (McGoldrick et al., 
2013). Alternatively, omission of T cell depletion showed a unique thymic-independent 
T cell reconstitution in children that underwent CBT. Although infections were frequent, 
these were resolved and the incidence of chronic GvHD was low (Chiesa et al., 2012).  
 
To overcome the low doses of HSCs in CB for adult patients, the use of two CB units 
preceded by a reduced intensity regimen, facilitated engraftment (Barker et al., 2005). 
It seems that double CBT results in better rates of engraftment compared to single 
CBT and does not increase GvHD (Barker et al., 2005; Scaradavou et al., 2013). Along 
the same lines, the co-infusion of a CB and haploidentical peripheral blood CD34+ cells 
results in a shortened time of neutropenia following CBT, providing some immune 
protection until the CB CD34+ cells engraft (Fernandez et al., 2003). Another approach 
to increase HSC doses is the expansion ex-vivo of cord blood stem cells (CBSC), this 
can be performed using cytokines or co-culture with stromal cells that provide the 
HSCs microenvironment or extrinsic regulators of stem cell fate (Notch) (Robinson et 
al., 2002; Delaney et al., 2010; de Lima et al., 2012). Other method to deliver high 
numbers of HSCs is the intra-bone injection of CB cells, which was associated with 
better engraftment, early platelet recovery and low incidence of GvHD (Frassoni et al., 
2010). Finally, an important disadvantage is the inability to collect additional cells from 
the CB donor in case of relapse or graft failure to perform a donor lymphocyte infusion.  
 
Although higher transplantation-related mortality was observed in CBT, relapse rates 
and GvHD were lower compared to transplants using PBSC and BM (V. Rocha and E. 
Baudoux, 2011). The results of the study performed by the Eurocord and the Centre for 
International Blood and Marrow Transplant Research (CIBMTR) concluded that CBT is 
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feasible in adults if the CB unit contains high numbers of HSCs and should be 
considered when no sufficiently HLA-matched donor exists (V. Rocha and E. Baudoux, 
2011). 
 
1.7.2 Natural Killer cells in haematopoietic stem cell transplantation 
 
NK cells can have both, a positive and a negative effect on HSCT according to whether 
they come from the donor or the host. Donor NK cells can potentially enhance 
engraftment providing GvL and suppressing GvHD. This is the case in particular when 
there is a KIR ligand-mismatch in the donor to host direction. On the contrary, host NK 
cells can increase GvHD and reject the graft by lysis of donor HSCs (Farag et al., 
2002; Ruggeri et al., 2002; Barao and Murphy, 2003). Pioneering results of Ruggeri et 
al. (Ruggeri et al., 2002) have reported that allogeneic NK cells can mediate anti-
leukaemic effects against AML (acute myeloid leukaemia) cells after haplo-identical 
HSCT with KIR-ligand incompatibility (Ruggeri et al., 2006). However, the beneficial 
effects are controversial, especially in advanced haematological diseases (Schaffer et 
al., 2004; Aversa et al., 2005). The discrepancies among studies could be due to 
different transplantation protocols, which vary in type of pre-conditioning, degree of T 
cell depletion, dose of HSCs and treatment post-transplantation. Some studies 
suggested that NK cells generated after haplo-identical HSCT are blocked at an 
immature stage and characterised by specific phenotypic features and impaired 
functions that may negatively affect transplantation outcome (Nguyen et al., 2005).  
 
Intense immunosuppression after CBT along with the naivety of the infused T cells and 
slow T cell reconstitution generated a long period of immunodeficiency increasing 
mortality due to infections. Surprisingly, no increased mortality due to relapse has been 
observed after CBT and studies have shown that the GvL effect is preserved. Studies 
on hematopoietic reconstitution after CBT showed that NK cells are the first lineage to 
be reconstituted and comprise most of the lymphocytes in circulation during the first 
year after CBT. Reconstituted NK cells are able to kill leukaemia cells ex-vivo (Beziat 
et al., 2009) supporting the hypothesis that NK cells may be responsible of the GvL 
effect observed after CBT and excludes the possibility of T cells performing this role 
since it takes between 6-12 months for T cells to reconstitute in the patient (Komanduri 
et al., 2007).  
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1.8 Natural Killer cell therapy 
 
1.8.1 Why Natural Killer cell therapy? 
 
The use of the immune cells as therapy has been widely explored. NK cells are not the 
only alluring option for this purpose. In fact, the biology and functions of T and B cells 
have been studied long before NK cells. T cell therapies have some limitations, mainly 
due to the escape mechanisms of malignant cells (described in section 1.7.4). 
Additionally, T cells are known to provide GvHD (Coghill et al., 2011). Unlike T cells, 
NK cells do not invoke GvHD, as non-malignant cells usually do not express enough 
activating ligands to induce NK cell cytotoxicity.  
 
Another immune cell subset that has been studied for anti-tumour therapies are DCs. 
DC therapy aims to prime T cells against specific anti-tumour antigens. The first 
attempts to cure cancer using DCs therapy were performed in patients with non-
Hodgkin’s lymphoma (Hsu et al., 1996). Through the years, other types of cancers 
have been added to the list: prostate cancer, myeloma, colorectal cancer and non-
small cell lung cancer. However, this therapy is still far from being optimal, as DC 
therapy has failed to eradicate malignant cells in many cancer patients and 
manipulation in vitro is costly and time consuming.  
 
Although currently T cell and DC based therapies are under study, NK cell 
immunotherapy is rapidly progressing. New approaches have been studied, from 
simple manipulation using cytokines to sophisticated NK cell engineering.  
 
1.8.2 Natural Killer cells in cancer 
 
A vast amount of literature-based knowledge has demonstrated the capacity of NK 
cells to recognise and lyse tumour cells (Wu and Lanier, 2003). Hence, NK cells have 
been considered an attractive tool for immunotherapy, as they do not require prior 
antigen priming like T cells. NK cells hold a great alloreactivity potential (Colonna et al., 
1993) that could be used in other scenarios besides HSCT. Studies in malignant 
glioma patients and neuroblastoma demonstrated that NK cell infusions are safe 
although partially effective (Ishikawa et al., 2004; Tarek et al., 2012). Several types of 
cancer could potentially benefit from NK cell immunotherapy and current clinical trials 
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include pancreatic, lung, head/neck, breast and renal cell carcinomas. Table 1.3 shows 
some studies using either autologous or allogeneic NK cells. 
 
Table 1.3. NK cell adoptive therapy. Modified with permission from Nature Publishing 
group. (Luevano et al., 2012b) 
!"#"$"%&"' ()%&"$' *+'&",,'-."$)/0'
(Escudier et al., 1994) Metastatic renal cell carcinoma (MRCC)   
 
 
Autologous 
 
(Ishikawa et al., 2004) Malignant glioma 
(deMagalhaes-
Silverman et al., 
2000) 
Metastatic breast cancer 
(Lister et al., 1995) Lymphoma and breast cancer 
(Miller et al., 2005) AML  
 
 
 
 
Allogeneic 
(Koehl et al., 2004) Acute Lymphoblastic Leukaemia (ALL) or 
AML 
(Passweg et al., 
2004) 
AML and Chronic Myeloid Leukaemia (CML) 
(Arai et al., 2008) Refractory Renal Cell Carcinoma and 
Melanoma 
(Bachanova et al., 
2010) 
B cell non-Hodgkin lymphoma (NHL) 
(Curti et al., 2011) AML 
(Iliopoulou et al., 
2010) 
Advanced non-small cell lung cancer 
(NSCLC) 
 
1.8.3 Tumour escape 
 
Unfortunately, not all tumours are susceptible to NK cell-mediated killing and different 
mechanisms evolved by tumour cells underlie this resistance. Studies from 
experimental models and human cancer revealed some of the mechanisms regulating 
evasion of tumour cells from NK cells (summarised in table 1.4): 
  
a) Loss of MHC class I molecules: cancer cells may alter the expression of MHC 
class I molecules. These molecules are known to play a pivotal role in the 
presentation of tumour antigens to T cells and also modulate NK cell function. 
This loss can occur in two ways: 1) through the loss of MHC class I proteins that 
will present these antigens to tumour-specific T cells, or 2) through the loss of 
Chapter 1 
 75 
antigen processing function within the tumour cell that is needed to produce the 
peptide and load it onto the MHC class I molecule (TAP1, TAP2, and 
components of the immunoproteasome) (Dunn et al., 2002).  
 
b) MICA production: Many tumours produce the soluble stress-induced molecule 
MICA. This molecule binds to NKG2D on the effector cells (NK cells) leading to 
endocytosis and degradation of the NKG2D molecule, which inhibits NK cell-
mediated killing (Groh et al., 2002). 
 
c) Treg cells: These cells are major mediators of peripheral immune tolerance 
through the regulation of Th1 and Th2 immune responses. Treg cells 
considerably suppress the proliferation and the function of CD4+ T cells, CD8+ T 
cells and NK cells by the secretion of immunosuppressive cytokines, such as 
TGF( and IL-10 (Beissert et al., 2006). 
a. Suppressive cytokines: 
i. IL-10: is an immunoregulatory cytokine with potent anti-inflammatory 
and immunosuppressive activities. IL-10 can suppress DC function and 
skew T cell responses toward a type 2 immune response and is less 
effective against malignant cells (Aruga et al., 1997). 
ii. TGF-(: a cytokine that mediates the suppression of immune responses 
as well as strong inhibition of epithelial-cell growth. It leads to inhibition 
of DC activation as well as direct inhibition of T cell and NK cell 
proliferation and function (Wrzesinski et al., 2007). 
 
d) FLIP: Fas-FasL binding plays an important role in immune regulation. Its function 
includes T cell homeostasis, cytotoxic T cell activity and tumour counterattack. 
Tumours may overexpress FasL to induce apoptosis of the infiltrated 
lymphocytes, allowing the tumour to escape the immune response. Fas activation 
induces trimerisation of the receptor and ligand; subsequently binding to FADD 
occurs which in turns recruits caspase-8, resulting in cell death by apoptosis. 
This chain of events can be inhibited by FLIP. FLIP expression correlates with 
resistance against death receptor-induced apoptosis in a variety of B-cell 
lymphomas and FLIP-transfected tumour cell lines develop more aggressive 
tumours in vivo (Igney and Krammer, 2002).   
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Table 1.4. Tumour escape strategies. 
Strategy Mechanism 
 
 
Ignorance 
Lack of danger signals 
Lack of tumour antigens in lymphoid organs 
Growth in immune privileged sites 
Lack of adhesion molecules 
Physical barrier by stroma 
Impaired antigen 
presentation 
Mutation or downregulation of tumour antigens 
 
Expression of 
immunosuppressive factors 
and molecules 
Mutation or downregulation of MHC antigens 
Defects in antigen processing (TAP, LMP [large 
multifunctional protease] deficiency) 
Cytokines (TGF-(, IL-10, VEGF, etc.) 
Prostaglandins 
RCAS1 (receptor binding cancer antigen expressed on SiSo 
cells) 
 
 
Tolerance induction 
Anergy induction (lack of costimulatory molecules) 
Immune deviation 
Tregs 
T cell deletion 
 
Apoptosis resistance 
Expression of anti-apoptotic molecules 
Downregulation and mutation of pro-apoptotic molecules 
 
1.8.4 Modulation of Natural Killer cell activity 
 
There have been some advances in the development of different immunotherapy 
strategies throughout the years. NK cells, being recently considered for cancer therapy, 
can be manipulated to enhance their cytotoxic activity. Different approaches can be 
taken to enhance effector functions such as use of cytokines or antibodies and genetic 
modification. 
 
1.8.5 Monoclonal antibodies 
 
To mimic a missing-self environment several groups have recently used antibodies 
directed against KIRs (figure 1.16). The preclinical characterisation of 1-7F9, a 
monoclonal antibody that blocks KIR2DL1, KIR2DL2 and KIR2DL3 receptors on NK 
cells, showed enhanced NK cell-mediated lysis of AML blasts expressing HLA-C in 
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vitro and in vivo (Romagne et al., 2009). Later concomitant administration of 
lenalidomide and 1-7F9, now known as IPH2101, was tested in multiple myeloma cells 
showing promising results leading to a phase II clinical trial (Benson et al., 2011). The 
company leading this project, Innate Pharma, announced recently a second phase I 
trial using IPH2101 combined with Anti-PD-1 antibody nivolumab for the treatment of 
solid tumours. The results of these trials will be of great value for the continuous effort 
to combat cancer.   
 
 
Figure 1.16. Use of monoclonal antibodies to modulate NK cell activity. Infusion of 
antibodies blocking inhibitory KIRs can be used to activate NK cells and enhance cytotoxicity. 
Modified with permission from Nature Publishing group. (Luevano et al., 2012b) 
 
1.8.6 Interleukins 
 
NK cell differentiation and activation can be modulated by different interleukins, such 
as IL-2, -12, -15, -18 and IL-21 (figure 1.17) (Colucci et al., 2003; Becknell and 
Caligiuri, 2005). IL-2 was the first cytokine used to augment NK cell activity, as 
experiments in vitro revealed increased NK cell cytotoxicity against targets that were 
previously NK cell resistant (Robinson and Morstyn, 1987; Torelli et al., 2002). Several 
clinical trials studied the effect of IL-2 administration in patients with cancer (Rosenberg 
et al., 1987; Rosenberg, 2000). Unfortunately, high doses of IL-2 are toxic and not well 
tolerated by patients (Fehniger et al., 2002). Nevertheless, the use of low doses of IL-2 
was introduced to promote NK cell activity in vivo. Although treatment with low doses of 
IL-2 had undesired effects due to the expansion of the immunoregulatory CD56bright NK 
cell subset. Further approaches included combination of IL-2 with other factors 
(Becknell and Caligiuri, 2005) such as the use of IL-2 combined with monoclonal 
antibodies (Cetuximab for example) that mediate ADCC was able to enhance NK cell 
activity (Roda et al., 2007). Nevertheless, there has been an inclination for the use of 
another interleukin that might represent a better option for NK cell activation: IL-15. IL-
Antibodies 
In vitro or 
 in vivo Activation 
KIR 
1-7F9  
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IFN-!; Interferon gamma 
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15 plays a key role during NK cell development and later in NK cell proliferation and 
survival; moreover, IL-15 is one of the top twelve agents listed by the National Cancer 
Institute to be used in immunotherapy (Cheever, 2008). It has been shown that IL-15 is 
more efficient in expanding NK cells and less cytotoxic than IL-2 (Munger et al., 1995; 
Ozdemir et al., 2005).  
 
There is a need for more studies investigating the use of cytokines for NK cell 
activation, either alone or in combination. Studies in mice have demonstrated that NK 
cells pre-activated with IL-12/15/18 persisted in vivo and had a potent anti-tumour 
activity. In this model, the presence of IL-2 secreted by CD4+ T cells enhanced 
proliferation and radiotherapy was needed for enhanced effector functions (Ni et al., 
2012). It still remains a challenge to translate the encouraging results obtained in mice 
to humans.  
 
 
Figure 1.17. NK cell modulation using cytokines. NK cells can be activated with interleukins 
in vivo or in vitro, enhancing effector NK cell functions. Modified with permission from Nature 
Publishing group. (Luevano et al., 2012b) 
 
1.8.7 Natural Killer cell genetic modification 
 
With advancement in technology, new approaches to defeat cancer arise. Within this 
new technology, the genetic manipulation of cells has opened new hopes for cancer 
therapy. In this regard, NK cells have been already manipulated in vitro in order to 
enhance proliferation, survival and specific targeting towards malignant cells (figure 
1.18). Studies in mice using NK cells bearing a chimeric-antigen specific receptor 
(against ErbB2 for breast cancer) and in humans directed against CD19 (malignant B 
cells) have proven an efficient approach against these diseases (Imai et al., 2005; 
Pegram et al., 2008). Another example is the transduction of the essential NK cell 
survival cytokine IL-2 into the cell line NK-92 (Nagashima et al., 1998). By transducing 
IL-2, NK-92 can maintain its own survival and increased the survival of mice bearing 
IL-2, IL-12, IL-15, 
IL-18 or IL-21 
In vivo or in vitro 
activation 
IFN-!  
Perforin 
IFN-! 
Granzyme B 
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cancer. Similarly, the transduction of IL-15 into NK-92 cells also increases NK cell 
proliferation and cytotoxicity (Jiang et al., 2008). 
 
 
Figure 1.18. Genetic modification of NK cells. Target genes can be transfected into NK cells 
in order to re-direct NK cell specificity. Likewise, genes that boost NK cell cytotoxicity can also 
be transfected. Reprinted with permission from Nature Publishing group. (Luevano et al., 
2012b) 
 
1.8.8 Adoptive Natural Killer cell immunotherapy 
 
The ability of NK cells to control leukaemia in the HSCT setting led to clinical studies of 
potential NK cell adoptive immunotherapy. NK cells can be isolated from CB or PB or 
even produced from HSCs in vitro to be used for immunotherapy (figure 1.19). The 
protocols using autologous NK cells revealed a lack of clinical effects (Burns et al., 
2003). Nevertheless, the promising results from HSCT revealing the potential benefits 
from alloreactive NK cells contributed to the notion of using allogeneic NK cells for 
adoptive immunotherapy. Miller and colleagues infused allogeneic NK cells together 
with IL-2 in patients with advanced cancer, demonstrating that donor NK cell infusions 
were feasible, and 5/19 patients with AML achieved complete remission (CR) (Miller et 
al., 2005). KIR-mismatch is a requisite for NK cell reactivity; many studies have taken 
advantage of this scenario and treat different malignancies like AML (Ruggeri et al., 
2002) and others (Miller et al., 2005; Pegram et al., 2008) (table 1.3).  
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Figure 1.19. NK cell adoptive immunotherapy. NK cells can be directly isolated from healthy 
donors or produced in vitro from HSCs. NK cells can be expanded/activated prior infusion into 
the recipient. Modified with permission from Nature Publishing group. (Luevano et al., 2012b) 
 
1.8.9 Natural Killer cell generation from haematopoietic stem cells  
 
To date, there have been multiple clinical trials exploring the NK cell potential to 
eliminate different types of cancer. NK cells have proved to be efficient killers of AML 
cells, as Ruggeri et al. has elegantly demonstrated in vitro, in animal models and finally 
in humans (Ruggeri et al., 1999; Ruggeri et al., 2002; Ruggeri et al., 2006). There are 
several sources of NK cells, including PB and CB as well as NK cells generated in vitro 
from HSCs. The following sections address the current approaches on NK cell 
generation protocols in vitro. 
 
1.8.9.1 Types of Natural Killer cell production 
 
The advances of NK cell immunotherapy relies on obtaining high numbers of non-
exhausted NK cells that will still be functional and able to proliferate in vivo. In this 
regard, different approaches have been explored. One option is to obtain NK cells 
directly by isolation from PB or CB although hindered by the limited number of NK cells 
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that can be obtained and the invasive nature of the procedure in the case of PB. 
Several protocols assessed the possibility to expand and/or activate PB NK cells in 
vitro using interleukins, cytokines, cell lines or chemicals for further use for 
immunotherapy (reviewed by Suck et al.) (Suck and Koh, 2010). CB represents a great 
source of NK cells due to the non-invasive collection procedure, the off-the-shelf 
availability and less stringent HLA-requirements. NK cells seem to be more naïve, but 
incubation with interleukins can potentially induce maturation and enhance their 
functions (Luevano et al., 2012a). Obtaining NK cells from PB and CB has the added 
advantage of immediate availability regardless of a long-term expansion in vitro. 
Nevertheless, exhaustion due to prolonged exposure to interleukins for NK cell 
activation is a disadvantage as NK cells are unable to kill and proliferate after infusion 
into the recipient. It has been reported that 1-2 x 107 cells/kg is a safe dose (Passweg 
et al., 2004) and even doses as high as 1 x 108 cells/kg have been tested for treatment 
of advanced cancers (Lundqvist et al., 2011). Due to the high NK cell doses needed, 
multiple infusions would be necessary for immunotherapy. Because freezing of NK 
cells is not considered an optimal procedure due to the reduced killing capacity after 
thawing (Fujiwara et al., 1986; Voshol et al., 1993), fresh samples are preferred for NK 
cell therapy in this context. Alternatively, in vitro systems to study NK cell ontogeny 
have shed light on the different factors and cytokines needed in the microenvironment 
to differentiate HSC into a NK cell (Kobari et al., 2000; McCullar et al., 2008; Bonanno 
et al., 2009). In light of these findings, a new alternative for obtaining high numbers of 
NK cells arose; the production of NK cells from HSCs in vitro. HSCs can be 
cryopreserved and used when needed for generation of large numbers of NK cells for 
immunotherapy. In this context, different sources of HSCs have been used with the 
direct/indirect aim to generate NK cells in vitro including BM (Miller et al., 1994; Mrozek 
et al., 1996), human embryonic stem cells (hESC) (Woll et al., 2005; Woll et al., 2009), 
mobilised PBSC (Yoon et al.; Zamai et al., 2012) and CBSC (Spanholtz et al., 2010; 
Spanholtz et al., 2011a; Dezell et al., 2012; Lehmann et al., 2012). All of these HSCs 
sources have their own advantages and disadvantages; their use will depend mostly 
on their availability and are briefly discussed in the following sections. 
1.8.9.1.1 Human embryonic stem cells 
  
hESC are obtained from 5-7 days old embryos, perhaps making this HSCs source one 
of the most controversial due to ethical and legal dilemmas. However, the 
establishment of cell lines from blastocysts has offered new perspectives in the use of 
hESCs for regenerative purposes and hundreds of cell lines have been established 
since 1989 (Allegrucci and Young, 2007). There are few protocols using hESC for NK 
cell generation purposes, for instance Woll et al. used the H9 hESC cell line to produce 
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NK cells (Woll et al., 2005). In the first publication in 2005, NK cells generated in vitro 
from this cell line expressed activating and inhibitory receptors, including KIRs and 
CD16. Moreover, NK cells were able to mediate cytotoxicity in vitro and produce 
cytokines. The same group later investigated the potential cytotoxicity of the generated 
NK cells in vivo (Woll et al., 2009). Interestingly, this work included a parallel 
experiments using CBSC, demonstrating better in vivo tumour clearance using hESC-
NK cells compared to CBSC-NK cells. Similarly, Knorr et al. just recently published a 
protocol to generate mature and functional NK cells from hESC and induced pluripotent 
stem cells (iPSC) (Knorr et al., 2013). Currently, immunotherapy using hESC is limited 
by the potential induction of a severe allogeneic immune response. However, as some 
authors suggest, a wide genetic diversity could be achievable by expansion of the 
hESC banks (Woll et al., 2005; Woll et al., 2009). 
 
1.8.9.1.2 Mobilised peripheral blood and bone marrow stem cells 
 
BM harbours a variety of stem cell populations, including endothelial stem cells, 
mesenchymal stem cells, multipotential adult progenitor cells, pluripotent stem cells 
and HSCs (Ratajczak et al., 2004). As NK cell development occurs mainly in the BM, 
certainly HSCs from this source should be able to successfully generate NK cells in 
vitro under the right conditions. Although BM is an alluring source of HSCs, its low 
numbers of cells along with the invasive collection procedure has disadvantages. 
Studies using BMSC have mainly focused on the study of NK cell ontogeny. For 
instance, the first NK cell progenitors (CD34+CD7+) were described using BM 
progenitors cultured over a murine feeder layer (Miller et al., 1994). Similarly, Shibuya 
et al. used CD34+ cells from BM to define the cytokine requirements for NK cell 
development. Although this study did not include a stromal feeder layer, it was reported 
that it is in fact needed for optimal NK cell differentiation, as NK cell percentages 
obtained were very low (Shibuya et al., 1995).  
 
The revolutionary introduction of G-CSF to mobilise HSC became a tool for simplifying 
and increasing harvests of these cells (Petit et al., 2002). Few studies have performed 
NK cell generation from PBSC. An interesting NK cell subset was generated during the 
culture of PBSC, termed NK immunoregulatory (NK-ireg) (Giuliani et al., 2008). This 
non-cytolytic subset showed a particular phenotype expressing HLA-G, NKp44 and 
CCR7. Of interest, NK-ireg generation is strictly dependent on trans-presentation of IL-
15. Another study using PBSC showed the generation of CD56dim and CD56bright NK 
cells, the former presenting predisposition to apoptosis (Zamai et al., 2012). Lastly, 
Yoon et al. used PBSC cells from HLA-mismatched donors to generate NK cells in vitro 
Chapter 1 
 83 
and performed post-transplant NK cell infusions. The generated NK cells had KIRs and 
NKG2D expression along with cytokine secretion. Overall, no cytotoxicity was reported 
although GvHD was observed in some cases (Yoon et al.).  
 
1.8.9.1.3 Cord blood stem cells 
 
Although controversial, the use of CBSC to generate NK cells in vitro has progressed 
rapidly especially since 2010. Some reports have demonstrated in the past that NK 
cells generated from CB are immature and less functional compared to the use of other 
sources such as BM or hESC (Kalberer et al., 2003; Woll et al., 2009). Nonetheless, 
supporting evidence from Grzywacs and colleagues suggest that CBSC under a proper 
microenvironment can give rise to functional and mature NK cells (Grzywacz et al., 
2006). These studies have also shed light into NK cell ontogeny, proposing the 
development of NK cells from myeloid precursors (Grzywacz et al., 2011). Similar to 
Miller et al. (Miller et al., 1994), the group of Haddad studied NK cell precursors but in 
CB finding a lymphoid T/NK precursor (CD34+CD7+) able to generate NK cells in vitro 
(Haddad et al., 2004). Even though these protocols were developed to study NK cell 
development, they provide the fundamentals needed to further development of NK cell 
protocols. Some other studies using CBSC to generate NK cells are shown in table 1.5.  
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Table 1.5. NK cells derived from CBSC. Reproduced with permission from Nature Publishing group. (Luevano et al., 2012b) 
Reference Source Feeder layer 
Fold 
expansion 
or cell 
number 
Phenotype Functionality 
Purity 
(end of 
culture) 
(Kao et al., 2007) CD133+ None 16 x 10
6 
cells CD56
+ cells: Perforin(-) and FasL(low) 
IFN-! production (2.77 
ng/mL) after IL-12/18 
stimulation 
 
Cr51 assay: 27% killing of 
K562 at 5:1 E:T ratio 
54% 
(McCullar et al., 2008) CD34+ EL08-1D2 and AFT024 
123,852 
cells Not described Not described 
Not 
described 
(Haddad et al., 2004) CD34+ MS-5 stromal cells 
112-130 
fold Not described Not described 95% 
(Grzywacz et al., 
2006) CD34
+ EL08-1D2 2852 fold 
CD56+CD117low:  
NKp44(+), CD161(+), NKp30(+), NKG2A(+/-), 
NKG2D(+/-) CD94 (+/-), CD16(-) and KIR(-)  
Cr51 assay: 48% killing of 
K562 at 5:1 E:T ratio 99% 
(Perez et al., 2006a) CD34+ None 910 x 10
6 
cells. 
CD161(+), NKG2D(+), NKp46(+), Perforin(+), 
CD16(+/-), CD94(+/-) and KIR(-) 
Cr51 assay: 78% killing of 
K562 at 5:1 E:T ratio 
Not 
described 
(Frias et al., 2008) CD34+ Human BM stromal cells 2 fold CD16(+/-) 
Cr51 assay: 15% killing of 
K562 at 5:1 E:T ratio 25.80% 
(Kobari et al., 2000) CD34+ MS-5 stromal cells 7-27 fold CD2(+/-), CD7(+/-), CD8(+/-) and CD16(-) Not described 72% ±7% 
(Bonanno et al., 
2009) CD34
+ None 
Using IL-15 
+ IL-21: 
400 fold 
UCB CD34+ derived: KIR(-)CD161(-)CD244(+) 
UCB CD34-lin- derived:  
KIR(-)CD244(+)CD161(+) 
CD34-lin- derived NK cells:  
CD107a assay K562: 
59.5% ratio 10:1 (IL-12+IL-
15 culture) 
92% 
E:T; effector to target ratio
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1.8.10 Feeder layers used in Natural Killer cell cultures 
 
During adult life, HSCs are maintained in the support microenvironment of the BM. The 
complete array of blood cell types are generated from HSCs as they differentiate and 
commit to specific cell lineages. Both, cell differentiation and commitment are 
controlled by complex interactions within the stromal microenvironment, consisting of 
different cell types (Lord et al., 1975). In an effort to examine the interactions between 
HSCs and stromal cells, several in vitro cultures using adherent cells from BM have 
been established (Gartner and Kaplan, 1980). Oostendorp and colleagues undertook 
the challenge of characterising the haematopoietic microenvironment using mouse 
embryos (Oostendorp et al., 2002). Studying the different organs that maintain 
haematopoiesis during embryogenesis, different feeder layers were established 
according to developmental stage from which they were derived. Haematopoiesis 
starts in the aorta-gonads-mesonephros region and later takes place in the foetal liver, 
which becomes a major haematopoietic organ during mid-gestation in mice. Notably, 
the feeder layer AFT024, derived from day 14.5 gestation of mouse foetal liver, has 
been shown to maintain HSCs activity for long periods of time (Moore et al., 1997). A 
major breakthrough using the feeder layer AFT024 for NK cell ontogeny came in 2001, 
where the need of stromal microenvironment and IL-15 was described to be critical for 
NK cell differentiation and receptor acquisition (Miller and McCullar, 2001). Later, the 
comparison between the feeder layers AFT024 and EL08.1D2 was performed in 2008, 
finding a superior capacity from EL08.1D2 to recapitulate the microenvironment 
needed for optimal NK cell development (McCullar et al., 2008). Another cell line used 
for NK cell expansion is M2-10B4 (murine BM) (Pierson et al., 1995), later compared to 
other cell lines (NRK-49F and NIH-3T3) in the search for factors controlling NK cell 
expansion (Pierson et al., 1996). These series of studies support the notion that of 
stromal feeder layers provide the necessary growth factors for optimal NK cell 
development in vitro.  
 
1.8.11 Good manufacturing practice procedures 
 
Good manufacturing practices (GMP) protocols have been established to assure 
quality of the final product. Although GMP guidelines may vary among countries, the 
basic concepts remain very similar- the final goal is to safeguard the health of the 
patients. Good progress has been made in the area of ex-vivo NK cell expansion in this 
regard. Several groups have isolated and expanded alloreactive NK cells for the 
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treatment of AML (Siegler et al., 2010) or other diseases (Sutlu et al., 2010). 
Additionally, CB NK cell expansion has been performed using low weight heparin and 
GMP-compliant procedures demonstrating high fold NK cell expansion (Tanaka et al., 
2011).  
 
In terms of NK cell production in vitro, the use of some reagents constitute a hurdle to 
comply with GMP. For example, foetal bovine serum (FBS), needed in culture due to 
the high content of growth factors, is complex in its contents and varies from batch to 
batch. Some protocols have been developed avoiding the use of FBS and substituting 
it with lipids, insulin or other ingredients. An example is that performed by Kao et al., in 
which a serum-free protocol was used to generate NK cells (CD56bright) from CB 
CD133+ cells (Kao et al., 2007). Along these lines, other serum-free cultures have been 
performed, where CB CD34-lin- (Bonanno et al., 2009) or CD34-CD7+ (Frias et al., 
2008) cells have been used to generate NK cells. Additionally, the work published by 
Spanholtz et al. during the last three years has demonstrated the feasibility of 
generating NK cells using CBSC and complying with GMP-procedures (Spanholtz et 
al., 2010; Spanholtz et al., 2011a). This may be the only group so far performing a 
clinical trial phase I using NK cells generated in vitro (NTR2818) and focuses on the 
treatment of AML patients that were not eligible for HSCT. The development of new 
reagents for clinical use will certainly speed up the incorporation of other NK cell 
protocols to be used in immunotherapy.   
 
1.8.12 Trafficking of Natural Killer cells after infusion 
 
One of the main questions regarding NK cell adoptive therapy is their potential 
trafficking. Initial studies by Walzer et al. performed in mice showed that NK cells traffic 
through blood, spleen, lung and liver (Walzer et al., 2007). Furthermore, Brand et al. 
performed infusion of labelled 111In-NK cells activated overnight to renal carcinoma 
patients. In order to assess circulation of NK cells in PB, they used a nested PCR 
technique to detect donor HLA-DRB1 alleles. Post-transfusion, all patients showed 
circulating NK cells by day 3 and after 7 days all donor cells were cleared. When 
assessing dissemination of NK cells, they found a systemic distribution with preference 
in liver, spleen and BM. No activity was observed in LNs (Brand et al., 2004).  
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1.9 Formulation of the problem and aims of this thesis 
 
Obtaining a large number of NK cells is an essential task and the most significant 
challenge to the development of successful NK cell adoptive transfer protocols. It has 
been previously reported that there is a dose-dependent effect of NK cells used in 
immunotherapy (Alici et al., 2007). Moreover, not only high NK cell numbers are 
needed, NK cell purity and optimal activation state are regarded as critical factors 
(Berg and Childs, 2010).  
 
As high numbers of NK cells can be generated in vitro from HSCs, CBSC and PBSC 
are promising sources for this approach. PBSC have become a more accessible cell 
source due to the use of mobilising agents and CBSC have the advantages of non-
invasive collection, less stringent HLA matching and off-the-shelf availability (; Mayani, 
2011). The use of cryopreserved HSCs would present a convenient option for 
immunotherapy. However, different studies reported that the expansion of frozen HSC 
could often be poor (Boissel et al., 2008a) with a decreased cell count and viability 
(Beshlawy et al., 2009), while others report that frozen CBSC could be used to 
generate NK cells (Spanholtz et al., 2010) because of their high proliferative and 
clonogenic capacity (Moezzi et al., 2005). In addition, with the rapid advancement in 
technology and new protocols supporting NK cell generation in vitro, the need for 
defining which source of HSCs, CBSC or PBSC, fresh or frozen, are better for this 
approach is critical. Thus, the specific aims of this thesis were: 
1) The optimisation of a NK cell generation protocol through the modification and 
comparison of a published protocol (chapters 3-5) 
2) The study of NK cell development and NK cell generation kinetics from CBSC 
and PBSC cultures (chapter 3) 
3) To investigate the phenotypic and functional characteristics of NK cells 
generated in vitro from CBSC and PBSC (chapters 4 and 5) 
4) To determine whether cryopreservation of CBSC has an effect on NK cell 
phenotypic and functional features (chapters 3-5) 
5) To investigate the role of the myeloid marker CD33 on the effector functions of 
NK cells generated in vitro (chapter 6) 
6) To study of the effects of IL-12 on phenotypic and functional characteristics of 
NK cells generated in vitro (chapter 6) 
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 Materials and Methods Chapter 2:
2.1 Materials 
2.1.1 Media, kits, buffers and plastic materials  
 
The culture media used for this thesis are listed in table 2.1. 
 
Table 2.1. Cell culture reagents 
CULTURE MEDIA COMPANY LOCATION 
Alpha MEM without L-glutamine Lonza Verviers, Belgium 
Dulbecco's Modified Eagle Medium (DMEM) 
high glucose with L-glutamine 
Lonza Verviers, Belgium 
Ham’s F12 Lonza Verviers, Belgium 
MyeloCult Stem cell  
Technologies 
Grenoble, France 
RPMI 1640 Lonza Verviers, Belgium 
 
The different types of serum used during this thesis are listed in table 2.2. 
 
Table 2.2. Serum 
SERUMS COMPANY LOCATION 
Bovine serum albumin (BSA) Sigma Poole, UK 
Foetal bovine serum (FBS) 
South America origin 
Lonza Verviers, Belgium 
Human Serum type AB (AB serum) Lonza Verviers, Belgium 
Mouse serum Sigma Poole, UK 
 
Cell isolation and labelling kits are listed in table 2.3. 
 
Table 2.3. Cell isolation and labelling kits 
KIT COMPANY LOCATION 
CD34 MicroBead kit Miltenyi Biotec Bergisch Gladbach, 
Germany 
CliniMACS CD133 Reagent  Miltenyi Biotec Bergisch Gladbach, 
Germany 
Human Granulocyte Depletion Kit Stem Cell 
Technologies 
Grenoble, France 
NK cell isolation kit Miltenyi Biotec Bergisch Gladbach, 
Germany 
PKH67 Fluorescent Cell Linker Kit Sigma Poole, UK 
 
Table 2.4 shows all the solutions and reagents used. 
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Table 2.4. Solutions and reagents 
 
Table 2.5 contains the buffers used and their composition.  
 
Table 2.5. Buffers 
Buffer Composition 
Blocking buffer for labelling 10% mouse serum in 1X PBS 
Freezing solution 90% FBS, 10% DMSO 
Labelling buffer (FACS), flow cytometry 1X PBS, 10% FBS 
Labelling buffer (MACS) for cell 
isolation 
1% BSA, 2 mM EDTA, 1X PBS 
Staining buffer for degranulation assay 1X PBS, 2% FBS, 2 mM EDTA 
Thawing buffer Dextran 40, 5% FBS, 0.63% Sodium citrate, 5 
mM MgCl2, 1000 IU/ml DNAse. 
Transport media 0.05 µM 2-Mercaptoethanol, 0.63% Trisodium 
citrate.  
Washing buffer for ELISA 1X PBS, 0.05% Tween-20 
SOLUTIONS & REAGENTS COMPANY LOCATION 
1450 microbeta Plus liquid Scintillation 
counter 
Perkin Elmer Cambridgeshire, UK 
AC-IETD-CHO (Granzyme B inhibitor) Life Technologies Paisley, UK 
!-mercaptoethanol (!-ME) Life Technologies Paisley, UK 
Bovine Gelatine Sigma Cambridgeshire, UK 
Chromium 51 Perkin Elmer Cambridgeshire, UK 
Dextran 40 Fresenius Kabi Barcelona, Spain 
Dimethylsuphoxide (DMSO) Sigma Poole, UK 
DNase  Merck KGaA Darmstadt, Germany 
Ethanolamine Sigma Cambridgeshire, UK 
Ethylenediaminetetraacetic acid (EDTA) 
0.5M ultra pure pH 8.0 
Life Technologies Paisley, UK 
Ficoll—Paque PLUS GE Healthcare Uppsala, Sweden 
GolgiStop™ BD Biosciences Oxford, UK 
Glutamax Life Technologies Paisley, UK 
Hydrocortisone Sigma Dorset, UK 
Heparin sodium 1000 IU/ml Sigma Cambridgeshire, UK 
Ionomycin (Iono) Sigma Cambridgeshire, UK 
Lympholyte VH BIO LTD. Gateshead, UK 
L-Glutamine 1640 Lonza Verviers, Belgium 
Magnesium chloride Sigma Poole, UK 
PBS 10X Lonza Verviers, Belgium 
Penicillin and streptomycin (Pen-Strep) Lonza Verviers, Belgium 
Perm/fix Buffer BD Biosciences Oxford, UK 
Phorbol myristate acetate (PMA) Sigma Cambridgeshire, UK 
BD Pharma lyse BD Biosciences Oxford, UK 
Sterile water Baxter Zurich, Switzerland 
Sodium Selenite Sigma Cambridgeshire, UK 
Trisodium citrate Sigma Poole, UK 
Triton 100X VWR International Leicestershire, UK 
Trypan blue (0.4%) Sigma Poole, UK 
Trypsin (0.25%) with EDTA  Life technologies Paisley, UK 
Tween 20 Sigma Poole, UK 
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Table 2.6 lists all the plastic materials used during this thesis. 
 
Table 2.6. Plastic material 
 
MATERIAL 
 
COMPANY 
 
LOCATION 
1 ml syringe BD Plastipack Madrid, Spain 
5 ml ploypropylene round bottom 
tube  
BD Biosciences Erembodegen, Belgium 
Blunt fill needle 21G BD Biosciences Erembodegen, Belgium 
Cell strainer 40 µM nylon BD Falcon Erembodegen, Belgium 
Cryotube vials (1.8 ml) foot round Nunc Roskilde, Denmark 
Falcon tubes, (15 and 50 ml) Sarstedt Numbrecht, Germany 
LS columns Miltenyi Biotec Bergisch Gladbach, 
Germany 
Minisart sterile filter Sartorius Stedim 
Biotech 
 Munich Germany 
Paraformaldehyde (PFA) Sigma Poole UK 
Pasteur pipettes Fisher                                Loughborough UK 
Serological pipettes, (5, 10 and 25 ml)  Sarstedt Numbrecht, Germany 
Tissue culture dish (92 x 17 mm) 
Nunclon surface 
Nunc Roskilde, Denmark 
Tissue culture flask (25, 75 and 150 
cm2) 
Sarstedt Numbrecht, Germany 
U-bottom 96-well plates Sarstedt Numbrecht, Germany 
V-Bottom 96-well plates Sarstedt Numbrecht, Germany 
 
2.1.2 Cell lines  
2.1.2.1 K562 
The cell line K562 was established from a 53-year-old female patient suffering from 
CML (Lozzio and Lozzio, 1975). Cells grow in suspension and form clumps. The K562 
cell line carries the Philadelphia chromosome, a chromosome translocation that results 
in the oncogenic BCR-ABL gene fusion. This cell line is sensitive to NK cell-mediated 
killing due to the absence of MHC class I antigens and the high expression of NKG2D 
ligands able to activate NK cells (Bae et al., 2012).  
 
2.1.2.2 EL08.1D2 
EL08-1D2 was cloned from an embryonic liver at day 11 of development, and it has 
been proven to support the generation of NK cells from human haematopoietic 
precursors (Grzywacz et al., 2011). This cell line was kindly provided by Dr. Robert 
Oostedrop. 
 
2.1.2.3 Raji 
Raji is a lymphoblast-like cell line established in 1963 from an 11-year-old Burkitt’s 
lymphoma patient by Pulvertaft (Pulvertaft, 1964). Raji is an NK-cell resistant cell line.  
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2.1.2.4 P815 
P815 is a mastocytoma mouse cell line derived by the treatment of methylcholanthrene 
of a DBA/2 male mouse (Gajewski et al., 2001). This cell line is Fc!R+ and is used for 
redirected cytotoxicity assays.  
 
2.1.3 Blood 
2.1.3.1 Umbilical cord blood  
CB samples were obtained after normal full-term delivery from the Anthony Nolan Cord 
Blood bank Nottingham, UK or from the Programa Concordia Banc de Sangi Teixits, 
Barcelona, Spain with written informed consent of the mother. Using routine banking 
procedures, samples were collected into a cord blood donation bag containing a 
citrate-phosphate-dextrose anticoagulant buffer and processed within 24 h.  
 
2.1.3.2 Peripheral blood  
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy 
volunteers, upon informed consent. Blood was collected into falcon tubes containing 
heparin or commercial tubes containing EDTA (BD Vacutainer). 
 
2.1.4 Flow cytometry 
2.1.4.1 Antibodies 
This work aimed to analyse the expression of activating and inhibitory markers as well 
as chemokine receptors and integrins on the generated NK cells. Table 2.7 includes 
the clones and fluorochromes for all the antibodies used in this work. 
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Table 2.7. Antibodies 
Antibody Company Catalogue number Clone Isotype Description 
7AAD BD Pharmingen  559925 -  - Apoptosis marker 
Anti-CD16 BD Pharmingen 555403 3G8 IgG1, ! ADCC assay 
Anti-CD33 eBiosciences 14-0338-82 WM-53 IgG1, ! Blocking assay, myeloid marker 
CCR5 R&D Systems 45531 45531 IgG2b, ! Chemokine receptor 
CCR6 R&D Systems 53103 53103 IgG2b, ! Chemokine receptor 
CCR7 BD Pharmingen 552176 3D12 IgG2a, ! Chemokine receptor 
CD3-PerCP BD Pharmingen 347344 SK7 IgG1, ! T cell marker 
CD7-PE eBiosciences 12-0079-42 124-1D1  IgG1, ! Lymphoid lineage marker 
CD8-FITC BD Pharmingen 345772 SK1 IgG1, ! CTL marker 
CD10-PE eBiosciences 12-0106-41 CB-CALLA  IgG2b, ! Myeloid lineage marker 
CD11a (LFA-1)-FITC BD Pharmingen 555383 HI111 IgG1, ! Integrin 
CD14-FITC Immunotools 21279143 MEM-15 IgG1, ! Monocyte marker 
CD19-PE Immunotools 21270194 LT19 IgG1, ! B cell marker 
CD33-PE BD Pharmingen 555450 WM53 IgG1, ! Myeloid lineage marker 
CD34-APC BD Pharmingen 555824 581 IgG1, ! Stem cell marker 
CD34-FITC BD Pharmingen 555821 581 IgG1, ! Stem cell marker 
CD34-PerCP BD Pharmingen 345803 8G12 IgG1, ! Stem cell marker 
CD38-APC BD Pharmingen 555462 HIT2 IgG1, ! Differentiation 
CD45-APC BD Pharmingen 555485 HI30 IgG1, ! Differentiation 
CD45RA-FITC BD Pharmingen 555488 HI100 IgG2b, ! Differentiation 
CD48-FITC BD Pharmingen 555759 TÜ145 IgM, ! Activating receptor 
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Antibody Company Catalogue number Clone Isotype Description 
CD49d-PE eBiosciences 12-0499-41 9F10  IgG1, ! Integrin 
CD56-APC BD Pharmingen 555518 B159 IgG1, ! NK cell marker 
CD56-PE BD Pharmingen 555516 B159 IgG1, ! NK cell marker 
CD94-FITC BD Pharmingen 555888 HP-3D9 IgG1, ! NK cell precursor marker 
CD95-FITC BD Pharmingen 555673 DX2 IgG1, ! Death receptor 
CD107a-FITC BD Pharmingen 555800 H4A3 IgG1, ! Degranulation  
CD117-PE BD Pharmingen 332785 104D2 IgG1, ! NK cell precursor marker 
CD133-PE Miltenyi 130-090-853 293C3  IgG2b, ! Stem cell marker 
CD158b-FITC BD Pharmingen 559784 CH-L IgG2b, ! Inhibitory receptor 
CD161-FITC BD Pharmingen 556080 DX12 IgG1, ! Cytotoxicity 
CD226 (DNAM-1)- 
FITC 
BD Pharmingen 559788 DX11 IgG1, ! Adhesion marker 
CD244 (2B4)-APC eBiosciences 16-2449 PP35  IgG1, ! Activating/inhibitory receptor 
CD253 (TRAIL)-PE BD Pharmingen 550516 RIK-2 IgG1, ! Death receptor 
CD314 (NKG2D)-PE Miltenyi 130-092-672 BAT221 IgG1, ! Activating receptor 
CXCR1 R&D Systems FAB330P 42705 IgG2a, ! Chemokine receptor 
CXCR4 R&D Systems FAB170P 12G5 IgG2a, ! Chemokine receptor 
CXCR7 R&D Systems FAB42271P 358426 IgG2a, ! Chemokine receptor 
Granzyme B-FITC BD Pharmingen 560211 GB11 IgG1, ! Cytotoxicity 
IFN-"-FITC BD Pharmingen 554551 4S.B3 IgG1, ! Immunomodulatory  
IL-2R! (CD25)-APC eBiosciences 17-0259 BC96 IgG1, ! Interleukin receptor 
IL-2R" (CD122)-PE BD Pharmingen 554525 Mik-B3 IgG1, ! Interleukin receptor 
IL-12R"1 (CD212)-
APC 
BD Pharmingen 558708 2.4 E6 IgG1, ! Interleukin receptor 
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Antibody Company Catalogue number Clone Isotype Description 
IL-15R! -PE eBiosciences 12-7159-42 eBioJM7A4 IgG2, # Interleukin receptor 
IL-18R-FITC eBiosciences 11-7183-42 H44 IgG1, ! Interleukin receptor 
Integrin "7-FITC eBiosciences 11-5867-42 FIB504  IgG2a, ! Integrin 
Isotype control-
FITC 
BD Pharmingen 554679 MOPC-21 IgG1, ! IgG1 Control  
Isotype-IgG1 BD Pharmingen 554721 107.3 IgG1, ! ADCC assay, control 
NKG2A-PE Beckman Coulter IM3291U Z199 IgG2b, ! Inhibitory receptor 
NKG2C-PE R&D Systems FAB138P 134591 IgG1, ! Activating receptor 
NKG2D-PE Miltenyi FAB139A BAT221 IgG1, ! Activating receptor 
NKp30-PE BD Pharmingen 558407 P30-15 IgG1, ! Activating receptor 
NKp44-APC Biolegend 325110 P44-8 IgG1, ! Activating receptor 
NKp46-APC BD Pharmingen 558051 9E2/NKp46 IgG1, ! Activating receptor 
 NKp80-PE Biolegend 346706 5D12 IgG1, ! Activating receptor 
Perforin-PE BD Pharmingen 556437 $G9 IgG2b, ! Cytotoxicity 
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2.1.5 Molecular biology  
2.1.5.1 RNA extraction 
The RNeasy Mini Kit from Qiagen (Crawley, UK) was used to extract RNA. The 
cleaning of pipettes and working surfaces was performed with RNaseZap (Pasley, Life 
Technologies, UK). 
 
2.1.5.2 Complementary DNA  
Reagents for the reverse transcription reaction are listed in table 2.8. 
 
Table 2.8. Complementary DNA reagents 
REVERSE TRANSCRIPTION 
REAGENTS 
 
COMPANY 
 
LOCATION 
dNTPs Life Technologies Paisley, UK 
DTT 0.1M Life Technologies Paisley, UK 
Random primers 500 µg/ml Promega Southampton, UK 
Recombinant RNA sin Inhibitor Promega Southampton, UK 
RNAse/DNAse free water Life Technologies Paisley, UK 
RNase Zap  Life Technologies Paisley, UK 
SuperScript II Reverse Transcriptase Life Technologies Paisley, UK 
 
2.1.5.3 Real time PCR 
The Precision 2X qPCR (real time PCR) Master Mix with Low ROX and SYBER green 
(Primer Design, Southampton UK) was used for all real time PCRs reactions. The 
reference gene kit geNorm (Primer Design) was used to determine optimal 
housekeeping genes for PB and CB samples. The selected genes include:  
• Homo sapiens actin, beta (ACTB), mRNA. 
• Homo sapiens ubiquitin C (UBC), mRNA. 
• Homo sapiens beta-2-microglobulin (B2M), mRNA. 
• Homo sapiens topoisomerase (DNA) I (TOP1), mRNA. 
• Homo sapiens ATP synthase, (ATP5B), mRNA. 
 
The reactions were carried out using 96 well optical reaction plates with barcodes and 
optical adhesive films from Applied Biosystems (Ca, US). The real time PCRs were 
performed using an AB 7500 Real time PCR system (Applied Biosystems, Ca, USA). 
 
2.1.5.4 Primers 
The sequence of the primers used is shown in table 2.9. All the primers were 
purchased from Sigma.  
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Table 2.9. Primer sequences 
Primer Sequence Source 
2B4 (CD244) F- 5’-GGTACAGAGGGAGCAAGCTG -3! R- 5’-CTCCTCCACACACAGAAGCA-3! (Zieker et al., 2005)  
BCL11B F: 5’-CTCTCACCCACGAAAGGCAT-3’ R: 5’-GCACGCAGAGGTGAAGTGAT-3’ (Pinho et al., 2012) 
E4BP4 F-5’-CCAAGGGCCCCATCCATTC-3! R-5’-GATGCCAGTGCTCCGATTTG-3’ (Vacca et al., 2011) 
EOMES F: 5’-ACTGGTTCCCACTGGATGAG-3’ R: 5’-CCACGCCATCCTCTGTAACT-3’ (Hertoghs et al., 2010) 
GATA-3 F: 5’-AGCACAGAAGGCAGGGAGTGT-3’ R: 5’-TTCGCTTGGGCTTAATGAGGGGC-3’ (Pinho et al., 2012) 
Granzyme B F: 5'-TGGGGGACCCAGAGATTAAAA-3' R: 5'-TTTCGTCCATAGGAGACAATGC-3' (Morissette et al., 2007) 
HELIOS F: 5’-ACACCTCAGGACCCATTCTG-3! 
R: 5’-TCCATGCTGACATTCTGGAG-3! 
(Cai et al., 2009) 
ID2 F-5’-CGGATATCAGCATCCTGTCC-3’ R-5’-TCATGAACACCGCTTATTCAG-3’  (Cupedo et al., 2009) 
IFN-! F-5’-CCAGGACCCATATGTAAAAG-3’ R-5’-TGGCTCTGCATTATTTTTC-3’ (Gober et al., 2008) 
IRF-2 F: 5’-CCTATGCAGAAAGCGAAACGACTGA-3! R: 5’-TCGAGTCCCCATGTTGCTGAGGT-3! (Pinho et al., 2012) 
KIR2DL1 
(CD158a) 
F-5’-GCAGCACCATGTCGCTCT -3! 
R-5’-GTCACTGGGAGCTGACAC-3’ (Cooley et al., 2007) 
KIR2DL2/DL3 
(CD158b) 
F-5’-GGAGGGGGAGGCCCATGAAT-3! 
R-5’-GTCGGGGGTTACCGGTTTTA-3’ (Cooley et al., 2007) 
NKG2A F-5’-ACTGAACAGGAAATAACCTAT-3! R-5’-ATGAGCTTCTCTGGAGCTGATC-3’ .(Arlettaz et al., 2004) 
NKG2C F-5’-CTCATGGATTGGTGTGTTTCGT-3! R-5’-CACTGTAAACGCAAATGCTTTACTTC-3’ 
Web resource: 
http://biowww.net/gene/g
ene-KLRC2.html 
Perforin F: 5'-CGCCTACCTCAGGCTTATCTC-3' R: 5'-CCTCGACAGTCAGGCAGTC-3 (Morissette et al., 2007)  
PU.1 F: 5’-TGTTACAGGCGTGCAAAATGGAAGG-3’ R: 5’-CTCGTGCGTTTGGCGTTGGTATAGA-3’ (Bonadies et al., 2010) 
RORC F-5’-AGTCGGAAGGCAAGATCAGA-3! R-5’-CAAGAGAGGTTCTGGGCAAG-3’ (Ortega et al., 2009) 
T-BET F: 5’-GGATGCGCCAGGAAGTTTCA-3’ R: 5’-CTCTGGCTCTCCGTCGTTCA-3’ (Pinho et al., 2012) 
TOX F: 5’-TATGTGCCAGCCAGCCAGTCCTA-3’ R: 5’-TGGTCTGGGAGGGAAGGAGGAGTAA-3’ (Pinho et al., 2012) 
 
All primers were tested by simulated PCR using Amplify 3x program (Bill Engels, 
University of Wisconsin 2005, http://engels.genetics.wisc.edu/amplify/).  
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2.3 Methods 
2.3.1 Overview 
This project combines different techniques in order to reach the proposed aims. A 
summary of the general methodology is described in figure 2.1. 
 
Figure 2.1. General methodology. Fresh CB was obtained and following ficoll separation, 
CD34+ stem cells were isolated from CB mononuclear cells (CBMCs) and used either 
immediately or frozen for further use. Mobilised peripheral blood stem cells were kindly provided 
in frozen cryovials by Dr Kwee Wong. Cells were plated in 96 flat bottom well plates over 
irradiated EL08.1D2 cells and cultured with a mixture of cytokines for 4-5 weeks. Throughout 
the culture, generated NK cells underwent a series of analysis, including intracellular staining 
(perforin, granzyme B, and IFN-"), degranulation assay by analysing CD107a expression, 
expression of chemokine receptors and integrins by flow cytometry, 51Cr killing assay and finally 
weekly RNA isolation for molecular work.  
 
2.3.2 Cell lines 
All cell lines except the adherent feeder layer were grown in suspension at 37°C with 
5% CO2 using 25, 75 or 125 cm2 flasks. The media for all suspension cell lines 
consisted of RPMI supplemented with heat inactivated FBS and 1% 
Penicillin/Streptomycin. The cell concentration was calculated using trypan blue to 
count only viable cells. Cells underwent a change of media every two to three days and 
were maintained at a concentration of between 0.3-1 x 106 cells/ml. 
 
The embryonic liver cell line EL08.1D2 was cultured on gelatinised plates at 32°C with 
5% CO2. Bovine gelatine 0.1% was used to coat the flasks for 15-30 min at 37°C and 
then washed with 1X PBS. The cells were plated in the appropriate volume (12 ml for 
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75 cm2, 24 ml for 125 cm2 and 30 ml for 175 cm2) of basic medium: 40.5% #–minimum 
essential medium (#-MEM), 50% myelocult, 7.5% FBS, with $-mercaptoethanol (50 
%M), glutamax (2 mM), penicillin (100 U/ml) / streptomycin (100 U/ml), and 
hydrocortisone (10-6 M) containing 20% of conditioning media (0.2 nm filtered 
supernatant from previous cultures). Cells were seeded at 4000 cells/cm2 and cultured 
until 95% confluence was reached. To detach and count the cells, the cells were 
trypsinised by washing the flask with 1X PBS and adding enough 0.25% Trypsin with 
EDTA to cover the surface of the flask (2, 5, and 7 ml for 75 cm2, 125 cm2 and 175 cm2 
respectively). After 4 min of incubation at 37°C and visual observation under the 
microscope of the detached cells, warm RPMI media with 10% FBS (basic media) was 
added to stop the trypsin’s action. Cells were collected and washed once with RPMI 
and centrifuged at 1200 rpm for 5 min. Prior to co-culture with progenitor cells, 
EL08.1D2 cells were irradiated for 7 min (3000 rads), plated in 96 well gelatin coated 
plates and left overnight to allow cell adhesion.  
2.3.3 Cell separation 
2.3.3.1 Mononuclear cell separation 
To obtain CBMCs, heparinised CB was mixed with an equal volume of transport media 
(table 2.5) and incubated at room temperature. After 45-60 min, CBMCs were isolated 
by density centrifugation through Ficoll—Paque PLUS (2000 rpm for 30 min without 
brake). The mononuclear cell layer was removed using a Pasteur pipette and washed 
twice with RPMI 1640. When needed, red cell lysis was performed with 1 ml of BD 
pharma lyse buffer for 4 min and an additional washing step was performed (10 min at 
1600 rpm at room temperature). Cells were resuspended at a concentration of 2 x 106 
cells/ml in basic media and counted using Turk’s (genetian violet and acetic acid 6%) 
staining reagent.  
 
When healthy control subjects were needed, isolated PBMCs were used. PB was 
mixed with an equal volume of RPMI medium and incubated at room temperature. 
Using 50 ml falcon tubes, the diluted blood was added to Lympholyte in a 2:3 ratio (3 
ml of Lympholite and 6 ml of diluted blood). The sample was centrifuged at 2000 rpm 
for 30 min at room temperature without brake. Next, PBMCs were isolated using the 
same procedure as CBMCs including washing, red cell lysis and cell counting.  
2.3.4 Freezing and thawing of cells 
 
Freezing cells 
Cells were resuspended on ice using a freezing solution (table 2.5). Cell lines were 
cryopreserved in liquid nitrogen in vials containing 5 x 106 cells in 1.8 ml final volume 
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(2.77 x 106 cells/ml). Isolated stem cells were frozen in the same solution at a 
concentration of 1 x 106 cells/ml). 
 
Thawing cells 
Cryovials were thawed in a 37°C water bath incubator. The freezing medium containing 
the cells was taken out using a Pasteur pipette and added to a 15 ml falcon tube 
containing 10 ml of warm basic media. Cells were centrifuged for 5 min at 1200 rpm 
and later resuspended in 10 ml of basic media. For isolated CD34+ or CD133+ stem 
cells a thawing buffer was used. Criovials were thawed in the 37°C water bath 
incubator and the mixture containing cells in freezing medium was added to 1 ml of 
thawing buffer. Next, 10 ml of basic media was added, cells were then centrifuged for 5 
min at 1200 rpm and then resuspended in 10 ml of basic media for enumeration. 
 
2.3.5 Cell isolation 
2.3.5.1 Natural Killer cell isolation 
NK cells were isolated using a negative selection kit (table 2.3). Cell labelling was done 
following the manufacturer’s instructions except for the final step in which the cells 
were resuspended in 5 ml instead of 500 %l of MACS buffer. Magnetic separation was 
carried out using LS columns (table 2.6). Cells were placed onto the magnetic columns 
and two washes of 7 ml of MACS buffer were performed. Unlabelled cells were 
collected in 50 ml falcon tubes, centrifuged at 1200 rpm for 10 min and counted using 
trypan blue.  
 
The mean of the purity (percentage) and standard deviation of the NK cell isolations 
was 85.2 ± 6.2% for PB and 89.4 ± 6.2% for CB (figure 2.2). 
 
 
Figure 2.2. NK cell isolations. NK cells were isolated from PBMCs or CBMCs by negative 
selection. A representative plot of isolated NK cells from PBMCs (A) and CBMCs (B) is shown; 
to determine purity, lymphocytes were gated according to forward versus side scatter (left 
panel) and from that gate the expression of CD56 versus CD3 was determined (right panel). NK 
cells are characterised by the expression CD56+ and absence of CD3-. 
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2.3.5.2 Stem cell isolation: 
 
Frozen CD34+ PBSC samples were kindly provided by Kwee Yong (UCL, Cancer 
Institute). Although fresh PBSC are regularly used for NK cell generation in vitro, only 
cryopreserved samples were available for this study. To isolate CB CD34+ cells, the 
CD34 MicroBead kit was used (table 2.3). The first isolations using the protocol 
provided by the manufacturer yielded very low purity (around 60%), therefore the 
protocol was modified according to a published protocol involving two labelling steps to 
improve purity (Jaatinen and Laine, 2007). All solutions were cold to avoid capping of 
antibodies. After CBMCs collection, 300 µL of labelling buffer (Table 2.5) with 20% AB 
serum was added per 108 cells (figure 2.3). The remaining labelling and magnetic 
separation procedure was performed according to the protocol. Isolated cells were 
collected, resuspended in basic media and counted with trypan blue. 
 
 
Figure 2.3. CD34 isolation. CBMCs were incubated with CD34+ MicroBeads plus FcR blocking 
reagent. After washing, cells were placed on a magnetic LS column and washed four times. 
Using the plunger provided by the manufacturer, cells were collected and a second labelling 
with MicroBeads and blocking reagent was performed. Cells were applied to a second column 
(MS) and after washes; cells were collected, resuspended and counted for further use. 
 
The purity of the isolations was analysed following the ISHAGE (International Society 
of Hematotherapy and Graft Engineering) guidelines (Sutherland et al., 1996). Figure 
2.4 shows a representative CD34 isolation. 
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Figure 2.4. Stem cell isolation from umbilical cord blood. 1) Forward versus side scatter 
analysis of CD34 isolated cells. 2) Sample stained with anti-CD45 APC gated in R1, stem cells 
are characterised by being CD45low. 3) 7AAD staining of R2 gate, gate R3 represents live 
CD45+ cells. 4) CD34+ versus side-scatter analysis of CD45+7AAD- cells. 5) Region 5 
represents CD34+CD133+7ADD- cells. 6) Gate R6 represents the lymphoblast gate from R5. 7) 
CD133+ versus CD34+ analysis showing live lymphoblastic double positive cells. The purity was 
calculated from the total events of double positive CD133+ and CD34+ divided by the total 
events of live cells: (R7/R3)*100. 
 
The purity of the performed isolations was analysed following the ISHAGE guidelines. 
The mean of the purity (percentage) and standard deviation of the CD34+ isolations 
was 93.2 ± 6%. 
 
2.3.6 Culture conditions  
2.3.6.1 Culture conditions for Natural Killer cell differentiation in vitro 
The Basal Culture Medium consisted of 2:1 (vol:vol) ratio of DMEM with 4.5g/l glucose, 
L-glutamine, and sodium pyruvate/Ham’s F12 Medium. This medium mixture was then 
supplemented with: 50 µM $ mercaptoethanol, 50 µM ethanolamine, 20 mg/l ascorbic 
acid, 50 µg/l sodium selenite, 1% penicillin + streptomycin and 20% heat-inactivated 
human AB serum. The media was kept at 4°C for up to one month. 
 
Two different cytokine mixes were used for NK cell cultures. In both cases, a 3 week 
period was maintained under the same condition (termed all cytokines): 10 ng/ml IL-15, 
5 ng/ml IL-3 (only for the first week), 20 ng/ml IL-7, 20 ng/ml c-kit ligand (SCF) and 10 
ng/ml Flt3 ligand. At week 3, all cytokines condition remains exactly the same for the 
rest of the culture time. Modified protocol: removal of all the factors and cytokines 
except for IL-15, a new concentration was assigned, 50 ng/ml (termed only IL-15). 
Cultures underwent weekly semi-depletion of fresh medium supplemented with the 
corresponding cytokines. 
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2.3.6.2 CD33 blocking 
In order to block CD33 on NK cells the anti-Human CD33 from eBiosciences (clone 
WM-53) antibody was used. NK cells were pre-incubated for 30 min with anti-CD33 at 
a concentration of 5 µg/ml (Hernandez-Caselles et al., 2006) for CD107a, intracellular 
staining for IFN-! and 51Cr killing assays. Cells were not washed and the antibody 
concentration was maintained during the assay.  
 
2.3.6.3 IL-12 incubation 
IL-12 was used to augment NK cell cytotoxicity and promote maturation. A 
concentration of 20 ng/ml for a period of 4, 24 and 40 h was used. Cells were plated in 
96 well plates at a final volume of 200 µl and incubated for 4, 24 and 40 h. The cells 
were then collected into a 50 ml falcon tube and washed with RPMI media before being 
used in assays.  
 
2.3.7 Characterisation by flow cytometry 
2.3.7.1 Cell surface staining 
Characterisation of NK cells was performed by flow cytometry. Prior to staining, Fc 
receptors were blocked with blocking buffer (Table 2.5) for 15 min at room temperature 
to inhibit the non-specific binding of the Fc portion of the fluorochrome-conjugated 
mAbs. After blocking, cells were incubated in the dark at 4°C for another 10 min 
(except for CXCR4 and CXCR7 for which 45 min incubation time was needed), washed 
and resuspended in FACS buffer. A FACS calibur (Becton & Dickson Oxford UK) was 
used to acquire data and FlowJo (Tree Star Inc., OR, USA) software for analysis.  
 
2.3.7.2 Functional assays 
2.3.7.2.1 Intracellular assay: 
!"#"$"!"%"% &'()!*
A total of 2 x 105 NK cells were transferred to 96 U shaped well plates and centrifuged 
for 3 min at 1800 rpm. Cells were incubated without stimulus or with cell lines (K562 or 
Raji ratio 1:1) or PMA 100 ng/ml and 1 %g/ml Ion as positive control for 1 h at 37°C, 5% 
CO2, 96% humidity in the incubator. After 1 h incubation, Golgi Stop (4 %l for every 6 x 
106 cells) was added to each well according to the manufacturer’s instructions and 
incubated for a further four hours. Cells were then blocked with mouse serum before 
antibodies were added (anti-CD56, -CD16 and -CD3) in 50 %l of labelling buffer and 
incubated for 10 min at 4°C in the dark. Next, cells were resuspended in 100 %l of 
Chapter 2 
 103 
permabilisation/fix buffer (BD cytofix/cytoperm plus, UK) and incubated for 5 min at 
room temperature. Following permeabilisation, cells were blocked, washed and 
resuspended in 50 %l of anti–IFN-! antibody or the appropriate isotype control made in 
Perm/Wash buffer and incubated for 1 h at room temperature in the dark. Cells were 
washed twice with and resuspended in Perm/Wash buffer before immediate analysis 
by flow cytometry.  
 
!"#"$"!"%"! +,-./-01*213*4-21567,*8*
A total of 2 x 105 NK cells were transferred to 96 U shaped well plates and were 
centrifuged 3 min at 1800 rpm. Cells were blocked with mouse serum before antibodies 
were added (anti-CD56, -CD16 and -CD3) in 50 %l of labelling buffer and incubated for 
10 min at 4°C in the dark. Next, cells were resuspended in 100 %l of permabilisation/fix 
buffer (BD cytofix/cytoperm plus, UK) and incubated for 5 min at room temperature. 
Following permeabilisation, cells were blocked, washed and resuspended in 50 %l of 
antibody anti–granzyme B, anti-perforin or the appropriate isotype control made in 
Perm/Wash buffer and incubated for 1 h at room temperature in the dark. Cells were 
washed twice with and resuspended in Perm/Wash buffer and immediately analysed 
by flow cytometry.  
 
2.3.7.2.2 Degranulation assay CD107a 
A total of 2 x 105 NK cells resuspended in 200 %l of complete medium were added to 96 
U shaped well plates. Cells were incubated for 2 h at 37°C, 5% CO2, 96% humidity in 
the incubator in the presence of only media, K562 or Raji (1:1 ratio), or PMA 100 ng/ml 
and 1 %g/ml Ionomycin as a positive control. Cells were then blocked for 15 min at 
room temperature with blocking buffer, centrifuged and stained for CD56, CD3 and 
CD16 in staining buffer for 10 min at 4°C. The cells were then washed and stained with 
anti-CD107a or the appropriate isotype control for 45 min at 4°C. Finally, the cells were 
washed, resuspended in 1X PBS containing 2% FBS and 2 mM EDTA before flow 
cytometry analysis. 
 
2.3.7.2.3 51Cr release assay 
Prior to the assay, the cell line K562 was sub-cultured and maintained at log phase 
(0.5-1 x 106 cells/ml). K562 cells were washed with 1X PBS and then labelled for 45 
min with 100 µCi / 1 x 106 at 37°C, 5% CO2, 96% humidity in the incubator. 
Subsequently, cells were washed twice with 1X PBS. Effector cells were plated in U-
bottom plates at effector-to-target ratios 1:1, 5:1 and 10:1 in triplicate in RPMI media 
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supplemented with basic media. Maximum Chromium release was obtained by 
incubating target cells with 1% Triton X in 1X PBS, while the minimum release was 
obtained by incubation with basic media. After 4 h co-culture at 37°C, cells were 
centrifuged at 1400 rpm for 4 min and 30 µl of supernatant was collected over 96 well 
plates and left overnight to dry. Once dried, 30 µl of scintillation solution was added in 
each well and the 96 well plate was read with the 1450 Micro beta counter. The 
percentage of specific lysis was calculated as (experimental release – spontaneous 
release)/(maximum release – spontaneous release) x 100.  
 
2.3.7.2.4 ADCC 
Prior to the assay, the murine cell line P815 was sub-cultured and left at log phase 
(0.5-1 x 106 cells/ml). P815 cells were washed with 1X PBS and then labelled for 45 
min with 100 µCi / 1 X 106 at 37°C. The cells were then washed twice with 1X PBS. 
P815 target cells were incubated for 30 min at 37°C with anti-CD16 (1 µg/ml) or the 
respective isotype at the same concentration. Finally, cells were washed twice with 1X 
PBS and the 51Cr release assay was performed as previously described.  
 
2.3.8 ELISA 
2.3.8.1 IFN-!  
To determine the amount of IFN-! in the samples, the Human Interferon–gamma 
Ready-set-go!® sandwich ELISA kit from eBioscience was used. Supernatants of 0.2 x 
106 NK cells stimulated (PMA, K562 or Raji cell lines ratio 1:1) and non-stimulated cells 
incubated at 37°C, 5% CO2, for 2 h were used. IFN-! was detected following the 
manufacturer’s instructions using the KC junior software (Bio-Tek, Vermont, USA).   
 
2.3.8.2 TNF- ! 
To determine the concentration of TNF-# in cell supernatants, the Human TNF alpha 
ELISA Ready-SET-Go!® kit from eBioscience was used. Supernatants of 0.2 x 106 NK 
cells stimulated (PMA, K562 or Raji cell lines ratio 1:1) and non-stimulated cells 
incubated at 37°C, 5% CO2, for 2 h were used. TNF-# was detected following the 
manufacturer’s instructions using the KC junior software (Bio-Tek, Vermont, USA). 
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2.3.9 Molecular characterisation of cord blood Natural Killer cells, peripheral 
blood Natural Killer cells and Natural Killer cells generated in vitro 
2.3.9.1 RNA 
RNA extraction was performed using the RNAeasy Minikit according to the 
manufacturer’s instructions except for the final step in which RNA was dissolved from 
the column with 30 µl (two spins of 15 µl each, to increase yield) of RNAse free water 
and immediately placed onto ice. The RNA concentration was measured using the 
Nano Drop ND-1000 spectrophotometer (NanoDrop Technologies, Inc., BE, USA) and 
then stored at -80°C.  
 
2.3.9.2 Reverse transcription  
Extracted RNA was used as a template to create complimentary DNA (cDNA). 200 ng 
of RNA were added to a PCR tube (Thermo Scientific, USA) together with distilled H20 
(d.H20), 2 µl of random primers and 1 µl of dNTPs. The mixture was incubated in the 
Eppendorf Mastercycler thermocycler (Eppendorf USA via Fisher Loughborough UK) 
for 5 min at 65°C and then 5 min on ice. Next, 4 µl of Buffer 5X were added, 2 µl of 
DTT (0.1M), and 1 µl of RNase inhibitor. This mix was incubated for 10 min at 25°C 
and then 2 min at 42°C. 1 µl of Superscript III was added to the tube and an additional 
incubation of 50 min at 42°C was performed. Lastly, a 15 min at 70°C step was made. 
The cDNA stock was diluted by the addition of 40 µl of d.H20 and used immediately or 
stored at -20°C.  
 
2.3.9.3 Real time PCR 
All PCR preparation work was performed on ice. The primer concentrations used are 
shown in table 2.10. The final volume in all reactions was 25 µl, containing 10 µl of 
PCR precision 2X precision Mix, the appropriate amount of forward and reverse 
primers according to the concentration used, 5 µl of cDNA and finally the d.H20 was 
adjusted according to the primer concentration. 
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Table 2.10. Real time PCR primer concentrations 
Primer HSC and CB NK cells (nM) PB NK cells (nM) 
2B4 (CD244) 900 900 
BCL11B 300 300 
E4BP4 300 300 
EOMES 200 300 
GATA-3 300 300 
Granzyme B 300 300 
HELIOS 600 600 
ID2 300 300 
IFN-! 300 300 
IRF-2 300 300 
KIR2DL1 (CD158a) 600 600 
KIR2DL2/DL3 (CD158b) 600 600 
NKG2A 900 600 
NKG2C 900 600 
Perforin 900 900 
PU.1 300 300 
RORC 900 900 
T-BET 300 300 
TOX 300 300 
 
All reactions (except E4BP4) were performed using the following programme, 2 min 50 
°C, 10 min 95 °C, and 50 cycles of 15 sec 95 °C and 1 min 60 °C. For E4BP4 we used: 
2 min 50 °C, 10 min 95 °C, and 40 cycles of 15 sec 95 °C and 30 sec 60 °C. 
 
2.3.10 Statistics 
Statistical comparisons were performed with GraphPad Prism software (GraphPad 
Software) using the nonparametric Mann–Whitney test or paired t-test. Results are 
presented as means ± standard deviation (SD), p<0.05 were considered statistically 
significant. For comparisons between fresh and frozen CBSC cultures, a blue asterisk 
(*) is shown if there was any statistical significance, whereas a black asterisk is shown 
between the comparisons of frozen CBSC and PBSC (*). In some instances where 
only “fresh CBSC” and “all cytokines” legends appear, fresh CBSC is the same as “only 
IL-15”. * p<0.05, ** p<0.01, ***p<0.001. 
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 Production of Natural Killer cells in vitro Chapter 3:
from haematopoietic stem cells 
 
3.1 Introduction 
 
Different sources of HSC have been used to generate NK cells in vitro including BM 
precursors (Miller et al., 1994; Mrozek et al., 1996), hESC (Woll et al., 2005; Woll et al., 
2009), PBSC (Yoon et al., 2010; Zamai et al., 2012) and CBSC (Spanholtz et al., 2010; 
Spanholtz et al., 2011a; Dezell et al., 2012; Lehmann et al., 2012). Each of these 
sources has their own advantages and disadvantages. 
 
BM has been a preferred source of HSC to study NK cell development but not 
particularly to produce NK cells for immunotherapy. Numerous studies used BM to 
generate NK cells in vitro in order to identify the precursors that give rise to NK cells in 
humans (Miller et al., 1994; Haddad et al., 2004; Grzywacz et al., 2011; Vacca et al., 
2011) and the cytokines and microenvironment requirements for these precursors to 
develop into NK cells (Mrozek et al., 1996; Kusadasi et al., 2001; Sivori et al., 2003). 
To our knowledge, there are currently no clinical protocols using BM precursors in 
order to generate NK cells for immunotherapy. The two major drawbacks to develop 
NK cells from BM precursors are the nature of its invasive collection delivering low 
HSC per sample (Korbling and Anderlini, 2001) and stringent HLA-matching 
requirements.  
 
The use of hESC for NK cell generation purposes has been tested with promising 
results (Woll et al., 2005; Woll et al., 2009). However, the nature of these cells is what 
has stopped further developments in this area as destroying 5-7 days old embryos for 
immunotherapeutic purposes would be unethical. Nevertheless, hESC cell lines have 
been developed and are currently tested for NK cell production in vitro but additional 
characterisation is needed and, notably, such an approach will have to overcome 
safety requirements in order to be translated to the clinic. 
 
As mentioned above, BM and hESC are great sources of HSC but carry ethical 
predicaments or involve invasive collection procedures. The introduction of G-CSF into 
the clinics has allowed the collection of HSC in a safe and less invasive procedure. A 
few studies report using PBSC as a HSC source to produce NK cells in vitro (Giuliani 
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et al., 2008; Zamai et al., 2012). In addition, CB is another promising HSC source 
providing convenient collection procedures and off-the-shelf availability. The number of 
units available worldwide (http://www.bmdw.org/) (Mayani, 2011) along with the less 
stringent HLA-matching makes CBSC an optimal source for NK cell generation in vitro. 
However, one study in particular reported unfavourable outcomes regarding the use of 
CBSC for this approach (Woll et al., 2009). The study performed by Woll et al. showed 
that hESC generated NK cells with a mature phenotype and a potent cytolytic activity 
as compared to a mix of immature/mature cells with less anti-tumour activity derived 
from CB (Woll et al., 2009). The need for defining whether CBSC or PBSC are better 
HSC sources for this approach is critical.  
 
The use of cryopreserved cells will enable the off-the-shelf availability of the cell 
products in clinical settings. Different studies showed that expansion of frozen HSC is 
often poor (Boissel et al., 2008a) with a decreased stem cell count and viability 
(Beshlawy et al., 2009), while others report that frozen CBSC could be used to 
generate NK cells (Spanholtz et al., 2010) because of their high proliferative and 
clonogenic capacity, ex vivo expansion (Lu et al., 1996; Moezzi et al., 2005), and 
engraftment potential in immunocompromised mice (Broxmeyer et al., 2003). There 
have been several studies using fresh or frozen CBSC with the direct or indirect aim of 
generating NK cells in vitro (Grzywacz et al., 2006; Spanholtz et al., 2010; Spanholtz et 
al., 2011a; Dezell et al., 2012; Pinho et al., 2012); however a comprehensive study of 
the impact of using both sources of HSC for generating NK cells for immunotherapy 
has not yet been performed.  
 
A variety of protocols for NK cell generation have been published (reviewed by 
Luevano et al.(Luevano et al., 2012b)). We chose to use the protocol developed by 
Grzywacs et al. (Grzywacz et al., 2006) for this study in which a combination of SCF, 
IL-7, IL-15, FLT3 ligand and the feeder layer EL08.1D2 was used. Because previous 
reports have shown that IL-15 plays a key role for NK cell development and that the 
remaining factors (SCF, IL-7 and FLT3 ligand) will only increase NK cell precursor 
frequencies (Cavazzana-Calvo et al., 1996; Mrozek et al., 1996), we decided to test the 
withdrawal of all factors except IL-15 at week 3 and increased IL-15 concentration 
(from 20 ng/mL to 50 ng/mL) as this modification decreased the amount of cytokines 
used and therefore reduced costs.  
 
In this work a comparison between CBSC and PBSC as HSC sources for NK cell 
generation in vitro because of their advantages over hESC and BMSC was performed. 
As the use of fresh samples is commonly used in protocols generating NK cells, the 
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first aim was to analyse the impact of using a published protocol (referred to as all 
cytokines) (Grzywacz et al., 2006) and a modified protocol (only IL-15 for the last two 
weeks, referred to as only IL-15) using fresh CBSC. Next, the use of fresh versus 
frozen CBSC and CBSC versus PBSC as HSC sources for NK cell generation in vitro 
was investigated. This chapter describes a detailed study of NK cell generation 
including NK cell fold expansion, NK cell number retrieved, expression of lymphoid and 
myeloid lineage markers and finally a comprehensive characterisation of NK cell 
development including a molecular profile of transcription factors.  
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3.2 Results 
3.2.1 Frozen cord blood stem cells cultures generate higher Natural Killer cell 
numbers than fresh cord blood stem cell cultures and peripheral blood 
stem cell cultures 
 
During this thesis, CB CD34+ cells (CBSC) were isolated using MACS as described in 
section 2.3.5.2, mobilised PB CD34+ cells (PBSC) were kindly provided by Dr Kwee 
Yong. CBSC (fresh or frozen) and PBSC (frozen) were cultured for up to 5 weeks and 
fold expansion, NK cell number, viability and NK cell yield were assessed on a weekly 
basis. We investigated the proliferation of the seeded cells by enumeration of the total 
cell number per well. A higher fold expansion in frozen CBSC cultures at day 21 and 28 
(p<0.05) compared to fresh CBSC and PBSC cultures was observed, nonetheless, at 
day 35 only a difference in fold expansion between fresh and frozen CBSC cultures 
was found (189.7 ± 88.5 versus 520.1 ± 134.3, respectively, p<0.05, figure 3.1A). 
When using fresh CBSC, all cytokines or only IL-15, no differences were observed in 
fold expansion or NK cell numbers (figure 3.1B and 3.2B respectively). In addition, 
higher NK cell numbers in frozen CBSC cultures than fresh CBSC and PBSC cultures 
were found (day 28 and 35, p<0.05) (figure 3.2A).  
 
Figure 3.1. NK cell production from HSC cultures in vitro. A) Median values ± SD of the 
total fold expansion of fresh CBSC (n=5), frozen CBSC (n=9) and PBSC (n=6) cultures at 
different time points. B) Total fold expansion of CBSC cultures using all cytokines (n=3) or only 
IL-15 (n=3). Total amount of cells were counted and fold expansion was calculated by division 
of this number by the initial number of HSC seeded (total number cells/500 initial cells)* 100. 
Mann-Whitney test was performed, * p<0.05, ** p<0.01, ***p<0.001. 
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Figure 3.2. Total NK cell number from HSC cultures. A) CD3-CD56+ cells from fresh CBSC 
(n=3), frozen CBSC (n=9), PBSC (n=6) cultures and B) from CBSC cultures using all cytokines 
(n=3) or only IL-15 (n=3). Cell numbers were calculated as follow: (initial amount of stem cells 
seeded [0.288 x 106] x fold expansion [for each time point] x NK cell percentage)/100. Mann-
Whitney test was performed, * p<0.05, ** p<0.001, ***p<0.001. 
 
In order to monitor viability, staining for 7AAD was performed on a weekly basis. All the 
cultures displayed good viability with no significant differences between HSC cultures 
(figure 3.3).   
 
 
Figure 3.3. Cell viability in HSC cultures. A) Percentage of 7AAD- cells from the lymphocyte 
gate of fresh CBSC (n=3), frozen HSC (n=9), PBSC (n=6) cultures and B) CBSC cultures using 
all cytokines (n=3) or only IL-15 (n=3) for all time points. 
 
NK cells are characterised by the expression of CD56 cell surface marker and the 
absence of CD3; we analysed the expression of these markers on a weekly basis to 
assess NK cell yield in each culture. Figure 3.4A depicts NK cell production from fresh 
and frozen CBSC and PBSC cultures throughout the culture. Figure 3.4B shows NK 
cell production from fresh CBSC cultures using all cytokines or only IL-15 throughout 
the culture. A rapid increase in NK cell percentage from day 14 to day 21 was 
observed; by day 35 the majority of the cells in culture were NK cells. Additionally, the 
cultures displayed different NK cell subsets as analysed by flow cytometry, especially 
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in NK cells derived from fresh CBSC cultures (CBSC-NK cells, figure 3.4). Fresh 
CBSC-NK cells exhibited two distinct populations according to CD56 expression, 
similar to CD56bright and CD56dim NK cell subsets. These two populations were also 
present in frozen CBSC cultures, but the majority of the cells appeared to be CD56dim 
NK cells. Interestingly, defined NK cell subsets in PBSC cultures were not observed. In 
addition, the mean fluorescent intensity (MFI) of CD56 on the generated NK cells was 
analysed. Although difference between cultures was not found, a trend for higher CD56 
MFI in fresh CBSC cultures was observed (figure 3.5).  
 
 
Figure 3.4. NK cell yield in HSC cultures. A) CD3-CD56+ NK cell percentages from the 
lymphocyte gate at different time points for fresh CBSC (n=3), frozen CBSC (n=9) and PBSC 
(n=6) cultures. The right panel shows a representative plot of CD56 versus CD3 expression for 
the aforementioned samples. B) Graph shows CD3-CD56+ cell percentages from the 
lymphocyte gate at different time points for CBSC cultures using all cytokines (n=3) or only IL-
15 (n=3). The right panel shows a representative plot of CD56 versus CD3 expression for 
CBSC cultures using all cytokines (n=3) or only IL-15 (n=3).  
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Figure 3.5. CD56 median fluorescent intensity. A) Median fluorescent intensity (MFI) of 
CD56 at different time points for fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) cultures 
and B) CBSC cultures using all cytokines (n=3) or only IL-15 (n=3). 
 
CD56 acquisition on the generated NK cells was very similar between CBSC cultures 
and slower in PBSC cultures (figure 3. 6). At day 21 only 52.1 ± 19.2% of the cells were 
CD56+ in PBSC cultures, compared to 78.2 ± 7.9% for frozen CBSC cultures and 73.7 
± 17.5% for fresh CBSC cultures. Nevertheless, CD56 expression was similar in all 
cultures by day 35 (figure 3.6). In summary, frozen CBSC showed a robust NK cell 
production in vitro exhibiting good viability and yielding higher NK cell numbers than 
other HSC sources.  
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Figure 3.6. CD56 receptor acquisition in HSC cultures. A representative FACS plot of SSC-
Height versus CD56 from the lymphocyte gate is shown from days 7-35 for fresh CBSC, frozen 
CBSC, PBSC and fresh CBSC cultures using all cytokines.   
 
3.2.2 Absence of T, NKT and B cells in haematopoietic stem cell cultures 
 
During the culture period, the presence of different cell lineages was analysed. The 
cytokine cocktail used in this study included IL-7, which is known to be important for T 
cell development (Puel et al., 1998). Several conditions like GvHD or Epstein-Barr-
virus-associated lymphoproliferative disease could be induced due to the presence of 
allogeneic T or B cells, respectively (Miller et al., 2005). Therefore, having high purity 
during the culture is critical for adoptive immunotherapy. The presence of B cells 
(CD19) and T cells (CD3 and CD8) at different time points in the different HSC cultures 
was monitored using flow cytometry. Very low percentages of T cells (CD3+, 0.9% ± 
1.7), CTL (CD8+, 5.7% ± 3.1) and B cells (0.7% ± 1) were found in each culture (figure 
3.7).  
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Figure 3.7. Different cell lineages in HSC cultures. Cells were stained with anti-CD3, -CD8 
and -CD19. A) The graph depicts the mean and SD of CD8+, CD3+ and CD19+ cells in all 
cultures from the lymphocyte gate: fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) cultures 
and CBSC cultures using all cytokines (n=3) or only IL-15 (n=3) at different time points. B) Flow 
cytometric analysis of a representative sample of frozen CBSC cultures at day 35. The left 
panel shows the FACS plots from the lymphocyte gate of CD3 versus CD19 and the right panel 
CD3 versus CD56.  
 
In summary, the data indicates that during the culture of HSCs, the majority of cells 
develop into NK cells with very low percentages of T or B cells present throughout the 
culture.  
 
3.2.3 Absence of monocytes in haematopoietic stem cell cultures 
 
Some groups have reported the generation of monocytes (CD14+) using in vitro culture 
systems to produce NK cells (Spanholtz et al., 2010; Lehmann et al., 2012). Therefore 
the screening in each culture for the presence of CD14+ cells was performed. 
Interestingly, a transitory expression of CD14 on days 7 and 14 only in frozen cultures 
was observed (Figure 3.8, CBSC and PBSC). Sconocchia et al. have shown the 
existence of NK cells with monocyte-like properties (Sconocchia et al., 2005a). These 
cells exist in PBMCs in very low frequency, around 1.2%, and can be generated in vitro 
from CBSC. This subset exhibits monocyte characteristics and is CD56low, CD33+, 
HLA-DR+, CD11bhigh and CD14+. Thus, the co-expression of CD14 and CD56 on the 
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generated NK cells was analysed. Figure 3.9 shows that the generated NK cells did not 
co-express CD56 and CD14 at day 35. 
 
 
 
Figure 3.8. CD14 expression in HSC cultures. Graphs shows the mean cell percentage and 
SD values of CD14+ cells from the lymphocyte gate for fresh CBSC (n=3), frozen CBSC (n=9), 
PBSC (n=6) cultures and CBSC cultures using all cytokines (n=3) at different time points. Mann-
Whitney test was performed, * p<0.05, ** p<0.001, ***p<0.001. 
 
 
Figure 3.9. CD14 expression at days 14 and 35 in HSC cultures. Flow cytometric analysis of 
a representative sample for fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) and CBSC 
cultures using all cytokines (n=3). FACS plots presented come from the lymphocyte gate, cells 
were labelled with anti-CD56 and anti-CD14 at day 14 (A) and day 35 (B).  
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In summary, although a transitory expression of CD14 was observed in some cultures, 
the absence of monocytes was confirmed during culture of HSCs irrespectively of the 
source of HSC or of the cytokine cocktail used.  
3.2.4 Analysis of lymphoid lineage marker expression 
3.2.4.1 CD10 expression 
 
HSC can give rise to all blood cell lineages. NK cells have been traditionally thought to 
originate from the lymphoid lineage; nevertheless, recent reports suggest that NK cells 
can also be generated from myeloid precursors (Perez et al., 2003; Grzywacz et al., 
2011). Haddad et al. have shown that the expression of CD45RA, CD34 and CD7 
commits cells to the T/NK cell lineage whereas the expression of CD45RA, CD34 and 
CD10 commits cells to the B cell lineage (Haddad et al., 2004). The presence of 
CD45RA on CB CD34+ cells was analysed; however, no CD34+CD45RA+ cells were 
detected (data not shown). Therefore, in this study the expression of CD45 and gated 
on CD45+CD7+/CD10+ cells from the lymphocyte gate was analysed. Figure 3.10A 
shows the expression of CD10 in lymphocytes during the complete culture, resembling 
a U-shape. CD10 expression was high during the first weeks of culture, which then 
decreased at day 14 and 21 and finally a slight increase in CD10 expression was noted 
at days 28 and 35. The same tendency was found in fresh CBSC cultures using all 
cytokines or only IL-15 (figure 3.10B). We did not find any significant differences 
between cultures. It was interesting to observe the expression of CD10 at day 35 on 
the generated cells in vitro, when almost 100% of the cells are NK cells.  
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Figure 3.10. CD10 expression in HSC cultures. The percentage of CD45+CD10+ positive cells 
from the lymphocyte gate are presented; cells were labelled with anti-CD45 and CD10 at 
different time points for A) fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) cultures and B) 
CBSC cultures using all cytokines (n=3) or only IL-15 (n=3). C) Histograms showing the 
expression of CD10 (black line) and the control (non-stained, grey solid line) of a representative 
sample for fresh CBSC, frozen CBSC, PBSC and CBSC cultures using all cytokines at day 35. 
 
Although CD10 expression has been described to define lymphoid precursors that give 
rise to B cells, we observed a substantial expression of CD10 on the initial HSC 
population and on NK cells generated in vitro. However, whether this population could 
or not differentiate into NK cells under our culture conditions remains unknown. 
 
3.2.4.2 CD7 expression 
 
Another lymphoid marker used to define the T/NK cell lineage together with the 
expression of CD45RA and CD34 is CD7 (Haddad et al., 2004). The CD7 expression 
was analysed in the different types of culture. Surprisingly, a similar U-shape 
expression pattern was observed, where CD7 expression was higher at the beginning 
and at the end of the culture. Additionally, at the end of the culture CD45+ cells from 
fresh CBSC cultures expressed more CD7 compared to frozen CBSC cultures 
(p<0.05), and CD45+ cells from frozen CBSC expressed more CD7 than PBSC cultures 
(p<0.05) (figure 3.11A). Figure 3.11B shows that CD7 expression was high among 
fresh samples using all cytokines or only IL-15, but no significant difference between 
these cultures was found.  
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Figure 3.11. CD7 expression in HSC cultures. The percentage of CD45+CD7+ positive cells 
from the lymphocyte gate are presented; cells were labelled with anti-CD45 and CD7 at different 
time points for A) fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) and B) CBSC cultures 
using all cytokines (n=3) or only IL-15 (n=3). C) Histograms showing the expression of CD7 
(black line) and the control (non-stained, grey solid line) of a representative sample for fresh 
CBSC, frozen CBSC, PBSC and CBSC cultures using all cytokines at day 35. Mann-Whitney 
test was performed, * p<0.05, ** p<0.01. 
 
Although not all HSCs were positive for CD7, it could be noted, especially for frozen 
CBSC cultures, that a high percentage of CD45+CD7+ cells was found. This could 
partly explain the higher number of NK cells obtained in frozen CBSC cultures, 
however the recruitment of other precursors is a scenario that cannot be excluded in 
this system.   
 
3.2.4.3 CD5 expression 
 
T-cell development occurs when T-cell precursors migrate to the thymus where they 
can proliferate and subsequently give rise to mature T-cells (Blom and Spits, 2006). 
Early T-cell progenitors express CD5, its expression increases as the cell matures and 
acquisition of CD3 occurs (Weiss et al., 1987). CD5 is also expressed by a subset of B 
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cells (Kaplan et al., 2001) and has been suggested to promote B-cell survival (Gary-
Gouy et al., 2002). As CD5 is expressed in early lymphoid progenitors, CD5 expression 
was followed during the culture of HSCs (figure 3.12A and B). Surprisingly, PBSC 
cultures had a trend for a higher expression during the whole culture (day 28, p<0.05). 
CD5 expression among CD45+ cells gradually decreased during the culture, especially 
in fresh CBSC cultures using all cytokines or only IL-15 (figure 3.12B).  
 
 
Figure 3.12. CD5 expression in HSC cultures. The percentage of CD45+CD5+ positive cells 
from the lymphocyte gate are presented; cells were labelled with anti-CD45 and CD5 at different 
time points for A) fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) and B) CBSC cultures 
using all cytokines (n=3) or only IL-15 (n=3). C) Histograms showing the expression of CD5 
(black line) and the control (non-stained, grey solid line) of a representative sample for fresh 
CBSC, frozen CBSC, PBSC and CBSC cultures using all cytokines at day 35. Mann-Whitney 
test was performed. ** p<0.01. 
 
As expected, CD5 expression was observed during the first weeks of HSC cultures, 
where lymphoid progenitors might be present; thereafter its expression decreased 
although PBSC cultures had higher expression of CD5 compared to CBSC cultures. 
  
3.2.5 Analysis of myeloid lineage marker expression 
 
Recently, there have been several works highlighting the possibility of deriving NK cells 
from myeloid progenitors (Perez et al., 2003; Grzywacz et al., 2011); as a 
consequence the expression of CD33, a myeloid marker, was analysed in the cultures 
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(figure 3.13). A high percentage of CD45+CD33+ cells throughout the culture of frozen 
samples was found (CBSC and PBSC). CD33 expression decreased in fresh CBSC 
cultures at day 21; nonetheless, values at day 35 were similar for all cultures.  
 
Figure 3.13. CD33 expression in HSC cultures. The percentage of CD45+CD33+ positive cells 
from the lymphocyte gate are presented; cCells were labelled with anti-CD45 and CD33 at 
different time points for A) fresh CBSC (n=3), frozen CBSC (n=9), PBSC (n=6) cultures and B) 
CBSC cultures using all cytokines (n=3) or only IL-15 (n=3).  
 
Due to the high CD33 expression observed, it was investigated whether NK cells were 
co-expressing this marker. The expression of CD33 versus CD56 was monitored from 
day 7 to day 35 (figure 3.14). From these data it was possible to observe the following:  
1) By day 35, almost the majority of CD56bright cells in fresh cultures express CD33 
whereas only a fraction of CD56dim do. 
2) In fresh cultures, CD33+ cells at day 7 switch to the CD56+CD33- quadrant at 
day 14 and 21, and later acquire CD33. 
3) CD33+ cells from frozen CBSC cultures gradually acquire CD56, whereas we 
can observe two distinct populations (CD33+CD56- and CD33-/low CD56+) at day 
21 and 28 in PBSC cultures.  
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Figure 3.14. CD33+CD56+ co-expression in HSC cultures. A representative flow cytometric 
analysis of the expression of CD56 versus CD33 from lymphocyte gate on samples from fresh 
CBSC, frozen CBSC, PBSC and CBSC cultures using all cytokines at different time points is 
shown.   
 
The expression of CD33 on NK cells was an unexpected observation; this myeloid 
marker is usually absent in PB and CB NK cells. Thus, further experiments regarding 
its potential role on NK cell functional features were performed and are described in 
chapter 6. 
 
Altogether, the data demonstrated the presence of lymphoid and myeloid markers in 
HSC cultures at different time points with singular kinetics depending on the marker.  
3.2.6 Natural Killer cell development in haematopoietic stem cell cultures 
 
NK cell differentiation in vitro offers the opportunity to study NK cell development and 
numerous in vitro studies contributed to the identification of the factors and cytokines 
that drive NK cell ontogenesis in vitro (Miller et al., 1994; Miller et al., 1998; Miller and 
McCullar, 2001; Briard et al., 2002; Grzywacz et al., 2006; Beziat et al., 2010; 
Grzywacz et al., 2011; Lee et al., 2011). The presence of NK cell precursors has been 
reported in different organs/tissues (Sanchez et al., 1994; Vacca et al., 2011) and the 
culture of these precursors has led to different concepts of NK cell development. The 
NK cell development model described by Freud and Caligiuri (Freud et al., 2006) 
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identifies four NK cell stages based on the expression of the surface markers CD117, 
CD94 and CD34. Stage 1 is defined by the expression of CD34+CD117-CD94-, stage 2 
by CD34+CD117+CD94-, stage 3 by CD34-CD117+CD94- and stage 4 by CD34-
CD117+/-CD94+. The frequency of these four stages was assessed in fresh CBSC 
(using all cytokines or only IL-15), frozen CBSC and PBSC cultures. 
 
The first objective was to assess whether the use of only IL-15 for the last two weeks of 
culture impacted on NK cell maturation. A representative graph showing the different 
stages according to time for fresh CBSC cultures using all cytokines or the modified 
protocol is shown in figure 3.15A and 15D, respectively. No significant difference 
among the distribution of NK cell stages throughout the culture was observed between 
the two cultures (figure 3.15-17). Moreover, two different stage 3 populations were 
found, CD117+CD94- and CD117brightCD94-, in fresh CBSC cultures when using all 
cytokines (figure 3.17). NK cell development is orchestrated by molecular events that 
regulate the transition from one stage to another (Hesslein and Lanier, 2011; Martin-
Fontecha et al., 2011; Luevano et al., 2012c). TFs are key for this molecular regulation 
(Bezman et al., 2012b; Pinho et al., 2012). The expression of different TFs controlling 
NK cell development such as ID2, E4BP4 and RORC (figure 3.18) was investigated. 
The expression of E4BP4 and RORC was higher during the first two weeks of culture, 
whereas ID2 showed slightly higher expression during the last two weeks (figure 
3.18A). These factors were expressed similarly in both types of culture without any 
significant difference. These results suggest that using IL-15 for the last two weeks 
instead of all factors did not impact negatively on NK cell development. 
 
Next, it was analysed whether the use of frozen HSC would impact on NK cell 
development and maturation. A representative graph showing the different stages 
according to time for fresh and frozen CBSC cultures is shown in figure 3.15A and 15B, 
respectively. No significant differences were observed when comparing percentages of 
NK cell stage 1 between fresh and frozen CBSC cultures at day 0. In accordance with 
previous publications, a high expression of CD117 on CBSC was found (Rappold et al., 
1997; Wisniewski et al., 2011); hence most of the cells at that time point were in stage 
2. The differentiation of fresh CBSC into NK cells appeared slower for the first 2 weeks 
of culture, evidenced by the presence of the 4 stages by week 2 in frozen CBSC 
cultures (figure 3.15B). By week 3, stage 2 was almost undetectable in both cultures 
(figure 3.16). Stages 3 and 4 represented the majority of cells during the last two 
weeks of culture and their distribution was the same for both cultures (figure 3.15 and 
17). Interestingly, the majority of the cells in stage 4 in fresh CBSC cultures were 
CD117+, compared to cells in stage 4 in frozen CBSC cultures, which were CD117low/- 
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(figure 3.17). In addition, analysis of the messenger expression for the transcription 
factors controlling NK cell development was performed for E4BP4, ID2 and RORC 
(figure 3.18). A higher expression of the these factors during the first three weeks in 
fresh CBSC cultures was found while the expression of these TFs was very similar in 
both cultures during the last two weeks of culture. In summary, frozen CBSC 
developed into NK cells faster, with a different expression of TFs for the first weeks of 
culture and a final NK cell distribution similar to that of fresh CBSC cultures with 
however a more mature CD117low/-population.  
 
Finally, the analysis of NK cell development using two different HSC sources was 
performed: frozen CBSC and PBSC. As mentioned before, CBSC expressed a high 
level of CD117 (Rappold et al., 1997), and a high incidence of stage 2 was therefore 
detected at day 0 (figure 3.15B) whereas both stage 1 and 2 were found in PBSC 
cultures at day 0 (figure 3.15C). A higher incidence of stage 3 in CBSC cultures by 
week 2 compared to PBSC cultures was observed, probably due to the high initial 
levels of stage 2 in these cultures (figure 3.17). Unlike CBSC, NK cell development 
was slower in PBSC cultures; however, the final distribution of stages 3 and 4 was 
similar at the end of the culture (figure 3.17). Moreover, we explored the expression of 
some TFs involved in NK cell differentiation (E4BP4, ID2, PU.1, RORC and TOX) and 
maturation (BCL11B, EOMES, GATA-3, HELIOS, IRF2 and T-BET) in the generated 
NK cells (figures 3.19 and 20). For both cultures, PU.1 was expressed more during the 
first 3 weeks of culture with a subsequent decrease in expression (figure 3.19), 
whereas E4BP4, ID2, RORC, TOX, BCL11B, EOMES, T-BET were expressed more 
during the last 2 weeks of culture (figures 3.19 and 20). There was a constant 
expression of IRF2 and a variable expression of GATA-3 during the whole culture and 
interestingly, HELIOS had a remarkably high expression in cells from CBSC cultures at 
week 1, but not in PBSC cultures (figure 3.20). The expression of some TFs was also 
analysed in resting CB and PB NK cells and compared to NK cells generated in vitro 
(day 35). Figure 3.21 shows that the expression of E4BP4 and HELIOS was similar 
among all the samples. However, ID2 was expressed more in NK cells generated in 
vitro (CBSC and PBSC, p<0.05) whereas a trend for a lower expression of T-BET was 
observed (CBSC and PBSC, p=0.075) compared to CB and PB NK cells. Altogether, 
the data suggest that PBSC cultures showed a delayed NK cell development but 
expressed similar levels of TFs compared to CBSC cultures.  
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Figure 3.15. NK cell precursors in HSC cultures. Percentages represent CD3- cells from the 
lymphocyte gate according to the NK cell stages: stage 1: CD34+CD117-CD94-, stage 2: 
CD34+CD117+CD94-, stage 3: CD34-CD117+CD94- and stage 4: CD34-CD117+/-CD94+. The 
graph shows one representative experiment for fresh CBSC (A, n=3), frozen CBSC (B, n=9), 
PBSC (C, n=6) and CBSC cultures using all cytokines (D, n=3) where stages 1-4 are plotted 
according to different time points. 
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Figure 3.16. Flow cytometric analysis of NK cell stages 1 and 2 in HSC cultures. Flow 
cytometric analysis showing a representative sample of fresh CBSC (n=3), frozen CBSC (n=9), 
PBSC (n=6) and CBSC cultures using all cytokines (n=3). FACS plots showing CD34 versus 
CD117 expression from the CD3-CD94- gate according to NK cell stages: stage 1: 
CD34+CD117-CD94-, stage 2: CD34+CD117+CD94-. 
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Figure 3.17. Flow cytometric analysis of NK cell stages 3 and 4 in HSC cultures. Flow 
cytometric analysis showing a representative sample of fresh CBSC (n=3), frozen CBSC (n=9), 
PBSC (n=6) and CBSC cultures using all cytokines (n=3). FACS plots showing CD117 versus 
CD94 expression from the CD3-CD34- gate according to NK cell stages: stage 3: CD34-
CD117+CD94- and stage 4: CD34-CD117+/-CD94+. 
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Figure 3.18. Transcription factors involved in NK cell differentiation in fresh CBSC 
cultures. Total RNA was extracted from fresh CBSC cultures using A) all cytokines (n=3) or B) 
only IL-15 (n=3) and analysed by qPCR. The mRNA expression of ID2, E4BP4 and RORC was 
measured at different time points. The mean and SD of the ratio target gene/reference gene is 
presented for each sample. 
 
 
Figure 3.19. Transcription factors involved in NK cell differentiation in frozen HSC 
cultures. Total RNA was extracted from frozen CBSC (n=4) and PBSC (n=3) cultures and 
analysed by qPCR. The mRNA expression of E4BP4, ID2, PU.1, RORC and TOX was 
measured at different time points. The mean and SD of the ratio target gene/reference gene is 
presented for each sample. 
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Figure 3.20. Transcription factors involved in NK cell maturation in frozen HSC cultures. 
Total RNA was extracted from frozen CBSC (n=4) and PBSC (n=3) cultures and analysed by 
qPCR. The mRNA expression of BCL11B, EOMES, GATA-3, HELIOS, IRF2 and T-BET was 
measured at different time points. The mean and SD of the ratio target gene/reference gene is 
presented for each sample. 
 
 
Figure 3.21. Expression of transcription factors in CB, PB, frozen CBSC and PBSC NK 
cells. Total RNA was extracted from resting NK cells negatively isolated from CB (n=4) and PB 
(n=3) and NK cells from frozen CBSC (n=4) and PBSC (n=3) cultures and analysed by qPCR. 
The mRNA expression of E4BP4, HELIOS, ID2 and T-BET was measured at day 35 for HSC 
cultures. The mean and SD of the ratio target gene/reference gene is presented for each 
sample. Mann-Whitney test was performed, * p<0.05. 
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3.3 Discussion 
 
In this chapter the potential of frozen CBSC to give rise to NK cells in vitro was 
investigated and different parameters between the use of fresh and frozen CBSC, and 
frozen CBSC and PBSC for this approach were compared. Among these parameters 
the impact of using only IL-15 for the last two weeks of culture instead of all cytokines 
used in a published protocol was studied (Grzywacz et al., 2006). Moreover, the cell 
expansion, viability, markers associated with different cell lineages and finally NK cell 
development among all cultures was studied.  
 
The use of frozen cells is one of the most important variables for the clinical translation 
of a NK cell expansion protocol. Clinically, it is easier to utilise frozen cells, as they are 
often available off-the-shelf and can be preserved for long periods of time. The majority 
of the published protocols aimed at generating NK cells in vitro use fresh CBSC. 
Therefore, fresh CBSC were used and a comparison of the use of only IL-15 during the 
last weeks of culture to the use of a complete cytokine mix as previously reported was 
performed (Grzywacz et al., 2006). The use of only IL-15 for the last weeks did not 
impact on the total fold expansion, NK cell numbers or viability. The role of IL-15 on NK 
cell development, proliferation, cytotoxicity and viability has been previously studied 
(Carson et al., 1997; Cooper et al., 2002; Becknell and Caligiuri, 2005). It was 
expected that the use of a higher IL-15 concentration for the last weeks would impact 
on cell expansion and viability, but it did not. One possibility would be that the IL-15 
concentration used (20 ng/mL) saturated the IL-15 receptors promoting good viability 
and proliferation, suggesting that higher IL-15 concentration (50 ng/mL) would then not 
impact on these parameters.  
 
Next, the use of frozen CBSC and fresh CBSC in terms of expansion, NK cell numbers 
and viability was studied. All cultures showed high viability in comparison to other 
works (Yoon et al.), and intermediate fold expansions of reported values were 
observed (Mrozek et al., 1996; Grzywacz et al., 2006). Frozen CBSC cultures showed 
higher and faster cell expansion than fresh CBSC cultures. This observation differs 
from published works where expansion of frozen HSC was often poor (Boissel et al., 
2008a; Boissel et al., 2008b) but agreed with another study that showed frozen CBSC 
could be used to generate NK cells (Spanholtz et al., 2010). In addition, higher NK cell 
numbers were retrieved using frozen CBSC compared to fresh CBSC. It is important to 
note that, during this work, separate CB samples were used, however, standard 
deviations from both cultures were low. A major difference in fold expansion between 
the cultures was observed from day 14 to 21, just before the withdrawal of all cytokines 
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and IL-15 maintenance. This suggests that the cytokine cocktail does not account for 
the differences in NK cell numbers and fold expansion. It is plausible that the starting 
population in fresh and frozen CBSC is different. Fresh CBSC may contain a 
combination of different HSC/progenitors; the freezing process might eliminate some of 
these cells leaving a population that is more viable, the ‘fittest’, leading to higher HSC 
expansion.  
 
From that point on, all analyses were performed using frozen CBSC and the modified 
protocol and a comparison to another HSC source, PBSC, was performed. The data 
indicate that CBSC generate higher NK cell numbers compared to PBSC, while total 
fold expansion and viability were similar. There are only a few reports using PBSC, for 
instance, Zamai et al. observed that cells cultured using IL-15 and IL-21 had a 
predisposition for apoptosis, whereas the withdrawal of IL-21 gave rise to immature 
cells that exhibited longer survival (Zamai et al., 2012). It is difficult to make a direct 
comparison among studies due to the use of different HSC sources and 
cytokine/feeder layer combinations. Though, it is interesting that Miller et al. observed 
different proliferation according to the HSC source (Miller and McCullar, 2001) and 
others have suggested that different hematopoietic precursors are present according to 
the CD34+ source (BM, PB and CB) (Sconocchia et al., 2004). Similar to the results in 
this study, Miller et al. reported that proliferation was greater using HSC earlier in 
ontogeny (foetal liver>UCB>BM) (Miller and McCullar, 2001).  
 
All cultures showed high NK cell yield, above 90%. While any difference in NK cell yield 
among fresh CBSC cultures (using all cytokines or only IL-15) and frozen CBSC 
cultures was observed, a slower CD56 acquisition in PBSC cultures was found. 
Regardless of this slower CD56 acquisition, the final yield remained similar compared 
to CBSC cultures. Overall, the cytometric analysis showed that the generated NK cells 
were all CD56+ but with a distinct distribution. Fresh CBSC cultures generated NK cells 
with two distinct populations, resembling CD56bright and CD56dim NK cell subsets. In 
contrast, the majority of the frozen CBSC derived NK cells appeared to be CD56dim, 
while PBSC-NK cells had no defined distribution. Confirming these findings, the CD56 
MFI analysis suggested that fresh CBSC-NK cells had a tendency for higher MFI 
compared to frozen CBSC and PBSC. The mechanisms responsible for these 
differences remain unknown in the model used in this study. The impact of this CD56 
distribution will have an effect on NK cell phenotype and functions, as described in the 
next chapters.  
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We also analysed the different cultures for the presence of cells that could potentially 
be a health risk when infused in an allogenic setting: T cells and B cells. Purity is one 
of the major concerns in today’s clinical protocols. A recent NK cell expansion protocol 
by Sutlu et al. received criticism for having a final product with low purity (Berg and 
Childs, 2010; Sutlu et al., 2010). As for in vitro generation of NK cells using HSC, the 
protocols in most instances favour the generation of NK cells preventing the 
emergence of other cell types (Spanholtz et al.; Miller et al., 1992). In this study, a 
transitory expression of CD14 especially in frozen cultures (CBSC and PBSC) was 
observed. CD14 is expressed mainly by monocytes and macrophages (Simmons et al., 
1989). There is no evidence to support the lack of CD14 expression during early 
stages of fresh CBSC cultures. Nonetheless, CD14 expression was transitory in frozen 
HSC cultures and very low levels were detected at the end of the culture. In fact, none 
of the generated NK cells expressed CD14, supporting the absence of monocyte-like 
NK cells in the present study. None of the cultures exhibited significant levels of CD3 or 
CD19 cells, which was a great advantage as the final product was more than 90% 
pure, negating the need for additional positive or negative selection to eliminate 
unwanted cells. This has an impact on cost and also NK cell retrieval by avoiding 
unnecessary cell loss.  
 
A better understanding of NK cell ontogeny has been gained in recent years. Miller et 
al. identified a CD34+CD7+ NK cell precursor using human primitive marrow progenitors 
(Miller et al., 1994). Similarly, Haddad and colleagues described lymphoid precursors 
in CB (Haddad et al., 2004) as characterised by the expression of CD34, CD45RA and 
either CD7 (T/NK-cell lineage) or CD10 (B-cell lineage). In this study, it was not 
possible to identify these populations (according to Haddad’s study) due to the 
absence of CD45RA expression in the isolated CBSC. It was previously reported that 
CBSC have low expression of this marker (Fritsch et al., 1993) at around 20%. 
Therefore, it was decided to gate from the lymphocyte gate on the CD45+ cells. When 
the percentage of CD45+CD7+ and CD45+CD10+ for both conditions were analysed, 
interesting differences in CD7 expression were found. Initially, CD7 expression on 
CD34+ cells had a tendency to be higher in frozen CBSC, than on fresh CBSC and 
PBSC cultures, which is possibly because the amount of committed NK cell progenitors 
was lower in PBSC. Although it has been previously described that resting NK cells 
have high expression of CD7 (Rabinowich et al., 1994), CD7 expression remained low 
throughout the complete culture in PBSC cultures. In addition, CD7 has been proposed 
as a marker for discrimination between NK cells from monocyte/DC-like cells; with the 
coexpression of CD7 and CD56 defining degranulating and IFN-γ secreting cells 
(Milush et al., 2009). By day 35, a higher CD7 expression on fresh CBSC cultures was 
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observed (fresh CBSC> frozen CBSC> PBSC). It is difficult to predict if NK cells will 
have less IFN-γ secretion or would be less able to degranulate based on CD7 
expression as this suggestion would conflict with evidence advocating that low CD7 
expression found on the generated NK cells can be caused by cell activation 
(Rabinowich et al., 1994). NK cells in the culture from this study have been exposed to 
IL-15 for prolonged periods, providing them with an activated phenotype (discussed in 
the next chapter). Conversely, while studying other lymphoid lineage markers 
interesting data suggesting co-expression of CD10 and CD56 was found. To our 
knowledge, the co-expression of CD10 and CD56 on NK cells from healthy individuals 
has not been reported. CD10 is mainly expressed in germinal centre B cells, lymphoid 
progenitors, granulocytes and some T cells (Knapp et al., 1989). The report of an 
Acute Lymphoblastic Leukaemia case co-expressing B-precursor-cell and NK-cell 
antigens is intriguing (Matsubara et al., 2004), suggesting that NK cells generated in 
vitro differ from this biological system. Moreover, a small percentage of cells (PBSC> 
frozen CBSC> fresh CBSC) expressed CD5, a marker for T cells and for a subset of B 
cells (Kaplan et al., 2001). A previous study in patients with pulmonary tuberculosis 
showed the presence of CD5low NK cells in low frequency but with high lytic activity 
(Ishiyama et al., 1993). If the same cells also expressed CD5 and CD10 along with 
CD56 remains unknown in the present study, as this staining was not performed. 
Therefore, the impact of CD10 and CD5 expression on NK cells would need to be 
investigated further. 
 
Several reports have suggested that NK cells can be derived from the myeloid lineage 
(Perez et al., 2003; Grzywacz et al., 2011) but not exclusively. In agreement with 
results of these studies, a recent report found that CB NK cell progenitors express 
CD33 from stage 2 to 3 (Eissens et al., 2012). Interestingly, NK cell development data 
reveals that even though stage 2 cells are not present in the cultures by week 3, stage 
3 cells were observed throughout the culture. It is possible that the presence of CD33 
in the final product was attributed to stage 3 cells (figure 3.22). However, these 
observations conflict with other studies. For instance, Montaldo et al. also showed that 
CD161-CD56-LFA1+CD33+ cells could give rise to CD161+CD56+LFA1-NKp44+(CD33-) 
(Montaldo et al., 2012). During this work, CD45+CD33+ cells also give rise to CD56+ 
cells. However, more than half of the generated NK cells co-expressed CD33 at day 
35. In our hands, fresh CBSC cultures generated CD56bright cells showing more CD33 
expression compared to the CD56dim subset. A recent report has shown that culture of 
G-CSF-mobilised CD34+ using IL-2 and SCF produces CD56dimCD33+ cells and a 
CD56brightCD33+population. The presence of CD33 on CD56bright cells was attributed to 
the presence of IL-2 (Sconocchia et al., 2004). In line with these findings, others 
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suggest that CD33 expression is present due to the environmental conditions in the 
culture (Kalberer et al., 2003); furthermore, Hernandez-Caselles described that 
activated NK cells express an isoform of CD33 (Hernandez-Caselles et al., 2006).  
 
In summary, there are several studies revealing the role of CD33 on NK cells, but they 
are inconsistent and contradictory. These reports suggest that CD33 is expressed in 
immature cells, CD56dim cells or activated cells, making it difficult to conclude the 
function of this receptor on the generated NK cells. Figure 3.22 shows a plausible 
scenario combining developmental stages, CD56 expression and CD33 expression. 
During this study, only discrete populations in fresh CBSC cultures were found, where 
CD33 expression is favoured in the CD56bright subset (stage 4). However in theory, 
CD33 should be expressed only in stages 2 and 3 but since only stage 3 is present at 
day 35, it is possible that CD33+ cells are actually in stage 3. The loss of CD33 might 
represent a maturation step that gives rise to stage 4 and 5 cells. Additional 
experiments were performed, and are described in chapter 6, that attempt to elucidate 
the role of CD33 in the cells generated in our cultures.  
 
 
 
Figure 3.22. Expression of CD33 on different subsets of the generated NK cells. The figure 
shows the FACS plots of CD33 versus CD56 from the lymphocyte gate of NK cells derived from 
fresh CBSC cultures (left panel), frozen CBSC cultures (middle panel) and PBSC cultures (right 
panel).  
 
NK cell development was investigated from fresh CBSC using all cytokines or only IL-
15 or from frozen CBSC and PBSC. Understanding NK cell development and 
maturation may have implications for cancer therapy and for immunity against 
infections. NK cell development analysis in our study was based on the model 
proposed by Freud et al. (Freud et al., 2006). This study was performed using lymph 
nodes (LN) precursors, thus our results might not strictly resemble those by Freud et 
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al., as our HSC sources are different. While analysing the final cell product in fresh 
CBSC culture using either all cytokines or only IL-15 we did not find any significant 
differences among the final NK cell stage distribution. Nevertheless, two different stage 
3 populations were found by cytometric analysis in CBSC cultures when using all 
cytokines (CD117+CD94- and CD177highCD94-). So far no differences have been found 
between the original protocol and the modified protocol; even the mRNA of the studied 
TFs remained similar between cultures. Grzywacz et al. described the coordinated 
acquisition of NK cell markers and defined stages using CD94 and CD117 receptors 
(Grzywacz et al., 2006). In fact, this study reports the presence of intermediary subsets 
between CD117+CD94- and CD117-CD94+: CD177highCD94-. Indeed, the presence of 
this subset only in fresh CBSC using all cytokines was observed, which was the same 
cytokine cocktail and cell source used in this report. We cannot exclude the existence 
of this subset in the fresh CBSC cultures using only IL-15 as we did not perform a daily 
screening. In summary, the system used supports the notion that factors like IL-7, SCF 
and FLT3L along with those secreted by the feeder layer are only needed for NK cell 
lineage commitment. Subsequently, IL-15 drives NK cell maturation as previously 
reported (McCullar et al., 2008).  
 
After establishing NK cell development was not affected by removal of all factors and 
IL-15 maintenance, we investigated whether the use of frozen CBSC would impact on 
NK cell development. Fresh and frozen CBSC cultures resulted in a heterogeneous 
population with both immature CD117+CD94- and mature CD117-/lowCD94+ NK cells, 
whereas other reports showed above 90% of cells in stage 4 by day 35 (Grzywacz et 
al., 2006; Dezell et al., 2012). This suggests that the transition from stage 3 to stage 4 
might take longer in our culture system or may need additional signals that were not 
provided. When two transcription factors involved in NK cell maturation were analysed, 
E4BP4 and ID2, a high expression of E4BP4 during the first two weeks of culture only 
in fresh CBSC cultures was found. This is interesting due to the fact that E4BP4 
contributes to the transition between NK cell precursors (stage 2) to iNK cells (stage 3) 
in previous mouse studies (Gascoyne et al., 2009). Taking into account that transition 
from stage 2 to 3 actually took place at weeks 2 and 3 (when the highest E4BP4 
expression was observed), our results correlate with the molecular profile for fresh 
CBSC cultures. Similarly, ID2 is essential for the transition of iNK to mNK cells (Colucci 
et al., 2001), this TF was expressed more during the last two weeks of culture when 
this transition might occur. In fact, Gascoyne et al. suggested that ID2 is probably 
downstream of E4BP4 in mice (Gascoyne et al., 2009). Accordingly, we observed a 
similar pattern in fresh HSC cultures, where E4BP4 was expressed during the first 
weeks and ID2 during the last two weeks.  
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Next, we investigated whether NK cell development in CBSC and PBSC cultures 
differed. Initially, PBSC cells contained a 50/50 ratio of NK cell stages 1 and 2 whereas 
CBSC contain mainly cells from stage 1. The impact of this different distribution at day 
0 was reflected on the slower CD56 acquisition and delayed NK cell development 
observed in PBSC throughout the culture. When studying expression of TFs, it was 
found that during the first weeks of culture, only PU.1 was highly expressed, which is 
important for regulating the expression of stem cell factor and IL-7 receptors that play a 
key role in the transition of NK cell precursors to iNK and mNK (Colucci et al., 2001). 
The data suggests that there is minimal importance of PU.1 in later stages of NK cell 
maturation, as previously described (Pinho et al., 2012). Conversely, low expression of 
BCL11B in the cultures may enable expression of other TFs such E4BP4 and ID2 (Li et 
al., 2010) that could restrict T-cell development. In line with previous reports that show 
that ID2 (Boos et al., 2007) and TOX (Aliahmad et al., 2010) are essential for the 
transition of iNK to mNK, these TFs were highly expressed during the last two-three 
weeks of the culture when this transition might occur. E4BP4 mRNA levels were similar 
to the one expressed by resting CB and PB NK cells. However, it was very interesting 
to observe that ID2 was expressed more in NK cells generated in vitro. A report from 
Pinho et al. found that ID2 was up-regulated during the complete culture of CB CD34+ 
cells. This correlates with our data, suggesting that the generated NK cells are still 
under development and that more mature cells such as CB and PB NK cells have 
lower expression.  
 
Another TF acting in the last steps of NK cell maturation is T-BET. Recent data in mice 
suggests that T-BET is necessary for the developmental maintenance of immature NK 
cells (Gordon et al., 2012). Additionally, T-BET controls cytokine, perforin and 
granzyme B production (Townsend et al., 2004; Werneck et al., 2008; Jenne et al., 
2009; Gordon et al., 2012) and, moreover, it has been reported that T-BET regulates 
NK cell homeostasis, promoting egress from LN and BM (Jenne et al., 2009). T-BET 
was expressed during the last three weeks of the culture. In this study there was a 
tendency for CB and PB NK cells to express higher amounts of T-BET compared to 
generated NK cells. This is interesting, as T-BET stabilises immature NK cells and 
would seem plausible that generated NK cells would express more of this TF than 
more mature CB and PB NK cells.  
 
A recently described TF called EOMES was reported as essential for the transition of 
iNK to mNK cells in mice (Gordon et al., 2012) and was indeed expressed during the 
last three weeks of PBSC and CBSC cultures. This expression follows NK cell 
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maturation in our system where acquisition of cytotoxic properties occurred (chapter 5). 
Although controversial, it has been suggested that EOMES and T-BET control distinct 
checkpoints in NK cell maturation (Gordon et al., 2012). T-BET stabilises the immature 
NK cell phenotype while EOMES allows maturation. In theory, if T-BET stabilises the 
immature phenotype, it should be downregulated as the cell matures, along with the 
increase of EOMES expression. Interestingly, CB and mature PB NK cells express 
higher T-BET mRNA than NK cells from CBSC and PBSC cultures. Accordingly, a 
suppression of T-BET when EOMES was expressed was not observed.  
 
The maintenance of the mature NK cell pool in peripheral blood is in part provided by 
the expression of IRF-2, deficiency of which causes accelerated apoptosis (Taki et al., 
2005). Although our system does not distinguish between biological compartments, we 
observed a constant and low expression of IRF-2 in the generated NK cells, suggesting 
this factor is not directly involved in NK cell development, but could be important for NK 
cell survival throughout the culture. Finally, we studied GATA-3 expression, another TF 
that is not directly involved in NK cell commitment but known to be important for IFN-γ 
production in mice (Samson et al., 2003; Vosshenrich et al., 2006) and highly 
expressed in CD56bright NK cells in humans (Vosshenrich et al., 2006). Some reports 
suggest that GATA-3 regulates T-BET; as T-BET regulates IFN-γ production it is 
possible that the effect of GATA-3 on IFN-γ production is an indirect result of GATA-3 
regulating T-BET (Samson et al., 2003). We hypothesised that the increasing 
expression of GATA-3 will correlate with T-BET expression; however a variable 
expression was found. The molecular data obtained during this work correlates with 
some of the current roles elucidated by work using mouse models, however, there are 
still some discrepancies. A complete screening of mRNA TFs in CB CD34+ in vitro 
differentiation system was recently performed (Pinho et al., 2012). Some of our findings 
differ from the ones published by Pinho et al., however a different system was used. 
Among the most interesting differences, Pinho et al. found a downregulation of TOX 
and E4BP4 and a gradual increase of GATA-3 throughout the culture (Pinho et al., 
2012). The authors suggested that TOX and E4BP4 may have an impact only during 
the first week of culture, and its involvement in later development stages is minimal. 
The results from this study suggest that PU.1 is the most important factor in the 
beginning of the culture and then other TFs play a key role as their expression 
emerges when the transition from iNK to mNK cells occurs. Our data does not exactly 
match those of published work in humans and in mice but provides a different insight 
into NK cell development that will be later complemented with phenotype and 
functionality maturation (chapters 4 and 5).  
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In summary, this chapter provides new evidence that frozen CBSC are a feasible 
source of HSC for producing NK cells with results comparable to fresh CBSC and even 
to PBSC. A detailed study of cell lineages in the different cultures and the study of the 
development of these cells provide evidence for the different behaviour of PBSC 
cultures. Importantly, we report here for the first time that higher NK cell numbers can 
be achieved using frozen CBSC rather than fresh CBSC or PBSC. If a thawed clinical 
grade UCB unit contains an average of 2.79 x 106 cells (Spanholtz et al., 2011a), we 
could produce as many as 1.6 x 109 NK cells. Alternatively, isolated HSC can be 
aliquoted and used to produce NK cells for multiple infusions at different time points. In 
the next chapters the phenotype and functions of the generated NK cells are analysed 
in detail.  
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 Phenotype of Natural Killer cells generated Chapter 4:
in vitro from haematopoietic stem cells 
4.1 Introduction 
 
NK cells are promising tools for immunotherapy due to their ability to kill malignant cells 
without prior antigen priming. Before NK cell generation in vitro was considered an 
option for NK cell adoptive therapy, PB was the main source of NK cells. There are two 
NK cell subsets in human PB based on CD56 expression, CD56bright and CD56dim. 
These subsets have a different distribution within the body, and exhibit different cell-
surface receptor repertoires and functions. Traditionally, it has been shown that 
CD56bright NK cells have a predominant immunoregulatory role and CD56dim cells are 
more cytotoxic. Nonetheless, a recent report suggested that CD56dim NK cells are rapid 
producers of IFN-", providing immunoregulatory properties to this subset (De Maria et 
al., 2011). Based on this, should we aim to produce NK cells in vitro with a CD56dim 
phenotype for immunotherapy? 
 
For decades, isolated PB NK cells have been expanded or activated ex-vivo using 
cytokines, such as IL-2 (Torelli et al., 2002). Several reports in which PB NK cells are 
expanded for immunotherapy perform a characterisation focusing mainly on the 
expression of activating and inhibitory receptors (Fujisaki et al., 2009; Siegler et al., 
2010; Voskens et al., 2010). It seems that NK cells that have been activated or 
manipulated for a long period of time (Escudier et al., 1994; Torelli et al., 2002; Alici et 
al., 2008) are more potent compared to NK cells activated overnight or for a short 
period of time (Burns et al., 2003; Krause et al., 2004) as shown in clinical studies. So 
what is the phenotype of these long-term activated NK cells making them effective 
killers? NK cells rely on a vast combinatorial array of receptors to initiate their effector 
function; to mount a response NK cells must integrate signals transmitted through 
stimulatory and inhibitory receptors and in particular counteract the influence of 
inhibitory receptors. Alici et al. suggest that upregulation of 2B4, NCRs, NKG2D and 
DNAM-1 contribute to the killing of malignant melanoma cells (Alici et al., 2008). 
Accordingly, the higher cytotoxicity of NK cells expanded in a bioreactor was attributed 
to the upregulation of NKp44 (Sutlu et al., 2010). So, is it possible to obtain a similar 
phenotype for NK cells that have been generated in vitro?  
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Each protocol for NK cell generation in vitro will provide cells with different phenotype 
and activation state. Such differences in NK cell characteristics will have an impact on 
their efficiency in a clinical setting. As previously mentioned, different sources of HSC 
have been used to generate NK cells in vitro (Yoon et al.; Miller et al., 1994; Mrozek et 
al., 1996; Spanholtz et al., 2010; Spanholtz et al., 2011a; Dezell et al., 2012; Lehmann 
et al., 2012; Zamai et al., 2012). Zamai et al. generated NK cells from PBSC CD34+ 
cells that resembled CD56bright cells. NK cells expressed granzyme B, perforin, LFA-1, 
low levels of KIRs and CD16. After stimulation with IL-15, NK cells upregulated 
granzyme B, TRAIL, Fas-L, CD16, KIRs and LFA-1 (Zamai et al., 2012). Yoon et al. 
also generated NK cells from PBSC, resulting in NK cells expressing NKp46 and 
NKG2D but that had very low KIRs expression (Yoon et al.). 
 
CB has been used in several studies to generate NK cells. As for NK cells generated 
from PBSC, NK cells generated from CB mainly had a CD56bright NK cell phenotype. 
The characterisation of the generated NK cells in vitro shows a lack of CD16 and KIRs 
expression, which suggests that NK cells generated in this system were still immature 
(Beck et al., 2009; Bonanno et al., 2009). Since 2010, Spanholtz et al. have been 
developing an in vitro system to generate NK cells from CBSC. This system deserves 
particular attention, as it is one of the first to produce NK cells under GMP guidelines, 
and additionally has a feeder layer-free system (Spanholtz et al., 2010; Spanholtz et 
al., 2011a). Generated NK cells in this system express a variety of activating markers: 
NKG2A/D, 2B4, CD161, NCRs. Their phenotype resembles that of CD56bright NK cells, 
with low expression of KIRs and CD16. Accordingly, Kao et al. used a serum-free 
protocol to expand CB CD34+ HSC and produce NK cells in vitro. Their 
characterisation only included perforin, Fas-L and CD16, concluding that 
CD56brightCD16- NK cells expressing Fas-L but not perforin were generated. Some 
reports have shown that CB CD34+ cells could be differentiated into CD56bright and 
CD56dim NK cell subsets (Yu et al., 2001; Sivori et al., 2003) whereas others suggested 
that CD34+ cells could only generate CD56bright cells in vitro (Mrozek et al., 1996; 
Sconocchia et al., 2005b).  
 
As described, the majority of current protocols give rise to CD56bright cells in vitro. In 
most studies, the characterisation of the generated cells is limited to the expression of 
some activating and inhibitory receptors with few of them assessing expression levels 
of adhesion molecules and receptors involved in migration (Beck et al., 2009; Woll et 
al., 2009). However, this is of great importance, as NK cells need to migrate to the 
tumour site and proliferate sufficiently (Albertsson et al., 2003). Moreover, NK cells 
need to express adhesion molecules to allow conjugate formation and cytolytic granule 
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polarisation in order to kill malignant cells effectively (Bryceson et al., 2005). To our 
knowledge, there is currently no study performing characterisation of NK cells 
generated in vitro and including chemokine receptors, integrins, interleukin receptors, 
activating/inhibitory receptors and even co-stimulatory receptors (see appendix 2). 
 
The characterisation of the NK cell repertoire would allow a better correlation between 
the phenotype of infused NK cells and the clinical outcome. Therefore, a full 
characterisation of NK cells derived from two different HSC sources and cultured under 
different conditions as described in the previous chapter was performed. Using flow 
cytometry and qPCR, the phenotypic characteristics of NK cells generated from fresh 
and frozen CBSC, fresh CBSC (using only IL-15 or all cytokines during culture) and NK 
cells produced from PBSC were assessed. After analysing the frequency of NK cell 
progenitors and their development in all HSC cultures, the work undertaken for this 
chapter will help to correlate the developmental status of NK cells generated in vitro 
together with their phenotype. 
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4.2 Results  
4.2.1 Natural Killer cells generated in vitro express NKG2A but lack KIRs 
expression 
 
Inhibitory receptors play a major role in protecting host cells against NK cell mediated 
killing. Some of these receptors act upon interaction with MHC class I molecules, 
whereas others bind to non-MHC class I molecules. These receptors include the 
inhibitory KIRs and the inhibitory NKG2A heterodimeric C-type lectin-like receptors. 
KIRs bind to classical MHC class Ia molecules (HLA-A, -B, and –C) while NKG2A binds 
to non-classical MHC class Ib (HLA-E) (Lanier, 2001; Lanier, 2008). The acquisition of 
some inhibitory receptors on the generated NK cells from all HSC cultures at day 35 
was analysed. NK cells from HSC cultures were used without further purification by 
magnetic isolation (NK cell content in HSC cultures varied from 93-97%). Cells were 
detached directly from the 96-well plates by resuspension, transferred to a falcon tube 
to be washed and counted for subsequent use in phenotypic and functional assays.  
Figure 4.1 shows the expression of the inhibitory markers CD158a (KIR2DL1/DS1), 
CD158b (KIR2DL2/3) and NKG2A on NK cells. A very low expression of CD158a and 
CD158b on NK cells from each culture was observed, whereas NKG2A was expressed 
on 40-50% of NK cells without any significant difference between cultures.  
 
 
Figure 4.1. Expression of inhibitory receptors on NK cells generated in vitro. Graphs show 
the cell expression (mean ± SD) of CD158a, CD158b and NKG2A on the generated NK cells 
(percentages come from the CD56+CD3- gate) at day 35 from A) fresh CBSC (n=3), frozen 
CBSC (n=9), PBSC (n=6) cultures and B) CBSC cultures using all cytokines (n=3) or only IL-15 
(n=3). Mann Whitney test was performed.   
 
Previous studies showed that as CD56dim NK cells mature they expressed more 
CD158a and CD158b and less NKG2A (Beziat et al., 2010). Thus, a further analysis of 
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CD158a, CD158b and NKG2A in CD56bright and CD56dim NK cell subsets from frozen 
CBSC and PBSC cultures was performed (figure 4.2 A-D). CD158a and CD158b 
expression was significantly higher in the CD56dim subset (p<0.05) in CBSC cultures 
and the same tendency was observed in PBSC cultures although it was not statistically 
significant (p=0.100). Likewise, NKG2A expression was higher in the CD56dim NK cell 
subset (CBSC, p<0.05).  
 
 
Figure 4.2. Expression of inhibitory receptors in CD56bright and CD56dim subsets. Graphs 
depict the expression at day 35 of CD158a (A), CD158b (B) and NKG2A (C) on NK cells 
(percentages come from the CD56+CD3- gate) from frozen CBSC (n=4) and PBSC (n=3) 
cultures. D) Figure shows the histograms of one representative sample for CD158a, CD158b 
and NKG2A expression in CD56bright and CD56dim subsets from frozen CBSC and PBSC NK 
cells. Mann Whitney test was performed. * p<0.05, ** p<0.01. 
 
4.2.1.1 KIRs mRNA expression 
 
During NK cell maturation, sequential acquisition of KIRs occurs as NKG2A 
progressively decreases (Beziat et al., 2010). Since these markers have been 
associated not only with NK cell maturation but also with NK cell licensing/education 
process (Anfossi et al., 2006; Foley et al., 2011a), their absence led us to investigate 
their mRNA expression levels using qPCR. Figures 4.3 and 4.4 show the relative 
expression of these markers in NK cells from HSC cultures at day 35. Resting NK cells 
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from CB and PB were included as controls. Figure 4.3 depicts the expression of KIRs; 
KIR2DL1 expression was similar among CB, PB and fresh CBSC cultures. NK cells 
from cultures where all cytokines were used exhibited the highest KIR2DL1 expression 
while NK cells from frozen cultures had the lowest expression. The expression of 
KIR2DL2 remained very similar among NK cells from CB, PB and all HSC cultures.  
 
 
Figure 4.3. KIRs mRNA expression. Total RNA was extracted from NK cells from PB (n=3), 
CB (n=3), fresh CBSC cultures (n=3), frozen CBSC cultures (n=4), PBSC cultures (n=3) and 
CBSC cultures with all cytokines (n=3) and analysed by qPCR. Figure shows the relative 
expression of KIR2DL1 and KIR2DL2 in NK cells at day 35. The mean and SD of the ratio target 
gene/reference gene for each sample is presented.  
 
In summary, KIRs expression in PB and CB NK cells as well as in the generated NK 
cells was very similar. Although the reason(s) for the low KIRs expression detected by 
flow cytometry are unclear, the possibility of other post-translational modifications 
cannot be excluded.  
 
4.2.1.2 NKG2A mRNA expression 
 
The analysis of NKG2A mRNA levels showed less expression in CB and PB NK cells 
compared to NK cells generated in vitro; a tendency for higher expression of NKG2A in 
NK cells from fresh CBSC cultures was found (figure 4.4). 
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Figure 4.4. NKG2A mRNA expression in NK cells from CB, PB and HSC cultures. Total 
RNA was extracted from NK cells from CB (n=3), PB (n=3), fresh CBSC cultures (n=3), frozen 
CBSC cultures (n=4), PBSC cultures (n=3) and CBSC cultures with all cytokines (n=3) and 
analysed by qPCR. Figure shows the relative expression of NKG2A in NK cells at day 35. The 
mean and SD of the ratio target gene/reference gene for each sample is presented.  
 
The acquisition of NK cell functions is correlated with NKG2A expression (Grzywacz et 
al., 2006), therefore mRNA expression of this marker in frozen CBSC and PBSC 
cultures was analysed. Figure 4.5 shows an increase in NKG2A mRNA levels 
throughout the culture. In recent studies, it has been suggested that CD57 cell 
expression correlates with a more mature stage than CD56dim only, characterised by 
the loss of expression of NKG2A and the gain of KIR receptor expression (Bjorkstrom 
et al.; Lopez-Verges et al.). Considering the majority of the generated NK cells were 
CD56bright, it is feasible that either the few CD56dim have not undergone the last step of 
maturation recently proposed, or that the number of cells in that stage was so low that 
we could not detect a decrease in NKG2A mRNA levels.  
 
 
Figure 4.5. NKG2A mRNA expression at different time points of culture of CBSC and 
PBSC. Total RNA was extracted from NK cells from frozen CBSC cultures (n=4) and PBSC 
cultures (n=3) at day 7, 14, 21, 28 and 35 and analysed by qPCR. Figure shows the relative 
expression of NKG2A in NK cells. The mean and SD of the ratio target gene/reference gene for 
each sample is presented.  
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4.2.2 Abundant NCRs expression on the generated Natural Killer cells 
 
NK cells express a large number of cell-surface markers that can be classified as 
activating or inhibitory receptors. The study of some of the inhibitory receptors was 
previously described. In this section, the presence of an important group of activating 
receptors named NCRs was investigated; NKp30, NKp44, NKp46 and NKp80. NKp30 
and NKp46 are expressed on resting and activated NK cells, whereas NKp44 is only 
expressed on activated NK cells (Moretta et al., 2000). NKp80 is expressed in fresh 
and activated NK cells, acting as an activating receptor (Vitale et al., 2001). Figure 4.6 
shows that except for NKp80, the remaining NCRs were highly expressed without any 
significant difference between NK cells from the different HSC cultures. It is not 
surprising to find high expression of NCRs on the generated NK cells, as the media 
used in the cultures contained IL-15, which is known to activate NK cells.  
 
 
Figure 4.6. Expression of natural cytotoxic receptors on NK cells generated. The graphs 
show the cell expression percentage and SD of natural cytotoxic receptors (NCRs) at day 35 on 
NK cells (percentages come from the CD56+CD3- gate) from A) fresh CBSC (n=3), frozen 
CBSC (n=9), PBSC cultures (n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 
(n=3). Mann Whitney test was performed.  
 
While analysing the CD56bright and CD56dim NK cell populations, it was observed that 
only NKp46 was differentially expressed between subsets with higher expression on 
CD56dim cells (CBSC-NK cells, p<0.05, figure 4.7). 
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Figure 4.7. Expression of NKp46 in CD56bright and CD56dim NK cell subsets. Graphs depict 
the expression of NKp46 at day 35 on NK cells (percentages come from the CD56+CD3- gate) 
from frozen CBSC (n=4) and PBSC (n=3) cultures. Mann Whitney test was performed, * p<0.05. 
 
 
 
4.2.3 Absence of 2B4 expression on the generated Natural Killer cells 
 
Recent advances in NK cell biology have highlighted novel roles for different NK cell 
receptors, such as 2B4. This receptor has a dual function; it acts as an inhibitory 
receptor during early development and as the cell matures, acts as an activating 
receptor (Sivori et al., 2002). Its ligand, CD48, is expressed on a variety of cells 
including NK cells; 2B4-CD48 interactions enhance NK cell proliferation in response to 
interleukins (Assarsson et al., 2004). Figure 4.8 depicts 2B4 and CD48 expression on 
NK cells from all HSC cultures. 2B4 is usually expressed in 100% of NK cells however 
2B4 expression was very low in NK cells from all HSC cultures (4.5-10.1%). On the 
contrary, CD48 was expressed on NK cells from frozen cultures (32.9 ± 28.8% and 
45.8 ± 22.3%, CBSC and PBSC, respectively). Interestingly, fresh CBSC-NK cells had 
very low CD48 expression (6.9 ± 4.6%).  
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Figure 4.8. Expression of co-stimulatory receptors on NK cells. The graphs show the cell 
expression percentage and SD of 2B4 (CD244) and CD48 at day 35 on NK cells (percentages 
come from the CD56+CD3- gate) from A) fresh CBSC (n=3), frozen CBSC (n=8), PBSC cultures 
(n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). Mann Whitney test was 
performed. 
 
4.2.3.1 2B4 mRNA expression 
 
Due to the low expression of the surface antigen 2B4 using flow cytometry, the 
analysis of the mRNA levels for this marker in NK cells using qPCR was performed. 
Figure 4.9 depicts the mRNA expression of 2B4 in CB NK cells, PB NK cells, and NK 
cells from all HSC cultures. mRNA levels of CBSC and PBSC samples resemble those 
of CB NK cells and PB NK cells respectively. This suggests that 2B4 expression in NK 
cells generated in vitro is similar to their counterparts in CB and PB.  
 
Figure 4.9. 2B4 mRNA expression in NK cells. Total RNA was extracted from NK cells from 
CB (n=3), PB (n=3), fresh CBSC cultures (n=3), frozen CBSC cultures (n=4), PBSC cultures 
(n=3) and CBSC cultures with all cytokines (n=3) and analysed by qPCR. Figure shows the 
relative expression of 2B4 in NK cells at day 35. The mean and SD of the ratio target 
gene/reference gene for each sample is presented. 
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Because 2B4 is an important receptor during NK cell development, its mRNA 
expression throughout CBSC and PBSC cultures was assessed. Figure 4.10 depicts 
the weekly levels of 2B4 mRNA for both HSC cultures. While a steady level was 
maintained in PBSC cultures, CBSC showed high expression at day 7 and 35.  
 
 
Figure 4.10. 2B4 mRNA expression at different time points of culture of CBSC and PBSC. 
Total RNA was extracted from NK cells from frozen CBSC cultures (n=4) and PBSC cultures 
(n=3) at day 7, 14, 21, 28 and 35 and analysed by qPCR. Figure shows the relative expression 
of 2B4 in NK cells. The mean and SD of the ratio target gene/reference gene for each sample is 
presented. 
 
Altogether, regardless of the presence of 2B4 mRNA in NK cells from CBSC and 
PBSC cultures at similar or even higher levels than CB and PB NK cells, additional 
events might be occurring preventing the expression of the protein.  
  
4.2.4 Generated Natural Killer cells are equipped with cell death-receptors and 
activating Natural Killer cell receptors 
 
The two major mechanisms effecting NK cell cytotoxicity are the perforin/granzyme and 
the death-receptor-mediated (Fas-L or TRAIL-mediated) induction of cell death 
pathways (Trapani et al., 1998; Wallin et al., 2003). NK cells can express death 
receptors: Fas-L and TNF-related-apoptosis-inducing ligand (TRAIL) (Caron et al., 
1999; Wallin et al., 2003). In this study, the receptors Fas-L and TRAIL were studied as 
part of the phenotypic characterisation of NK cells. Fas belongs to the TNF receptor 
family of molecules containing a conserved intra-cytoplasmic “death domain” that 
indirectly activates the caspase enzymatic cascade and ultimately induces apoptotic 
mechanisms in numerous cell types (Screpanti et al., 2005). Fas-L expression on NK 
cells contributes to suppression of tumour cells in vitro (Oshimi et al., 1996; Zamai et 
al., 1998a). Fas-L was expressed similarly between fresh and frozen CBSC-NK cells 
(figure 4.11). Conversely, PBSC-NK cells had a higher Fas-L expression compared to 
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CBSC-NK cells (figure 4.11, p<0.05). TRAIL can bind to death receptor (DR)4 and DR5 
leading to the recruitment of the protein FADD, which functions as a molecular bridge 
to caspase 8, a protease that initiates cell death cascade (Gibson et al., 2000). NK 
cells use TRAIL to mediate apoptosis in some tumours (Takeda et al., 2002) or 
immature DCs (Hayakawa et al., 2004). A higher expression of TRAIL was found in 
frozen cultures (CBSC-NK and PBSC-NK cells) compared to fresh CBSC-NK cells 
(p<0.05); and between the frozen cultures CBSC-NK cells had higher expression 
compared to PBSC-NK cells (figure 4.11, p<0.05). 
 
On the other hand, NK cells are equipped with activating receptors able to trigger NK 
cell killing. The heterodimer CD94/NKG2C also binds to HLA-E, but associates with 
DAP12, a membrane receptor containing an ITAM motif. NKG2D is expressed as a 
homodimer that associates with another adaptor molecule, DAP10. NKG2D recognises 
at least eight ligands on the surface of human cells, each with MHC class I homology: 
four transmembrane proteins, MICA and MICB, ULBP4-5, and four 
glycophosphatidylinositol-anchored proteins, ULBP1-3 and ULBP6 (Raulet et al., 
2013). These two receptors play an important role in cellular activation. NK cells 
generated from all HSC cultures expressed NKG2D but had very low expression of 
NKG2C (figure 4.11), although a high variation in frozen CBSC-NK cells was found. 
Thus, NKG2C mRNA levels in CB NK cells, PB NK cells and NK cells generated in 
vitro were investigated. mRNA levels in NK cells generated in vitro were similar to CB 
NK cells; PB NK cells had slightly lower expression levels (figure 4.12). NK cells from 
all cultures expressed NKG2D without any significant difference (figure 4.11).  
 
 
Figure 4.11. Expression of activating receptors on NK cells. The graphs show the cell 
expression (mean ± SD) of Fas-L, NKG2C and NKG2D at day 35 on NK (percentages come 
from the CD56+CD3- gate) cells from A) fresh CBSC (n=3), frozen CBSC (n=9), PBSC cultures 
(n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). Mann Whitney test was 
performed, * p<0.05. 
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Figure 4.12. NKG2C mRNA expression in NK cells. Total RNA was extracted from NK cells 
from CB (n=3), PB (n=3), fresh CBSC cultures (n=3), frozen CBSC cultures (n=4), PBSC 
cultures (n=3) and CBSC cultures with all cytokines (n=3) and analysed by qPCR. Graph shows 
the relative expression of NKG2C in NK cells at day 35. The mean and SD of the ratio target 
gene/reference gene for each sample is presented. 
 
Finally, we investigated the presence of one of the most important NK cell activating 
receptors able to trigger NK cell cytotoxicity without costimulation: CD16 (Bryceson et 
al., 2005). The engagement of CD16 receptor facilitates ADCC against 
transformed/malignant cells coated with IgG antibodies. Previous studies report the 
generation of CD56+CD16low/- cells in vitro using CBSC or PBSC (Mrozek et al., 1996; 
Sconocchia et al., 2005b). Fresh CBSC-NK cells from either all cytokines or only IL-15 
cultures had a tendency for higher CD16 expression (p=0.0714) while frozen CBSC-NK 
and PBSC-NK cells had reduced expression (no significant difference, figure 4.13).  
 
 
Figure 4.13. NK cells generated in vitro express CD16. Graph shows the percentage of 
CD56+CD16+ cells from the lymphocyte gate of fresh CBSC cultures with all cytokines (n=3) or 
only IL-15 (n=3), frozen CBSC cultures (n=5) and PBSC cultures (n=3). Mann Whitney test was 
performed. 
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In summary, NK cells generated in vitro had high expression of death-ligand receptors 
and NKG2D, and low expression of NKG2C and CD16.  
 
4.2.5 Interleukin receptor expression profile on Natural Killer cells generated in 
vitro 
 
NK cells can proliferate and secrete IFN-" and other factors in response to interleukins. 
The study of the interleukin receptor repertoire on NK cells generated in vitro can be 
helpful for the prediction of NK cell responses when these interleukins are administered 
in vivo or in vitro. The expression of IL-15R#, IL-18R, IL-2R#, IL-2R$1 and IL-12R$1 at 
day 35 on the generated NK cells was investigated. From all the receptors studied 
during this work, the screening of interleukin receptors showed the most variable 
expression among cultures (figure 4.14). IL-15R# and IL-12R$1 were more expressed 
in fresh CBSC-NK cells, while IL-2R# and IL-2R$1 expression was higher in frozen 
CBSC-NK cells (p<0.05, figure 4.14). IL-18R was more expressed on PBSC-NK cells 
compared to frozen CBSC-NK cells (p<0.005). No significant differences between 
CBSC cultures using all cytokines or only IL-15 were found.  
 
 
Figure 4.14. Expression of interleukin receptors on NK cells. The graphs show the cell 
expression (mean ± SD) of IL-15R#, IL-18R, IL-2R#, IL-2R$1 and IL-12R$1 at day 35 on NK 
cells (percentages come from the CD56+CD3- gate) from A) fresh CBSC (n=3), frozen CBSC 
(n=9), PBSC cultures (n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). 
Mann Whitney test was performed, * p<0.05, ** p<0.01.  
 
Due to the different functions of NK cell subsets (immunoregulatory or cytotoxic), 
interleukin receptors can be differentially expressed accordingly. Indeed, IL-12R$1 was 
more expressed in CBSC CD56bright NK cells (figure 4.15A). Conversely, IL-18R was 
more expressed in CBSC CD56dim NK cells (figure 4.15B). A representative analysis 
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using flow cytometry to analyse expression of IL-12R$1 and IL-18R in CBSC-NK and 
PBSC-NK cells is presented in figure 4.15C. 
 
 
 
 
Figure 4.15. Interleukin receptor expression in CD56bright and CD56dim subsets. Graphs 
depict the expression at day 35 of IL-12R$1 (A) and IL-18R (B) on NK (percentages come from 
the CD56+CD3- gate) cells from frozen CBSC (n=4) and PBSC (n=3) cultures. C) Figure shows 
the histograms of one representative sample for IL-12R$1 and IL-18-R in CD56bright and 
CD56dim subsets from frozen CBSC and PBSC NK cells. Mann Whitney test was performed. * 
p<0.05. 
 
In summary, frozen CBSC-NK cells had higher expression of CD25 and CD122 
compared to fresh CBSC-NK cells. Both receptors are important for IL-2 and IL-15 
signalling, suggesting that frozen CBSC-NK cells might respond better to these 
cytokines.  
 
4.2.6 Frozen CBSC-NK cells generated in vitro express CXCR4   
 
NK cells have been tested for immunotherapeutic properties with promising results in 
non-solid malignancies (Miller et al., 2005) and less encouraging outcomes in solid 
tumours (Ishikawa et al., 2004). Regardless of the nature of the tumour, NK cells must 
be able to make contact with malignant cells in order to mediate cytotoxicity. 
Characterising the trafficking potential of the generated NK cells will provide valuable 
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information for immunotherapeutic uses. This work included the analysis of the 
expression of chemokine receptors that allow cell trafficking to different organs/tissues 
such as CCR5 (liver), CCR6 (gut mucosa) (Hirata et al.), CCR7 (lymph nodes) 
(Campbell et al., 2001), CXCR1 (inflammatory sites) (Maghazachi, 2010), CXCR4 and 
CXCR7 (bone marrow) (Beider et al., 2003; Hartmann et al., 2008). Figure 4.16 shows 
the expression of these chemokine receptors on the NK cells generated in vitro. High 
variability among samples was observed, especially frozen samples, whereas fresh 
CBSC-NK cells had a very low expression of most of the studied chemokine receptors. 
The only significant difference was found in the expression of CXCR4 between NK 
cells from fresh and frozen CBSC cultures (p<0.05). The use of different all cytokines 
or only IL-15 had no effect on the expression of the aforementioned chemokine 
receptors (figure 4.16B).  
 
 
Figure 4.16. Expression of chemokine receptors on NK cells. The graphs show the cell 
expression (mean ± SD) of CCR5, CCR6, CCR7, CXCR1, CXCR4 and CXCR7 at day 35 on NK 
cells (percentages come from the CD56+CD3- gate) from A) fresh CBSC (n=3), frozen CBSC 
(n=9), PBSC cultures (n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). 
Mann Whitney test was performed. * p<0.05. 
 
In addition, the expression of these markers in CD56bright and CD56dim NK cell subsets 
from frozen CBSC and PBSC cultures was analysed. CXCR4 expression was higher in 
the CBSC CD56bright subset (figure 4.17A). A representative sample for NK cell subsets 
of frozen CBSC and PBSC cultures is shown in figure 4.17B.  
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Figure 4.17. Expression of CXCR4 in CD56bright and CD56dim subsets. A) Graph depicts 
the expression at day 35 of CXCR4 on NK cells (percentages come from the CD56+CD3- gate) 
from frozen CBSC (n=4) and PBSC (n=3) cultures. B) Figure shows the histograms of one 
representative sample for CXCR4 in CD56bright and CD56dim subsets from frozen CBSC and 
PBSC NK cells. Mann Whitney test was performed. * p<0.05. 
 
Taking into consideration the importance of CXCR4 in BM homing, frozen CBSC-NK 
cells and PBSC-NK cells would have the potential to migrate to the BM whereas fresh 
CBSC-NK cells may not.  
 
4.2.7 Natural Killer cells generated in vitro express adhesion molecules  
 
Finally, the expression of integrins that allow cell adhesion and homing was studied: 
CD49d (transendothelial migration) (Humphries et al., 1995), integrin "7 (interaction 
with extracellular matrix and endothelial cells) (Perez-Villar et al., 1996), L-selectin 
(lymph node homing), DNAM-1 and LFA-1 (cell adhesion) (Tahara-Hanaoka et al., 
2004; Mace et al., 2010). CD49d was expressed in the majority of fresh and frozen 
CBSC-NK cells, while its expression tended to be higher in PBSC-NK cells (although 
not statistically significant, figure 4.18A). NK cells from all cultures expressed DNAM-1; 
fresh and frozen CBSC-NK cells had similar expression levels while PBSC-NK cells 
had significantly higher DNAM-1 expression compared to frozen CBSC-NK cells 
(p<0.05, figure 4.18A).  
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Fresh CBSC-NK cells had low expression of integrin "7 compared to frozen CBSC-NK 
cells (although not statistically significant), whereas frozen CBSC and PBSC had 
similar expression (figure 4.18A).  
 
L-selectin expression was similar among CBSC samples (1 ± 0.3% and 3.9 ± 2.3% for 
fresh and frozen CBSC-NK cells respectively) and PBSC-NK cells (17 ± 14.6%, 
p=0.1137 when compared to frozen CBSC-NK cells). LFA-1 expression was low 
among frozen CBSC-NK cells samples, PBSC-NK cells and fresh CBSC-NK cells 
showed a trend for higher expression (p=0.0649). When we compared the expression 
of these integrins between CBSC cultures using all cytokines or only IL-15 no 
significant differences were found (figure 4.18B).  
 
 
Figure 4.18. Expression of adhesion molecules receptors on NK cells. The graphs show 
the cell expression (mean ± SD) of CD49d, DNAM-1, Integrin $7, L-selectin and LFA-1 at day 
35 on NK cells (percentages come from the CD56+CD3- gate) from A) fresh CBSC (n=3), frozen 
CBSC (n=9), PBSC cultures (n=6) and B) CBSC cultures with all cytokines (n=3) or only IL-15 
(n=3). Mann Whitney test was performed. * p<0.05. 
 
Finally, the expression of adhesion molecules was analysed in the two different CD56 
subsets in frozen CBSC and PBSC cultures. The expression of L-selectin and LFA-1 
was found to be higher among CD56dim cells for frozen CBSC cultures (p<0.05, figure 
4.19) compared to CD56bright cells.  
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Figure 4.19. Expression of adhesion molecules receptors on CD56bright and CD56dim 
subsets. Graphs depict the expression at day 35 of L-selectin (A) and LFA-1 (B) on NK cells 
(percentages come from the CD56+CD3- gate) from frozen CBSC (n=4) and PBSC (n=3) 
cultures. Mann Whitney test was performed. * p<0.05. 
 
In summary, NK cells generated in vitro expressed a wide variety of adhesion 
molecules with the exception of L-selectin. The expression of adhesion molecules will 
play an important role in NK cell-mediated killing, as these molecules are not only 
involved in adhesion but also in activating signalling.   
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4.3 Discussion 
 
During this study high numbers of NK cells were generated. Although high numbers of 
NK cells are needed for NK cell immunotherapy, an optimal activation state is also 
critical. In this chapter a complete phenotypic characterisation was performed. Only a 
few studies performed a phenotypic characterisation of NK cells derived from CBSC 
(Spanholtz et al., 2010; Lehmann et al., 2012) or from PBSC (Yoon et al.; Zamai et al., 
2012). We believe the most complete characterisation of NK cells generated in vitro so 
far was achieved in this study. In addition, a complete characterisation of CB and PB 
NK cells was performed (appendix 1). The results of this publication were key in order 
to compare NK cell phenotype from different sources and are discussed in this chapter 
and also chapter 5.  
 
While studying the final NK cell product, generated NK cells had some similarities with 
those of stage 3/4 described by Freud et al. (Freud et al., 2006). Nevertheless, our 
approach integrates molecular data along with a detailed examination of marker 
expression in CD56bright and CD56dim cell subsets. The findings of this study suggest 
that the system used supports NK cell differentiation with a final product expressing 
activating receptors and low KIRs expression. Notably, the produced NK cells have a 
distinct phenotype that does not precisely resemble CB or PB NK cells.  
 
The expression of KIRs and recently NKG2A has been linked to functional maturation 
and NK cell licensing/education (Kim et al., 2005b; Anfossi et al., 2006). The inhibitory 
receptors CD158a and CD158b are characteristics of NK cell stage 4/5. Even though 
stage 4 cells were present in all HSC cultures (chapter 3), a low expression of CD158a 
and CD158b in NK cells generated in vitro was observed. It is worth mentioning that 
the low expression observed (1-3%) was very similar to that described by other authors 
using either CBSC or PBSC (Yoon et al.; Bonanno et al., 2009; Spanholtz et al., 2010; 
Zamai et al., 2012). Although no differences in KIRs expression between CBSC-NK 
and PBSC-NK cells were observed, it has been reported that there is a relationship 
between HSC source and KIR acquisition on NK cells. Miller et al. suggest that the 
capacity for obtaining KIR+ NK cells in vitro increased, as the ontogeny of HSC was 
more immature (foetal liver>CB>BM) (Miller and McCullar, 2001). Regardless of the 
low KIRs expression, the KIRs distribution on CD56dim and CD56bright subsets was 
analysed and a higher percentage in CD56dim cells was found. This percentage (10%) 
was not as high as in PB and CB CD56dim cells (20-50%) (Luevano et al., 2012a). 
Nevertheless, this data correlates with current development models of NK cells 
indicating that CD56dim have a higher KIR expression (Andre et al., 2000; Jacobs et al., 
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2001). KIR2DL1 and KIR2DL2 mRNA expression was also investigated in PB NK cells, 
CB NK cells and NK cells generated in vitro. Surprisingly, KIR2DL1 and even KIR2DL2 
mRNA expression in the generated NK cells was very similar to that of NK cells from 
CB and PB. Therefore, is there a missing signal or stimulus that will enable KIRs 
mRNA translation in NK cells generated in vitro? Dezell et al. used CBSC to generate 
NK cells in vitro; their results suggest that early signals from the feeder layer (from day 
0-14) are needed for KIR acquisition (Dezell et al., 2012). It could be the case that 
additional signals are required in our system for KIR acquisition, though all these 
signals have not yet been fully identified. In an effort to identify these signals, Cichocki 
et al. found that the transcription factor c-Myc enhances the transcription of KIR genes. 
Moreover, c-Myc binding was augmented upon IL-15 stimulation (Cichocki and Miller, 
2010). Along these lines, IL-15 has been reported to induce KIR expression in mature 
NK cells in vitro (de Rham et al., 2007) and in vivo (Huntington et al., 2009). The 
cultures in this study included IL-15; for fresh CBSC cultures we maintained either a 
constant IL-15 concentration along with other factors (20 ng/ml) or only IL-15 after 
week 3 at a higher concentration (50 ng/ml). No differences in KIRs expression were 
observed between these cultures. Some studies have shown that IL-15 trans-
presentation is needed at different stages for NK cell maturation, homeostasis and 
effector function acquisition (Huntington et al., 2009; Lee et al., 2011). We are not 
aware of any IL-15 trans-presentation in our system; perhaps this could be a reason 
why IL-15 did not increase KIRs expression in the generated NK cells.  
 
Whether or not the absence of KIRs on NK cells generated in vitro could be an 
advantage for immunotherapeutic purposes still remains unknown in our model. 
Recent studies have suggested that blocking KIR interactions with HLA-C ligands can 
enhance NK cell cytotoxicity; this can be achieved by the use of IPH2101 antibody 
(formerly 1-7F9), blocking KIRs2DL1, -2 and -3 in order to “uninhibit” NK cells and 
mount an anti-tumour response (Romagne et al., 2009; Vey et al., 2012). This 
“uninhibition” should be taken with care, as the risk of NK cell autoreactivity conveys a 
potential drawback for immunotherapy.  
 
According to Grzywacz et al., the absence of expression of NKG2A and KIRs may 
suggest that NK cells are still immature (Grzywacz et al., 2006). Moreover, Foley et al. 
suggested that the lack of inhibitory receptors on NK cells can result in 
hyporesponsiveness (Foley et al., 2011b). However, the generated NK cells in this 
work expressed NKG2A, the only screened inhibitory receptor besides KIRs. NK cells 
expressed NKG2A at similar levels to those published by Spanholtz et al. (Spanholtz et 
al., 2010; Spanholtz et al., 2011a); other studies do not report NKG2A expression 
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(Yoon et al.; Zamai et al., 2012). A further characterisation revealed that CD56dim NK 
cells from frozen CBSC cultures had a higher NKG2A expression. Contrary to this 
data, our characterisation of CB and PB NK cell subsets showed a higher expression 
of NKG2A in CD56bright NK cells (Luevano et al., 2012a). 
 
Studies using mice suggested that NKG2A could be responsible for the self-tolerance 
mechanism during NK cell development (Sivakumar et al., 1999), whereas others claim 
that it is dispensable for NK cell education (Orr et al., 2010). An increase in NKG2A 
mRNA expression throughout the culture was observed during this study, especially 
during the last three weeks. During NK cell development, NKG2A is expressed after 
NCRs and NKG2D. Indeed, at day 35, NCRs and NKG2D were expressed in the 
majority of the cells. CD56dim cells had a higher NKG2A expression. From there, as NK 
cells mature, there should be a decrease of NKG2A expression and an increase of 
KIRs expression that is not occurring in our system (Bjorkstrom et al.). In line with 
these observations, when analysing NKG2A mRNA expression, a tendency for higher 
expression in NK cells generated in vitro compared to CB and PB NK cells was 
detected (Lutz et al., 2011). Possibly a decrease in NKG2A expression along with KIRs 
acquisition will occur under different culture conditions or even in vivo.  
 
According to the NK cell development model proposed by Freud et al., NK cells acquire 
NKp46 during stage 4; in this model NKp44 and NKp30 were absent (Freud et al., 
2006). NKp30 and NKp46 are expressed in resting and activated NK cells, whereas 
NKp44 is only expressed in activated NK cells (Pessino et al., 1998; Vitale et al., 1998; 
Pende et al., 1999). In agreement with the results presented here, numerous reports 
show high expression of NKp30, NKp44 and NKp46 while generating NK cells in vitro 
(Yoon et al.; Perez et al., 2006b; Spanholtz et al., 2010; Beck, 2011; Spanholtz et al., 
2011a). Nevertheless, NKp80 (virtually expressed by all NK cells (Vitale et al., 2001)) 
was absent in the generated NK cells; similar results were reported in another study 
(Spanholtz et al., 2010). Due to the nature of the culture conditions, where the use of 
interleukins is standard (like IL-15), it is expected that NK cells generated in vitro will 
express NCRs (de Rham et al., 2007). Likewise, a high NKp30 and NKp46 expression 
on CB and PB NK cells was observed. Contrary to CB and PB NK cells in which 
NKp46 expression is higher in CD56bright cells (Luevano et al., 2012a), a higher NKp46 
expression in the CD56dim subset from CBSC cultures was found. Along with this 
particular phenotype, in which there is low resemblance with either traditional CB or PB 
NK cells, we noticed the absence of expression of an important co-receptor; 2B4. 2B4 
may exert inhibitory functions during the first NK cell development stages and 
progressively as the cell matures, plays a role as activating receptor (Sivori et al., 
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2002). In addition, it has been proposed as a marker for NK cell lineage commitment 
(Eissens et al., 2012). In general, other reports have shown the generation of NK cells 
with 2B4 expression in 20-30% (Perez et al., 2006b) or 100% of NK cells (Beck et al., 
2009; Spanholtz et al., 2010; Beck, 2011; Spanholtz et al., 2011a). Additionally, the 
majority of PB and CB NK cells express 2B4 (Luevano et al., 2012a). Although 2B4 
was not detected by flow cytometry in NK cells generated in vitro, high mRNA 
expression at day 7 and 35 in CBSC cultures was observed. The levels in PBSC 
cultures remained constant and low during the whole culture. From here, we face two 
important questions: 1) Why were we unable to detect 2B4 by flow cytometry? 2) Does 
2B4 play a different role in NK cell development from CBSC and PBSC? To answer the 
first question, it can be argued that commercial antibodies recognise specific epitopes. 
However, a characterisation in CB and PB NK cells using the same antibody was 
performed: the results showed optimal staining (Luevano et al., 2012a). Antibodies 
recognise specific epitopes, either linear or conformational. The majority of the 
epitopes are conformational, where the recognised structure is formed by segments of 
proteins that are not continuous in the amino acid sequence, forming a 3-D structure. It 
could be that the conformational structure of 2B4 on NK cells generated in vitro is not 
recognised by the antibody used in this work. The clone PP35 was used, other reports 
use C1.7.1 or do not report the clone used. Certainly 2B4 mRNA was detected in all 
our cultures, CBSC samples had higher expression compared to PBSC. To answer the 
second question, our work cannot conclude whether 2B4 plays a different role in PBSC 
NK cells, as directed assays were not performed. Nevertheless, our results on CB and 
PB characterisation show that CB NK cells have a higher 2B4 expression compared to 
PB NK cells (Luevano et al., 2012a). Interestingly, CD48 (2B4 ligand) was expressed in 
frozen CBSC-NK and PBSC-NK cells, while absent in fresh CBSC-NK cells. 
Interactions between 2B4-CD48 in NK cells have been reported to augment 
proliferation in response to IL-2 (Assarsson et al., 2004). The reason for the absence of 
CD48 in fresh CBSC-NK cells remains unknown in our system. Regardless of the 
absence of 2B4 expression in all generated NK cells, it would be expected that CD48 
might participate in adhesion and as co-stimulator for NK cell activation in frozen 
CBSC-NK and PBSC-NK cells.  
 
Besides NCRs, there are also other receptors of major importance; the death receptor 
family (Fas-L and TRAIL) and CD94/NKG2 family (NKG2C and NKG2D). Fas-L and 
TRAIL are able to induce apoptosis of targets (Montel et al., 1995; Takeda et al., 
2001). Differences in the expression of Fas-L between frozen CBSC-NK and PBSC-NK 
cells were found. The data obtained showed that unlike CB and PB NK cells (where 
Fas-L expression is around 10% (Luevano et al., 2012a)), almost 100% of PBSC-NK 
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cells expressed Fas-L, whereas fresh and frozen CBSC-NK cells had lower expression 
(20-40%). Fas-L is usually expressed at very low and steady levels on NK cells; 
however, they express significant levels of intracellular Fas-L (Wallin et al., 2003). In 
fact, the same report suggests that the ligation of MHC class-I prevents upregulation of 
cell surface Fas-L. The absence of KIRs expression and therefore the lack of 
interactions with MHC in our system could contribute to the abundant Fas-L expression 
observed. Similarly, TRAIL was expressed abundantly in all generated NK cells, 
especially frozen CBSC-NK and PBSC-NK cells. CB and PB NK cells express low 
levels of TRAIL, around 15% (Dalle et al., 2005; Luevano et al., 2012a). TRAIL can 
mediate apoptosis in tumour cells, contributes to NK cell-mediated killing of immature 
DCs (Hayakawa et al., 2004) and is expressed in immature NK cells (CD161+CD56-) 
(Zamai et al., 1998b). The high expression of this receptor on NK cells could be useful, 
a recent report shows that TRAIL overexpression on NK cells using zoledronic acid 
was able to augment cytotoxicity against TRAIL-sensitive tumour cells (Sarhan et al., 
2013). Overall, the high expression of Fas-L and TRAIL can be translated to a better 
killing capacity in a granule-independent manner.  
 
Following the screening of activating receptors, the absence of NKG2C and expression 
of NKG2D on the generated NK cells was observed. Compared to PB NK cells, CB NK 
cells do not express NKG2C (Luevano et al., 2012a). Likewise, other reports show the 
absence of expression of NKG2C on NK cells generated in vitro (Spanholtz et al., 
2010; Beck, 2011). Regardless of the surface expression, NKG2C mRNA levels were 
very similar between NK cells generated in vitro and CB and PB NK cells. Lehemann et 
al. found low levels of activating NKG2C mRNA on NK cells generated in vitro 
(Lehmann et al., 2012). It seems that NKG2C expression is very variable among 
samples; it has been associated with HCMV seropositivity (Guma et al., 2006a). In that 
sense, the lack of NKG2C expression would be expected due to the nature of our 
culture, where NK cells were not exposed to HCMV.  
 
Another important activating receptor and perhaps one of the best characterised is 
NKG2D. Almost 100% of CB and PB NK cells express NKG2D (Freud et al., 2006; 
Luevano et al., 2012a). In agreement with our observations, the majority of the NK cells 
generated in vitro expressed NKG2D (Yoon et al.; Spanholtz et al., 2010; Beck, 2011; 
Spanholtz et al., 2011a). This receptor plays a key role in the control of infected and 
transformed cells and recently it was suggested to play an important role in NK cell 
development (Zafirova et al., 2011). The expression of NKG2D on the generated NK 
cells suggests the possibility of tumour recognition and potential killing of jeopardised 
cells infected by virus or DNA damage.  
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Bryceson and colleagues studied the combination of activating receptors needed to 
elicit cytotoxicity or cytokine secretion; their work concluded that none of these 
receptors could trigger a response alone, except CD16 (Bryceson et al., 2006b). 
Differences in the level of expression of CD16 have an impact on ADCC functions. 
ADCC is an effective mechanism in which CD16 on NK cells recognises the Fc portion 
of IgG antibodies bound to malignant cells. Almost 100% of PB NK cells and around 
50% of CB NK cells (highly variable) express CD16 (Luevano et al., 2012a). The 
majority of protocols that generate NK cells in vitro give rise to CD56brightCD16-/low. 
During this work, a small fraction (10-25%) of NK cells expressing CD16 was detected. 
Few studies report the generation of CD56+CD16+ cells, either using PBSC (100% 
CD16+) (Giuliani et al., 2008) or CBSC (24% CD16+) (Frias et al., 2008). CD16 
acquisition depends on the type of system and conditions used. Dezell et al. found a 
higher CD16 percentage in NK cells generated using a heparin-based system 
compared to the use of the feeder layer EL08.1D2 (Dezell et al., 2012). The absence of 
CD16 in the majority of the generated NK cells predicts a deficient ADCC activity. 
Nevertheless, we believe that additional signals would be provided in vivo that will 
support NK cell maturation and therefore CD16 acquisition.  
 
While studying the phenotype of the generated NK cells in vitro we observed the 
expression of abundant activating receptors and low expression of KIRs. In addition, 
the characterisation of interleukin receptors on NK cells generated in vitro was included 
in this study. Four out of the five investigated interleukin receptors were expressed 
differentially between fresh and frozen CBSC-NK cells. Conversely, only IL-18R was 
differentially expressed between frozen CBSC-NK cells and PBSC-NK cells. Frozen 
CBSC-NK cells expressed more IL-2R# and IL-2R$1 and less IL-15R# and IL-12R$1 
(IL-12R$1 had increased expression in the CD56bright subset) compared to their fresh 
counterpart. Like CB and PB CD56bright cells (Luevano et al., 2012a), frozen CBSC-NK 
cells and PBCS-NK cells should have capacity to respond to IL-2 due to CD25 and 
CD122 expression (IL-2R# and IL-2R$1, respectively). This profile resembles that of 
CD56bright cells, providing a better proliferation and activation capacity, as IL-2 effects 
on NK cells have been well studied (Poli et al., 2009). On the other hand, the absence 
in fresh CBSC-NK cells of the high affinity IL-2 receptor (CD25) might indicate a more 
mature stage, resembling the CD56dim subset. Fresh CBSC-NK cells might have a 
better response to IL-12 and IL-15, therefore producing more IFN-!, increasing survival 
and enhancing NK cell cytotoxicity (Kobayashi et al., 1989; Naume et al., 1992; 
Gamero et al., 1995; Carson et al., 1997). The overall repertoire of interleukin receptor 
expression direct us toward the assumption that fresh CBSC-NK cells resemble the 
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CD56dim subset while frozen CBSC-NK cells and PBSC-NK cells resemble the 
CD56bright subset. Finally, the expression of IL-18R is more common in the CD56bright 
subset (Poli et al., 2009); interestingly it was expressed in PBSC-NK cells (increased 
expression in the CD56dim subset) and not CBSC-NK cells (fresh and frozen). IL-18 is 
produced by macrophages during infection, which synergises with other factors in 
order to increase IFN-" production (Sareneva et al., 1998; Strengell et al., 2003). The 
lack of IL-18R on CBSC-NK cells could thus impact on IFN-" production; nevertheless, 
other cytokines like IL-12 induce its expression (Sareneva et al., 2000). 
 
Until recently, very little was known about NK cell migration and trafficking. Current 
research has implicated that chemokine receptors are able to control migration and 
functions of NK cells. Because the different CD56 subsets have unique distribution and 
function, their chemokine receptor profile is also different. CD56bright cells express little 
CXCR1, CXCR2 and CXCR3 but high levels of CCR5 and CCR7 (Robertson, 2002). 
CD56dim cells express CXCR1, CXCR2, CXCR3 and CXCR4 but not detectable levels 
of CC receptors (Robertson, 2002). Our characterisation showed a higher expression 
of CXCR1 and lower CXCR4 in PB CD56dim cells (Luevano et al., 2012a). CB CD56dim 
cells also showed a higher expression of CXCR1, but CXCR4 had a higher expression 
on CD56dim cells (Luevano et al., 2012a). The chemokine receptor characterisation will 
vary according to staining protocols, clones used and taking into consideration the 
status of NK cells, either resting or activated. We allowed 2-3 h resting of the cells 
before all cell-surface labelling. Therefore, a direct comparison with other studies was 
difficult. During this work the expression of the majority of the chemokine receptors was 
very variable, especially in the frozen cultures (CBSC and PBSC). Fresh CBSC-NK 
cells had very low or no chemokine receptor expression at all. Because of the high 
variability, only the chemokine receptors that had no variation among samples will be 
discussed; namely CCR7, CXCR7 and CXCR4. The absence of CCR7, frequently 
expressed in CD56bright cells (Poli et al., 2009), suggests these cells will not be able to 
migrate to the lymph nodes (Campbell et al., 2001). LNs are the site of interaction 
between different types of cells. DCs upregulate CCR7 after encountering a pathogen, 
then, migration to lymph nodes occurs, followed by interaction with CD56bright cells and 
T cells (Palucka and Banchereau, 2002). NK cells can induce maturation of DCs, either 
by secretion of IFN-! and TNF or in a cell-cell dependent manner (Gerosa et al., 2002). 
However, this cross-talk between NK cells and DCs can also lead to blocking of 
antigen presentation (Gerosa et al., 2002). The lack of CCR7 could be taken as a sign 
of NK cell maturity. 
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In the case of CXCR7, inconsistent results have been reported (Hartmann et al., 2008; 
Berahovich et al., 2010a). In agreement with our data, a recent study suggests that NK 
cells do not express CXCR7 (Berahovich et al., 2010a; Berahovich et al., 2010b). 
Fresh CBSC-NK cells did not express CXCR4, but frozen CBSC-NK cells and PBSC-
NK cells did. Nevertheless, this observation deserves further investigation, as this work 
did not include migration assays. Furthermore, we found that CD56bright cells from 
frozen CBSC cultures expressed more CXCR4. Some researchers propose that 
CXCR4 is expressed by both PB CD56 subsets (Robertson, 2002), others have found 
CXCR4 to be more expressed in PB CD56dim cells (Campbell et al., 2001) or CB 
CD56dim cells (Luevano et al., 2012a). As previously mentioned, there are many 
discrepancies in the literature due mainly to different cell isolation procedures, staining 
protocols and even the antibodies used.  
 
In addition to signals for tissue-specific migration, NK cells need to undergo additional 
steps in order to carry out their functions: migration and cell adhesion. NK cells are 
equipped with a variety of integrins and adhesion molecules. For instance, CD49d 
(integrin #4) mediates cell to cell and cell to extracellular-matrix interactions, and is 
also known to be crucial for transendothelial migration (Humphries et al., 1995). NK 
cells from fresh CBSC and CBSC and PBSC frozen cultures expressed CD49d to a 
lesser extent compared to PB and CB NK cells (Luevano et al., 2012a). The 
expression of integrin "7 was less compared to CD49d, especially in fresh CBSC-NK 
cells. Regardless, integrin "7 expression in all NK cells generated in vitro was higher 
compared to that of CB and PB NK cells (Luevano et al., 2012a). Integrin "7 forms 
heterodimers with CD49d (integrin #4) and plays an important role in interaction with 
both extracellular matrix and endothelial cells (Perez-Villar et al., 1996). According to 
our characterisation, integrin "7 will be able to form heterodimers thanks to the 
availability of CD49d. We did not screen for integrin "1, another integrin that can bind 
to CD49d. However, CD49d is potentially shared by these two integrins. Our results 
suggest that the generated NK cells may be able to interact with the extracellular 
matrix and with other cells.   
 
Another cell adhesion molecule studied was L-selectin, which facilitates the migration 
of lymphocytes from blood into secondary lymphoid tissues (Bevilacqua et al., 1991). 
Similar to our results, it has been reported that PB CD56bright cells express L-selectin 
(Frey et al., 1998; Luevano et al., 2012a), whereas CB NK cells (CD56bright or CD56dim 
subsets) do not (Luevano et al., 2012a). As NK cells mature they lose L-selectin 
expression (Andre et al., 2000). During this work, the absence of this molecule in 
CBSC cultures and very low expression in PBSC-NK cells was detected. This profile 
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resembles that of CB NK cells (Luevano et al., 2012a). The absence of L-selectin 
reaffirms the probable inability of the generated NK cells to migrate to lymphoid 
tissues. The questions to address would be: 1) can NK cells shape their repertoire and 
acquire molecules that allow homing to LNs? 2) What would be the consequences if 
the generated NK cells cannot home to LNs? There are some studies reporting that NK 
cell phenotype is shaped by the microenvironment (Di Santo, 2008; Shi et al., 2011). 
Regarding the consequences, studies in HIV infected individuals have shown the 
presence of CCR7-CD56bright cells; moreover, these cells can be present in healthy 
individuals but in low frequencies (Hong et al., 2012). These cells have a high cytotoxic 
activity, with mature phenotype and an activated state. Keeping in mind that our work 
does not include migration assays, we suggest that the expression of L-selectin and 
CCR7 for homing to lymph nodes will be shaped according to the physiological needs.   
 
Adhesion molecules are important not only for cellular binding, but also for signal 
transduction (Hogg and Landis, 1993). For instance, LFA-1 is required for efficient lysis 
of target cells through cell adhesion in addition to initiating activating signals in NK cells 
(Barber et al., 2004; Mace et al., 2010). NK cells from fresh CBSC and PBSC had a 
tendency for higher expression of LFA-1, suggesting that lysis could be facilitated at a 
greater extent compared to NK cells from frozen CBSC cultures. It has been shown 
that LFA-1 interacts with DNAM-1 (also known as CD266) and was expressed by all 
PB NK cells and to a lesser extent by CB NK cells (Luevano et al., 2012a). DNAM-1 is 
an adhesion molecule that can trigger NK cell cytotoxicity. Shibuya et al. reported that 
DNAM-1 activation is dependent upon functional interaction with LFA-1 (Shibuya et al., 
1999). We observed a higher expression of DNAM-1 in PBSC-NK cells compared to 
CBSC-NK cells. The levels of LFA-1 in CBSC CD56dim cells were higher compared to 
the CD56bright subset. Altogether these data suggest that PBSC-NK cells have higher 
levels of LFA-1 and DNAM-1, indicating a probable advantage over CBSC-NK cells 
(fresh and frozen).  
 
Figure 4.20 depicts the complete phenotypic characterisation of NK cells generated in 
vitro from fresh and frozen CBSC cultures. Little differences were found when using 
fresh or frozen CBSC for the majority of the NK cell receptors tested. Overall, the most 
interesting differences were the tendencies for a lower expression of CD16 and LFA-1 
and a higher expression of TRAIL, CXCR4 and integrin "7 in frozen CBSC-NK cells 
compared to fresh CBSC-NK cells. The mechanisms responsible for these differences 
are unclear. The low expression of LFA-1 and CD16 and higher expression of CXCR4 
and integrin "7 in frozen CBSC-NK cells suggests an immature phenotype (Freud et 
al., 2006; Zamai et al., 2009; Montaldo et al., 2012). 
Chapter 4 
 167 
 
Figure 4.20. Phenotypic characterisation of CBSC-NK cells. The figure shows the 
characterisation of fresh CBSC-NK cells and frozen CBSC-NK cells. The markers in bold red 
are significantly higher compared to their counterpart. The markers in italics and bold black are 
different but not statistically significant.  
 
Conversely, fewer differences in the phenotype between frozen CBSC-NK and PBSC-
NK cells were found. CBSC-NK cells expressed more TRAIL and less DNAM-1, Fas-L 
and IL-18-R (Figure 4.21). This suggests that PBSC-NK cells could have a better killing 
capacity due to the expression of adhesion/activation molecule DNAM-1 and death 
receptor Fas-L. 
 
 
Figure 4.21. Phenotypic characterisation of frozen CBSC and PBSC NK cells. The figure 
depicts the phenotype of frozen CBSC-NK cells and PBSC-NK cells. The markers in bold red 
are significantly higher compared to their counterpart. The markers in italics and bold black are 
different but not statistically significant.  
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Although NK cells generated in vitro do not precisely resemble either PB or CB NK 
cells, the expression of some receptors like CXCR4 and integrin "7 or lack of KIRs 
suggest that the generated NK cells could behave like CD56bright cells. The question 
would now be: would a CD56bright cell phenotype be a disadvantage? Just recently, a 
study followed NK cell turnover in adults; the results suggested that CD56bright NK cells 
were able to proliferate rapidly and die slowly compared to CD56dim (Lutz et al., 2011). 
In addition, Lehmann et al. suggested that in vitro generated NK cells that resemble 
CD56bright NK cells display a gene expression profile similar to those of CD56dim NK 
cells in PB (Lehmann et al., 2012). This data is in accordance to our study where we 
found that mRNA levels for most of the markers are expressed similarly or even at 
higher levels compared to CB and PB NK cells. Altogether, these data support the 
notion that CD56bright NK cells could be a good option for immunotherapeutic uses. 
These cells will have several advantages over CD56dim cells: higher proliferation and 
survival rates and the probability of better killing due to less inhibitory receptors 
expression. 
 
The dynamic process of acquisition of NK cell receptors makes it difficult to assess if 
the phenotype of the generated NK cells will remain after infusion. The most probable 
outcome will be a change of this repertoire according to the environment. 
Nevertheless, it is important to carry out this characterisation, as it will provide 
information that will allow a correlation with the outcome of the NK cell therapy.  
 
To summarize, we achieved one the most complete characterisation of NK cells 
generated in vitro. Furthermore, NK cells generated in vitro express NCRs, NKG2D 
and DNAM-1, cell markers that contribute to tumour killing according to Alici et al. (Alici 
et al., 2008). 
 
The findings discussed in this chapter were:  
 
1) Frozen CBSC-NK cells had a similar phenotype compared to fresh CBSC-NK 
cells and even to PBSC-NK cells. 
2) Evidence that removal of IL-15 for the last 3 weeks did not affect the phenotype 
of the generated NK cells was provided. 
3) NK cells were generated that expressed activating receptors and low KIRs 
expression, but also expressed NKG2A and were potentially capable of BM 
homing and responding to different cytokines. 
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4) This phenotype does not precisely resemble CB or PB NK cells; instead, NK 
cells generated in vitro have a unique phenotype and a similar transcriptional 
profile.  
  
Chapter 5 
 170 
 Functionality of Natural Killer cells Chapter 5:
generated in vitro 
5.1 Introduction 
 
NK cells are able to perform their function through two important mechanisms: 
production of cytokines such as IFN-", TNF-#, GM-CSF and cytotoxicity mediated via 
granule-secretion of perforin/granzyme or via death-receptors. NK cell cytotoxic and 
immunoregulatory functions have been widely studied, both in CB and PB. It is well 
established that NK cell subsets have different phenotype and functions (Cooper et al., 
2001a). Studies have revealed the different cytotoxic potential held by CD56bright and 
CD56dim NK cells in CB and PB. CD56bright NK cells from both sources exhibit low 
cytotoxicity (Cooper et al., 2001b) and CB CD56dim NK cells are considerably less 
cytotoxic than their PB counterpart (Tanaka et al., 2003; Luevano et al., 2012a). 
Moreover, resting CB NK cells are more naïve and heterogeneous compared to PB NK 
cells (Hoshina et al., 1999; Tanaka et al., 2003). CB NK cells have been shown to have 
a more immature phenotype (Luevano et al., 2012a), and to exhibit a higher expression 
of inhibitory receptors (Wang et al., 2007) and lower expression of adhesion molecules 
(Tanaka et al., 2003), features that could contribute to the lower CB NK cell cytotoxicity 
observed in different studies. Nevertheless, activation with IL-2, IL-12 or IL-15 can 
restore CB NK cell functions (Hoshina et al., 1999; Luevano et al., 2012a). These 
observations raise important questions: if CB NK cells are naïve and immature, would 
NK cells generated in vitro from CBSC have similar characteristics? Would NK cells 
generated from different HSC sources have different phenotype and effector functions 
as observed for PB and CB NK cells? The answers to these questions may influence 
decision as to which HSC source should be used for NK cell generation in vitro.  
 
Efforts have been made to characterise effector functions of NK cells generated in 
vitro. In the majority of reports using CBSC (Kao et al., 2007; Spanholtz et al., 2010; 
Beck, 2011; Spanholtz et al., 2011a; Dezell et al., 2012) or PBSC (Woll et al., 2005; 
Giuliani et al., 2008; Woll et al., 2009) NK cell effector functions were studied using a 
standard 51Cr release assay and K562 cells. Some reports included the assessment of 
intracellular IFN-", granzyme B and perforin (Woll et al., 2009; Lehmann et al., 2012; 
Zamai et al., 2012), very few included cytokine secretion or degranulation assays 
(Bonanno et al., 2009; Spanholtz et al., 2010; Spanholtz et al., 2011a) and only one 
performed ADCC assays (Lehmann et al., 2012) (see appendix 3). Furthermore, the 
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literature regarding the functional study of NK cells generated in vitro comparing 
different HSC sources is scarce (Carayol et al., 1998; Woll et al., 2009). For instance, 
Woll et al. compared the use of hESC to CBSC for NK cell generation in vitro (Woll et 
al., 2009) and reported that CBSC-NK cells displayed low cytotoxicity and an immature 
phenotype compared to NK cells from hESC (Woll et al., 2009). If indeed there is a 
difference in effector functions of NK cells generated in vitro according to HSC source, 
choosing the right HSC source will therefore be crucial as this will impact on the clinical 
outcome. A complete study including not only phenotypic but also functional 
characterisation of NK cells generated in vitro from different HSC source will help 
address this question.  
 
Each protocol for NK cell generation in vitro has been optimised with cytokine cocktails 
that will vary in composition. Components in the media and the use or omission of a 
feeder layer for HSC culture will determine the acquisition of receptors on the 
generated NK cells and thus their function. Although many comparisons are probably 
performed while optimising a protocol, very few have been published (McCullar et al., 
2008; Dezell et al., 2012). During this work, a functional analysis of NK cells generated 
in vitro using a modified published protocol was included (Grzywacz et al., 2006).  
 
In this chapter we performed what we believe is one of the most complete 
characterisations in terms of functionality of NK cells generated in vitro. We tested the 
impact of using a modified protocol on the generated NK cells in vitro, in addition to 
determining whether the use of cryopreserved CBSC cells would jeopardise NK cell 
functions. Finally, this complete characterisation was also performed using PBSC and 
compared to CBSC. This chapter includes a variety of assays to determine the 
cytotoxic and immunoregulatory properties of NK cells generated in vitro. The results of 
this chapter complement the phenotypic characterisation and provide a more thorough 
characterisation of NK cells generated in vitro.  
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5.2 Results  
5.2.1 Frozen CBSC-NK cells secrete high amounts of IFN-! and TNF-α  
 
5.2.1.1 IFN-" 
 
In order to assess the functional features of NK cells generated in vitro a variety of 
assays were performed. NK cell subsets have different immunoregulatory and cytotoxic 
properties; CD56bright cells appear to have an intrinsic capacity to produce high levels of 
cytokines compared to CD56dim cells. Thus, immunoregulatory properties have been 
attributed to CD56bright NK cells (Cooper et al., 2001a). IFN-" is one of the main 
cytokines secreted by NK cells and can lead to activation of other cells (Cooper et al., 
2001b). In fact, IFN-" is the primary macrophage-activating factor leading to increased 
tumour cytotoxicity, anti-microbial activity as well as antigen processing and 
presentation to lymphocytes (Young and Hardy, 1995). In addition, IFN-" acts on CD4+ 
T cell development, affecting the balance between Th1 and Th2 sub-populations 
(Young and Hardy, 1995). Although CD56bright cells have been shown to secrete high 
levels of IFN-" a recent report suggests that CD56dim cells can also (De Maria et al., 
2011). 
 
Due to the important role of IFN-", the secretion of this cytokine by NK cells generated 
in vitro was analysed. Supernatants of non-stimulated NK cells or NK cells stimulated 
for 2 h with K562 or Raji (only for fresh samples) and PMA&Iono (for all samples) were 
collected and used for ELISA analysis (figure 5.1). A minimal secretion of IFN-" when 
cells were stimulated with K562 or RAJI cells was observed (range from 17.5 - 180 
pg/ml). However, figure 5.2A shows that secretion of IFN-" using PMA&Iono was 
significantly higher in NK cells from frozen CBSC cultures compared to fresh CBSC 
and to PBSC cultures (4180.4 ± 1848 pg/ml for frozen CBSC, 188.7 ± 101.7 pg/ml and 
180.3 ± 244 pg/ml for fresh CBSC and PBSC respectively, p<0.05). No differences 
were observed between NK cells from fresh CBSC cultures using all cytokines or only 
IL-15 (figure 5.1B).  
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Figure 5.1. IFN-! secretion of NK cells generated in vitro. A) Secreted IFN-" by NK cells as 
measured by ELISA without stimuli, or stimulated with the cell lines K562 or Raji or with 
PMA&Iono for fresh CBSC-NK cells (n=3), frozen CBSC-NK cells (n=7), PBSC-NK cells (n=6) 
and NK cells from CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). Mann Whitney test 
was performed. * p<0.05, ** p<0.01. 
 
Regardless of the striking difference in secreted IFN-" by frozen CBSC-NK cells, 
intracellular IFN-" expression did not significantly differ between frozen CBSC-NK cells 
(23.1 ± 7.5%) and fresh CBSC-NK cells (35.6 ± 8.6%), or even between frozen CBSC-
NK and PBSC-NK cells (17.7 ± 2.9%) (figure 5.2A). Similarly, there were no differences 
in intracellular IFN-" expression between fresh CBSC-NK cells (35.6 ± 8.6% versus 
31.8 ± 0.9%, all cytokines and only IL-15, respectively, figure 5.2B).  
 
 
Figure 5.2. Intracellular IFN-! expression in NK cells generated in vitro. Intracellular 
expression of IFN-" analysed by flow cytometry in NK cells stimulated with PMA&Iono, K562 or 
Raji cells in the presence of GolgiStop™. A) Expression of IFN-" for NK cells (percentages 
come from the CD56+CD3- gate) from fresh (n=3) and frozen (n=9) cultures, PBSC-NK cells 
(n=6) and B) NK cells from CBSC cultures with all cytokines (n=3) or only Il-15 (n=3). 
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Flow cytometry data for intracellular IFN-" revealed that there was no specific NK cell 
subset producing IFN-" according to the CD56 surface density expression (figure 5.3 
and 5.4).  
 
 
Figure 5.3. Flow cytometry analysis of intracellular IFN-! in NK cells generated in vitro. 
Flow cytometry analysis showing a representative sample of frozen CBSC-NK cells (upper 
panel) and PBSC-NK cells (lower panel). The plots show IFN-" versus CD56 expression from 
the lymphocyte gate in NK cells without stimuli or in the presence of cell lines Raji, K562 or 
PMA&Iono. 
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Figure 5.4. Flow cytometry analysis of intracellular IFN-! in NK cells generated in vitro. 
Flow cytometry analysis showing a representative sample of fresh CBSC-NK cells using all 
cytokines (upper panel) or only IL-15 (lower panel). The plots show IFN-" versus CD56 
expression from the lymphocyte gate in NK cells without stimuli or in the presence of cell lines 
Raji, K562 or PMA&Iono. 
 
The intracellular data revealed no differences in intracellular IFN-" expression, 
however IFN-" secretion was considerably higher in frozen CBSC-NK cells. Thus, IFN-
" mRNA levels were studied in NK cells from fresh CBSC and frozen CBSC. 
Additionally, IFN-" mRNA expression in resting NK cells from CB and PB were 
included. Figure 5.5 shows the relative expression of IFN-" mRNA in resting NK cells 
from CB, PB, fresh CBSC and frozen CBSC cultures. Although no significant 
differences were found between cultures, there was a tendency for a higher expression 
of IFN-" mRNA in frozen CBSC-NK cells compared to PB NK cells (figure 5.5, p= 
0.057).  
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Figure 5.5. mRNA analysis of IFN-!. Total RNA was extracted from resting NK cells from CB 
(n=3) and PB NK cells (n=3), and fresh CBSC (n=3) and frozen CBSC-NK cells (n=4) harvested 
at day 35. The graph depicts the ratio of IFN-" and the reference genes expression.  
 
Altogether, frozen CBSC-NK cells demonstrated to have a remarkable capacity to 
secrete IFN-". Regardless of the similar intracellular IFN-" expression, CBSC-NK cells 
are able to secrete vast amounts of this cytokine as confirmed by ELISA and the 
detection of IFN-" mRNA in the generated NK cells. 
 
5.2.1.2 TNF-! 
 
Another important cytokine secreted by NK cells is TNF-#. TNF-# is a cytokine able to 
regulate other immune cells, such as T cells (Scheurich et al., 1987). Similar to IFN-", 
low TNF-# secretion was found when NK cells from all HSC cultures were stimulated 
with K562 cells; the secretion was even lower with Raji cells (figure 5.6A and B). NK 
cells stimulated with PMA&Iono from frozen CBSC cultures had significantly higher 
TNF-# expression compared to fresh CBSC cultures (p<0.05, figure 5.6A). NK cells 
from PBSC cultures had a variable secretion of TNF-# and no differences were found 
when compared to frozen CBSC-NK cells (figure 5.6A). Similarly, no significant 
differences between NK cells from fresh CBSC-NK cultures using all cytokines or only 
IL-15 were found (figure 5.6B).  
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Figure 5.6. TNF-" secretion in the generated NK cells. A) Secreted TNF-# by NK cells as 
measured by ELISA without stimuli, or stimulated with the cell lines K562 or Raji and with 
PMA&Iono for fresh CBSC-NK cells (n=3), frozen CBSC-NK cells (n=6), PBSC-NK cells (n=3) 
and NK cells from CBSC cultures with all cytokines (n=3) or only IL-15 (n=3). Mann Whitney test 
was performed. * p<0.05,. 
 
In summary, CBSC-NK cells showed higher TNF-# secretion compared to fresh CBSC-
NK cells in response to PMA&Iono, whereas TNF-# secretion was similar between 
CBSC-NK cells and PBSC-NK cells. 
 
5.2.2 Natural Killer cells from haematopoietic stem cell cultures degranulate 
against K562 cells and after stimulation with PMA&Iono  
 
NK cells are able to kill via exocytosis of their granules or via death-receptor binding. 
CD107a is a membrane protein (LAMP-1) associated with lysosomes residing in 
cytolytic granule membranes located within the cytoplasm. CD107a is mobilised to the 
cell surface following activation-induced granule exocytosis. A degranulation assay 
detecting CD107a when NK cells generated in vitro were exposed to cell lines K562 
and Raji, or stimulated with PMA&Iono was performed during this study. A high 
percentage of NK cells from all HSC cultures degranulated when stimulated with 
PMA&Iono (range 41-56%) and K562 cells (11.9-23.7%) but not Raji cells (around 3%, 
figure 5.7A and B). Although no significant differences between cultures were 
observed, the flow cytometry analysis showed that a stronger response was observed 
in fresh CBSC-NK cells (figure 5.8, PMA&Iono).  
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Figure 5.7. CD107a degranulation assay. Degranulation assay using CD56+CD3- cells from 
the lymphocyte gate stimulated with PMA&Iono, K562 or Raji cells from A) fresh CBSC-NK cells 
(n=3), frozen CBSC-NK cells (n=6), PBSC-NK cells (n=6) and B) NK cells from CBSC cultures 
with all cytokines (n=3) or only IL-15 (n=3). 
 
Figure 5.8. Flow cytometry analysis of CD107a. The figure shows representative CD107a 
histograms of gated CD56+CD3- cells from the lymphocyte gate against PMA&Iono, K562, Raji 
or without stimuli for A) fresh CBSC-NK cells, B) frozen CBSC-NK cells, PBSC-NK cells and D) 
CBSC-NK cells using all cytokines. 
 
5.2.3 Natural Killer cells from frozen cord blood stem cell cultures are 
characterised by low intracellular granzyme B expression but abundant 
perforin expression  
 
NK cells can lyse virus-infected and tumour cells through activation of granule 
exocytosis and release of cytotoxic mediators, such as perforin (mediating entry to 
target cells) and granzymes (initiating apoptosis). The presence of these components 
in NK cells generated in vitro was investigated. Figure 5.9A shows that NK cells from 
all HSC cultures expressed granzyme B and perforin. Nonetheless, a striking 
difference in the expression of granzyme B was found; frozen CBSC-NK cells had 
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significantly less granzyme B expression than fresh CBSC-NK cells and PBSC-NK 
cells (p<0.05). Granzyme B expression in NK cells from fresh CBSC cultures using all 
cytokines or only IL-15 was similar (figure 5.9B). Moreover, no preferential expression 
of granzyme B or perforin by a specific NK cell subset according to the surface density 
expression of CD56 was observed (figure 5.10). Perforin expression was higher in 
fresh CBSC-NK cells (97.2 ± 0.9%) and PBSC-NK cells (97.9 ± 1.3%) compared to 
frozen CBSC-NK cells (80.7 ± 14.2%, figure 5.9A), while levels in fresh CBSC-NK cells 
were similar (96.7 ± 1.6% versus 97.2 ± 0.9%, all cytokines and only IL-15, 
respectively). 
 
 
Figure 5.9. Intracellular expression of granzyme B and perforin in NK cells generated in 
vitro. A) Expression of granzyme B and perforin in CD56+CD3- cells from the lymphocyte gate 
of fresh CBSC cultures (n=3), frozen CBSC cultures (n=9), PBSC cultures (n=6) and B) 
CD56+CD3- cells from CBSC cultures using all cytokines (n=3) or only IL-15 (n=3). Mann 
Whitney test was performed. * p<0.05, ** p<0.01. 
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Figure 5.10 Flow cytometry analysis of granzyme B and perforin in NK cells generated in 
vitro. A representative flow cytometry analysis of NK cells from the lymphocyte gate of fresh 
CBSC, frozen CBSC, PBSC and CBSC cultures using all cytokines for Granzyme B (upper 
panel) and perforin (bottom panel) is presented.  
 
The low expression levels of granzyme B in NK cells generated in vitro led us to 
determine mRNA levels in these cells. First, granzyme B expression between days 21-
35 was screened, as this is when NK cells emerged in HSC cultures. An increase in 
mRNA expression throughout the weeks was observed, reaching a peak at day 35 
(figure 5.11A). Moreover, the comparison of granzyme B mRNA expression at day 35 
from NK cells generated in vitro to that of resting CB and PB NK cells was performed 
(figure 5.11B). Although only a trend was observed, it is noteworthy that granzyme B 
mRNA expression seemed to be higher in NK cells generated in vitro compared to CB 
and PB NK cells.  
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Figure 5.11. mRNA analysis of granzyme B. A) Total RNA was extracted from frozen CBSC-
NK cells and PBSC-NK cells harvested at days 21, 28 and 35. B) Total RNA was extracted from 
resting NK cells from CB (n=3) and PB NK cells (n=3), fresh CBSC (n=3) and frozen CBSC-NK 
cells (n=4) and PBSC-NK cells (n=3) harvested at day 35. The graphs depict the ratio of 
granzyme B and the references genes.  
 
In summary, NK cells generated in vitro had high expression of perforin, however 
granzyme B levels were remarkably low in frozen CBSC-NK cells compared to fresh 
CBSC-NK cells and PBSC-NK cells. Nevertheless, the molecular analysis of granzyme 
B mRNA revealed that frozen CBSC-NK cells had indeed high expression, comparable 
to that found in resting CB NK cells and PB NK cells.  
 
5.2.4 51Cr release assay 
5.2.4.1 Killing of K562 in vitro by Natural Killer cells from haematopoietic stem 
cell cultures 
 
The killing capacity of the generated NK cells using a standard 51Cr release assay with 
the cell line K562 was investigated. Due to the deficiency of MHC class I in K562 cells, 
these cells are highly sensitive to NK cell-mediated lysis. K562 cells were labelled with 
51Cr and exposed to NK cells generated in vitro. Figure 5.12 shows the percentage of 
specific lysis using different E:T ratios. The percentage of specific lysis observed when 
using fresh and frozen CBSC-NK cells was very similar at the E:T ratio of 10:1 (41.7 ± 
17.2% versus 32.8 ± 3.8% respectively). However, data comparison between frozen 
CBSC-NK cells and PBSC-NK cells revealed a higher killing capacity by frozen CBSC-
NK cells (32.8 ± 3.8% versus 22.4 ± 3.6%; respectively, p<0.05). There was no 
difference in K562 cell lysis by NK cells from fresh CBSC cultures using all cytokines or 
only IL-15 (figure 5.12B). 
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Figure 5.12. 51Cr release assay. A) NK cells from fresh CBSC cultures (n=3), frozen CBSC 
cultures (n=4), PBSC-NK cells (n=6) and B) NK cells from CBSC cultures using all cytokines 
(n=3) or only IL-15 (n=3) were co-incubated with 51Cr K562 labelled cells in a standard 4 h 51Cr-
release assay. Mann Whitney test was performed. * p<0.05. 
 
5.2.4.2 Similar ADCC killing by Natural Killer cells from haematopoietic stem 
cell cultures 
 
ADCC is an effective mechanism in which CD16 on NK cells recognises the Fc portion 
of IgG antibodies bound to malignant cells; engagement of CD16 triggers NK cell 
cytotoxicity against malignant cells. In this experiment anti-CD16 antibodies or an 
isotype were used to coat murine cell line P815 and used in a standard 4 h 51Cr release 
assay. We previously described that the expression of CD16 in fresh CBSC-NK cells 
from either all cytokines or only IL-15 cultures had a tendency for higher CD16 
expression (chapter 4, p=0.0714); frozen CBSC-NK cells and PBSC-NK cells having a 
lower expression. Interestingly, no significant differences were found in ADCC activity 
between NK cells from HSC cultures (figure 5.13A and B). In general, ADCC was low 
in NK cells from all HSC cultures, with high variability in fresh CBSC samples.  
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Figure 5.13. Antibody-dependent cell-mediated cytotoxicity. A) NK cells from fresh CBSC 
(n=3), frozen CBSC cultures (n=8), PBSC-NK cells (n=6) and B) NK cells from CBSC cultures 
with all cytokines (n=3) or only IL-15 (n=3) were co-incubated with 51Cr labelled P815 cells 
coated with anti-CD16 or isotype control in a standard 4h 51Cr-release assay. Dotted lines 
represent the isotype control.  
 
In summary, CBSC-NK cells (fresh and frozen) had similar killing capacity against the 
cell line K562 and a better killing activity was observed by frozen CBSC-NK cells 
compared to PBSC-NK cells. ADCC activity did not differ among cultures regardless of 
the different CD16 expression on NK cells generated in vitro.  
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5.3 Discussion 
 
Many studies have been published describing the basic NK cell killing machinery. We 
have learned, to a certain extent, how to use these features for immunotherapy 
purposes. Even though we still have a long way ahead, the current clinical trials have 
proven than NK cells are safe to infuse with positive effects in the treatment of certain 
malignancies. Unravelling the functional features of NK cells generated in vitro is 
critical. This will allow us to correlate clinical outcomes with the full characterisation of 
the infused product. In this chapter we explored the functional potential of NK cells 
generated in vitro. A variety of assays shed light into the remarkable killing capabilities 
that generated cells in vitro have. In particular, frozen CBSC had superior features that 
enhanced their potential for immunotherapeutic purposes.  
 
During this work, frozen CBSC-NK cells had a superior IFN-" secretion capacity 
compared to fresh CBSC-NK cells and PBSC-NK cells. The assessment of IFN-" in NK 
cells generated in vitro is important due to its potential role in host responses to 
tumours (Yokoyama et al., 2004) and viral infection (French and Yokoyama, 2004). 
IFN-" secretion detected in frozen CBSC-NK cells was similar (PMA&Iono: 4000 pg/ml) 
to other reports where NK cells derived from CBSC were stimulated with IL-12 and IL-
18 (Perez et al., 2006b; Kao et al., 2007); whereas this assay was not performed for 
PBSC-NK cells (Woll et al., 2005; Giuliani et al., 2008; Woll et al., 2009; Zamai et al., 
2012). The intracellular and secreted IFN-" was very low (3-5%) in NK cells from all 
HSC cultures when cells were stimulated with K562 cells. The data using freshly 
isolated CB or PB NK cells also showed very low intracellular IFN-" expression against 
K562 cells (Luevano et al., 2012a). Regardless of the difference in secretion of IFN-", 
intracellular IFN-" remained similar in all HSC cultures when PMA&Iono was used. This 
indicates that even though the level of intracellular IFN-" was similar between cultures, 
frozen CBSC-NK cells were able to produce a vast amount of IFN-" in response to 
PMA&Iono. This substantial secretion of IFN-" is usually associated with the CD56bright 
subset (Cooper et al., 2001b). This common observation would suggest that CBSC-NK 
cells resemble this subset. But very interesting data suggests that the CD56dim subset 
is also able to secrete vast amounts of IFN-" (De Maria et al., 2011). In contrast to 
CD56bright cells, CD56dim cells secrete IFN-" as early as 2 – 4 h after stimulation. 
CD56bright cells start releasing IFN-" after 16 h (De Maria et al., 2011). Likewise, during 
this work NK cells were stimulated for 2 h with PMA&Iono, suggesting that CD56dim 
cells from frozen CBSC cultures could be responsible for this IFN-" secretion. This also 
suggests that fresh CBSC-NK cells and PBSC-NK cells comprise CD56bright cells, which 
will secrete IFN-" after 16 h stimulation. A further analysis of the molecular expression 
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of the IFN-" mRNA revealed that resting frozen CBSC-NK cells had a tendency for 
higher IFN-" mRNA expression compared to resting CB and even PB NK cells. This 
result is in agreement with a recent study confirming that resting NK cells have high 
expression of genes encoding effector molecules, like IFN-", protease inhibitors and 
proteases (Bezman et al., 2012a).  
 
Another important factor secreted by NK cells is TNF-#, which can have an anti-tumour 
effect by downregulating the anti-apoptotic gene bcl-2 in tumour cells (Gillio Tos et al., 
1996). TNF-# can also augment NK cell cytotoxicity and response to IL-2 (Owen-
Schaub et al., 1988). A moderate secretion of TNF-# when cells were exposed to the 
cell line K562 was observed, similar to that detected by Cooper and colleagues using 
CD56bright cells incubated with PMA&Iono (below 300 pg/ml) (Cooper et al., 2001b). 
Furthermore, CBSC-NK cells showed higher TNF-# secretion when incubation with 
PMA&Iono was used. This secretion was considerably high (around 900 pg/ml) but far 
less than that observed by Perez et al. using a combination of IL-12 and IL-18 (4000 
pg/ml) (Perez et al., 2006b). Although it has commonly been thought that cytokine 
production and cytolytic functions are not linked, a recent report observed that IFN-" 
and TNF-# are functionally linked to their cytolytic activity via upregulation of the 
adhesion molecule ICAM-1 (Wang et al., 2012). The analysis of ICAM-1 expression on 
the generated cells was not performed in this study, but NK cells from frozen CBSC 
cultures certainly have an advantageous IFN-" and TNF-# secretion profile over fresh 
CBSC and PBSC cultures that in theory should enhance cytolytic activity.  
 
Besides cytokine secretion, NK cells are able to release cytotoxic granules upon cell 
activation. Degranulating cells are identified by their surface expression of CD107a. 
According to some studies, CD107a correlates with cytokine secretion and efficient 
lysis of target cells (Alter et al., 2004; Penack et al., 2005). The presence of surface 
CD107a upon exposure of NK cells to K562 or Raji cell lines and PMA&Iono was 
assessed during this work. The results are similar to the few reports regarding NK cells 
generated in vitro that perform this assay using K562 cell line (20-30%) (Bonanno et 
al., 2009; Spanholtz et al., 2010; Spanholtz et al., 2011b). In addition, NK cells 
generated in vitro showed degranulation values similar to those exhibited by freshly 
isolated CD56dim NK cells in CB and PB (Luevano et al., 2012a). As expected, high NK 
cell degranulation using PMA&Iono (up to 60%) was observed during this work, 
additionally, it was unexpectedly higher compared to that of CD56dim NK cells in PB 
(25-35%) (Luevano et al., 2012a). Furthermore, the data showed very low 
degranulation against Raji cell line, a NK cell-resistant cell line due to the expression of 
HLA class I. A previous report demonstrated that NK cell priming occurs via CD2 
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binding to CD15 on tumour cells (Sabry et al., 2011). The absence of CD15 on Raji 
cells could account for this resistance, however we believe that recognition of HLA by 
KIRs may also play an inhibitory role. Supporting this statement, a recent study using 
Raji cells demonstrated that HLA interactions with KIR3DL1 could inhibit NK cell 
functions (Hasenkamp et al., 2006). The data suggests that a high percentage of NK 
cells from all HSC cultures were able to degranulate against K562 cells and PMA&Iono 
and not against Raji cells. Nevertheless, a further characterisation including the 
screening of KIR3DL1 will provide information on the mechanisms responsible for this 
inhibition.  
 
NK cell killing can occur via release of granules able to trigger apoptosis of target cells. 
The presence of granzyme B and perforin in the generated NK cells was investigated 
during this work using intracellular staining. Granzyme B directly activates Bid, a 
specific substrate for granzyme B, resulting in caspase activation. Granzyme B 
depends on being appropriately delivered by perforin. Upon degranulation, perforin 
inserts itself into the target cell's plasma membrane, forming a pore and allowing 
granzyme B entry. In fact, a recent report has found that perforin can permeabilise the 
target cell membrane within an extraordinary short time frame of 30 seconds (Lopez et 
al., 2013). A higher expression of perforin in NK cells from fresh CBSC and PBSC 
cultures was found compared to frozen CBSC-NK cells. This high expression of 
perforin in fresh CBSC-NK cells and PBSC-NK cells was even higher compared to PB 
CD56dim NK cells. Our results showed a low expression of perforin in CD56bright NK cell 
subsets from CB and PB and even in CB CD56dim NK cells (Luevano et al., 2012a). 
The high perforin expression in NK cells generated in vitro can be partly explained by 
the presence of IL-15 in the culture media, reported to upregulate mRNA perforin 
expression (Gamero et al., 1995). 
 
Conversely, granzyme B expression was significantly lower in frozen CBSC-NK cells 
(fresh CBSC>PBSC>frozen CBSC). This low expression by frozen CBSC-NK cells 
resembled that of CD56bright NK cells from CB and PB (Luevano et al., 2012a). 
Granzyme B greatly contributes to NK cell mediated killing through the activation of 
caspases directly or indirectly through the mitochondria (Lord et al., 2003). The reason 
why the intracellular protein was produced in such low amounts (unlike fresh CBSC-NK 
cells and PBSC-NK cells) remains unknown in our study. The TFs T-BET and EOMES 
are involved in granzyme B and perforin regulation (Townsend et al., 2004), PBSC and 
frozen CBSC cultures had a similar T-BET and EOMES mRNA expression (chapter 3) 
suggesting that these TFs do not account for the low granzyme B expression in frozen 
CBSC-NK cells. Additionally, high levels of granzyme B mRNA were found in CBSC-
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NK cells that could be available for rapid translation and effective killing regardless of 
the low protein expression. This mRNA expression increased over time and was highly 
expressed compared to CB NK cells, PB NK cells and NK cells from fresh CBSC and 
PBSC cultures. Furthermore, it has been reported that rapid translation of perforin and 
granzyme B messengers occurs when NK cells become activated (White et al.). Maybe 
additional activation signals are needed for granzyme B production in frozen CBSC-NK 
cells.  
 
In line with other reports showing that ex-vivo generated NK cells from CB are highly 
cytotoxic (Spanholtz et al., 2010; Spanholtz et al., 2011a; Lehmann et al., 2012), NK 
cells generated in this work also showed high cytotoxicity. Undistinguishable killing 
capacity was observed when fresh and frozen CBSC-NK cells were used. As IL-15 has 
been repeatedly reported to augment NK cell cytotoxicity (Decot et al., 2010; 
Szczepanski et al., 2010), we were expecting to observe a difference between fresh 
cultures using all cytokines (IL-15: 20 ng/ml) and only IL-15 (50 ng/ml); however, no 
differences were found. Frozen CBSC-NK cells were significantly better at killing K562 
cells than PBSC-NK cells. Moreover, this killing ability without further activation 
matched that observed by resting PB NK cells (Luevano et al., 2012a) and that 
observed by Gryzwacz et al. in which a mixture of CD56+CD94-CD117high and 
CD56+CD94+CD117low/- populations was used in a similar assay (Grzywacz et al., 
2006). Other studies have reported higher percentages of specific lysis; nonetheless, 
these studies used longer E:T incubation times (Spanholtz et al., 2010; Spanholtz et 
al., 2011a) or the addition of cytokines in order to assess NK cell killing (Perez et al., 
2006b; Lehmann et al., 2012).  
 
Finally, NK cells are also able to kill via ADCC. Current therapies include the use of 
ADCC in order to facilitate tumour clearance. For instance, Rituximab is a monoclonal 
antibody that binds CD20. CD20 is expressed in 95% of B cells in non-Hodgkins 
lymphomas and not in HSC or healthy cells. NK cells express CD16 (Fc"RIIIA); this 
receptor recognises the Fc portion of antibodies bound to malignant cells. The 
engagement of CD16 triggers a downstream cascade that elicits NK cell-lysis of the 
ab-opsinised cell (Campbell and Colonna, 2001). When the Fab portion of Rituximab 
binds CD20, the Fc portion of this antibody is able to recruit NK cells and therefore 
mediate ADCC. Bryceson et al. highlighted the importance of CD16 in NK cell 
functions, with CD16 being the only receptor able to elicit a cytotoxic response without 
the need of co-stimulation (Bryceson et al., 2006b). The ADCC potential in all NK cells 
generated in vitro was assessed using a murine cell line: P815. Due to the higher 
expression of CD16 in fresh CBSC-NK cells a higher ADCC killing from these NK cells 
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was expected. Nevertheless, this was not the case, low killing among all HSC cultures 
without a significant difference between them was observed, although a trend for better 
killing for frozen CBSC-NK cells was found. It is difficult to compare our results to 
others using NK cells generated in vitro, as we only found one study that includes the 
ADCC assay (Lehmann et al., 2012) (appendix 3). Additionally, ADCC in CB and PB 
NK cells was performed; high P815 lysis percentage was found, correlating with the 
higher CD16 expression on CB and PB NK cells (Luevano et al., 2012a). So in this 
context, NK cells generated in vitro failed to replicate CB and PB ADCC activity. 
Several studies have now highlighted that CD16 polymorphisms will have an impact on 
CD16 affinity (Weng and Levy, 2003; Dall'Ozzo et al., 2004). These studies have 
described a low-affinity Fc"RIIIA receptor and a higher-affinity Fc"RIIIA receptor 
according to these polymorphisms (Dall'Ozzo et al., 2004). The polymorphism analysis 
was not performed during this work. Besides the low expression of CD16 on the 
generated NK cells, we speculate that the ADCC will also be dependent on the affinity 
of CD16 conferred by these polymorphisms.  
 
Although testing the generated NK cells against allogeneic targets (K562 or Raji) 
provides an estimation of the functional capacities of the cells, a more predictive test 
would include the analysis of the cytotoxicity against fresh autologous tumour cells. 
These experiments were not performed in our study, but the functional data obtained 
provides an insight into the cytotoxic capacities of NK cells generated in vitro. 
 
The functional characteristics of NK cells generated from HSC cultures comparing 
fresh versus frozen CBSC and frozen CBSC versus PBSC are shown in figure 5.14 
and 5.15, respectively. 
 
Figure 5.14. Functional characteristics of NK cells derived from CBSC cultures. The figure 
shows the characterisation of fresh CBSC NK cells and frozen CBSC NK cells. The elements in 
bold red are significantly higher compared to their counterpart source.  
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Figure 5.15. Functional characteristics of NK cells derived from frozen CBSC and PBSC 
cultures. The figure shows the characterisation of frozen CBSC NK cells and frozen PBSC NK 
cells. The elements in bold red are significantly higher compared to their counterpart HSC 
source.  
 
Overall, frozen CBSC-NK cells had superior cytokine secretion compared to fresh 
CBSC-NK cells and PBSC-NK cells, as well as good degranulation capacity 
accompanied by high levels of intracellular perforin and low granzyme B expression. 
Nevertheless, high mRNA granzyme B levels were found in the generated NK cells 
probably accounting for the high cytolytic capacity observed by 51Cr killing assay 
against cell line K562. The use of only IL-15 for the last three weeks did not impact on 
any of the features tested. As mentioned before, it could be the case that the use of 20 
ng/ml is enough for NK cells to perform their effector functions and the increase of IL-
15 concentration (50 ng/ml) will not have an impact on these functions. Altogether, NK 
cells generated in vitro have demonstrated a good cytotoxic capacity along with 
immunoregulatory potential.  
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 Role of CD33 expression and effects of IL-12 Chapter 6:
on Natural Killer cells generated in vitro 
6.1 Introduction 
 
CD33, a myeloid receptor 
Sialic acid-binding Ig-like lectins (siglecs) are proteins involved in signalling and 
adhesive functions (Crocker et al., 1998). There are two siglec subgroups according to 
their similarity in intra/extracellular regions: a) the evolutionary conserved ones (siglec-
1, -2, 4 and -15) and b) the rapidly evolving CD33-related ones (CD33 [siglec-3], and 
siglecs 5–11 (Crocker, 2002)). CD33 is commonly known as a myeloid marker 
expressed by monocytes, neutrophils, dendritic cells, eosinophils, basophils, 
macrophages and mast cells (Lock et al., 2004). The role of CD33 on myeloid cells has 
been studied for several years (Paul et al., 2000; Lock et al., 2004). Nevertheless, as 
CD33 expression is rarely found on lymphocytes, there are few studies regarding its 
role in these immune cell subsets. NK cell precursors express CD33; however, as 
development occurs, CD33 expression is lost (Eissens et al., 2012). A study from 
Hernandez-Caselles found that mitogen- or alloantigen-activated NK cells or T cells 
could express CD33. This group found a different CD33 mRNA isoform expressed in 
lymphoid cells and suggested an inhibitory role for this receptor (Hernandez-Caselles 
et al., 2006).  
 
Because CD33 is expressed in malignancies like AML, it has been used as an 
immunotherapeutic target. Current approaches include the use of monoclonal 
antibodies directed against CD33 (Singer et al., 2010; Schubert et al., 2011) or 
genetically engineered cells specific for CD33 (Marin et al., 2010). For instance, Marin 
et al. transduced cytokine-induced killer cells with a chimeric receptor encoding CD33 
and demonstrated enhanced cytotoxicity against different AML targets although toxicity 
was observed towards normal haematopoietic CD34+ progenitor cells (Marin et al., 
2010). As mentioned in chapter 3, around 50% of NK cells generated in vitro during 
this study expressed CD33. Hence, investigating the role of CD33 expression in NK 
cells generated in vitro is critical. In theory, concomitant anti-CD33 therapies with cell 
therapy using NK cells generated in vitro would likely impact on NK cell functions. 
Thus, the effect of blocking CD33 on cytolytic and immunoregulatory features on NK 
cells generated in vitro was analysed using a variety of assays.  
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Modulation of NK cell functions via cytokines; IL-12 
Cytokines have been used for decades to activate NK cells and enhance cytotoxicity. 
Previously, IL-2 was the predominant cytokine used due to promising results observed 
in vitro (Robinson and Morstyn, 1987). Rosenberg and colleagues used autologous 
lymphokine-activate killer (LAK) cells along with IL-2 infusion in patients with metastatic 
and advanced cancers, resulting in marked tumour regression in some patients but 
also toxicity (Rosenberg et al., 1985; Rosenberg et al., 1987). Further studies 
documented the specific expansion of the immunoregulatory CD56bright cell subset by 
low doses of IL-2 infusions (Caligiuri et al., 1990; Caligiuri et al., 1993). Moreover, IL-2 
acts upon other cells in vivo causing severe side effects (Rosenstein et al., 1986; 
Atkins et al., 1999). In addition, lack of tumour regression as demonstrated by 
Parkhurst et al. has been observed while studying melanoma and renal cell carcinoma 
(Parkhurst et al., 2011).  
 
Nonetheless, other interleukins have been studied for NK cell activation such as IL-15, 
IL-21 and IL-12 among others (de Rham et al., 2007; Wendt et al., 2007; Jakobisiak et 
al., 2011). Our research group has studied the effect of these cytokines either alone or 
in combination in order to improve CB and PB NK cell cytotoxicity. A promising 
candidate for NK cell activation in vitro is IL-12. This cytokine plays an important role in 
the regulation of NK cell effector functions (Condiotti and Nagler, 1998) and secretion 
of IFN-" (Marcenaro et al., 2005). IL-12 also plays an essential role in the interaction 
between the innate and the adaptive immune system (Trinchieri, 1995). In vivo, 
phagocytic cells have capacity to produce and secrete IL-12, usually in response to 
bacteria or intracellular parasites. The signalling pathways of IL-12 in NK cells have 
been widely studied (Bacon et al., 1995; Lawless et al., 2000; Huang et al., 2011a; 
Huang et al., 2011b). Additionally, some groups have studied the potential use of IL-12 
to enhance NK cell cytotoxicity (Hoshina et al., 1999; Lehmann et al., 2001; Marcenaro 
et al., 2005) and others have focused on the effect of IL-12 on IFN-" secretion 
(Trinchieri, 1995; Lawless et al., 2000). However, the effects of IL-12 on phenotypic 
and functional features from NK cells generated in vitro have not been performed. As a 
consequence, the present work included assays to assess phenotypic, 
immunoregulatory and cytolytic features of NK cells generated in vitro upon IL-12 
incubation. The results from this section will allow manipulation of effector functions of 
NK cells generated in vitro using IL-12. 
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6.2 Results 
6.2.1 Role of CD33 on Natural Killer cells generated in vitro 
6.2.1.1 Low expression of CD33 expression on cord blood and peripheral blood 
Natural Killer cells 
 
CD33 is expressed on the surface of normal HPCs (myeloid, erythroid and 
megakaryocytic) (Andrews et al., 1983) and Kuppfer cells (Rajvanshi et al., 2002). 
Besides, CD33 has been described as a specific marker for the myeloid lineage 
(Freeman et al., 1995). In chapter 3 a high expression of CD45+CD33+ in all HSC 
cultures was shown. The role of this marker in NK cells generated in vitro was 
investigated. First, CD33 expression on NK cells from CB and PB was analysed and 
compared to that of NK cells generated in vitro. Figure 6.1 shows the percentage of NK 
cells that were CD33 positive. Only 4.9 ± 0.9% of CB NK cells and 2.9 ± 0.7% of PB 
NK cells expressed CD33. However, it was expressed on around 50% of fresh/frozen 
CBSC-NK cells and PBSC-NK cells. NK cells from all HSC sources had similar CD33 
expression without any statistical difference. Thus, the percentage of naturally 
occurring CD56+CD33+ cells is particularly low in blood NK cells. 
 
 
Figure 6.1. CD33 expression on NK cells. Expression of CD33 on CD56+CD3- cells from CB 
(n=19), PB (n=12), fresh (n=3) and frozen (n=8) CBSC cultures, PBSC (n=6) cultures and 
CBSC cultures with all cytokines (n=3).  
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Regarding the expression of CD33 on HSC, it was observed that the majority of 
CD34+CD45+ cells from CBSC and PBSC were positive for CD33 (see section 3.2.5 in 
chapter 3). 
 
6.2.1.2 Effect of blocking CD33 on cytokine production and secretion by Natural 
Killer cells generated in vitro 
 
CD33 has two ITIM sequences in its cytoplasmatic domain that convey inhibitory 
functionality (Crocker, 2005; Hernandez-Caselles et al., 2006). Using a published 
protocol (Hernandez-Caselles et al., 2006), the effect of blocking CD33 on NK cells 
generated in vitro was investigated. Figure 6.2 depicts intracellular IFN-" expression of 
NK cells stimulated with either K562 or PMA&Iono. Blocking CD33 did not impact on 
IFN-" expression by NK cells generated in vitro.  
 
Figure 6.2. Effect of blocking CD33 in NK cells generated in vitro on intracellular IFN-! 
expression. The figure shows IFN-" production by non-treated and CD33 blocked (blocked) NK 
cells from fresh and frozen CBSC and PBSC cultures after stimulation with A) K562 or B) 
PMA&Iono. Paired t-test was performed.  
 
Furthermore, IFN-" secretion in treated and non-treated cells was analysed (figure 
6.3). Surprisingly, IFN-" secretion against the cell line K562 was increased when CD33 
was blocked on fresh and frozen CBSC-NK cells (p<0.05). This was not the case for 
PBSC-NK cells and NK cells from fresh CBSC cultures using all cytokines (K562, 
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p>0.05). Treated and non-treated NK cells stimulated with PMA&Iono had similar IFN-" 
secretion (not significant) (figure 6.3).  
 
 
Figure 6.3. Effect of blocking CD33 in NK cells generated in vitro on IFN-! secretion. The 
figure shows IFN-" secretion by non-treated and CD33 blocked (blocked) NK cells from fresh 
and frozen CBSC and PBSC cultures after stimulation with A) K562 or B) PMA&Iono. Paired t-
test was performed. * p<0.05, ** p<0.01. 
 
In addition, TNF-# secretion was also investigated in supernatants from NK cells 
generated in vitro after blocking CD33 (figure 6.4). Fresh CBSC-NK cells did not 
secrete TNF-# when stimulated with the cell line K562, and TNF-# secretion by frozen 
CBSC-NK cells and PBSC-NK cells was similar among treated and non-treated cells 
(figure 6.4A). Accordingly, treated and non-treated NK cells from all HSC cultures 
stimulated with PMA&Iono had similar TNF-# secretion that was not significantly 
different.  
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Figure 6.4. Effect of blocking CD33 in NK cells generated in vitro on TNF-" secretion. The 
figure shows TNF-# secretion by non-treated and CD33 blocked (blocked) NK cells from fresh 
and frozen CBSC and PBSC cultures after stimulation with A) K562 or B) PMA&Iono. Paired t-
test was performed. * p<0.05, ** p<0.01. 
 
6.2.1.3 Blocking CD33 does not affect Natural Killer cell degranulation capacity  
 
As described in the previous chapter, CD107a is mobilised to the cell surface following 
activation-induced granule exocytosis. We decided to investigate if this process would 
be affected by blocking CD33 on NK cells generated in vitro. The results suggest that 
there is no significant difference between treated and non-treated NK cells from all 
HSC cultures when cells were stimulated either with the cell line K562 or with 
PMA&Iono (figure 6.5). 
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Figure 6.5. Effect of blocking CD33 in NK cells generated in vitro on CD107a 
degranulation. The figure shows degranulation by non-treated and CD33 blocked (blocked) NK 
cells from fresh and frozen CBSC and PBSC cultures as measured using anti-CD107a antibody 
after stimulation with A) K562 or B) PMA&Iono. Paired t-test was performed.  
 
6.2.1.4 Blocking CD33 does not impact Natural Killer cell killing  
 
Engagement of CD33 has been shown to inhibit NK cell activity (Hernandez-Caselles 
et al., 2006). As the majority of NK cells generated during this study expressed CD33, 
its expression might have clinical implications. The myeloid nature of this receptor and 
its low expression on healthy cells has made CD33 a therapeutic target. Current 
therapies include the use of monoclonal antibodies targeting CD33 or engineered killer 
cells with CD33 specificity. The inhibitory role attributed to CD33 could also be 
exploited, as blocking of this receptor would in theory enhance NK cell functions. In this 
section, the role of CD33 was tested in NK cells generated in vitro. A standard 51Cr 
release assay using the cell line K562 and non-treated or CD33-blocked NK cells for all 
HSC cultures was performed. Figure 6.6 depicts the percentage of specific lysis by 
treated or non-treated NK cells. No differences in killing of K562 were observed 
between treated or non-treated cells by NK cells of all HSC cultures.   
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Figure 6.6. Effect of blocking CD33 on K562 killing. The figure shows killing of K562 in a 4 h 
release assay by non-treated and CD33 blocked (blocked) NK cells from fresh and frozen 
CBSC and PBSC cultures. Paired t-test was performed.  
 
6.2.2 Impact of IL-12 on Natural Killer cells generated in vitro  
6.2.2.1 IL-12 incubation allows optimal Natural Killer cell viability  
 
NK cell immunotherapy relies on the presence of NK cells able to perform cytotoxic 
functions and maintain optimal survival and proliferation. Here, the aim of the study 
was to enhance the phenotypic and functional features of NK cells generated in vitro. 
NK cell functions can be enhanced by the use of interleukins. A member of the 
laboratory (Rehab Alnabhan, PhD student) has performed studies highlighting the 
promising use of IL-12 for NK cell activation. In addition, it is known that IL-12 
enhances NK cell cytotoxicity (Naume et al., 1992), secretion of IFN-" (Kobayashi et 
al., 1989) and TNF-# (Naume et al., 1992), and increases the expression of adhesion 
molecules (Rabinowich et al., 1993). Therefore, the effects of IL-12 were evaluated on 
the generated NK cells; NK cells were harvested at day 35 from CBSC (n=4-9) and 
PBSC (n=3-6) cultures and incubated with IL-12 (20 ng/ml) for 4, 24 or 40 h. The data 
generated in the laboratory showed that full NK cell activation (as measured by 
activating maker expression) was achieved by incubation with IL-12 for 40 h.  
 
First, the effects of IL-12 on NK cell viability were investigated. Living cells translocate 
phosphatidylserine (PS) from the inner leaflet of the plasma membrane to the outer 
leaflet in early events of apoptosis. Annexin V preferentially binds to PS, allowing the 
detection of early apoptotic cells. When combining staining for Annexin V with 7-
Amino-actinomycin D (7AAD, binds to double stranded DNA), it is possible to detect 
cells that underwent apoptosis or necrosis. Thus, live cells would be AnnexinV-7AAD-, 
cells in early apoptotic stages would be AnnexinV+7AAD- and necrotic cells or those in 
late stage of apoptosis would be AnnexinV+7AAD+. Figure 6.7 shows a representative 
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sample using flow cytometry to assess NK cell viability throughout the incubation time 
using IL-12.  
 
The percentages of NK cells in early apoptotic stages varied and remained high for 
CBSC cultures (figure 6.7A). The percentages of NK cells in early apoptotic stages 
remained stable in PBSC cultures showing lower AnnexinV+7AAD- cells during 0, 4 and 
24 h incubation with IL-12. Furthermore, percentages of necrotic cells remained low for 
all time points and all HSC cultures, ranging from 1-5.9%. This suggests, that the use 
of IL-12 provides optimal viability for up to 40 h in this study.  
 
Figure 6.7. Viability of NK cells treated with IL-12. NK cells (percentages come from the 
CD56+CD3- gate) from A) CBSC and B) PBSC cultures were incubated for 4, 24 or 40 h with IL-
12. Viability was measured using Annexin V and 7AAD; the plots show Annexin V versus 7AAD 
stainings for each time point.  
 
6.2.2.2 IL-12 modifies the repertoire of CBSC-NK cells but not of PBSC-NK cells  
 
NK cell repertoire can be shaped according to the microenvironment and the presence 
of different interleukins and factors (Di Santo, 2008). Therefore, a full characterisation 
of NK cells generated in vitro and incubated for 40 h with IL-12 was performed. First, 
the expression of activating and inhibitory markers on the treated cells was analysed. 
Figure 6.8 shows the expression of activating and inhibitory markers on non–treated 
NK cells or NK cells incubated for 40 h with IL-12. Unlike PBSC-NK cells (figure 6.8B), 
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a change of expression of some receptors was observed on CBSC-NK cells treated 
with IL-12. An increase in CD48 and Fas-L expression and a decrease in NKG2D 
expression on CBSC-NK cells after 40 h of IL-12 incubation were observed. The 
expression of inhibitory receptors remained unaltered with IL-12 incubation on NK cells 
from both HSC cultures.  
 
Figure 6.8. Effect of IL-12 on the expression of NK cell activating and inhibitory 
receptors. NK cells (percentages come from the CD56+CD3- gate) from A) CBSC (n=9) and B) 
PBSC (n=6) cultures were incubated without stimulation or with IL-12 for 40 h. After incubation, 
cells were collected, washed and labelled with the appropriate surface antigen or isotype 
control. Mann-Whitney test was performed, * p<0.05, ** p<0.01, ***p<0.001. 
Besides analysing the expression of activating and inhibitory receptors, the impact of 
IL-12 on the expression of interleukin receptors was studied. Figure 6.9 illustrates the 
expression of these receptors on CBSC-NK cells and PBSC-NK cells before and after 
IL-12 incubation. The expression of interleukin receptors on PBSC-NK cells remained 
unaltered, however IL-12 incubation increased IL-18R and IL-2R# (CD25) expression 
on CBSC-NK cells (p<0.05).  
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Figure 6.9. Effect of IL-12 on the expression of interleukin receptor by NK cells. NK cells 
(percentages come from the CD56+CD3- gate) from A) CBSC (n=9) and B) PBSC (n=6) cultures 
were incubated without stimulation or with IL-12 for 40 h. After incubation, cells were collected, 
washed and labelled with the appropriate surface antigen and isotype control. Mann-Whitney 
test was performed, * p<0.05, ** p<0.01, ***p<0.001. 
 
The impact of IL-12 on the chemokine receptor repertoire and expression of cell 
adhesion molecules on NK cells generated in vitro was also investigated. The 
expression of CD49d decreased (p<0.05, figure 6.10A) while LFA-1 expression 
increased on CBSC-NK cells incubated for 40 h with IL-12 (p<0.05, figure 6.10A). The 
expression of chemokine receptors on CBSC-NK cells remained unaltered after 
incubation with IL-12. PBSC-NK cells were not affected by IL-12 incubation, 
maintaining the same chemokine receptor and adhesion molecules repertoire (figure 
6.10B). 
 
 
Figure 6.10. Effect of IL-12 on NK cell chemokine receptors and adhesion molecules. NK 
cells(percentages come from the CD56+CD3- gate)  from A) CBSC (n=9) and B) PBSC (n=6) 
cultures were incubated without stimulation or with IL-12 for 40 h. After incubation, cells were 
collected, washed and labelled with the appropriate surface antigen and isotype control. Mann-
Whitney test was performed, * p<0.05, ** p<0.01, ***p<0.001.  
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These data suggest that incubation with IL-12 for 40 h did not alter NK cell phenotype 
of PBSC-NK cells whereas IL-12 modified the phenotype of CBSC-NK cells. 
 
As previously mentioned, CD33 is considered to be a myeloid marker, however, it has 
also been proposed to be expressed when NK cell activation occurs (Kalberer et al., 
2003; Sconocchia et al., 2004; Hernandez-Caselles et al., 2006). The expression of 
CD33 after incubation with IL-12 was investigated during this study. A gradual increase 
of CD33 expression on CBSC-NK cells (figure 6.11A) was observed, whereas a 
decreased expression of CD33 was noted on PBSC-NK cells during the first 24 h 
incubation with IL-12 (figure 6.11B). Nevertheless, after 40 h incubation with IL-12 
PBSC-NK cells showed an increased CD33 expression (figure 6.11B).  
 
 
Figure 6.11. Effect of IL-12 on CD33 expression by CBSC-NK cells and PBSC-NK cells. 
The figure shows a representative sample of CD56+CD3- cells from A) PBSC and B) CBSC 
cultures incubated without IL-12 or for 4, 24 or 40 h with IL-12. The FACS plots show CD56 
versus CD33 expression on NK cells for each time point.  
 
6.2.2.3 IL-12 enhances IFN-" and TNF-! secretion in CBSC-NK cells  
 
IFN-" secretion plays an important role during viral infection (French and Yokoyama, 
2003) and serves as a bridge for activation of other immune cells (Young and Hardy, 
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Figure 11 (CD33 expression with IL-12) 
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1995; Agaugue et al., 2008). As described in the previous chapter, low intracellular 
IFN-" was detected when NK cells were stimulated with K562 cells. In an effort to 
enhance IFN-" production, NK cells generated in vitro were incubated with IL-12. 
Frozen CBSC-NK cells had an enhanced IFN-" expression when they were incubated 
for 4 and 40 h with IL-12 (p<0.05, figure 6.12A). PBSC-NK cells had a gradual increase 
of intracellular IFN-" against K562 cells that peaked when 40 h of IL-12 incubation was 
used (p<0.05, figure 6.12A). Intracellular IFN-" expression was considerably and 
significantly increased after stimulation with PMA&Iono in CBSC-NK cells incubated for 
24 h with IL-12 (figure 6.12B, from 23.1 ± 7.5% to 69.5 ± 18.9% with 24 h incubation 
with IL-12). Similarly, intracellular IFN-" expression was also significantly increased in 
PBSC-NK cells, from 17.7 ± 2.9% to 31.1 ± 7.5% with 40 h incubation with IL-12 (figure 
6.12B). 
 
 
Figure 6.12. Impact of IL-12 incubation on IFN-! expression of CBSC-NK cells and PBSC-
NK cells. Intracellular expression of IFN-" was analysed by flow cytometry in IL-12 incubated 
NK cells (percentages come from the CD56+CD3- gate) from CBSC (n=9) and PBSC (n=6) 
cultures stimulated with A) K562 cells or B) PMA&Iono in the presence of GolgiStop™. Mann-
Whitney test was performed, * p<0.05, ** p<0.01, ***p<0.001. 
 
Additionally, the secretion of IFN-" in NK cell supernatants after incubation with IL-12 
was investigated. CBSC-NK cells stimulated with K562 and PMA&Iono secreted high 
amounts of IFN-" as described in chapter 5. Pre-incubation with IL-12 for 4 or 24 h 
dramatically increased the secretion levels of IFN-" by CBSC-NK cells (K562 and 
PMA&Iono, figure 6.13A, p<0.05), whereas PBSC-NK cells showed a slight increase of 
IFN-" secretion but no significant differences were found (K562 and PMA&Iono, figure 
6.13B).   
Figure 12 (IFNg expression with IL-12) 
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Figure 6.13. Impact of IL-12 incubation on IFN-! secretion of CBSC-NK cells and PBSC-
NK cells. Secretion of IFN-" was analysed by ELISA in IL-12 incubated NK cells from CBSC 
(n=9) and PBSC (n=6) cultures stimulated with A) K562 cells or B) PMA&Iono. Mann-Whitney 
test was performed, * p<0.05, ** p<0.001, ***p<0.001. 
 
Levels of TNF-# were also assessed in supernatants of NK cells incubated with IL-12. 
When CBSC-NK cells and PBSC-NK cells were stimulated with K562 cells or Raji cells, 
no differences in TNF-# secretion were found after incubation with IL-12 (figure 6.14A 
and B). However, when CBSC-NK cells were stimulated with PMA&Iono, an increase 
in TNF-# secretion was observed when cells were incubated for 24 h with IL-12 
(p<0.05). PBSC-NK cells secreted similar amounts of TNF-# regardless of IL-12 
incubation (figure 6.14B). 
 
Figure 6.14. Impact of IL-12 incubation on TNF-" secretion by CBSC-NK cells and PBSC-
NK cells. Secretion of TNF-# was analysed by ELISA in IL-12 incubated NK cells from CBSC 
(n=9) and PBSC (n=6) cultures stimulated with A) K562 cells B) RAJI cells or C) PMA&Iono. 
Mann-Whitney test was performed, * p<0.05, ** p<0.001, ***p<0.001. 
 
Figure 13 (IFNg secretion with IL-12) 
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Figure 14 (TNFa secretion with IL-12) 
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Overall, 4 and 24 h incubation with IL-12 enhanced IFN-" and TNF-# secretion in 
CBSC-NK cells, whereas the impact of IL-12 on PBSC-NK cell cytokine secretion was 
subtle and needed 40 h incubation with IL-12.  
 
6.2.2.4 Degranulation of Natural Killer cells from haematopoietic stem cell 
cultures after incubation with IL-12  
 
IL-12 has been previously used to enhance NK cell cytotoxicity (Marcenaro et al., 
2005). In this section, the expression CD107a, used as a degranulation marker as 
described in chapter 5, was analysed on NK cells generated in vitro treated or not with 
IL-12. Surprisingly, CD107a expression on CBSC-NK cells stimulated with K562 cells 
decreased after incubation with IL-12, being less significant after 40 h incubation with 
IL-12 than without (p<0.05, figure 6.15A). This was not the case for PBSC-NK cells, 
where a subtle increase (not statistically significant) was observed with IL-12 
incubation (figure 6.15A). CBSC-NK cells and PBSC-NK cells stimulated with 
PMA&Iono had a similar behaviour, a subtle increase (not statistically significant) was 
observed with IL-12 incubation (figure 6.15B). 
 
 
Figure 6.15. Impact of IL-12 incubation on degranulation of CBSC- and PBSC-NK cells. 
Degranulation was analysed by FACS analysis of surface expression of CD107a in IL-12 
incubated NK cells (percentages come from the CD56+CD3- gate) from CBSC (n=9) and PBSC 
(n=6) cultures stimulated with A) K562 cells or B) PMA&Iono. Mann-Whitney test was 
performed, * p<0.05, ** p<0.001, ***p<0.001. 
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Figure 15 (CD107a with IL-12) 
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6.2.3 IL-12 incubation increases granzyme B expression in CBSC-NK cells and 
has a minor impact on perforin expression 
 
One of the main concerns while studying the killing machinery of the generated NK 
cells was the low expression of granzyme B in frozen CBSC-NK cells. It was previously 
demonstrated that granzyme B mRNA expression was abundant with a higher trend in 
frozen CBSC-NK cells compared to CB and PB NK cells (chapter 4). Incubation with 
IL-12 has been shown to increase mRNA levels of granzyme B in human NK cells 
(Zhang et al., 2008). We investigated whether IL-12 would increase granzyme B 
expression in NK cells generated in vitro. Indeed, as shown in figure 6.16A, incubation 
with IL-12 for 24 and 40 h significantly increased granzyme B expression (from 7.8 ± 
9.2% to 27.5 ± 20.5% with 24 h and 43.6 ± 20.8% with 40 h IL-12 incubation, p<0.05). 
Although there was a slight increase in granzyme B expression using IL-12 incubation 
in PBSC-NK cells, no significant differences were found between the different IL-12 
incubation times (figure 6.16A). Additionally, the intracellular expression of perforin in 
CBSC-NK cells and PBSC-NK cells incubated with IL-12 was evaluated. The majority 
of CBSC-NK cells and all PBSC-NK cells had high intracellular perforin expression 
without IL-12 incubation. However, there was a slight increase in perforin expression in 
CBSC-NK cells when IL-12 incubations for 4, 24 or 40 h were performed (not 
statistically significant) while perforin expression in PBSC-NK cells remained unaltered 
(figure 6.16B).   
 
Figure 6.16. Impact of IL-12 incubation on granzyme B and perforin expression from 
CBSC-NK cells and PBSC-NK cells. Intracellular expression of granzyme B and perforin was 
analysed by flow cytometry in IL-12 incubated NK cells (percentages come from the CD56+CD3- 
gate) from CBSC (n=9) and PBSC (n=6) cultures stimulated with A) K562 cells or B) PMA&Iono 
in the presence of GolgiStop™. Mann-Whitney test was performed, * p<0.05, ** p<0.001, 
***p<0.001. 
Figure 16 (Perforin and Granzyme B with IL-12) 
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6.2.4 The cytotoxicity of Natural Killer cells generated in vitro is enhanced by 
IL-12 incubation 
 
IL-12 has been previously reported to enhance NK cell cytotoxicity (Naume et al., 
1992). First, the expression of one of the most important activating receptors able to 
trigger NK cell cytotoxicity was followed: CD16. CBSC-NK cells showed a decrease in 
CD16 expression after 4 and 40 h incubation with IL-12; a peak in CD16 expression 
was observed when cells were incubated for 24 h with IL-12 (figure 6.17A). As with 
CBSC-NK cells, CD16 expression on PBSC-NK cells was increased when cells were 
incubated for 24 h with IL-12 (figure 6.17B). Incubation with IL-12 of PBSC-NK cells for 
4 or 40 h did not alter CD16 expression (figure 6.17B).  
  
Figure 6.17. Effect of IL-12 on CD16 expression from CBSC-NK cells and PBSC-NK cells. 
A representative sample of CD56+CD3- cells from A) CBSC and B) PBSC cultures incubated 
without IL-12 or for 4, 24 or 40 h with IL-12. The plots show CD56 versus CD16 expression on 
NK cells for each time point.  
 
Next, NK cell cytotoxicity in vitro against the cell line K562 was monitored. A standard 
51Cr release assay using CBSC-NK cells and PBSC-NK cells generated in vitro and 
incubated with IL-12 was performed. An increase in K562 killing by CBSC-NK cells was 
observed, although not statistically significant, when cells were incubated for 4 h and 
24 h with IL-12. However 40 h IL-12 incubation led to a decline in CBSC-NK cell killing 
capacity (p<0.05, figure 6.18A). PBSC-NK cells showed a better specific lysis with 4 
and 24 h IL-12 incubation (p<0.05) compared to 40 h IL-12 incubation (figure 6.18A). 
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Figure 17 (CD16 expression with IL-12) 
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ADCC is a major killing mechanism used by NK cells to eliminate malignant or infected 
cells. According to the CD16 expression pattern on NK cells after IL-12 incubation, 
both cultures were expected to show a higher ADCC activity when 24 h incubation with 
IL-12 was used. Indeed, CBSC-NK cells showed a higher ADCC activity when cells 
were incubated with IL-12 for 24 h (figure 6.18B). In the case of PBSC-NK cells, 
incubation for 24 h with IL-12 did not show the highest ADCC activity, 40 h of IL-12 
incubation demonstrated the best ADCC activity (p<0.05, figure 6.18B). The expression 
of CD16 did not correlate with the observed ADCC activity using 40 h of IL-12 
incubation. Conversely, when CBSC-NK cells were incubated for 4 h CD16 expression 
was low, correlating with the reduced ADCC killing observed (figure 6.18B).  
 
 
Figure 6.18. Impact of IL-12 incubation on CBSC-NK cells and PBSC-NK cell killing 
capacity. Killing capacity was analysed in NK cells from CBSC (n=9) and PBSC (n=6) cultures 
incubated with IL-12 with a standard 51Cr 4 h release assay using labelled A) 51Cr K562 cells or 
B) 51Cr P815 coated with anti-CD16 or IgG1 isotype (ADCC). Mann-Whitney test was 
performed, * p<0.05, ** p<0.001, ***p<0.001. 
Figure 18 (Normal killing and ADCC) 
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6.3 Discussion 
 
During this work a distinctive phenotype of NK cells generated in vitro was observed, 
including the expression of the myeloid marker CD33. In this chapter the impact of this 
myeloid marker on the functions of NK cells generated in vitro was studied. On the 
other hand, the potential use of IL-12 in order to enhance phenotypic and functional 
features of NK cells generated in vitro was investigated. 
 
NK cell ontogenesis has been widely studied. The belief that cells have stringent 
potential to commit to a specific lineage is slowly changing. The findings from separate 
studies showing that NK cells can be derived from myeloid precursors suggests cell 
plasticity (Perez et al., 2003; Grzywacz et al., 2011). Taussig et al. showed that well-
established myeloid markers, such as CD33, CD13, and CD123, are expressed in 
human long-term repopulating cells from CB and BM (Taussig et al., 2005). 
Accordingly, the majority of NK cell precursors in our system expressed CD33. 
Nevertheless, CD33 expression persisted on NK cell precursors during the whole 
culture and was present in the final NK cell product from all HSC cultures. The search 
for similar phenotypes (CD56+CD33+) in blood NK cells revealed the low frequency of 
these cells in CB and PB. Indeed, CD33 is usually only expressed in myeloid cells and 
not present in healthy lymphocytes (Tanimoto et al., 1989). Others also found low 
frequency of CD33+ NK cells in PB or CB (Handgretinger et al., 1993; Hernandez-
Caselles et al., 2006). In fact, due to this specific expression, therapies using anti-
CD33 monoclonal antibodies (Lintuzumab or Gemtuzumab Ozogamicin 
[Mylotarg]) were previously used for the treatment of AML (Sievers et al., 1999; Raza 
et al., 2009). These treatments were abandoned in 2010 since they failed to provide 
benefits over other conventional therapies (Feldman et al., 2005; FDA, 2010). 
Nevertheless, other therapies using CD33 are currently studied, such as the use of 
dual-targeting antibodies (CD123/CD33 (Kugler et al., 2010) or CD19/CD33 (Schubert 
et al., 2011)) for AML or mixed leukaemia treatments. Although these studies are in 
pre-clinical phases, anti-CD33 therapies should in theory be administered prior to NK 
cell immunotherapy. Although not studied in this work, the concomitant administration 
of such anti-CD33 antibody therapies with NK cells generated in vitro would definitely 
have an impact on NK cells expressing CD33.  
 
A recent study on NK cell development using BM and CB precursors by Eissens et al. 
found that CD33 was only expressed from stages 2-3 (Eissens et al., 2012). To our 
knowledge, there is only one study reporting expression of CD33 on NK cells 
generated in vitro (Vitale et al., 2008). Vitale et al. observed the appearance of a 
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CD33+ population with myelomonocytic features as shown by forward scatter (FSC) 
and side scatter (SSC) parameters (Vitale et al., 2008). Conversely, NK cells 
generated in vitro in our study expressed CD33 but were within the lymphocyte gate 
and lacked myelomonocytic features as shown by FSC and SSC (data not shown). 
From these data several questions arise. What is the role of CD33 during NK cell 
development? What are the consequences of CD33 expression on NK cells generated 
in vitro? Apparently CD33 is dispensable for NK cells, as CB or PB NK cells have very 
low or undetectable expression (Handgretinger et al., 1993; Hernandez-Caselles et al., 
2006). But, what about the few NK cells that are expressing CD33 in CB or PB? Does 
CD33 expression confer different cytotoxic properties? Since CD33 is mostly 
considered a myeloid marker, few studies have addressed the role of CD33 in 
lymphocytes (Hernandez-Caselles et al., 2006). CD33 has a putative function in cell 
adhesion through sialic acid cell binding (Ulyanova et al., 1999); moreover, due to its 
ITIM motif it may be implicated in cellular activity inhibition (Taylor et al., 1999) via src 
homology region 2-containing protein tyrosine phosphatase-1 (SHP-1) and SHP-2 
(Paul et al., 2000). Actually, previous reports suggested an inhibitory role of CD33 on 
myeloid cells (Paul et al., 2000) and recently in NK cells derived from CB CD34+ 
(Handgretinger et al., 1993) or from NK cell lines (Hernandez-Caselles et al., 2006). 
With this in mind, we decided to investigate if CD33 expression would have a similar 
effect on effector functions of NK cells generated in vitro.  
 
It is important to consider that FACS-sorting was not performed during this study, thus 
each assay comprises a mixture of CD56+CD33+ and CD56+CD33- cells. In the 
previous chapter it was reported that intracellular IFN-" in NK cells from all HSC 
cultures was very similar but secretion was higher in frozen CBSC-NK cells. After 
treatment with anti-CD33, no effect on intracellular IFN-" expression was observed in 
NK cells from CBSC or PBSC cultures stimulated either with K562 cells or PMA&Iono. 
Similarly, blocking of CD33 did not affect secretion of IFN-" in NK cells stimulated with 
PMA&Iono. Nevertheless, a difference in secreted IFN-" by NK cells from fresh and 
frozen CBSC-NK cells was observed when stimulation with K562 was performed. 
When CD33 was blocked, IFN-" secretion by NK cells was increased. CD33 ITIM motif 
recruits SHP-1 and SHP-2 (Paul et al., 2000). Working with NK cell lines, Purdy et al. 
found that SHP-2 suppresses cytolytic activity and IFN-" secretion (Purdy and 
Campbell, 2009). Moreover, Handgretmger et al. described that about 8% of CB NK 
cells express CD33 and these cells exhibit low cytotoxicity against cell lines such as 
K562 in comparison to CD56+CD33- cells (Handgretinger et al., 1993). Maybe blocking 
CD33 on NK cells generated in vitro inhibited the phosphorylation of SHP-1 and SHP-
2, thus preventing the suppression of IFN-" secretion. Regarding the cell adhesion role 
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of CD33, the study from Freeman et al. revealed that the K562 cell line showed little 
binding to CD33 in a solid-phase binding assay with Fc-CD33 (Freeman et al., 1995). 
In fact, according to this study myelomonocytic-like and promonocytic-like cells express 
CD33 ligands; these cells are found in the BM. The interactions of NK cells generated 
in vitro with these cells were not investigated in this study. It would be interesting to 
study these interactions as NK cells generated in vitro hold the potential to migrate to 
the BM due to CXCR4 expression, where myeloid and lymphoid development occurs. 
Figure 6.19 shows a possible scenario in which binding of CD33 and ligands in K562 
cells occurs acting as an inhibitory receptor, although further investigations should be 
performed to pinpoint potential ligands and signalling pathways. In this context, 
administration of anti-CD33 in the treatment of AML would actually enhance NK cell 
ability to secrete IFN-". This enhancement would only be effective for IFN-" secretion. 
Regardless of the use of K562 or PMA&Iono stimulation on NK cells generated in vitro, 
we did not observe an alteration of TNF-# secretion, degranulation or killing capacity 
when CD33 receptor was blocked. This could be attributed in part to CD33 
internalisation, as some studies reported rapid CD33 internalisation after antibody 
binding (van Der Velden et al., 2001; Walter et al., 2008).  
 
 
Figure 6.19. Possible inhibitory role of CD33 on NK cells. The upper panel depicts the 
interaction between a treated NK cell (CD33 blocked) and a K562 cell. The bottom panel shows 
the interaction of a non-treated NK cell with a K562 cell.  
 
During the second section of this chapter we studied the effects of IL-12 on the 
functions of NK cells generated in vitro. Previous studies in our laboratory have shown 
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that IL-12 is able to activate PB and CB NK cells (Rehab Alnabhan), 40 h being the 
optimal incubation time. We first investigated whether NK cell viability would be 
affected by IL-12 incubation. A study by Huang et al. reported that NK cell exposure to 
IL-12 resulted in cell activation but prolonged exposure induced apoptosis (Huang et 
al., 2011b). In this study, the use of IL-2 and of 40 ng/ml of IL-12 for 48 h resulted in 
50% apoptosis of NK cells. A direct comparison with our study cannot be performed as 
we used 20 ng/ml of IL-12 and a maximum of 40 h of incubation. However, dead cell 
percentages in our cultures were lower (maximum 5.92%). Therefore, in our hands, 
viability of NK cells during IL-12 incubation was barely affected.  
 
Since viability remained unaltered, the phenotypic changes that IL-12 could induce on 
NK cells generated in vitro were studied. Regardless of the abundant literature 
studying IL-12 effects on NK cell functions and signalling pathways, few studies 
performed a phenotypic NK cell characterisation (Rabinowich et al., 1993; Loza and 
Perussia, 2004b). In our hands, incubation with IL-12 did not modify the repertoire of 
PBSC-NK cells: activating receptors, inhibitory receptors, adhesion molecules, 
chemokine receptors and interleukin receptor expression remained unaltered. In 
contrast, IL-12 incubation of CBSC-NK cells modified the expression of some activating 
receptors (CD48, Fas-L and NKG2D), interleukin receptors (IL18R and IL-2R#) and 
adhesion molecules (CD49d and LFA-1). In an effort to study a CD56+high cell subset in 
PB, Loza et al. found that this cell subset represents IL-12 activated cells in vivo (Loza 
and Perussia, 2004b). During the characterisation of this CD56+high cell subset, an 
increased 2B4 expression and decreased NKp44 expression after IL-12 incubation was 
found (Loza and Perussia, 2004b). We did not observe an increased expression of 
these markers on CBSC-NK cells or PBSC-NK cells during our study; but CD48 and 
Fas-L expression was higher on CBSC-NK cells when 40 h of IL-12 incubation was 
used. We previously discussed the low expression of Fas-L in CB and PB NK cells and 
the potential advantages of Fas-L expression on NK cells generated in vitro in chapter 
4. The use of IL-12 increased Fas-L expression of CBSC-NK cells to similar values 
observed in PBSC-NK cells. Again, this expression could be translated into a better 
killing potential of NK cells generated in vitro. The higher CD48 expression would also 
have a positive impact, since interactions between 2B4 and CD48 are known to 
activate NK cells (Messmer et al., 2006). In accordance with our results, incubation of 
PB NK cells with IL-12 had no effect on CD49d expression but increased the 
expression of LFA-1 (Rabinowich et al., 1993), which would confer adhesion and cell 
activation advantages. Similarly to our results in CBSC-NK cells incubated with IL-12, it 
has been reported that IL-12 up-regulated IL-2R# in PB NK cells (Naume et al., 1992) 
and CB MNCs (Condiotti and Nagler, 1998) suggesting better proliferation capacity. IL-
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12 also increased the expression of IL-18R in CBSC-NK cells; Lawless et al. reported a 
similar outcome while studying the signalling pathway of IL-12 (Lawless et al., 2000). 
IL-12 signalling involves activation of STAT4, which in turn has been reported to 
increase the expression of IL-18R (Lawless et al., 2000). On the other hand, IL-12 has 
been reported to increase L-selectin expression (Loza and Perussia, 2004b); yet, our 
data did not corroborate this observation. The downside of the effect of IL-12 on 
CBSC-NK cells was the reduction of NKG2D expression; an important receptor 
involved in recognition of transformed cells (Burgess et al., 2008). Another interesting 
fact was the increased CD33 expression observed in CBSC-NK cells with IL-12. 
Hernandez-Caselles et al. suggest that CD33 expression can be induced on activated 
NK cells (IL-2 and allogeneic stimuli) (Hernandez-Caselles et al., 2006). We used IL-
12, although these cytokines do not clearly share a signalling pathway (IL-2 activates 
JAK1 AND JAK3 (Yu and Burakoff, 1997) and IL-12 JAK2 and TYK2 (Watford et al., 
2003)), perhaps there is a common intermediary that regulates CD33 expression. At 
this point, our data suggested that CBSC-NK cells could have a better killing potential 
upon IL-12 incubation due to the modification of their repertoire compared to PBSC-NK 
cells.  
 
Although not studied in this work, IL-12 is able to activate different pathways, among 
these, the Jak-signals and activator of TFs (STATs). STAT4 might be one of the most 
important, playing a key role in the secretion of IFN-" (Bacon et al., 1995). Indeed, 
intracellular IFN-" expression and secretion were drastically improved in CBSC-NK 
cells upon IL-12 activation. It was interesting to observe that depending on the 
stimulation source, IFN-" would be differentially expressed/secreted. When cells were 
stimulated with K562, 4 h incubation with IL-12 showed the highest 
expression/secretion in CBSC-NK cells, while the effects using PMA&Iono were clearly 
higher when 24 h incubation with IL-12 was performed. Similar results for TNF-# were 
observed in CBSC-NK cells using PMA&Iono. It was also evident that PBSC-NK cells 
had a different response upon IL-12 activation regardless of the similar IL-12R$1 
expression in CBSC-NK cells (chapter 4). Only intracellular IFN-" expression increased 
upon IL-12 incubation (peak at 40 h), whereas the secretion of IFN-" and TNF-# did not 
change. In line with our observations, low levels of TNF-# were produced in PB NK 
cells when cells were treated with IL-12 (Naume et al., 1992). 
 
The killing capacity of CBSC-NK cells and PBSC-NK cells upon IL-12 activation using 
several assays was also studied. CBSC-NK cells stimulated with K562 showed 
decreased CD107a detection after IL-12 incubation, however CD07a expression was 
not altered when PMA&Iono was used. Therefore, according to our study, CD107a 
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expression may not accurately correlate with NK cell cytokine secretion. Next, the 
expression of granzyme B and perforin upon IL-12 incubation was studied. One of the 
major concerns discussed in chapter 4 was the absence of granzyme B in frozen 
CBSC-NK cells, although high mRNA levels were found. In fact, IL-12 incubation of 
frozen CBSC-NK cells considerably increased granzyme B expression to a level 
comparable to that of PBSC-NK cells. This data is in accordance with a previous study 
reporting mRNA granzyme B and perforin upregulation by IL-12 (Salcedo et al., 1993). 
The majority of the generated cells expressed perforin even without IL-12 incubation, 
thus further incubation with IL-12 did not have a major impact on perforin expression. 
These data suggest that NK cells generated in vitro were equipped for NK cell 
cyotolytic functions. In our study, 24 and 40 h of IL-12 incubation provided CBSC-NK 
cells with intracellular granzyme B. Similarly, Marcenaro et al. showed that NK cells 
incubated overnight with IL-12 displayed strong cytotoxicity against various tumour cell 
lines (Marcenaro et al., 2005). In fact, 24 h incubation showed the highest K562 lysis 
by CBSC-NK cells and PBSC-NK cells, while 40 h caused a decrease in K562 lysis in 
both cultures. Another report showed enhanced NK cell cytotoxicity even with 
incubation with IL-12 for 3 days (Naume et al., 1992).  
 
Finally, the impact of IL-12 on ADCC capacity of the generated cells was studied. The 
expression of CD16 upon IL-12 incubation was first analysed. A peak in CD16 
expression was observed on CBSC-NK cells and PBSC-NK cells after 24 h incubation 
with IL-12, while incubation for 40 h led to a decline in CD16 expression. During this 
work the data regarding CD16 expression and IL-12 activation showed no correlation. 
One study reported that exposure of PB NK cells to IL-12 decreases CD16 expression 
(Loza and Perussia, 2004b), although a 5-day incubation was performed in this study. 
Another study using PB and CB MNCs found that incubation for 18 h with IL-12 did not 
alter CD16 expression (Condiotti and Nagler, 1998). Although metalloproteinases have 
been involved in the shedding of CD16 (Grzywacz et al., 2007; Romee et al., 2013), 
this phenomenon was not studied in our system however shedding of CD16 cannot be 
ruled out.  
 
The results from the previous chapter showed low ADCC potential from NK cells 
generated in vitro. CB NK cell cytotoxicity via ADCC can be enhanced with IL-12 
according to a previous study (Nguyen et al., 1998). Even though a high expression of 
CD16 was found when CBSC-NK cells and PBSC-NK cells were incubated for 24 h 
with IL-12, the highest ADCC killing was not observed at this time point. PBSC-NK 
cells showed a higher ADCC killing with 40 h incubation with IL-12, and CBSC-NK cells 
had similar ADCC killing after 0, 24 and 40 h incubation with IL-12. Nguyen et al. 
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suggested that the enhanced ADCC activity of CB and PB NK cells was related to the 
increased CD16 expression after incubation with IL-12 (Nguyen et al., 1998). The data 
from our study suggests that IL-12 incubation of CBSC-NK cells does not enhance 
ADCC activity while a positive effect on ADCC activity from PBSC-NK cells was 
observed. The mechanisms responsible for this different ADCC activity between 
CBSC-NK cells and PBSC-NK cells might involve additional factors such as expression 
of adhesion molecules. 
 
Some studies have shown that CB cells and in particular NK cells are more sensitive to 
IL-12 compared to BM cells or PB cells (Lee et al., 1996; Condiotti and Nagler, 1998). 
IL-12 had a greater impact on cytokine secretion of CBSC-NK cells compared to 
PBSC-NK cells. This is of great importance due to the important role that IFN-" and 
TNF-# play in the protection against viral infections (French and Yokoyama, 2003). 
However, caution should be heeded when manipulating NK cells in vitro to enhance 
NK cell functions because in many instances excessive production of IFN-" may be 
detrimental by stimulating the development of autoimmune diseases (Skurkovich and 
Skurkovich, 2003). On the other hand, prolonged IL-12 stimulation might provide a 
negative feedback mechanism in NK cells (Huang et al., 2011b). These mechanisms 
have been linked to the expression of micro-RNAs (miRNAs) (Huang et al., 2011a). 
Additional studies in this regard will elucidate the different NK cell behaviors observed 
after IL-12 incubation.  
 
In summary, the results of this chapter highlighted CD33 blocking on NK cells 
generated in vitro only affected IFN-" secretion when CBSC-NK cells were stimulated 
with K562, otherwise, no effects on NK cell effector functions were observed. 
Conversely, our data regarding the use of IL-12 incubation suggests that NK cells from 
CBSC and PBSC cultures may have a different activation threshold; while CBSC-NK 
cells react earlier (24 h) PBSC-NK cells take up to 40 h. Importantly, IL-12 considerably 
enhanced cytokine secretion in CBSC-NK cells. The use of the information derived 
from this study may allow improved NK cell manipulation in vitro for immunotherapy 
uses. 
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 Discussion and future work Chapter 7:
 
The aims of this thesis were to compare the potential of fresh and frozen CBSC to 
generate NK cells in vitro by analysing the phenotype and functionality of the 
generated product. Additionally, a comparison with another source of HSC was 
performed: PBSC. The results from this thesis show that frozen CBSC are a suitable 
source of HSC for NK cell generation in vitro, able to generate high numbers of NK 
cells without jeopardising cytotoxic and immunoregulatory properties. It also reports the 
effects of IL-12 on NK cells generated from CBSC and PBSC and the role of the 
myeloid marker CD33 on NK cell effector functions. This chapter discusses the data 
from all chapters and proposes future work and potential clinical application derived 
from the results obtained. 
7.1 The scope of this study 
 
One of the main challenges in assessing the feasibility of generating NK cells in vitro 
for immunotherapy is the direct comparison of the multiple variables affecting these 
protocols. Figure 7.1 summarises characterisations performed during this study and 
contributions by other groups. The majority of the current studies on NK cells 
generated in vitro focuses on the phenotypic and functional features of the generated 
product (figure 7.1) while a few studies focus on NK cell ontogenesis, the comparison 
of different HSC sources or the study of the role of specific markers on NK cell 
functions. This thesis focused on the areas that will likely have an impact on the design 
of protocols for NK cell generation in vitro (figure 7.1).  
 
Chapter 7 
 216 
 
Figure 7.1. Studies of NK cells generated in vitro. 
 
7.2 Natural Killer cell generation and development in vitro from 
haematopoietic stem cells  
 
Using fresh CBSC, an initial comparison between a modified protocol and a published 
one (Grzywacz et al., 2006) was performed demonstrating that NK cell features 
remained unaltered using a protocol that required less cytokines. In addition, one of the 
major finding of this work was the superior capacity of frozen CBSC to generate high 
numbers of NK cells in vitro. This is of major importance, as cryopreserved cells are an 
attractive option for clinical settings. However, different CB units were used to compare 
NK cell production in vitro from fresh and frozen CBSC. The CB units provided for this 
study were classified as research samples, having a lower blood volume and 
consequently lower HSC numbers. The access to units with high numbers of HSC or 
non-research samples will allow additional comparisons using CBSC from the same 
unit for fresh and frozen cultures and will reinforce the findings from this thesis. As NK 
cell therapy relies on the use of high doses of NK cells, the use of frozen CBSC will 
definitely suit the current demands. NK cells should be able to recognise and kill the 
majority of malignant cells. Currently, several groups have explored the potential 
application of NK cell immunotherapy in several types of cancers but NK cell 
immunotherapy could also be considered in the context of HSCT to enforce GvL. 
Clinical studies have been performed on the treatment of metastatic renal cell 
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carcinoma (MRCC) (Escudier et al., 1994), malignant glioma (Ishikawa et al., 2004), 
metastatic breast cancer (deMagalhaes-Silverman et al., 2000), acute lymphoblastic 
leukaemia (ALL) (Koehl et al., 2004) and CML (Passweg et al., 2004). Partial results 
have been obtained from the aforementioned studies, as not all patients showed an 
improvement on survival or disease-free survival. As mentioned, the main drawbacks 
in these therapies are the limited numbers of available NK cells when obtained from 
autologous or allogeneic apheresis and the state of NK cell activation. Sufficient 
numbers of NK cells derived from HSC with optimal activation states could be used for 
these therapies.  
 
There have been reports questioning the use of CBSC as HSC source for NK cell 
generation in vitro, as it is believed that BM or hESC are better sources for this 
purpose. Thus, in addition to CBSC, PBSC were included as another HSC source. 
Frozen CBSC have higher expansion and were able to generate higher NK cell 
numbers than frozen PBSC. Frozen PBSC samples were kindly provided by Dr Kwee 
Yong, UCL, through collaboration. When comparing the expression of NK cell 
receptors and NK cell effector functions between CBSC-NK cells and PBSC-NK cells 
high variability was observed, with a lower sample number in the latest group (n=3-6 
versus n=9 from CBSC) accounting for the lack of statistical significance. Mann-
Whitney test was performed for the majority of the analysis since the assumption that 
the sample had a normal distribution was not made. Even though other publications in 
the same field use student’s t-test even with low number of samples (n=3) (Spanholtz 
et al., 2011a), during this work we opted for Mann-Whitney test following statistician’s 
recommendations. Regardless of the fact that frozen CBSC had better potential for 
generating NK cells compared to fresh CBSC, a similar interpretation for fresh and 
frozen PBSC cultures could not be made, since it was not performed. Some studies 
demonstrated that frozen PBSC would have impaired functions compared to fresh 
PBSC in the context of HSCT (Lioznov et al., 2008); therefore, this study can only 
claim that frozen CBSC are a better source of HSC compared to frozen PBSC. Even 
though the use of frozen samples is ideal, the addition of experiments performed on 
fresh PBSC will certainly complement this work. Moreover, the comparison of CBSC to 
BM progenitors using the protocol in this thesis will also provide useful information to 
aid choice of the correct HSC source for NK cell generation in vitro. 
 
During this thesis, NK cell development was followed closely using the model proposed 
by Freud et al (Freud et al., 2006). In addition, the expression of TFs and markers of 
the lymphoid and myeloid lineages was also investigated. After integrating the data 
from CD56 acquisition and the expression of lymphoid precursor markers and TFs, an 
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interesting observation was noted: key events occurred from day 14 to day 21 in the 
cultures. Figure 7.2 shows the combination of these data for fresh and frozen CBSC 
and PBSC cultures.  
 
 
Figure 7.2. NK cell development integrating flow cytometry and molecular data. NK cell 
development for fresh and frozen CBSC and PBSC cultures are presented along with the 
expression of TFs and lymphoid lineage markers. Semi-transparent red circles highlight day 14 
and day 21 in graphs. 
 
From day 14 to 21, the expression of CD56 increased from approximately 10% to 80% 
and the expression of PU.1, E4PB4 and ID2 was high especially in fresh CBSC 
cultures. A shortcoming from the TFs mRNA analysis was the analysis of a mixture of 
cells (stages 1-3 and other precursors), but cell sorting could be a good strategy to 
overcome this limitation in the future. An interesting observation was also the lower 
levels of CD7 and CD10 expression at days 14 and 21. Figure 7.2 shows that NK cell 
stages 1, 2 and 3 were present at day 14 and only stages 2 and 3 at day 21, however 
only 30-60% of cells in culture comprise NK cell precursors. This suggests that other 
cells could have been recruited for NK cell generation. There is a possibility of 
recruitment of myeloid precursors to generate NK cells, as others have suggested 
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(Grzywacz et al., 2011). Additional experiments including cell sorting and separate 
culture of NK cell precursors and the cell fraction that does not correspond to NK cell 
precursors from day 14 could reveal if indeed CD33+ or other cells were recruited for 
NK cell differentiation in vitro.  
 
7.3 Phenotype and functions of Natural Killer cells generated in 
vitro compared to cord blood and peripheral blood NK cells 
 
The study of the phenotype and effector functions of NK cells from CB and PB has 
been performed previously, to a certain extent (Jacobs et al., 2001; Dalle JH, 2005). 
This work included the study of NK cells subsets CD56bright and CD56dim from CB and 
PB NK cells (appendix 1). This publication represents a major aid hence allowing the 
comparison of NK cells generated in vitro to those present in CB and PB. It was shown 
during this study that CD56bright cells from CB have a higher expression of CXCR4, 
NKG2A, 2B4 and CD48 whereas CD56bright cells from PB showed higher expression of 
adhesion molecules and activating receptors. PB CD56bright cells had higher intracellular 
perforin expression and higher degranulation compared to CB CD56bright cells (figure 
7.3). PB CD56dim cells exhibited higher inhibitory receptors expression, higher 
expression of activating receptors, L-selectin, granzyme B, perforin, IFN-" and better 
degranulation compared to CB CD56dim cells (figure 7.3). These features are part of the 
trademark of cytotoxic activity in PB CD56dim cells. NK cell characterisation from CB, 
PB and NK cells generated in vitro are compared in figure 7.3. The data presented 
during this work suggests that NK cells generated in vitro do not precisely resemble CB 
or PB NK cell subsets.  
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Figure 7.3. Phenotypic and functional features of CB NK cells, PB NK cells and NK cells generated in vitro. The upper panel shows the characterisation of 
CB and PB CD56dim and CD56bright NK cells. The receptors in bold red are more expressed compared to their counterpart (PB or CB). The lower panel shows the 
complete characterisation of NK cells generated in vitro.  
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Fresh CBSC-NK cells have features of PB CD56dim cells; these include the high 
expression of granzyme B, perforin and CD16 expression. However, the low 
expression of KIRs, CXCR1 and NKG2C suggest features characteristic of CB 
CD56bright NK cells. Similar observations in which CD56dim and CD56bright features are 
present were found from frozen CBSC-NK cells. For instance, an enhanced ability to 
kill K562 cells in vitro (CD56dim feature) and high secretion of IFN-! and TNF-" 
(CD56bright feature). PBSC-NK cells also had CD56dim features in terms of granzyme B 
and perforin expression, but the low expression of CD16 and KIRs are CD56bright 
features. 
 
An interesting observation during this study was the absence of KIRs expression on 
the generated NK cells. mRNA analysis revealed a similar transcriptional pattern from 
NK cells generated from HSC to CB and PB NK cells, post-translational modifications 
could be occurring, accounting for the differences observed by flow cytometry. These 
modifications include phosphorylation, acetylation, methylation and glycosylation 
among others. Several studies have addressed the question of KIR transcriptional 
regulation (Trompeter et al., 2005; Cichocki et al., 2011), but of special interest would 
be the study of post-translational modifications for KIRs mRNA. Another aspect 
regarding NK cell immunotherapy is the possible prediction of alloreactivity according 
to KIRs mismatch. Although a genotypic analysis was performed during this work (data 
not shown), only KIR2DL1/DS1, KIR2DL2/3 were screened in NK cells generated in 
vitro thus limiting the knowledge of potential alloreactivity. In addition, this alloreactivity 
should, if possible, be tested in vitro prior to infusion in order to select the best suitable 
donor HSC for generation of NK cells in vitro.  
 
Additional experiments addressing the consequences of low KIRs expression in terms 
of education/licensing would clarify whether this could be a disadvantage. To assess 
NK cell education, Anfossi et al. tested the functions of human KIR-NKG2A- and 
KIR+NKG2A+ NK cells using the same assays as used in this thesis (51Cr release assay 
with K562, CD107a expression and IFN-! expression) (Anfossi et al., 2006). The same 
assays could be used in future experiments but taking into account some 
modifications. Since only the expression of a few KIRs were included in this thesis, 
further studies including the analysis of other KIRs expression (KIR2DL1, KIR2DS1, 
KIR2DL2, KIR2DL3, KIR2DS2, KIR2DS4 and KIR3DL1) and further sorting of KIR+ and 
KIR- populations will shed light on the education/licensing status of NK cells and the 
therapeutic potential of KIRlow/- cells generated in this work.  
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7.4 Does the phenotype of Natural Killer cells generated in vitro 
resemble that of other tissue-specific Natural Killer cells? 
 
NK cells are not only found in PB or CB, but also in different tissues. For instance, uNK 
cells are characterised by their lack of expression of L-selectin, CD16 and CD57 while 
expressing KIRs, CD69 and being CD56 superbright. Moreover, uNK cells have been 
described as having low cytolytic activity against K562 cells (Ferry et al., 1990). Liver 
CD56dim NK cells express KIR, NKG2A, CD69 and NKp44, and interaction with Kupffer 
cells can lead to cytolytic activity and cytokine production of these cells (lower 
compared to PB CD56dim NK cells) (Tu et al., 2008; Burt et al., 2009). NK-22 cells are 
characterised by the expression of NKp44 and CCR6, IL-22 secretion and do not 
express perforin and have little granzyme B (Cella et al., 2009).  
 
Like some of these subsets, NK cells generated in vitro also expressed CD69 (around 
50%, data not shown), NKp44 and low levels of L-selectin. However, they were able to 
kill target cells in vitro unlike the majority of other tissue NK cell subsets that have low 
cytotoxic activity. A more detailed analysis reveals the lack of expression of VEGF in 
the generated cells as measured by qPCR (data not shown), usually expressed by 
uNK cells (Moffett-King, 2002; Vacca et al., 2011), lack of the transcription factor 
GATA-3 present in thymic NK cells (Vosshenrich et al., 2006) and lack of IL-22 
secretion, hallmark of NK22 cells (data not shown) (Cella et al., 2009). Therefore, NK 
cells generated in vitro have little resemblance with the subsets mentioned above. The 
microenvironment probably plays an important role in establishing NK cell phenotype. 
The signals that determine this process are still undefined, but it is clear that the 
signals giving rise to uterine, thymic, liver NK cells or NK-22 cells are probably absent 
in the system used in this thesis.   
 
7.5 The myeloid marker CD33 
 
The data presented during this thesis contributes to the notion that NK cell 
development might not exclusively occur from the lymphoid lineage. It was shown that 
CD45+CD33+ cells were present at the beginning and throughout the culture of HSC. 
Moreover, around 50% NK cells generated in vitro co-expressed CD33. The data 
acquired during the experiments for blocking CD33 on NK cells generated in vitro 
demonstrated that intracellular IFN-! increased when stimulated by K562 cells. As 
discussed, this could be beneficial if concomitant anti-CD33 and NK cell therapy is 
applied. Further experiments in vitro could include testing of anti-CD33 commercial 
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drugs (Gemtuzumab ozogamizin or Lintuzumab) during the final assessment of NK cell 
effector functions. Other functional features tested were not affected by CD33 blocking. 
One of the reasons could be the internalisation of the CD33 receptor during anti-CD33 
blocking. In this regard, sorted CD33+CD56+ populations (CD33+CD56+ and CD33-
CD56+) could be tested for their ability to secrete cytokines, degranulate and perform 
cytotoxic functions against K562 and during ADCC assays. During this work it was also 
shown that incubation with IL-12 increased CD33 expression on NK cells generated in 
vitro. Additional experiments could be performed using PB and CB NK cells to 
determine if a similar effect is observed and the consequences.  
 
7.6 Impact of IL-12 
 
IL-12 has been shown to be a promising candidate for NK cell activation in vitro in our 
laboratory. During this thesis, the data regarding the use of IL-12 showed a different 
activation threshold by CBSC-NK cells and PBSC-NK cells. A complete phenotypic 
analysis was performed before and after incubation with IL-12 for 40 h. The results 
revealed that the repertoire of PBSC-NK cells was altered, while the expression of 
some receptors changed in CBSC-NK cells. The cytokine secretion of IFN-! and TNF-" 
was improved in CBSC-NK cells with IL-12 incubation; PBSC-NK cells showed slightly 
increased secretion of these cytokines. Importantly, the expression of granzyme B 
increased with IL-12 incubation, reaching expression levels similar to those of PBSC-
NK cells. The expression of perforin in CBSC-NK cells and PBSC-NK cells was not 
altered with IL-12 incubation. The expression of CD16 on NK cells changed with IL-12 
incubation, as did ADCC activity in CBSC-NK cells and PBSC-NK cells after IL-12 
incubation. The killing of K562 cells by CBSC-NK cells and PBSC-NK cells was also 
improved using IL-12 incubation for 24 h while a decrease in capacity was observed 
using 40 h in both HSC cultures. It would also be beneficial to know if cells should be 
activated prior-infusion with IL-12 or if IL-12 administration would have a similar effect 
on the generated NK cells in vivo. It has been reported that administration of IL-12 in 
the treatment of some malignancies can cause severe toxicity (Car et al., 1999). 
Moreover, with the exception of non-Hodgkin’s lymphoma (Younes et al., 2004), 
cutaneous T cell lymphomas (Rook et al., 1999) and Kaposi sarcoma related to AIDS 
(Little et al., 2006), the efficacy of IL-12 infusion on the treatment of some 
haematological diseases and solid tumours has been minimal (Bajetta et al., 1998; 
Motzer et al., 1998; Wadler et al., 2004). Taking into account this background the need 
for in vivo information using mouse models would help in the decision on how to 
administer IL-12. Non-obese diabetic severe combined immune deficient (NOD-SCID) 
mice are deficient in T, B and NK cells, this model allows the establishment of different 
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tumours and could contribute in determining whether NK cells should be activated in 
vivo or in vitro.  
 
Although some of the mechanisms that regulate NK cell activation by IL-12 have been 
studied, this work provides further opportunities to explore additional molecular events 
that regulate NK cell activation during IL-12 incubation. During this thesis, RNA was 
extracted from NK cells generated in vitro incubated without IL-12 or with IL-12 for 4, 
24 and 40 h (fresh CBSC-NK cells n=3, frozen CBSC-NK cells n=7, PBSC-NK cells 
n=6). These samples are currently stored and ready to be used for further experiments. 
The use of microarray technologies (Affymetrix) would shed light on the signalling 
molecules, transcription factors and proteins involved in NK cell activation with IL-12. 
Overall, IL-12 can effectively improve NK cell functions, taking into consideration that 
CBSC-NK cells and PBSC-NK cells hold different threshold of activation. Additionally, 
other cytokines either alone or in combination with others are currently under 
investigation in the laboratory and the findings from these studies could also be utilised 
to test NK cells generated in vitro.  
 
7.7 Killing in vivo of Natural Killer cell generated in vitro 
 
NK cells generated in vitro in this thesis exhibited immunoregulatory and cytotoxic 
properties. The findings of this study can be extrapolated to a certain extent to predict 
NK cell activity in vivo. However, solid evidence is limited due to the lack of functional 
assays using leukaemia cells in vitro or in an in vivo system. An effort to explore NK 
cell killing potential in vivo was initiated during this work using a humanised mouse 
model (NSG:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). In this model, labelled K562 cells were 
injected intra-peritoneally with or without injection of PB NK cells. After 48 h, peritoneal 
washes were performed to retrieve cells and determine NK cell killing using FACS. The 
labelling of K562 cells was standardised using a fluorescent cell linker (PKH67, Sigma-
Aldrich) and the use of PB NK cells with or without IL-15 activation at different effector-
to-target ratios was explored in three different sets of experiments. The preliminary 
data provide the background for further modifications of the system to successfully 
evaluate NK cell-mediated killing in vivo using this model however, because of time 
constraints, this work could not be done.  
 
Access to patients’ cells would also facilitate the generation of helpful information 
regarding the effector functions of NK cells generated in vitro. For instance, AML cells 
could be used as target cells for killing assays in vitro. Once the animal model is set 
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up, the concomitant administration of malignant cells and NK cells generated in vitro 
into mice could illuminate the cytotoxic capacities of the generated NK cells.  
 
7.8 Parallel research using the Natural Killer cell generation in vitro 
protocol 
 
This project was initiated with the purpose of maximising the use of CB as a source of 
HSC, which does not require invasive collection and for which the numbers of units 
available are continuously growing. The optimisation of this NK cell generation system 
in vitro was useful for other research projects and was not only limited to this study. 
Once the standardisation of the NK cell generation protocol was performed, additional 
studies were performed in parallel to this study. Figure 7.4 depicts some of these 
studies. The NK cell generation protocol allows the use of CBSC and PBSC for NK cell 
ontogeny studies. The current research in the laboratory includes the impact of 
immunosuppressive drugs or other cells (Tregs) on NK cell development (figure 7.4). 
This thesis also provides the basis for additional research on IL-12, CD33 and NK cell 
effector functions in vivo, all of which that could potentially contribute to NK cell 
manipulation for immunotherapy (figure 7.4).  
 
 
Figure 7.4. Current applications of the NK cell generation in vitro protocol and future 
directions. The figure shows the current projects performed parallel to this work and black bold 
sentences represent future work that will complement this thesis.  
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7.9 Translation to the clinic 
 
The data presented during this work have potential clinical applications. Although these 
applications will certainly need additional in vitro and in vivo experiments, this thesis 
provides the knowledge for better decision-making regarding HSC source, cytokine mix 
for NK cell generation protocols and the use of cryopreserved cells that should be 
taken into consideration while establishing NK cell immunotherapy protocols. NK cells 
play a key role in the eradication of haematological malignancies, small solid tumours 
and even tumour metastases (Ljunggren and Malmberg, 2007; Chan et al., 2008). NK 
cells would be more effective in scenarios in which the tumour burden is small. A 
correlation between NK cell doses and eradication of malignant cells has been 
observed previously (Clausen et al., 2007; Tanaka et al., 2012). Hence the importance 
of developing new protocols that allow the generation of high numbers of NK cells with 
an optimal activation state and from the appropriate HSC source. 
 
The results from this work have a number of important implications for the design of 
future clinical NK cell protocols. First, it is recommended to use frozen CBSC in order 
to generate higher numbers of NK cells with optimal immunoregulatory and cytotoxic 
functions. Although the methodology used in this study involved the processing of CB 
units within 24 h for HSC isolation, in some instances this might not be feasible. 
However, previous studies have reported the optimal isolation of HSC from frozen CB 
units (Spanholtz et al., 2011a) and similar isolations have been performed in our lab 
(CD133 isolation). It was also suggested to use of a cytokine cocktail with only IL-15 for 
the last two weeks of the culture. This modification would reduce costs in reagents and 
does not jeopardise NK cell effector functions. The improvement of NK cell effector 
functions can be achieved using IL-12 (projected to be approved by the Federal Drug 
Administration in 2014) and 24 h incubation prior-infusion.  
 
Due to the introduction of new therapies involving the manipulation of HSC, several 
guidelines have been established by regulatory agencies in the USA and in Europe. 
European Medicines Agency (EMA), a decentralised agency from the European Union, 
is responsible for the scientific evaluation of medicines. Thus, additional considerations 
should be taken into account before a possible translation of this study from the 
“bench” to the clinic can be performed. The starting material to generate NK cells 
during this work was HSC, either from CB or PB. The background information of these 
materials should be documented, including cell banking and viral safety. This can be 
easily achieved as current practices in CB banks include serological tests for viral 
detection and HLA typing (low-resolution). HSC are a heterogeneous cell population 
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with variable differentiation capacity and probably are in different development stages. 
Thus, pre-clinical studies should include a standardised characterisation and a robust 
manufacturing process allowing reproducibility and consistency of the final product. 
Although not extensive, a characterisation including NK cell progenitors, expression of 
myeloid and lymphoid lineage markers and a panel for stem cell receptors was 
included during this study using a four-colour FACS machine. This knowledge can be 
easily translated into protocols for clinical use, as flow cytometry facilities are usually 
available in hospitals or CB banks, therefore this analysis to cryopreservation. 
 
The next challenge is the compliance with GMP guidelines. So far, the use of murine 
feeder layers provides the microenvironment for optimal NK cell generation using HSC. 
However, these systems are a potential source of xeno-biological contamination, 
carrying the risk of xeno-toxicity and the presence of viral contaminations. Few studies 
have overcome the use of murine feeder layers and developed xeno-free systems in 
which NK cell generation from HSC can be obtained. These systems have been 
performed using CBSC, showing promising results, including the generation of high NK 
cell numbers with an activated phenotype able to kill K562 and leukaemia cells in vitro. 
Based on these results, a clinical trial was initiated in 2011 (NTR2818, 
http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2818). During these studies 
however, a comprehensive characterisation or the comparison of other HSC sources 
was not performed. EMA has highlighted a variety of murine viruses that may or may 
not be pathogenic in humans. While there is a lack of information regarding 
CBSC/PBSC susceptibility to murine viruses, Amit et al. have reported that hESC are 
resistant to certain murine viruses (Amit et al., 2005). Although further research would 
need to be performed for the feeder layer used in this work (EL08.1D2), additional 
alternatives arise from the fact that the murine cells die by week 3. Dead cells as well 
as viruses (18-100 nm) could be removed using physical methods (filtration, see 
appendix 4) or magnetic labeling. In order to validate and confirm the absence of 
murine cells, it would also be helpful to incorporate the use of commercial kits 
available, able to detect murine DNA (StemElitetm ID System, Promega). 
 
NK cells should ideally be infused after reduction of tumour mass (either by 
chemotherapy, surgery or radiotherapy) or after immunosuppressive regimen in 
haematological diseases. Regarding HSC transplant (either BMSC, PBSC or CBSC), 
NK cell immunotherapy could be used at day 0 (transplantation day) or post-transplant. 
A recent phase II study has revealed that allogeneic NK cell infusions after 
haploidentical HSC transplantation (day +0, +44 and +100) had no significant effect on 
relapse or survival rates. During this study, the timing of infusions was questioned and 
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the importance of the purity and NK cell activation state was emphasised (Stern et al., 
2013). This might suggest that multiple NK cell infusions are needed in order to 
achieve complete remission, but this will depend on the disease treated. It should also 
be taken into account that in vivo expansion and functions of NK cells might be limited 
by the host, where rejection by myeloid, lymphoid and Tregs can occur (Geller et al., 
2011). Therefore, the secretion of molecules (cytokines, interferons, chemokines 
among others) by both the host receiving the therapy and the infused NK cells should 
be monitored and the impact on therapy outcome should be documented. 
 
Previous studies have demonstrated the considerable alloreactivity potential that NK 
cells hold (Colonna et al., 1993; Ruggeri et al., 1999; Ruggeri et al., 2002), particularly 
when there is KIR-ligand mismatch (donor to host). Great lessons have been learned 
from AML treatment, where T-cell depleted PBSC transplants from haploidentical 
family members were used. From the 57 patients treated, 90.2% achieved engraftment 
and 26% achieved event-free survival, more importantly GvHD was only present in 
8.6% of the cases (Ruggeri et al., 2002). Another study showed 90% event-free 
survival in patients with KIR ligand mismatch in HSCT from unrelated donors (Giebel et 
al., 2003). These data provide evidence supporting the use of third party HSC for NK 
cell generation instead of autologous HSC. The increasing amount of CB units 
worldwide and the availability of this HSC source complying with viral safety and HLA 
typing would allow the use of these HSC for NK cell immunotherapy purposes.  
 
A clinical trial (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2818) started in 
2011 with the purpose of determining the optimal NK cell dose for the treatment of AML 
in patients unable to receive HSCT. The main focus of this trial is to test the safety of 
NK cells infusion involving dose escalation. Although in another context, the safety of 
NK cells in HSCT has previously been studied. Just recently, higher doses of NK cells 
(>2.8 x 106/kg) in BMT have been reported to prevent GvHD compared to low doses 
(<2.8 x 106/kg) (Tanaka et al., 2012). Moreover, even higher doses of NK cells were 
tested in allogeneic PBSCT (>5 x 107/kg), improving transplant outcomes in terms of 
non-relapse mortality and infectious events (Kim et al., 2005a). It seems that in the 
context of HSCT, high doses of NK cells are safe and well tolerated. If research CB 
units contain 3.8 x 106 CD34+ cells (range 1.7-8.7 x 106) (Spanholtz et al., 2010), 2 x 
109 NK cells (range 0.9- 4.5 x 109 NK cells) could potentially be generated in vitro. 
Taking into account the highest NK cell dose tested in adult patients (70 kg), around 
3.5 x 109 NK cells would be needed. Clinical grade CB samples could provide enough 
starting material to supply these needs and even for multiple infusions. NK cells 
generated in vitro could be infused at different time points (day +0, +44 and +100) 
Chapter 7 
 229 
(Stern et al., 2013) along with or after allogenic HSCT in the treatment of 
haematological diseases like AML, ALL and CML. Regarding the treatment of solid 
tumours, 2.2 x 107/kg NK cells from PB apheresis have been used in the treatment of 
recurrent ovarian cancer and breast cancer (Geller et al., 2011). Further work is 
needed in this field, as NK cell immunotherapy was not successful in this report and 
the need to augment NK cell proliferation and persistence was emphasised in this 
study. The use of NK cells generated in vitro could provide an alternative source of NK 
cells, although additional experiments should confirm NK cell proliferation and 
persistence in vivo. 
  
For the purposes of generating NK cells for adoptive immunotherapy, the work 
presented in this thesis has demonstrated CBSC as a superior product over PBSC. In 
summary, the data provides evidence supporting the generation of high numbers of NK 
cells using CBSC that have enhanced phenotypic and functional features. For 
example, analysis of CBSC-NK cells revealed their potential to proliferate was due to 
their interleukin receptor repertoire and the high expression of activating receptors 
such as NKp44 and NKG2D augmented a more efficient killing capacity in vitro against 
K562 cells and higher secretion of IFN-! and TNF-". The success of CBSC-NK cell 
immunotherapy for the treatment of cancers will vary according to the expression of 
ligands on the malignant cells for activating NK cell receptors. Potentially, high doses 
of pure and activated NK cells generated in vitro could be used in the treatment of 
MRCC (Escudier et al., 1994), malignant glioma (Ishikawa et al., 2004), metastatic 
breast cancer (deMagalhaes-Silverman et al., 2000), ALL (Koehl et al., 2004) and CML 
(Passweg et al., 2004). Additionally, CBSC generated NK cells could be used as 
immunotherapy to treat patients with chronic viral infections such as HMCV, EBV, 
HCV, Varicela Zoster Virus (VZV) and HSV as the cells were equipped with DNAM-1, 
NKp30, NKp44, NKp46 and NKG2D receptors, known to recognise ligands on virus-
infected cells enabling NK cell-mediated lysis (Tomasec et al., 2005; Andoniou et al., 
2006; Brooks et al., 2006; Chalupny et al., 2006). In the field of HSCT, NK cell therapy 
conveys promising potential benefits for the patient including less GvHD and more 
efficient GvL as well as more successful engraftment. Patients could receive single or 
multiple infusions, and with the use of CBSC, less stringent HLA-matching is required 
which increases availability and renders CBSC as an ideal off-the-shelf therapeutic 
product.  
 
Altogether, the results from this work provide the basis for a better selection of HSC, 
protocol design and even enhancement of effector NK cell functions of NK cells 
generated in vitro for immunotherapy. While further research using in vivo models will 
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complement the data generated, fundamental data was retrieved regarding NK cell 
development and the role of the myeloid marker CD33 that will be useful for further 
studies in the future.  
  241 
8.2 Appendix 2 
  
ND; not determined 
Study CD158a CD158b NKG2A NKp30 NKp44 NKp46 NKp80 2B4 CD48 Fas-L NKG2C NKG2D TRAIL CD16 IL-15R! IL-18R IL-2R! (CD25)
IL-2R"1 
(CD122)
IL-12R"1 
(CD212) CCR5 CCR6 CCR7 CXCR1 CXCR4 CXCR7 CD49d DNAM-1
Integrin 
"7
L-selectin 
(CD62L) LFA-1
Spanholtz 
et al. 
(2010)
4% 5% 50% 70% 100% 100% 0% 100% ND ND 0% 90% ND 5% ND ND 10% 30% % ND ND ND ND ND ND ND ND ND ND ND
Spanholtz 
et al. 
(2011)
ND ND ND 51% 60% 100% ND 100% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Kao et al. 
(2007) ND ND ND ND ND ND ND ND ND 26% ND ND ND 0% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Grzywacs 
et al. 
(2006)
10% 10% 90% 87% 97% 94% ND ND ND 25% 27% 96% ND 35% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Perez et 
al. (2006) 2% 4% ND ND ND 81% ND 35% ND ND ND 83% ND 21% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Bonnano 
et al. 
(2009)
0.1% 0.4% ND ND ND 66% ND 89% ND ND ND 14% ND 3% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Lehmann 
et al. 
(2012)
6% 4% 82% ND 79% ND ND 84% ND ND 1% 100% ND 23% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Woll et al. 
(2005) 0% 6% 58% 24% 54% 43% ND ND ND ND ND ND ND 1% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Woll et al. 
(2009) 2% 6% ND ND 40% 8-% ND ND ND ND ND 5% ND 12% ND ND ND ND ND ND ND 0% ND 0% ND ND ND ND 1% 100%
Miller et al. 
(2001) 1% 21% 22% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Dezell et 
al. (2012) 34% 34% ND ND ND ND ND ND ND ND ND ND ND 0.40% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Beck et al. 
(2009) 0.40% 0.40% 15% 81% 21% 92% ND 91% ND ND 1.40% 45% ND 30% ND ND ND ND ND ND ND 3% 3% ND ND ND 74% ND 65% 71%
Study CD158a CD158b NKG2A NKp30 NKp44 NKp46 NKp80 2B4 CD48 Fas-L NKG2C NKG2D TRAIL CD16 IL-15R! IL-18R IL-2R! (CD25)
IL-2R"1 
(CD122)
IL-12R"1 
(CD212) CCR5 CCR6 CCR7 CXCR1 CXCR4 CXCR7 CD49d DNAM-1
Integrin 
"7
L-selectin 
(CD62L) LFA-1
Zamai et 
al. (2012) 10% 10% ND ND ND ND ND ND ND 100% ND ND 60% 18% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 100%
Woll et al. 
(2005) 2% 32% 79% 50% 72% 87% ND ND ND ND ND ND ND 17% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Woll et al. 
(2009) 32% 37% ND ND 72% 100% ND ND ND ND ND 20% ND 44% ND ND ND ND ND ND ND 0% ND 0% ND ND ND ND 0% 100%
Giuliani et 
al. (2008) ND ND ND 100% 100% 100% ND ND ND ND ND 100% ND 100% ND ND ND ND ND ND ND 7% ND ND ND ND ND ND ND ND
PBSC, BM or hESC
Chemokine receptors Adhesion molecules
Inhibitory receptors NCRs
Co-
stimulatory 
receptors
Activation receptors Interleukin receptors Chemokine receptors Adhesion molecules
CBSC
Inhibitory receptors NCRs
Co-
stimulatory 
receptors
Activation receptors Interleukin receptors
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ND; not determined 
Killing assay 
(various 
ratios)
ADCC
Study IFN-! (K562)
IFN-! 
(PMA&Io
n)
Perforin Granzyme B
IFN-! 
(K562)
IFN-! 
(PMA&Ion)
TNF-" 
(K562)
TNF-" 
(PMA&Ion)
K562 (ratio 
1:1) PMA&Ion
51 Cr ADCC Notes
Miller et 
al. (2001) ND ND ND ND ND ND ND ND ND ND ND ND -
Woll et al. 
(2005) ND 21% ND ND ND ND ND ND ND ND 59% ND Killing assay ratio 10:1
Grzywacs 
et al. 
(2006)
ND ND 78% 100% ND ND ND ND ND ND 40% ND Killing assay ratio 10:1
Perez et 
al. (2006) ND ND 54% ND ND
5000 
(IL12+IL18) ND
4000 
(IL12+IL18) ND ND 60% ND Killing assay ratio 5:1 without IL-21
Kao et al. 
(2007) ND ND 0.1% ND ND
3000 
(IL12+IL18) ND ND ND ND 25% ND Killing assay ratio 5:1
Beck et al. 
(2009) ND ND ND ND ND ND ND ND ND ND 40% ND Killing assay ratio 15:1, delta 4.
Bonnano 
et al. 
(2009)
ND ND ND ND ND ND 150 (no stimuli) ND 32% ND ND ND -
Woll et al. 
(2009) ND ND 45% 60% ND ND ND ND ND ND 60% ND Killing assay ratio 10:1
Spanholtz 
et al. 
(2010)
ND ND ND ND 300 ND ND ND 25% ND 40% ND Killing assay ratio 2:1
Spanholtz 
et al. 
(2011)
ND ND ND ND ND ND ND ND 20% ND 60% ND Killing assay ratio 10:1, 18 h co-incubation
Dezell et 
al. (2012) ND ND ND ND ND
100000 (IL-
12 + IL-18) ND ND ND ND 60% ND Killing assay ratio 10:1
Lehmann 
et al. 
(2012)
ND 40% ND ND ND ND ND ND ND ND 60% 70%
Killing assay ratio 10:1, pre-incubation for 3 
days with IL-2 (1000 U), ADCC using Europium 
release, ratio 12:1
Killing assay 
(varios ratios) ADCC Notes
Study IFN-! (K562)
IFN-! 
(PMA&Ion
)
Perforin Granzyme B IFN-! (K562) IFN-! (PMA&Ion)
TNF-" 
(K562)
TNF-" 
(PMA&Ion)
K562 (ratio 
1:1) PMA&Ion
51 Cr ADCC
Woll et al. 
(2005) ND 34% ND ND ND ND ND ND ND ND 50% ND Killing assay ratio 10:1
Giuliani et 
al. (2008) ND ND ND ND ND ND ND ND ND ND 50% ND Killing assay ratio 10:1, activated with IL-2
Woll et al. 
(2009) ND ND 95% 93% ND ND ND ND ND ND 80% ND Killing assay ratio 10:1
Zamai et 
al. (2012) ND ND 84% 69% ND ND ND ND ND ND ND ND
CBSC
Intracelluar Secreted (pg/mL) CD107a
PBSC, BM or hESC
Intracelluar Secreted (pg/mL) CD107a
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Company 
Sartorius 
PP7 
bacteriophage 
26 nm 
Retrovirus 
80-130 nm 
Millipore 
Retrovirus 
80-130 nm 
!X-174 
bacteriophage 
26 nm 
Pall 
PP7 
bacteriophage 
26nm 
PR772 
Bacteriophag
e 76-88 nm 
Asahi-Kasei
 
Parvovirus 
18-26 nm 
Polioviurs 
28-30 nm 
HIV 80-130 
nm 
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Saudemont A. The unique profile of cord blood natural killer cells balances incomplete 
maturation and effective killing function upon activation. Hum Immunol  2012; 73: 248-
257. 
 
2. Luevano M, Madrigal A, Saudemont A. Generation of natural killer cells from 
hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol  2012; 9: 310-
320. 
 
3. Luevano M, Madrigal A, Saudemont A. Transcription factors involved in the 
regulation of natural killer cell development and function: an update. Frontiers in 
immunology  2012; 3: 319. 
  
4. Luevano M, Domogala A, Pedroza-Pacheco I, Derniame A, Escobedo-Cousin M, 
Querol S, Madrigal A and Saudemont A. Frozen umbilical cord blood CD34+ cells 
generate higher number of functional natural killer cells in vitro than mobilized 
peripheral blood CD34+ cells. Blood, manuscript in preparation for submission. 
 
Presentations at scientific meetings 
 
Oral presentations: 
 
1. 2010 NIMR/UCL Seminar Day 2010. Oral presentation: “Generation of NK 
cells from cord blood stem cells, characterization and application for 
immunotherapy”. Anatomy Building, UCL main campus, May 10th 2010. 
 
2. Manchester, Mexican Symposium. Oral presentation: “Generation of NK cells 
from cord blood stem cells, characterization and application for 
immunotherapy”. 2nd July 2010. 
 
3. First CONACyT’s student symposium. Oral presentation “Generation of NK 
cells from cord blood stem cells, characterization and application for 
immunotherapy”. Paris, France. 13th-15th October 2011. 
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4. RCAI international program. Oral presentation “Generation of NK cells from 
cord blood stem cells, characterization and application for immunotherapy”. 
Yokohama, Japan. 21th-29th June 2013. 
 
Poster presentations: 
 
1. UCL graduate school research Poster competition 2009/2010. Poster entitled: 
“Generation of NK cells from cord blood stem cells, characterization and 
application for immunotherapy”. UCL Graduate School. March 5th 2010. 
 
2. 3rd annual Cancer Institute Open Day/ the 1st Annual UCL Cancer Research UK 
Centre Conference. Poster entitled: “Generation of NK cells from cord blood 
stem cells, characterization and application for immunotherapy”. 
 
3. British Immunology Society 2010. Poster entitled: “Generation of NK cells from 
cord blood stem cells, characterization and application for immunotherapy”. 
Liverpool, UK. 6-10th December 2010. 
 
4. UCL graduate school research Poster competition 2010/2011. Poster entitled: 
“Generation of NK cells from cord blood stem cells, characterization and 
application for immunotherapy”. UCL Graduate School. 1st March 2011. 
 
5. 2011 NIMR/UCL Seminar Day 2011. Poster: “Generation of NK cells from cord 
blood stem cells, characterization and application for immunotherapy”. 19th May 
2011. 
 
6. British Immunology Society 2011. Poster titled “Generation of NK cells from 
cord blood stem cells, characterization and application for immunotherapy”. 
Liverpool, UK. 5-8th December 2011. 
 
7. Society for Natural Immunity NK2012. Poster presentation entitled “Generation 
of NK cells from cord blood stem cells, characterization and application for 
immunotherapy”. Pacific Grove, CA USA. 20th-24th April 2012. 
 
8. NK2012 symposium. Poster presentation “Characterisation of Natural Killer 
cells generated from fresh and frozen umbilical cord blood stem cells”. 
Heidelberg Germany. 26th-29th September 2012.  
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9. RCAI International Summer Program. Poster presentation “Generation of NK 
cells from cord blood stem cells, characterization and application for 
immunotherapy”. Yokohama, Japan. 21th-29th June 2013 
 
 
Awards 
 
1. Award on the Primer Design sponsorship worth £3600 on qPCR reagents. Feb 
2011. 
 
2. UCL Graduate School Student Conference Fund to attend the NK2012 Society 
for Natural Immunity meeting. Pacific Grove, CA USA. 20th-24th April 2012. 
 
3. Kitty Cookson Conference Travel Funds, to attend the NK2012 Society for 
Natural Immunity meeting. Pacific Grove, CA USA. 20th-24th April 2012 
 
4. UCL Graduate School Student Conference Fund, to attend the NK2012 
Symposium. Heidelberg Germany. 26th-29th September 2012.  
 
5. British Society Travel Award UCL Graduate School Student Conference Fund, 
to attend the NK2012 Symposium. Heidelberg Germany. 26th-29th September 
2012.  
 
6. Fellowship to attend RCAI International Summer Program and summer 
internship, Yokohama Tokyo. June –July 2013. 
 
7. Best presentation award of RCAI International Summer Program 2013. RIKEN 
centre for Integrative Medical Sciences and LGS at Chiba University. June 27 
2013. 
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